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Abstract 
KATIE M. O’BRIEN: Race and subtype differences in the replication of previously 
identified breast cancer susceptibility loci: A Bayesian approach 
(Under the direction of Robert C. Millikan and Stephen R. Cole) 
 
 Over the last twenty-five years, researchers have identified several dozen genetic 
polymorphisms associated with breast cancer susceptibility. While many of these loci are 
now considered well-established risk factors for the disease, previous attempts to replicate 
variant-disease associations in African Americans or to identify subtype-specific risk variants 
have been imprecise and inconsistent.  
 I examined the association between breast cancer subtypes and previously established 
candidate gene and genome-wide association study “hits” among white and African 
American women in the Carolina Breast Cancer Study. Maximum likelihood and Bayesian 
methods were used to estimate race and subtype-specific odds ratios (ORs) for each of 83 
candidate single nucleotide polymorphisms (SNPs). Selected SNPs included several previous 
GWAS hits (n=22), near-GWAS hits (n=19), otherwise well-established risk loci (n=5), or 
SNPs in the same gene as another selected variant (n=37). Subtypes were defined using 5 
immunohistochemical markers: estrogen receptors (ER), progesterone receptors (PR), human 
epidermal growth factor receptors 1 and 2 (HER1/2) and cytokeratin (CK) 5/6. 
 Eighteen GWAS-identified SNPs successfully replicated in whites and ten GWAS-
identified SNPs successfully replicated in African Americans. SNPs in FGFR2 and 
TNRC9/TOX3 were strongly associated with breast cancer in both races. Additionally, SNPs 
in MRPS30, MAP3K1, CDKN2A/B, ZM1Z1, LSP1, H19, and TP53 were 
 iv 
associated with breast cancer in whites and SNPs in TLR1, ESR1, and H19 were associated 
with breast cancer in African Americans. Several SNPs in TNRC9/TOX3 were associated 
with luminal A (ER/PR+, HER2-) or basal-like disease (ER-, PR-, HER2-, HER1 or CK 
5/6+), and one SNP (rs3104746) was associated with both. SNPs in FGFR2 were associated 
with luminal A, luminal B (ER/PR+, HER2+), and HER2+/ER-, but not basal-like disease. 
There were also subtype differences in the effects of SNPs in 2q35, 4p, TLR1, MAP3K1, 
ESR1, CDKN2A/B, ANKRD16, and ZM1Z1. 
 These analyses provide precise, well-informed race and subtype-stratified ORs for 
several key breast cancer-related SNPs. These results also demonstrate the utility of Bayesian 
methods in genetic epidemiology and provide evidence of subtype-specific etiologies. This 
work may help to identify specific causal variants, locate targets for research on directed 
therapies, and identify high-risk individuals.  
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1. Specific Aims 
 Although advances in breast cancer detection, prevention and treatment have helped 
reduce incidence and mortality over the last decade, breast cancer still afflicts nearly one in 
every eight US women and kills one in 36 [1, 2]. A crucial next step in reducing the public 
health burden of breast cancer is to identify and better characterize genetic mutations 
affecting breast tumorigenesis. By examining these mutations we can better understand how 
the disease develops and progresses, identify individuals at higher risk of developing the 
disease, and locate targets for further research on directed therapies. We can gain additional 
insights by investigating these genetic mutations within strata of disease subtype and race, as 
there is strong evidence that breast cancer is a heterogeneous disease with several distinct 
etiologies and that subtypes and risk variants are not evenly distributed across race or age 
groups [3-12]. 
Aside from a few highly influential genetic variants identified through linkage or 
candidate gene analyses, most of the known genetic risk factors for breast cancer were first 
detected in genome-wide association studies (GWAS). With so much about breast cancer 
etiology and the human genome still unknown, GWAS have been invaluable discovery tools. 
Yet, the expansiveness of these studies also limits their precision and thus their ability to 
identify causal variants or discern subtype-specific risk profiles.  
To better understand the role of genetic polymorphisms in breast carcinogenesis and 
more specifically, the carcinogenesis of individual breast cancer subtypes in specific racial 
groups, I studied the association between several previously identified genetic risk factors
  2 
and the risk of breast cancer. In this analysis, I used Bayesian statistical methods to 
incorporate information on the linkage disequilibrium of the variants within the gene and the 
likely magnitude of the association to better inform statistical models. These theoretically 
sound but computationally challenging methods are expected to produce more precise and 
informative effect estimates than traditional statistical techniques [13-17]. I conducted this 
research using data from the Carolina Breast Cancer Study (CBCS), a population-based, 
case-control study with large samples of both white (n= 1247 cases, 1105 controls) and 
African American women (n=766 cases, n=681 controls). The specific aims of this study are 
as follows.  
 
Specific aim 1: Estimate associations between identified genetic risk variants and 
overall breast cancer in whites and African Americans using Bayesian and frequentist 
methods. 
 
a) Describe the application of Bayesian methods, including hierarchical modeling and full 
Bayes regression analysis  
b) Generate race-specific effect estimates for the association between invasive and in situ 
breast cancer and 83 candidate polymorphisms from 28 well-established breast cancer-
related genes or gene regions [18-20]  
i. Estimate individual SNP effects using frequentist logistic regression models 
and full Bayes logistic regression models with informative priors  
ii. Estimate individual and group-level SNP effects for SNPs in the same linkage 
disequilibrium block using hierarchical regression analysis  
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Specific aim 2: Estimate effects between the candidate SNPs and each breast cancer 
subtype. 
 
a) Estimate the effect of each candidate gene on each breast cancer subtype, relative to 
controls, using frequentist and Bayesian methods 
b) Estimate race-stratified effects for each candidate gene on each breast cancer subtype, 
relative to controls, using frequentist and Bayesian methods 
c) Conduct sensitivity analyses to demonstrate the robustness of the effect estimates under 
alternative model assumptions  
 
  
  
2. Review of the Literature 
2.1 Public health impact of breast cancer 
Despite recent advances in detection and prevention, breast cancer remains the most 
common female cancer in the United States (US) and worldwide [21]. In 2012, an estimated 
226,870 US women were diagnosed with the disease [22], which corresponds to an average 
lifetime risk of 12%, or one in eight, for US women [23].  
 With a 5-year relative survival rate of nearly 90% in the US [23], deaths due to breast 
cancer are fairly rare, with approximately 1 in 35 women dying annually from the disease 
[2]. However, breast cancer is the second most common cause of cancer death in the US, 
claiming the lives of nearly 40,000 US women in 2012 [23], and remains the leading cause of 
cancer death in females worldwide [21]. 
Age-adjusted incidence rates for the state of North Carolina (NC) are slightly above the US 
average, with 127.5 NC cases versus 123.1 US cases per 100,000 women per year in 2009 
[24]. Breast cancer mortality rates in NC are slightly lower than the US average, with 21.4 
NC deaths and 22.2 US deaths per 100,000 in 2009 [24].   
 
2.2 Race and age disparities in incidence and mortality 
 Data from the National Cancer Institute’s Surveillance Epidemiology and End Results 
(SEER) database indicate that although breast cancer incidence rates are very similar for 
White and African American women younger than 50 at diagnosis (44.7 and 44.4 cases per 
100,000 women in 2009 for Whites and African Americans, respectively), the disease is 
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more common among White women aged 50 or older than African American women of the 
same age group (360.9 versus 344.8 cases per 100,000 women) [1]. In contrast, mortality 
statistics from 2009 indicate much higher rates for African Americans than Whites in both 
age groups (8.1 versus 4.5 deaths per 100,000 women aged <50; 89.1 versus 66.6 deaths per 
100,000 women aged 50 or older) [2]. As shown in Figure 1, a plot of race and age-group 
specific mortality rates from 1969-2009, racial differences in mortality in the 50 or older age 
group have not shown a meaningful decrease since reaching a peak in 1997, at which point 
there were approximately 23 more deaths per 100,000 per year in African Americans than 
Whites [2]. All rates have been decreasing over time since the mid-1990s. 
 
2.3 Breast cancer histology 
 The National Cancer Institute defines breast cancer as “cancer that forms in the 
tissues of the breast, usually the ducts and lobules” [22]. More specifically, invasive breast 
cancer develops when abnormal cells multiply without constraint, forming a tumor within 
one part of the breast that eventually penetrates the basement membrane and infiltrates 
adjacent tissues. These tumors can be classified based on their histological subtype, which 
describes the anatomical structure in which the malignant cells originate [25].  
The majority of invasive breast cancers are ductal carcinomas not otherwise specified 
(NOS) that originate in women’s milk ducts, then grow through the ductal walls to invade 
other stromal tissues [25]. Approximately 8-15% of all invasive breast cancers occurring in 
US women originate in a lobule, or milk gland [26, 27]. Several rare histologic subtypes 
make up the remaining 15-20% of invasive breast cancers, including tubular carcinoma, 
medullary carcinoma, inflammatory breast carcinoma, papillary carcinoma, mucinous 
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carcinoma and Paget’s disease, with each accounting for less than 2% of all invasive cases. 
Ductal carcinoma in situ and lobular carcinoma in situ are non-invasive breast tumors that 
have not spread beyond their point of origin [25]. These malignant cells may grow into 
invasive tumors if left untreated.  
 
2.4 Breast cancer and hormone receptors 
 The presence or absence of specific hormone receptors within the breast tumor can 
also be used to classify breast tumors. Hormone receptor expression is determined using 
immunohistochemical (IHC) analysis and may be an important indicator of where and how 
the malignant cells first arose [28-30].  
Estrogen receptors (ER) and progesterone receptors (PR) are the most common types 
of hormone receptor in breast tumor cells, with approximately 80% and 60-70% of all US 
breast cancers arising from ER positive cells and PR positive cells, respectively [7, 26, 31-
33]. ER and PR status are highly correlated, with concordance estimated at 85% [34-37]. A 
third commonly evaluated hormone receptor is human epidermal growth factor receptor-2 
(HER2), which appears in 12-20% of breast tumors collected from US population-based 
samples [7, 33, 38]. 
 
2.5 Breast cancer intrinsic subtypes 
The development of gene expression analysis methods, which quantify the activity 
levels of certain genes as they are transcribed from deoxyribonucleic acid (DNA) into 
messenger ribonucleic acid (mRNA) and sent for translation into proteins, allows for more 
thorough evaluations of breast tumor heterogeneity. In one of the first gene expression 
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analyses of breast tissue, Perou et al. [39] identified 496 genes that sufficiently captured the 
variation between tumor cells. When these 496 genes were analyzed using a hierarchical 
clustering method to group tumors with similar expression patterns, the investigators 
observed interesting parallels with the traditional IHC markers of ER and HER2. For 
example, tumor samples that over-expressed the estrogen receptor-α gene and several other 
transcription factors were also ER positive. Similarly, HER2+ tumor samples were the only 
ones that expressed high levels of genes from a small region on chromosome 17. The 
remaining gene expression-derived subgroups could be differentiated based on the presence 
or absence of expression of cytokeratin 5/6 (CK 5/6), a protein found in basal epithelial cells 
but not in the more differentiated luminal epithelial cells.  
 Based on these findings and more refined analyses [40-42], breast cancer researchers 
created a classification system for breast cancer tumors based on five IHC tumor markers 
(ER, PR, HER2, CK 5/6, and human epidermal growth factor receptor-1 [HER1]) that serve 
as adequate, inexpensive surrogates for more complex gene expression profiles. Based on 
these IHC markers, breast cancer can be classified into four subtypes with unique biological 
characteristics: luminal A (ER+ and/or PR+, HER2-), luminal B (ER+ and/or PR+, HER2+), 
HER2+/ER- (ER-, PR-, HER2+), and basal-like (ER-, PR-, HER2-, HER1+ and/or CK 5/6+). 
Despite evidence that the gene expression of tumors negative for these five IHC markers is 
still rather varied, claudin-low, HER2-enriched, apocrine expressing, normal-like, and other 
potentially unique subtypes are generally lumped together as ‘unclassified’ due to their rarity 
and complicated features [43-46].  
 While the 5 IHC marker categorization system does not classify the heterogeneity of 
breast tumors perfectly [47], its adoption has already furthered our understanding of breast 
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cancer etiology and uncovered topics in need of further research. In particular, this subtype 
classification system has lead to insights in racial differences in the incidence of each breast 
cancer subtype, furthered explorations of how genetic and behavioral risk factors vary by 
subtype, and motivated development of targeted therapies.  
2.5.1 Intrinsic subtypes and race 
 Luminal A is the most common subtype, but the proportion of tumors of each subtype 
varies widely depending on the age and race of the population [3, 5, 6, 48-59]. This 
phenomenon was first observed by Carey et al. [3] in the Carolina Breast Cancer Study 
(CBCS), a population-based, case-control study of breast cancer in North Carolina with 
approximately equal proportions of white and African American women, and pre and 
postmenopausal women. In this population, luminal A was the most common subtype in 
postmenopausal African Americans (59%), premenopausal non-African Americans (51%) 
and postmenopausal non-African Americans (58%), but not premenopausal African 
Americans, who had a higher proportion of basal-like breast cancer (39% basal-like vs. 36% 
luminal A). In contrast, postmenopausal African Americans, premenopausal non-African 
Americans and postmenopausal non-African Americans had 14%, 16%, and 16% basal-like 
breast cancer, respectively. Premenopausal African Americans also had slightly higher 
proportions of HER2+/ER- tumors than the other subgroups (9% vs. 6-7%) and lower 
proportions of luminal B tumors (9% vs. 16-18%). These results were replicated in later 
analyses of an expanded CBCS population [4].  
 Although data on basal markers (CK 5/6 and HER1) has not been collected for any 
other largely African American study populations, other studies have confirmed that African 
Americans, particularly young African Americans, have a higher proportion of ‘triple 
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negative’ tumors (ER-, PR- and HER2-) [7, 8, 60-67] relative to other racial groups. 
Additionally, several studies of breast cancer subtype distributions in African populations 
have observed proportions of basal-like breast cancer [50, 68, 69] or triple negative breast 
cancer [64] that are equal to, if not greater than those found in US African American 
populations.  
Asians and Europeans seem to have similar subtype distributions as white Americans, 
with studies reporting approximately 50-60% luminal A tumors and 10-20% basal-like 
tumors [7, 33, 48, 52, 53, 55, 56, 58-60, 62, 63, 70-83]. The only study to analyze basal 
markers in Hispanic individuals found a low prevalence of basal-like breast cancer (5%) [49], 
but the prevalence of triple negative disease was consistent with that of white Americans, 
Europeans, and Asians [7, 60, 62, 65, 67, 84, 85].  
2.5.2 Intrinsic subtypes and prognosis 
 Carey et al. [3] was also the first study to examine whether intrinsic subtypes affect 
survival, though an update from O’Brien et al. [86] in 2010 examined an expanded study 
population and longer follow-up period. Here, 26% of CBCS participants with the 
HER2+/ER- subtype and 24% of those with basal-like breast cancer died of their disease 
within 5 years of their diagnosis, compared to only 9% of those with luminal A tumors. 
These breast cancer specific mortality rates corresponded to hazard ratios of 2.3 (95% 
confidence interval [CI]: 1.5- 3.6) and 1.7 (95% CI: 1.2- 2.4) for women with HER2+/ER- 
and basal-like tumors, respectively, relative to women with luminal A tumors.  
Other investigators have observed that HER2+/ER- tumors and basal-like tumors 
have worse prognoses than luminal A or B tumors in their study populations [5, 51-53, 56, 
58, 67, 87], thereby lending support to the theory that these subtypes are biologically distinct 
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diseases with diverse prognoses. As breast cancer specific survival was worse for basal-like 
tumors than tumors negative for all 5 IHC markers in most of these studies [5, 51, 53, 56, 58, 
86-88], these analyses provide further evidence that combining these two diseases into a 
single ‘triple-negative’ subtype limits our ability to study their divergent outcomes and 
possibly unique etiologic origins [28, 29, 41, 89-91].   
Of note, while these prognostic discrepancies do provide evidence of distinct subtype 
etiologies, the availability and effectiveness of subtype-targeted treatments also plays a 
substantial role in subtype-specific mortality rates. Anti-estrogen drugs, such as tamoxifen or 
raloxifen, can bind to the estrogen receptors in ER positive tumors, thereby inhibiting 
growth-stimulating estrogen molecules from binding to the receptors [92]. Similarly, 
aromatase inhibitors such as letrozole (Femara®) decrease the amount of estrogen a woman 
produces [93]. Although the development and FDA approval of trastuzumab (brand name 
Herceptin®) is too recent to affect survival statistics in any long-term observational studies, 
the HER2 protein binding anti-body is now used to treat HER2 positive tumors [94, 95]. To 
date, there is no FDA approved targeted therapy for women with triple negative disease, 
though additional research on gene expression patterns among triple negative tumors has 
identified some potential therapeutic markers [44, 45, 96]. 
 
2.6 Non-genetic risk factors for breast cancer  
 Decades of research on breast cancer etiology have consistently shown associations 
between the disease and several non-genetic traits and lifestyle patterns. Female gender, older 
age, and African American race are three such well-established, positively associated risk 
factors [97-99]. Reproductive traits associated with an increased number of menstrual cycles, 
  11 
including early age at menarche, older age at first birth, low parity (especially nulliparity), 
lack of breast-feeding, and late age at menopause have all been linked to higher disease rates 
as well [100]. Other well-established factors associated with increased disease risk are use of 
hormone replacement therapy (HRT), previous chest radiation, radiation treatment for 
lymphoma and other cancers, high alcohol consumption, being overweight or obese after 
menopause, lack of physical activity, having dense breasts, and a history of benign breast 
disease. Tobacco smoke, exposure to certain environmental chemicals, oral contraceptive 
(OC) use, and certain dietary patterns may also increase breast cancer risk, but the results 
from studies on these topics have been inconsistent [97-99]. 
2.6.1 Non-genetic risk factors by estrogen receptor (ER) status 
Once researchers realized how strongly hormone receptors influence patients’ 
responses to specific treatments and overall prognoses, they began to question whether breast 
cancer subtypes had unique etiologies and, accordingly, unique risk factors. In their earliest 
and most basic approach to this question, epidemiologists examined traditional risk factors in 
ER+ and ER- tumors separately, accounting for PR status if available. These studies revealed 
some noteworthy discrepancies.  
Due to known associations between high-risk reproductive patterns and increased 
lifetime estrogen exposure [100], researchers originally hypothesized that ER+ tumors would 
be more strongly associated with the established reproductive risk factors than ER- tumors. 
Two systematic reviews [101, 102] and one pooled analysis [103], which together represent 
years of work and dozens of studies on the subject, partially corroborated this theory. These 
authors conclude that ER+ tumors were more strongly and consistently associated with early 
age at menarche, nulliparity, and later age at first full term pregnancy than ER- tumors, 
  12 
though early menarche is also a risk factor for ER- disease. However, these authors also 
found that breastfeeding was associated with a reduced risk of both disease types, and that 
HRT and OC use did not meaningfully affect the risk of either. Studies of other established 
risk factors indicated that postmenopausal obesity is probably associated with ER+ but not 
ER- disease [101, 104], and that family history, smoking, and alcohol are associated with 
comparable increases in risk for both subgroups [101, 105, 106]. Consideration of PR status 
did not lead to any additional insights [103, 104, 106].  
2.6.2 Non-genetic risk factors by subtype 
 Testing for HER2 status became more common after the development of Herceptin, 
and the identification of intrinsic subtypes prompted some researchers to assess basal-marker 
status as well. This allowed researchers to conduct more etiologically relevant risk factor 
analyses for each ER/PR/HER2 or intrinsic subtype separately. Although these studies were 
often small and not representative of all cases, they have contributed greatly to our 
understanding of what causes specific breast cancer subtypes and aided in the development 
of new treatment and prevention strategies.  
 To date, three research groups have published analyses of breast cancer risk factors 
by intrinsic subtype. This includes the Carolina Breast Cancer Study (CBCS) [4], the Nurses’ 
Health Study (NHS) [83], and the Poland Breast Cancer Study (PBCS) [82]. Some effect 
estimates for basal-like breast cancer are also available from the pooled analysis by Yang and 
colleagues [103], which includes PBCS and 33 other studies.  
 Many other research groups assessed risk factors by combined ER, PR, and HER2 
status, with no differentiation between basal-like breast cancer and other triple negative 
subtypes. While these less refined definitions may produce biased effect estimates for basal-
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like breast cancer, the discrepancy is minimal if most triple-negative tumors are basal-like, as 
is usually the case [45], and relative risks for luminal A, luminal B, and HER2+/ER- breast 
cancers are the same for either classification system. In the following risk factor summary, 
conclusions are based on confounder-adjusted ORs comparing cases to non-cases, or 
confounder-adjusted case-case odds ratios (ccORs) comparing one subtype directly to 
another referent subtype, usually luminal A. The results are further summarized in Table 1 
(case-control comparisons) and Table 2 (case-case comparisons).  
2.6.2.1 Age 
 Millikan et al. [4] found that younger age was a stronger risk factor for luminal B, 
HER2+/ER-, basal-like, and unclassified breast cancers than for luminal A breast cancers. 
Studies without basal marker data found similar trends for all subtypes relative to luminal A 
[62, 66, 78, 107], for triple-negative relative to luminal A [108], or for triple-negative relative 
to non-triple negative [65].  
 Results from three case-control comparisons [66, 109, 110], were less consistent and 
poorly generalizable, as all three were conducted in relatively young populations (maximum 
ages of 45, 56, and 54, respectively). Dolle et al. [109] found that the risk of triple-negative 
breast cancer was highest for women in their 30s. Gaudet et al. [110] observed a positive 
correlation between age and the risk of luminal A or HER2+/ER- breast cancer, but not 
luminal B or triple-negative. Trivers et al. [66] reported a lower risk for luminal A breast 
cancer among younger women, but an increased risk for luminal B or triple-negative disease. 
In general, the combined case-case and case-control results suggest that younger women are 
more likely to be diagnosed with basal-like or other non-luminal A breast cancer than older 
women, who are more likely to get luminal A breast cancer.  
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2.6.2.2 Race 
 As expected based on previous comparisons of subtype prevalence by race, effect 
estimates from all studies reporting race-stratified analyses indicated that African Americans 
had a greater risk of basal-like, unclassified or triple-negative breast cancer than luminal A 
[4, 62, 66] or non triple-negative breast cancer [65, 108]. African Americans also had an 
elevated risk of HER2+/ER- breast cancer versus Luminal A breast cancer [4, 62, 66]. 
Hispanics had a higher risk of HER2+ than Luminal A disease when compared to non-
Hispanic whites, but the relative risk of triple-negative disease was unclear [62, 65, 78]. 
Women of Asian descent also appeared to get HER2+ disease more often than non-Hispanic 
whites, but had a reduced risk of triple-negative disease [62, 78, 108]. In the only study to 
examine whether African American race was a risk factor for breast cancer subtypes relative 
to controls, Trivers et al. [66] reported an inverse association for luminal A, a null association 
for luminal B, and positive associations for HER2+/ER- and triple negative.   
2.6.2.3 Family history  
 Most studies reported a positive association between family history and each subtype, 
relative to non-cases [79, 82, 83, 110-113], with a slightly weaker or null effect for luminal 
B, HER2+/ER-, basal-like, or triple-negative disease relative to luminal A [4, 62]. The only 
exception to this was the pooled analysis, which exhibited a positive OR for the effect of first 
degree family history on basal-like breast cancer relative to luminal A [103].  
2.6.2.4 Menopause  
 While there were no consistent patterns for the effect of menopausal status on 
subtype, later age at menopause was a risk factor for luminal A breast cancer. In CBCS, 
being premenopausal was negatively associated with HER2+/ER- breast cancer, relative to 
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luminal A breast cancer, but did not affect the risk of luminal B, HER2+/ER-, basal-like or 
unclassified disease [4]. One other study identified a slight increase in luminal B versus 
luminal A breast cancer in premenopausal women [62], and a third study found that being 
premenopausal increased the risk of luminal A or B breast cancer, relative to controls [79].  
 The Nurses’ Health Study [83], PBCS [82], a registry-based, US case-control study 
[114], the Women’s Health Initiative [115] and a Chinese case-control study [79] all found 
evidence that increasing age at menopause was positively associated with risk of luminal A 
disease relative to non-cases. Both the Nurses’ Health Study and the US case-control study 
also reported a non-null association between age at menopause and Luminal B or 
HER2+/ER- disease. As for basal-like and triple-negative breast cancers, effect estimates 
from the Nurses’ Health Study, the US case-control study, the Women’s Health Initiative and 
a Japanese case-control study supported a null association [83, 113-115], while a Chinese 
case-control studies reported slightly increased risk for triple-negative disease among women 
with late onset menopause [79], and PBCS reported an increased risk for unclassified, but not 
basal-like tumors [82]. No studies estimated ccORs.  
2.6.2.5 Age at menarche  
 In nearly all of the populations examined, women with luminal A, basal-like, or triple 
negative breast cancer were more likely than non-cases to have started menstruating at an 
early age [4, 66, 79, 82, 83, 109, 110, 113-116]. Several studies also found a positive 
association between early age at menarche and luminal B or HER2+/ER- disease [66, 79, 
110, 114], but a few others reported only null effects [66, 82, 83, 113, 116]. In two of the 
three studies with ccOR estimates, women who menstruated at a very young age were more 
likely to get basal-like or triple negative than luminal A breast cancer [4, 66, 103]. Trivers et 
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al. [66] was the only study to observe an increased risk for HER2+/ER- versus luminal A 
among women with early age at menarche, and all luminal B versus luminal A ccORs were 
near-null.  
2.6.2.6 Parity and lactation  
 Giving birth to one or more children had an inverse association with luminal A breast 
cancer in all eleven case-control comparisons [4, 66, 79, 82, 83, 110, 114-118]. Most studies 
that evaluated the effect of parity on luminal B breast cancer also found a reduced risk [66, 
79, 82, 110], and case-case analyses indicated that the effect was roughly equivalent for the 
luminal B versus luminal A subtype [4, 62, 66, 103]. Whether compared to controls or 
luminal A cases, most studies found no evidence of an association between parity and 
HER2+/ER- breast cancer. The two exceptions to this were Trivers et al. [66], who reported 
an increased risk of HER2+/ER- disease among women with higher parity, relative to either 
controls or luminal A cases, and Xing et al. [79], who identified a substantially reduced risk 
for HER2+/ER- disease among women with one child, relative to controls. 
 The effect of parity on basal-like or triple-negative breast cancer was less clear. While 
only two of the twelve case-control comparisons detected a positive association between any 
parity and risk of either basal-like or triple-negative breast cancer relative to controls [4, 
115], parity was associated with an increased risk of triple-negative, basal-like or unclassified 
breast cancer relative to luminal A in several investigations [4, 62, 66, 103, 108]. 
Additionally, four studies examined the effect of increased parity (i.e. giving birth to more 
than one child versus only one child) on triple-negative disease, two of which estimated a 
positive association [108, 115]. The other two studies did not find a similar pattern [114, 
116]. 
  17 
  Breastfeeding, regardless of duration, had an inverse association with each breast 
cancer subtype in most case-control comparisons [4, 66, 79, 83, 109, 110, 113-116]. 
Estimated ccORs less than 1 for luminal B and triple-negative breast cancer suggest that lack 
of breast-feeding is a particularly important risk factor for these two subtypes [4, 62, 66, 
108].  
 Interestingly, when Millikan et al. [4] examined the joint effects of parity and 
lactation in women with basal-like breast tumors, they found that parity was only associated 
with an increased risk of cancer in women who did not breastfeed. Similarly, Kwan et al. 
[62] found that higher parity was associated with greater odds of having luminal B, 
HER2+/ER- or triple-negative versus luminal A breast cancer in women who did not lactate, 
but not in women who did.  
2.6.2.7 Age at first full term pregnancy  
 Subtype-specific effect estimates for late age at first full term pregnancy were 
inconsistent and difficult to separate out from the effect of parity in general. Lack of a 
common referent group made comparisons across studies especially difficult.  
 Four studies used nulliparous women as the referent group [4, 66, 109, 115] when 
comparing subtypes to non-cases. Accordingly, all effect estimates for luminal A cancers 
were less than 1, but were higher for women in older age categories than younger age 
categories. The same was true for luminal B cancers in the one study with estimated effects 
[66]. The reported findings for HER2+/ER- and basal-like or unclassified breast cancers were 
too inconsistent to draw conclusions.  
 Five other studies analyzed the effect of age at first full term pregnancy on breast 
cancer subtype as a continuous variable [82, 83, 103, 110, 116]. In four of these five studies, 
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every 1-5 year increase in age at first full term pregnancy was associated with an increased 
risk of luminal A breast cancer. The pattern held for luminal A in four of six studies [79, 113-
117] comparing relative risks for older versus younger mothers. 
 The results from case-case comparison studies reported positive associations between 
parity and luminal B, HER2+/ER-, basal-like or unclassified breast cancer relative to luminal 
A in younger mothers, but noted attenuated effects as maternal age increased [4, 62, 66, 103].  
2.6.2.8 Other reproductive risk factors  
 Subtype-stratified analyses of less established reproductive risk factors for breast 
cancer, such as OC use, HRT use, time since last full term pregnancy, and abortion also 
revealed some interesting results.  
 When OC use was limited to an ever versus never comparison, most subtype-specific 
estimates for non-luminal A breast cancer were null, though the luminal B estimates 
demonstrated some striking inconsistencies [4, 62, 110, 117]. Dolle et al. [109] identified 
statistically significant increases in the risk of triple-negative disease, relative to controls, 
with long term OC use, especially if women were under the age of 40 when they initiated 
use. Gaudet et al. [110] also found an elevated risk of triple-negative breast cancer for ever 
versus never OC use in a similar age group, as well as an inverse association between ever 
OC use and luminal A breast cancer.  
 Subtype-specific analyses of ever versus never HRT use revealed null associations 
between HRT and luminal A, basal-like or triple-negative disease, but contradictory findings 
for luminal B or HER2+/ER- disease [4, 62, 119]. More detailed exposure classifications 
indicated that current HRT users were at higher risk of luminal A, luminal B, and possibly 
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basal-like and unclassified breast cancer, relative to non-cases, particularly if progestin was 
also included [83, 114, 119]. 
 Three studies examined the association between subtype and time since last 
pregnancy [66, 116, 120]. In two of these three studies, cancers diagnosed soon after giving 
birth were more likely to be HER2+ than hormone receptor positive cases, HER2- cases or 
controls. Trivers et al. [66] and Li et al. [116] both found that women who were more 
recently pregnant had reduced risk of luminal A or B disease, but only Trivers et al. observed 
a similar protective effect for recent pregnancy and triple-negative disease.  
 Lastly, in the only two studies to examine whether spontaneous or induced abortions 
were related to subtype-specific breast cancer risk, one found a non-significant, positive 
association between abortion and triple-negative breast cancer, relative to controls [109], and 
another found an increased risk of luminal A or HER2+/ER- breast cancer with induced 
abortions, but a decreased risk for all four subtypes for spontaneous abortions [79].  
2.6.2.9 Body size  
 Because postmenopausal adiposity is a known risk factor for breast cancer, most 
subtype analyses of body size are stratified by menopausal status. Body mass index (BMI) is 
the most common measure of body size, and is usually categorized according to the World 
Health Organization criteria: underweight (<18.5), normal (18.5-24.99), overweight (25.0-
29.99) or obese (≥30.00) [121]. Based on these criteria, Millikan et al. [4] found an inverse 
association between higher category of BMI and postmenopausal luminal A and 
postmenopausal basal-like breast cancer, relative to controls. Phipps et al. [122] found a 
positive association between higher category of BMI and risk of any breast cancer among 
postmenopausal women participating in the Women’s Health Initiative. Three additional 
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studies of BMI in postmenopausal women, Phipps et al., Gaudet et al., and Yang et al. [82, 
110, 123] reported only near-null findings. All case-case comparisons were also near-null [4, 
103, 110].  
 In a pooled analysis, Pierobon et al. [124] found a positive association between 
obesity (BMI >30) and triple-negative breast cancer. The association was particularly strong 
among premenopausal women. Effect estimates for premenopausal BMI and breast cancer 
subtype revealed a possible negative association between high BMI and luminal A breast 
cancer, as found in three studies [4, 66, 82], but not two others [109, 110]. The relationship 
between high BMI and premenopausal luminal B cancer was inconsistent in these studies, 
with Trivers et al. [66] reporting an inverse association, Gaudet et al. [110] reporting a 
positive association and Yang et al. observing no effect [82]. Effect estimates from case-
control comparisons of premenopausal HER2+/ER breast cancer were mostly null, though 
results from case-case comparisons indicated that women with larger body size had a higher 
risk of HER2+/ER- relative to luminal A [4, 62, 66, 103].  
 Waist-to-hip ratio (WHR), weight and hip circumference, and weight gain were also 
examined as potentially relevant body size indicators. Millikan et al. [4] and [122] both found 
positive associations between high WHR and postmenopausal luminal A breast cancer, 
relative to non-cases. This association held for premenopausal women in Millikan et al [4]. 
Millikan et al. also found an association between high WHR and basal-like breast cancer 
among pre- and postmenopausal women, but Phipps et al. saw no effect in their sample of 
postmenopausal women. In a case-case analysis, high WHR was a greater risk factor for 
postmenopausal luminal A breast cancer than either luminal B or HER2+/ER-, but a lesser 
risk factor than for basal-like breast cancer [4]. Among premenopausal women, basal-like 
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breast cancer again had the highest increase in risk associated with high WHR, while luminal 
B, HER2+/ER-, and unclassified tumors all had null effects relative to luminal A tumors [4]. 
 Additionally, Tamimi et al. [83] found that higher BMI at age 18 was associated with 
a reduced risk in luminal A and basal-like breast cancer, and that weight gain since age 18 
was positively associated with unclassified, but not basal-like breast cancer. Phipps et al. 
[122] reported positive effect estimates for the association of weight gain, waist 
circumference, and hip circumference with luminal A breast cancer, and negative effect 
estimates for the association of waist circumference and triple-negative breast cancer. These 
findings were inconsistent with an earlier paper by Phipps et al. [123], which reported 
predominantly null subtype-specific effect estimates for BMI at age 30 and weight gain or 
loss. Corresponding analyses for luminal B and HER2+/ER- subtypes were also mostly null, 
with the exception of a negative association between higher BMI at age 18 and HER2+/ER- 
breast cancer identified by Tamimi et al [83]. No case-case analyses of these alternative body 
size measures were conducted.  
2.6.2.10 Physical activity  
 Increased physical activity was associated with a reduced risk of luminal A, 
HER2+/ER-, and triple-negative breast cancer in two studies [66, 122], but a third reported 
predominantly null findings [113]. The effect of increased physical activity on luminal B 
breast cancer was null in a case-control comparison, but was positively associated with risk 
relative to luminal A [66]. Increased physical activity was also associated with an increase in 
triple-negative breast cancer relative to luminal A.   
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2.6.2.11 Alcohol and smoking  
 The luminal A subtype has a strong positive association with high alcohol and 
cigarette consumption and the HER2+/ER- subtype may be associated with increased alcohol 
consumption and a history of smoking. Luminal B, basal-like, and triple-negative breast 
cancers are probably not associated with alcohol consumption, but former smoking may 
affect the risk of these subtypes.   
 Compared to never drinkers, women with increasingly higher alcohol consumption 
had greater relative risks of developing luminal A breast cancer than non-cases [66, 83, 113, 
125]. Despite some evidence of a negative association between increased alcohol 
consumption and triple-negative breast cancer in the Women’s Health Initiative [125] and an 
Atlanta-based case-control study [66], the Nurses’ Health Study [83], and a SEER registry 
study [109] reported null effects, and a Japanese case-control study [113] reported a positive 
trend. Alcohol consumption was positively associated with HER2+/ER- breast cancer in both 
the Atlanta-based case-control study [66] and the Nurses’ Health study [83], but not with 
luminal B breast cancer in either study. Relative to luminal A breast cancer, the effect of 
alcohol on luminal B, HER2+/ER- or triple-negative disease was either null or inconsistent 
[4, 62, 66].  
 Increased smoking intensity and duration were associated with an increased risk of 
luminal A breast cancer in one study [125] and with a decreased risk in another study [113]. 
Being a former smoker rather than a current smoker or non-smoker was associated with 
increased risk of luminal A disease [66, 125]. Former smokers also had an increased risk of 
luminal B and HER2+/ER- breast cancer [66], while current smokers had a reduced risk of 
luminal B, but an increased risk of HER2+/ER-. Estimates for the effect of smoking intensity 
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and duration on triple-negative tumors were mostly null and the effect of former or current 
smoking status was inconsistent [66, 109, 125]. In case-case comparisons, former smoking 
was associated with an increased risk of luminal B relative to luminal A, and current smoking 
was associated with an increased risk of HER2+/ER- relative to luminal A [66]. Subtype-
specific ccORs for smoking intensity and duration were null for luminal B and HER2+/ER- 
and inconsistent for triple-negative tumors [4, 62, 113, 125].  
2.6.2.12 Benign breast disease and breast density  
 Subtype-specific estimates for the effects of high breast density and previous benign 
breast disease were provided in one and two studies, respectively. Ma et al. [126] observed a 
positive association between high breast density and risk of both luminal A and basal-like 
breast tumors. The effect was roughly equivalent for both subtypes, as indicated by a null 
ccOR.  
 The Nurses’ Health Study [66] and the Cancer and Steroid Hormone study [110] both 
reported a positive association between benign breast disease and luminal A breast cancer. 
The Nurses’ Health Study also observed positive associations between benign breast disease 
and luminal B, basal-like and unclassified breast cancer, while the Cancer and Steroid 
Hormone study estimated a positive but imprecise association between benign breast disease 
and luminal B breast cancer and null effects for the remaining subtypes.  
2.6.2.13 Summary of risk factors by subtype  
 Although the exact relationship between breast cancer subtypes and some of their 
possible risk factors is still poorly understood, many such associations are well characterized. 
The variability between each subtype-specific risk factor profile provides strong evidence 
that the subtypes represent etiologically distinct diseases.  
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 Luminal A is the most common subtype and is associated with most previously 
established breast cancer risk factors, such as family history of breast cancer, later age at 
menopause, early age at menarche, nulliparity, lack of breastfeeding, later age at first full 
term pregnancy, decreased physical activity, increased alcohol consumption, history of 
benign breast disease and high breast density. The risk factors for luminal B breast cancer are 
fairly similar to those for luminal A, with the exception of older age at diagnosis, which is 
negatively associated with luminal B and positively associated with luminal A. Several other 
luminal A risk factors had null or inconsistent associations with luminal B disease, including 
race, age at menopause, age at menarche, lack of physical activity, and alcohol consumption. 
Only a few of the established risk factors are associated with HER2+/ER- disease, including 
younger age at diagnosis, African American race, family history of breast cancer, lack of 
breastfeeding, recent pregnancy, and high alcohol consumption. Lastly, triple-negative breast 
cancer is associated with several of the well-established risk factors, but its risk factor profile 
still varies quite a bit from that of luminal A. When compared directly to luminal A, triple 
negative tumors are more strongly associated with younger age at diagnosis, African 
American race, family history of breast cancer, early age at menarche, higher parity, lack of 
breastfeeding and high premenopausal BMI than luminal A tumors.  
 
2.7 Genetic risk factors for breast cancer 
 The high correlation between family history and breast cancer risk has inspired 
countless investigations of the disease’s genetic origins. Even though the currently identified 
susceptibility loci account for only a small proportion of the disease’s measured heritability 
[127-129], their discoveries have helped elucidate some of the biological underpinnings of 
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the disease and offered new targets for screening or therapeutic intervention. Furthermore, 
the ever-growing body of literature on variability in genetic risk factors by breast cancer 
subtype provides additional evidence that these subtypes have unique etiologies. 
2.7.1 BRCA1 and BRCA2 
 The first high penetrance breast cancer susceptibility genes identified were aptly 
named Breast Cancer Gene 1 (BRCA1) and Breast Cancer Gene 2 (BRCA2) [130-132]. Both 
genes were discovered through linkage analysis, a technique that uses genetic markers to 
identify chromosomal regions disproportionately shared by diseased family members. Due to 
linkage disequilibrium (LD), proximal chromosomal regions are not randomly distributed 
during gametogenesis. Therefore, a marker strongly associated with disease incidence is 
likely physically near a causal locus, even if it does not tag the causal mutation. Family-
based linkage analyses are particularly powerful for identifying susceptibility genes with 
high penetrance. 
 BRCA1 and BRCA2 are both DNA repair genes and tumor suppressor genes. 
Although their specific mechanisms are slightly different, the proteins encoded by these 
genes help activate DNA double strand break repair mechanisms and initiate homologous 
recombination to replace damaged sequences [133, 134]. Individuals born with mutations in 
BRCA1 or BRCA2 may be less equipped to fix or suppress cells with damaged DNA, thereby 
increasing the likelihood that these damaged cells proliferate and form tumors.  
 BRCA mutations are very rare but highly penetrant. According to population-based 
estimates, approximately 0.04% and 0.4% of all individuals have BRCA1 and BRCA2 
mutations, respectively [135], with a mutation prevalence of 2-3% for each gene among 
female breast cancer cases [135-137]. Mutation frequencies vary greatly by race and 
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ethnicity, with around 8% of all Ashkenazi Jewish cases exhibiting a mutation in BRCA1, but 
only 0.5% of Asian-Americans [137]. Compared to white women with breast cancer, African 
American cases are less likely to have a BRCA1 mutation and more likely to have a BRCA2 
mutation [10, 135], although one study reported a BRCA1 mutation prevalence of 17% (95% 
CI: 7%, 34%) in African Americans diagnosed before age 35 [137]. In terms of penetrance, 
around 60% of BRCA1 mutation carriers will develop breast cancer by age 70, as will 
approximately 50% of BRCA2 mutations carriers [127, 138]. 
 Cases with BRCA1 mutations are much more likely to have triple-negative disease 
than cases with wild type BRCA1 [41, 139-147]. The association is particularly strong in 
young women [147]. BRCA1 mutations are also associated with increased basal-marker 
expression [41, 148]. There is no consistent association between BRCA2 and any breast 
cancer subtype.  
2.7.2 Candidate genes 
 As noted previously, family-based linkage studies can effectively identify 
chromosomal regions associated with disease susceptibility in affected, related individuals, 
but they rarely pinpoint specific, causal mutations and cannot detect low-penetrant variants. 
The next step in determining which variants are causally related to the disease (or disease 
subtype) of interest is to conduct association analyses of single nucleotide polymorphisms 
(SNPs) or other genetic anomalies in unrelated individuals. Alternatively, investigators may 
select SNPs because of their location in a functionally-relevant gene or because a particular 
base-pair deletion, insertion, or mutation alters the amino acid sequence for a disease-related 
protein.  
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 In a comprehensive review and meta-analysis published in 2011, Zhang et al. [20] 
summarized the findings of more than 1000 breast cancer candidate gene studies. Overall, 
they examined 521 candidate genes or chromosomal regions and conducted meta-analyses of 
279 variants. Twenty-nine variants had statistically significant associations in meta-analyses, 
but only 10 variants in 6 genes met the authors’ criteria for strong evidence of association, 
which required replication and protection from bias in addition to statistical significance. 
These 6 genes were: ATM, CASP8, CHEK2, CTLA4, NBN, and TP53. The authors considered 
three additional genes, CYP19A, TERT and XRCC3, to have moderate evidence of 
association. Though purposefully excluded from this review, PTEN, BRIP1, and PALB2 were 
also mentioned as well-established, highly penetrant susceptibility genes. Variants identified 
in genome-wide association studies (GWAS) were also excluded.  
 Results from less comprehensive reviews of breast cancer candidate gene association 
studies are generally consistent with the findings of Zhang at el. For example, Antoniou and 
Easton [149] state that BRCA1, BRCA2, TP53, PTEN, ATM, and CHEK2 are well-established 
breast cancer susceptibility genes, though they also mention LKB1 (also known as STK11). 
Freisinger and Domchek [150] and Hirschfield et al. [151] consider BRCA1, BRCA2, TP53, 
PTEN, and STK11 to be well-established, highly penetrant genes and CHEK2, ATM, BRIP1 
and PALB2 to be uncommon, but well-established susceptibility genes of low to moderate 
penetrance.  
 Relatively few studies have addressed how these well-established breast cancer 
susceptibility genes relate to ER or PR status, and even fewer have included subtype-
stratified analyses. Though limited, these reports provide evidence that some genes may be 
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differentially related to the expression of hormone receptors in female breast tumors. A 
summary of the existing evidence is provided in Table 3.  
 The best-studied example of subtype differentiation by candidate gene status is 
CHEK2, located on chromosome 22. Of the four specific mutations Zhang et al. [20] deemed 
strongly associated with breast cancer, three (1100delC, IVS2+1G>A, and I157T) have been 
assessed within strata of ER, PR or intrinsic subtype. A base pair deletion in exon 10 of the 
gene (1100delC) showed evidence of an association with ER+ breast cancer in four studies 
[152-155], while a fifth showed no association [156] and a sixth observed a stronger 
association with ER- than ER+ tumors [157]. The 1100delC mutation was also associated 
with ER- tumors in Cybulski et al. [153], though to a lesser degree than ER+ tumors. The 
same was true for a similar mutation involving deletions in exon 9 and 10 (del5395). In a 
gene-expression analysis, all CHEK2 1100delC tumors clustered with the luminal A and 
luminal B tumors [158].  
 The two other CHEK2 mutations identified by Zhang et al. in their meta-analysis 
were not associated with ER status in Meyer et al. [156], though Cybulski et al. [153] found a 
strong association between ER+ breast cancer and IVS2+1G>A substitution, and Domagala 
et al. [159] observed a positive association between the I157T/ rs17879961 polymorphism 
and luminal A and B breast cancer, and an inverse association between I157T and basal-like 
and triple-negative breast cancer. The pattern held when Domagala et al. examined whether 
having any CHEK2 mutation affected intrinsic subtype, but Cybulski observed statistically 
significant, positive associations between CHEK2 mutations and both ER+ and ER- disease.   
 Subtype-stratified analyses for ATM (chromosome 11), TERT (chromosome 5), 
CASP8 (chromosome 2) and TP53 (chromosome 17) also revealed some possible 
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discrepancies in genetic risk factors by hormone receptor status. In a large consortium study, 
Cox et al. [160] identified a SNP in ATM (rs1800054) that was positively associated with 
PR+ breast tumors. Barroso et al. [161] replicated this association for nine SNPs in the same 
LD block (see Figures 2 and 3) [161]. Most SNPs in this LD block had no association with 
ER status, though three SNPs were positively associated with ER- disease [162, 163]. LD 
blocks were defined using Haploview (Haploview 4.2, Version 1.0, Broad Institute, 
Cambridge, MA, USA) [164], International HapMap version 3, release 2 for Utah residents 
with ancestry from northern and western Europe (CEU) and Yorubans from Ibadan, Nigeria 
(YRI) populations [9], and haplotype block criteria established in Gabriel et al. [165].  
 Although the association between breast cancer and TERT was first identified through 
a candidate gene approach, the only study with subtype-specific effect estimates is a genome-
wide association study of African American and triple-negative cases [166]. Here, 
rs10069690 was a strong, positive genetic risk factor for triple-negative breast cancer. In a 
different pooled analysis of triple-negative cases, Stevens et al. [167] identified a rs17468277 
in CASP8 (Figures 4 and 5) that was inversely associated with triple-negative disease. Two 
other SNPs in CASP8 (rs1861270 and rs1045485) were associated with all breast cancer 
subgroups with approximately equal magnitude and direction [160, 162, 168-170]. Lastly, 
multiple studies of rs1042522 in TP53 (Figures 6 and 7) indicated a possible positive 
association between the SNP and ER+ disease [171-174]. 
 Subtype-specific analyses were conducted for SNPs in CTLA4, XRCC3, CYP19A1 
(Figures 8 and 9), PALB2 (Figures 10 and 11), and BRIP1, but the results were either too 
sparse or too conflicting to make meaningful inferences [161, 171, 172, 174-182]. To date, 
no studies have evaluated how LKBI, NBN, or PTEN affect hormone receptor status.  
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2.7.3 Genome-wide association studies 
 A genome-wide association study (GWAS) is “a study that compares the complete 
DNA of people with a disease or condition to the DNA of people without the disease or 
condition” [183]. In practice, GWAS examine the association between a disease of interest 
and at least 100,000 SNPs selected to represent the entirety of the genome via LD patterns. 
To be established as a true GWAS-hit, a SNP must have a p-value <1 x 10-5 in the overall 
study population, which usually includes the original sample and one or more replication 
samples [184]. In practice, this α-level is often set as high as 5 x 10-8, as this corresponds to 
α=0.05 corrected for 1,000,000 independent SNP tests.  
 As of January 2013, 23 breast cancer GWAS have been published, the first of which 
was published in June 2007. Basic descriptions of these 23 studies and the GWAS-significant 
SNPs identified by each can be found in Table 4. All information was downloaded from the 
National Human Genome Research Institute Catalog of Published Genome-Wide Association 
Studies [185].  
 In total, 58 unique GWAS hits have been identified in these 23 studies. These SNPs 
appear in the following genes or gene regions: 1 on chromosome 1 (1p11.2) [186], 3 on 
chromosome 2 (2p16.1, 2q35, and ERBB4) [186-192], 2 on chromosome 3 (SLC4A7 and 
SIAH2) [189, 190, 193], 8 on chromosome 5 (TERT, ROPN1L, 2 on 5p12, MRPS30, 2 on 
MAP3K1, and 5q34) [166, 186, 188-191, 194, 195], 8 on chromosome 6 (ECHDC1/RNF146, 
6q25, FAM46A, TAB2 and 4 on ESR1/C6orf97) [189, 190, 196-199], 2 on chromosome 7 
(7q11.22 and 7q32.3) [188, 200], 2 on chromosome 8 (both on 8q24.21) [189, 190, 194], 2 
on chromosome 9 (CDKN2A/CDKN2B and RAD23B/KLF4/ACTL7A) [189, 190], 10 on 
chromosome 10 (ANKRD16/FBX018, 2 on ZNF365, ZMIZ1, and 6 on FGFR2) [186, 189-
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191, 193, 194, 200-202], 4 on chromosome 11 (MYEOV/CCND1, BARX2, and 2 on LSP1) 
[189, 194, 199], 1 on chromosome 12 (12q21.1) [188], 1 on chromosome 13 (ABCC4) [188], 
2 on chromosome 14 (RAD51L1 and GALC) [186, 203], 1 on chromosome 15 (FBN1) [188], 
4 on chromosome 16 (3 on TOX3 and GLG1) [186, 187, 189-191, 194, 204, 205], 1 on 
chromosome 17 (COL1A1) [188], 1 on chromosome 18 (18q21.2) [188], 3 on chromosome 
19 (19p13.11, ABHD8 and ZNF577) [195, 198, 206], 1 on chromosome 20 (RALY) [198]and 
1 on chromosome 21 (GRIK1) [188]. Li et al. [207] conducted a GWAS among women with 
ER- disease, but failed to identify any genome-wide significant associations. Of the 
remaining 22 GWAS studies, 13 provided effect estimates stratified by hormone-receptor 
status [186, 187, 189, 192, 193, 197-200, 203-206], though this was usually limited to those 
SNPs achieving GWAS-significance.  
  Additionally, both Easton et al. and Hunter et al. [194, 201] identified several 
strongly associated SNPs that were just shy of the GWAS inclusion criteria. Easton et al. 
obtained association p-values of 6 x 10-5, 2 x 10-5 and 0.001 for rs4666451 on chromosome 
2p, rs2107425 on the H19 gene and rs30099 on chromosome 5q, respectively, while Hunter 
et al. identified 4 SNPs (rs12505080 on 4p, rs7696175 on TLR1/TLR6, rs17157903 on 
RELN, and rs10510126 on 10q) that had very strong associations with breast cancer in the 
initial study population, but failed to replicate in a secondary analyses. Two other SNPs of 
potential genome-wide significance were identified in Stacey et al. [208] and Ahmed et al. 
[209], both of which were follow-ups to previous GWAS (Stacey et al. [187] and Easton et 
al. [194], respectively). Although neither rs10941679 in MRPS30 or rs6504950 in COX11 
reached GWAS-significance in the initial studies, further analyses in additional populations 
produced p-values less than 1 x 10-5. 
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 Of the 58 GWAS SNP hits and 9 nearly GWAS-significant SNP hits, 31 were 
successfully genotyped in Carolina Breast Cancer Study (CBCS) participants and are thus 
included in this review. The other GWAS hits were either not yet discovered at the time the 
genotyping was requested or failed preliminary quality control checks. This review also 
covers several additional SNPs from GWAS-identified genes that were genotyped by CBCS 
investigators to augment analyses of these genomic regions. A brief discussion of each of 
these regions is described below and in Table 5. Unless otherwise noted, this table includes 
the range of estimates for log-additive models with the major allele in the HapMap CEU 
population as the referent genotype [9]. Also included in this table are minor allele 
frequencies (MAFs) from the HapMap YRI population and African Americans living in the 
Southwest USA (ASW). Results from studies conducted in special populations (e.g. women 
with BRCA1 or BRCA2 mutations or women with contralateral disease) are not included in 
these summary tables. Previously reported effect estimates from the CBCS population are 
also excluded [210]. Lastly, as few studies collected data on HER2 status and even fewer 
collected data on intrinsic breast cancer subtypes, the term ‘subtype’ is used to indicate any 
type of differentiation by IHC marker status.    
2.7.3.1 1p12: rs11249433  
 First identified in Thomas et al. [186], rs11249433 was later confirmed by both 
Turnbull and Li [189, 191]. The MAF was around 40% in most European samples, [169, 186, 
189, 191, 211-213] but much lower in African Americans (13-16%) [11, 169, 214-216]. In 
women of European descent, the SNP’s relationship with breast cancer appeared to follow a 
log-additive pattern with each copy of the risk allele corresponding to a 10-15% increase in 
the odds of developing breast cancer. There was no association among African Americans. 
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Subtype analyses indicated that the SNP was most strongly associated with ER+, PR+, 
HER2-, Luminal A and Luminal B breast cancer [167, 169, 186, 212, 214, 217]. 
2.7.3.2 2p: rs4666451  
 As mentioned previously, SNP rs4666451 just missed the criteria for GWAS 
significance in Easton et al. [194], with p=6 x 10-5 and OR=0.97 (95% CI: 0.94-1.00) for a 
log-additive model. Three of four subsequent studies confirmed the approximate magnitude 
and direction of the association [162, 186, 211, 218]. The effect was similar in both ER+ and 
ER- breast cancers, but there was no clear association with HER2 status [162, 186]. No 
studies have examined the effect of rs4666451 among African Americans.  
2.7.3.3 2q35: rs13387042  
 Despite its location in a gene desert, rs13387042 is one of the most well studied 
breast cancer-related polymorphisms. Approximately half of all women of European descent 
carried the variant allele [162, 168, 169, 186, 187, 189-191, 213, 218-223], as did 25-30% of 
all African Americans [11, 12, 169, 187, 214-216]. Among women of European ancestry, 
each copy of the variant allele was associated with a 10-15% reduction in the odds of getting 
breast cancer. The association was weaker and less precise in African Americans, but seemed 
consistent for each subtype versus control comparison, including ER+, ER-, PR+, PR-, 
HER2+, HER2-, luminal A, luminal B, HER2+/ER-, triple-negative, and basal-like breast 
cancer [162, 167, 168, 169, 187, 198, 214, 216, 217, 219, 221, 222, 224]. 
2.7.3.4 SLC4A7: rs4973768  
 Located on chromosome 3 in the SLC4A7 gene, rs4973768 was first identified in 
Turnbull et al [189]. With one exception [213], all studies found that the SNP was positively 
associated with the risk of breast cancer in women of European ancestry, with OR estimates 
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of 1.08-1.16 [168, 169, 189-191, 209, 211, 220, 223]. In contrast, the SNP had a much 
weaker and statistically null association with breast cancer among African Americans [11, 
169, 214-216]. A recent meta-analysis found a strong overall association between the SNP 
and breast cancer, but null effects when limited to women of European or African ancestry 
[225].  In subtype-stratified analyses, rs4973768 was most strongly associated with luminal 
A breast cancer, with no apparent association with triple-negative disease [167-169, 209, 
214, 216, 217, 226]. 
2.7.3.5 4p: rs12505080 and TLR1: rs7696175  
 These SNPs were identified in a GWAS investigation using participants of the 
Nurses’ Health Study [201]. In both cases, effect estimates for log-additive model showed no 
association, but general model estimates indicated that compared to women homozygous for 
the wildtype allele, heterozygotes had an increased risk of breast cancer (OR=1.22, 95% CI: 
1.02-1.45 for rs12505080 and OR=1.39, 95% CI: 1.15-1.68 for rs7696175), while women 
homozygous for the minor allele had a decreased risk of breast cancer (OR=0.51, 95% CI: 
0.35-0.73 for rs12505080 and OR=0.86, 95% CI: 0.67-1.09 for rs7696175). These patterns 
were replicated in Stage II of Hunter et al., but no other studies have examined the 
association. To date, no one has examined subtype differences in the effect of rs7696175 in 
whites or African Americans, but one study of Chinese women observed statistically 
significant associations between one or more copies of the minor allele and ER- and HER2- 
disease [227]. 
2.7.3.6 MRPS30: rs4415084 and rs10941679  
 In a follow-up to their original GWAS paper [187], Stacey et al. [208] identified two 
correlated SNPs (r2=0.51 in HapMap CEU) in the MRPS30 gene that were strongly 
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associated with breast cancer risk. Fletcher et al. confirmed the association of rs4415084 and 
breast cancer in a later GWAS [190].  
 Among women of European ancestry, each copy of the rare variant at rs4415084 or 
rs10941679 conferred a 10-15% increase in the odds of breast cancer [169, 186, 190, 191, 
208, 211, 220, 223, 228-230]. These SNPs were not correlated in HapMap YRI (r2=0.12) and 
effect estimates among African American women were inconsistent, with many null findings 
[11, 12, 169, 208, 214-216, 231]. Both SNPs showed stronger associations with ER+, PR+, 
luminal A, and luminal B cancers, with null associations with ER-, PR- or triple-negative 
disease [167, 169, 186, 198, 208, 214, 216, 217, 230, 231].  
2.7.3.7 5p12: rs981782  
 In 5 separate study populations, the presence of a rare variant at rs981782 was 
inversely associated with breast cancer risk in women of European ancestry [162, 194, 208, 
218, 230]. In the only study to report subtype-stratified estimates, Reeves et al. [162] 
observed a similar reduction in risk in ER+, ER- and HER2+ disease. rs981782 was not 
polymorphic in women of African descent. 
2.7.3.8 5q: rs30099 
  rs30099 was strongly associated with breast cancer risk in Easton et al. [194], but fell 
short of genome-wide significance (OR=1.05, 95% CI: 1.01-1.10, p=0.001). Harlid et al. 
[218] and Reeves et al. [162] confirmed the association in two later studies, with Reeves et 
al. reporting stronger effects for ER- and HER2+ disease subtypes. No studies have estimated 
the effect of rs30099 in African Americans.  
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2.7.3.9 MAP3K1: rs889312  
 SNP rs889312, located on the MAP3K1 gene on chromosome 5, was equally common 
in women of European and African descent, with a MAF of approximately 30%. The 10-15% 
increase in risk was well-replicated among women of European descent [162, 168, 169, 189, 
194, 213, 218, 220, 222, 229, 232-237], but was weak or null in African American women 
[11, 169, 214-216, 236, 238]. A meta-analysis including 6 separate studies estimated a 
pooled OR of 1.09 (95% CI: 1.07-1.12), assuming a log-additive model [239].  Subtype-
stratified analyses indicated that the SNP was associated with approximately equal risk 
increases in all disease subtypes, including ER+, ER-, PR+, PR-, HER2+, HER2-, luminal A, 
luminal B, HER2+/ER-, triple-negative and basal-like breast cancer [162, 167-169, 198, 214, 
216, 217, 222, 224, 226, 232, 234, 236, 238, 240].  
2.7.3.10 ECHDC1: rs2180341  
 Gold et al. [196] discovered rs2180341 in a GWAS conducted among Ashkenazi 
Jewish women with strong family histories but no BRCA1 or 2 mutations. Kirchhoff et al. 
[241] replicated these findings in both Jewish and non-Jewish women, but two other 
investigations yielded only null results [169, 213]. The SNP was not associated with breast 
cancer in African Americans [11, 12, 215, 216, 241] and subtype analyses generated 
predominantly null findings [169, 216, 241].   
2.7.3.11 ESR1: rs2046210, rs851974, rs2077647, rs2234693, rs1801132, rs3020314 and 
rs3798577  
 
 Four SNPs near the ESR1 gene were identified in GWASs, though only rs2046210 
will be discussed here. Zheng et al. [197] discovered this SNP in a GWAS of Chinese women 
in the Shanghai Breast Cancer Study and replicated the finding in a sample of white women 
from the Nashville Breast Cancer Study. Three other large studies confirmed the positive 
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association among women of European ancestry [169, 242, 243], with a fourth smaller study 
reporting null results [213]. rs2046210 had no effect on breast cancer in a study of African 
Americans [12], but a nearby correlated SNP (r2=0.38 in YRI), rs851974, had a positive 
association with the disease [12]. Most of the seven other studies of rs2046210 in African 
Americans estimated near-null associations [11, 169, 197, 214-216, 242, 243]. Subtype-
stratified analyses suggested that rs2046210 had a positive association with all subtypes, 
though most of these analyses were conducted in Asian women [167, 169, 192, 197, 198, 
214, 216, 217, 224, 226, 227, 242, 244].  
 As ESR1 is the gene responsible for encoding the alpha form of estrogen receptors, it 
is a frequent candidate in studies of genetic risk factors for breast cancer. Among the most 
frequently studied SNPs are rs2234693 (also known as the Pvull T397C mutation), 
rs1801132 (Pro325Pro), rs2077647 (Ser10Ser), rs3798577 (UTR-3, T>C) and rs3020314 
(C5029T), all of which were included in a meta-analysis by Zhang et al. [20]. Of these SNPs, 
rs3020314, rs1801132 and rs2234693 had statistically significant, but likely biased effect 
estimates (ORs for additive models were 1.12, 95% CI: 1.06-1.18; 0.95, 95% CI: 0.90-1.00; 
and 0.94, 95% CI: 0.89-1.00, respectively), with the effect of rs2234693 limited to women of 
Asian descent. The pooled effect estimates for rs2077647 and rs3798577 were both null 
(OR=0.98, 95% CI: 0.93-1.03 and OR=0.97, 95% CI: 0.90-1.04, respectively). An LD map 
of ESR1 SNPs genotyped in HapMap is included as Figures 12 and 13. Though not picture 
here, the two other GWAS-significant SNPs, rs3734805 and rs3757318, are located even 
further away from the 5’ end of ESR1 than rs20406210.  
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2.7.3.12 RELN: rs17157903  
 SNP rs1715903 in RELN was strongly associated with breast cancer in Hunter et al. 
[201], but fell short of GWAS-defined significance levels in both the original and replication 
analyses. No other investigators have attempted to validate the association in whites or 
African Americans.  
2.7.3.13 8q24: rs13281615 and rs1562430  
 A gene desert on 8q24 contains two SNPs that are strongly associated with breast 
cancer. rs13281615 was identified in the first breast cancer GWAS [194] and rs1562430 was 
identified a few years later [189]. These SNPs were in the same LD block in HapMap CEU 
(r2=0.43) but not YRI (r2=0.25). More than a dozen studies have validated the association 
between rs13281615 and breast cancer, with effect estimates ranging from 1.07 to 1.31 for 
the log-additive model [162, 168, 169, 189, 213, 218, 220, 229, 232-235, 237, 245]. The 
polymorphism was equally common in African Americans (MAF≅0.43) as in whites, though 
most studies observed only null associations [11, 12, 169, 214-216]. In subtype-specific 
analyses, rs13281615 was most strongly associated with luminal A and B tumors [162, 167-
169, 198, 214, 216, 217, 232, 234, 246], with no observed association with triple-negative 
disease. rs1562430 was re-assessed in two other GWAS investigations and one replication 
study, all of which confirmed the inverse association between the rare variant and all breast 
cancer in women of European descent [186, 190, 223]. In a Chinese GWAS, rs1562430 was 
associated with ER+, ER-, PR+ and PR- disease [192]. 
2.7.3.14 CDKN2A/CDKN2B: rs1011970, rs3731257 and rs3731249  
 SNP rs1011970, located near CDKN2A and CDKN2B, was discovered by Turnbull et 
al. [189] and was later replicated in one study of women of European descent [247]. Four 
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studies of African Americans [11, 214-216] reported predominantly null associations. In both 
studies of whites, each additional copy of the rare allele was associated with an increased risk 
of 5-10%. In limited subtype analyses, rs1011970 was positively associated with ER+ breast 
cancer and triple-negative breast cancer, but not ER- breast cancer [167, 189, 198, 214, 216, 
247]. Although poorly studied, analysis of rs3731257 and rs3731249 may provide additional 
information about the role of the CDKN2A/CDKN2B region, as both are located downstream 
of CDKN2A, rather than upstream of CDKN2B, as is the case with rs1011970 (Figures 14 
and 15). In previous analyses, rs3731249 (A148T) was strongly associated with breast cancer 
in young Polish women (OR for dominant model =1.5, p=0.0002) [248], but rs3731257 had 
no effect in a population of British women (OR for homozygous variant versus homozygous 
wildtype= 0.95, 95% CI: 0.74-1.20) [249]. 
2.7.3.15 ANKRD16: rs2380205, ZNF365: rs10995190, and ZMIZ1: rs704010  
 Three SNPs in three separate genes on chromosome 10 were originally identified in 
Turnbull et al [189]. Both rs2380205 in ANKRD16 and rs10995190 in ZNF365 had inverse 
associations with breast cancer (OR=0.94, 95% CI: 0.91-0.98 and OR=0.86, 95% CI: 0.82-
0.91 for rs2380205 and rs10995190, respectively), while rs704010 in ZMIZ1 had a positive 
association with the disease (OR=1.07, 95% CI: 1.03-1.11). All three SNPs were confirmed 
in at least one other white population [247, 250]. All three were also examined in African 
American populations [11, 214-216], though rs704010 was the only SNP to demonstrate 
evidence of an association [216]. Both rs2380205 and rs10995190 were inversely associated 
with ER+ disease in women of European descent [189, 247], while rs704010 was positively 
correlated with all ER and PR subtypes [189, 198, 247]. Neither rs2380205 nor rs704010 
were associated with triple-negative disease [167].  
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2.7.3.16 FGFR2: rs3750817, rs10736303, rs11200014, rs2981579, rs1708806,  
rs1219648, rs2912774, rs2936870, rs2420946, rs2981582, and rs3135718  
 Although the causal relationship between the FGFR2 gene and breast cancer is not 
completely understood, multiple GWAS, GWAS-validation studies, and fine-mapping 
studies have confirmed that one or more SNPs in the gene are strongly associated with the 
disease. Easton et al. [194] were the first to detect a strong association between breast cancer 
and rs2981582. In Hunter et al. [201], rs1219648 had the strongest association and in 
Thomas et al. [186] it was rs2981579. In a later GWAS limited to Japanese hormone positive 
breast cancer cases [193], a fourth FGFR2 SNP, rs3750817, showed the strongest association 
with disease. All four SNPs were strongly correlated in the HapMap CEU population, but not 
the YRI. Estimated effects for women of European descent were consistent for rs2981582, 
rs1219648 and rs2981579, with each copy of the rare allele conferring approximately a 20-
30% increase in the odds of breast cancer [162, 168, 169, 186, 189-191, 194, 201, 213, 218-
220, 222, 223, 229, 232-237, 251-256]. The rare allele of rs3750817 was inversely associated 
with disease in studies of whites [169, 252], but positively associated with disease in the 
Japanese GWAS [193].   
 In a recent meta-analyses, rs2981582 had an OR of 1.23 (95% CI: 1.20-1.26) among 
women of European descent [257]. In the same meta-analyses, the effect of rs1219648 was 
OR=1.26 (95% CI: 1.22-1.31). A meta-analysis of rs2981579 reported an OR of 1.34 (95% 
CI: 1.28, 1.38) in women of European descent [258].  
 Effect estimates for rs2981582 and rs2981579 were inconsistent or null in African 
American samples [11, 12, 169, 214-216, 236, 259], with meta-analysis ORs of 1.08 (95% 
CI: 0.97, 1.21) [257] and 1.09 (95% CI: 0.92, 1.30) [258], respectively. In contrast, 
rs1219648 was positively associated with breast cancer in African Americans (meta-analysis 
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OR= 1.13, 95% CI: 1.01, 1.26) [257]. To date, no studies have examined the relationship 
between rs3750817 and breast cancer in African Americans. 
 rs1219648 or rs2981582 were more strongly associated with ER+ and PR+ disease 
than ER- or PR- disease [257]. rs1219648 also demonstrated a strong association with HER2- 
disease in white US women [236]. In the three studies that examined the effect of rs2981582 
by combined ER/PR/HER2 status, the SNP was associated with luminal A and B disease, but 
not HER2+/ER- or triple-negative disease [167, 168, 226].  rs2981579 was associated with 
ER+/PR+ disease in one study of African Americans [216] and with ER+, ER-, PR+, HER2+ 
and HER2- disease in a study of Chinese breast cancer patients [227]. The SNP was not 
associated with ER- disease in women of European descent [198]. rs3750817 was associated 
with ER+ and PR+ disease in whites, but effect was in the opposite direction of the Japanese 
GWAS [193].  
 Eight other SNPs in the same CEU LD block as the four GWAS hits were genotyped 
in CBCS (Figures 16 and 17). These include rs1076303, rs11200014, rs1078806, rs1219648, 
rs2912774, rs2936870, rs2420946, and rs3135718. Of these SNPs, rs2420946 and 
rs11200014 were the most extensively studied. Each had effect estimates comparable to 
those seen for the three GWAS SNPs. For rs2420946, the estimated meta-analysis ORs was 
1.25 (95% CI: 1.19-1.32) [257]. Only one study looked at the SNP in an African American 
population, finding a small positive association [12]. No one has examined subtype-specific 
effects. For rs112000014, the log-additive meta-analysis ORs were 1.28 (95% CI: 1.21, 1.35) 
for whites and 1.03 (95% CI: 0.85, 1.24) for African Americans [258]. In a subtype analyses 
among Chinese women, the SNP was positively associated with ER+, PR+, HER2+ and 
HER2- disease [227].    
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 rs2912774 also had well-replicated effect estimates of approximately 1.25 per copy of 
the rare allele among women of European descent [194, 252, 254-256] and the limited 
evidence on rs10736303, rs1778806, rs2981578, rs2936870, and rs3135718 suggested that 
these SNPs have similar associations [169, 194, 196, 252]. Two of the SNPs, rs10736303 and 
rs2981578, were also positively associated with breast cancer in African Americans, with 
some evidence that rs2981578 was a causal variant in this population [12, 214, 215, 258, 
259]. When studied in subtype-specific analyses, most of these SNPs were associated with 
ER+ or PR+, but not ER- or PR- disease [169, 214, 259].  
2.7.3.17 10q: rs10510126  
 Like rs12505080 on 4p, rs7696175 on TLR1/TLR6, and rs17157903 on RELN, 
rs10510126 had an extremely low p-value in Hunter et al.’s [201] initial analysis (OR=0.62, 
95% CI: 0.51-0.75, p=7.1 x 10-7), but failed to reach genome-wide significance levels in 
replication analyses (OR=0.83, 95% CI: 0.74-0.93, p=0.001). The SNP was not assessed in 
any other study populations.   
2.7.3.18 LSP: rs3817198 and rs909116  
 Easton et al. [194] discovered the association between rs3817198 and breast cancer in 
their 2007 GWAS. In this initial GWAS, the SNP was associated with a mere 7% increase in 
the odds of having breast cancer (OR=1.07, 95% CI: 1.04-1.11). Since then, several studies 
have replicated this small effect with reasonable precision [162, 168, 186, 189, 218, 220, 
232, 233], while others reported null or even slightly contradictory findings [169, 211, 213, 
229, 234, 235, 237]. Results from a meta-analysis of six of these studies indicated a null 
effect (OR=1.01, 95% CI: 0.94-1.09) [260]. Effect estimates among African Americans were 
imprecise and inconsistent [11, 12, 169, 214-216], as were subtype-specific estimates [162, 
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167-169, 198, 214, 216, 217, 232, 234, 246], though there was some indication that the SNP 
was associated with unclassified disease [168]. 
  Of note, while attempting to replicate the association between rs3817198 and breast 
cancer, Turnbull et al. [189] found that rs909116, another SNP on LSP1, had a stronger effect 
and lower p-value in their population of white women (OR=1.17, 95% CI: 1.10-1.24, p=7.3 x 
10-7). The two SNPs were not correlated (CEU r2=0.24, YRI r2=0.03). No other studies have 
replicated this observation.  
2.7.3.19 H19: rs2107425  
 In Easton et al. [194], rs2107425 on H19 was inversely associated with breast cancer, 
but the p-value for the association was above the threshold for genome-wide significance. In 
the only other study to examine the effect of this SNP on breast cancer risk, Teraoka et al. 
[261] found that it was not related to the risk of contralateral versus unilateral disease.  
2.7.3.20 MYEOV/CCND1: rs614367  
 A single SNP near the MYEOV and CCND1 genes on chromosome 11 demonstrated a 
positive, genome-wide significant association with breast cancer in Turnbull et al. [189] 
(OR=1.15, 95% CI: 1.1-1.2, p=1.3 x 10-8), which was later replicated by Lambrechts et al 
[247]. The effect seemed strongest in women with ER+ or PR+ disease [189, 198, 216, 247]. 
There was no clear association in African Americans [11, 214-216] or among those with 
triple-negative disease [167]. 
2.7.3.21 TNRC9/TOX3: rs8051542, rs12443621, rs3803662, rs4784227, rs3104746,  
and rs3112562  
 As with FGFR2, multiple GWAS pinpointed the TNRC9 gene (also known as TOX3) 
as strongly associated with breast cancer. Of these GWAS, five identified rs3803662 as the 
SNP with the strongest signal [186, 187, 189, 194, 207], while a sixth [205] and a seventh 
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[190] detected stronger effects for rs4784227 and rs3112612, respectively. The latter SNP 
was not genotyped in CBCS, but rs3803662, rs4784227 and seven other TNRC9 SNPs were.  
 Including the seven GWAS mentioned above, more than twenty papers have reported 
ORs for the effect of rs3803662 on breast cancer. In these papers, MAFs ranged from 0.20- 
0.39 for women of European descent [162, 163, 168, 169, 186, 187, 189, 194, 205, 207, 213, 
218-220, 222, 229, 232-235, 237, 262] and 0.47-0.54 for women of African descent [11, 12, 
169, 187, 214-216, 262, 263]. Other than one paper reporting an imprecise, inverse 
association [233], effect estimates for log-additive models in women of European descent 
ranged from 1.01-1.33, with most approximating a 20% increase in the odds of breast cancer 
per copy of the more rare ‘A’ allele. A meta-analysis of eight of these studies estimated an 
OR of 1.18 (95% CI: 1.09- 1.28) [264]. Interestingly, most studies among African Americans 
indicated that the ‘A’ allele had an inverse association with breast cancer (range 0.75-1.04), 
with most showing a 10% decrease in risk. In subtype-specific analyses, rs3803662 was 
positively associated with all subtypes [162, 167-169, 187, 192, 198, 214, 217, 222, 224, 226, 
232, 234, 265, 266].  
 The other GWAS-identified SNP, rs4784227, was in LD with rs3803662 in the 
HapMap CEU population (r2=0.81) but not the HapMap YRI population (r2=0.03). Although 
far less studied that rs3803662, two studies in women of European ancestry [205, 262] and 
three studies in African American women [11, 214, 262] indicated that the SNP was 
positively associated with disease in both racial groups (OR range of 1.17-1.29 and 1.09-
1.23, respectively). In the only study to assess subtype-specific effects, Kim et al. [192] 
found that all ER and PR-defined subtypes were positively associated with the minor allele at 
rs4784227. 
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 None of the remaining TNRC9 genotyped SNPs were correlated in CEU or YRI 
populations (Figures 18 and 19). Several investigators have estimated effects for rs8051542 
and rs12443621, which are both located between the 3’ end and rs3803662 [194, 205, 234, 
237, 262]. Meta-analyses generated ambivalent results, with effect estimates on opposite 
sides of the null (OR=1.07, 95% CI: 0.93-1.23 for rs8051542 and OR=0.94, 95% CI: 0.85-
1.05 for rs12443621) [264]. Both SNPs were analyzed in African Americans and within 
strata of ER and PR status, but only the effect of rs8051542 on ER+ breast cancer was non-
null [12, 217, 224, 234, 263, 265, 266].  
 rs3104746 and rs3112562 are located on the other side of rs3803662 and rs4784227, 
closer to the 5’ end of the gene. Ruiz-Narvaez et al. observed strong associations between 
breast cancer and rs3104746 (OR=1.23, 95% CI: 1.05-1.44) and rs3112562 (OR=1.17, 95% 
CI: 1.02-1.34) among participants in the Black Women’s Health Study [263]. Chen et al. 
replicated these observations for rs3104746 and observed similar effects in ER+ and ER- 
breast cancer cases [214].  
2.7.3.22 COX11- rs7222197 and rs6504950  
 In their follow-up to Easton et al. [194], Ahmed et al. [209] found that rs6504950, a 
SNP in the COX11 gene, was strongly and inversely associated with breast cancer (OR=0.95, 
95% CI: 0.92-0.97, with p=1.4 x 10-8 across all replication stages). These findings were 
replicated with varying degrees of precision in five other studies of Europeans or European-
Americans (OR range 0.80- 0.95) [168, 169, 211, 213, 220] and a meta-analysis [267]. Two 
of five other studies in African Americans [11, 169, 214-216] reported effect estimates of 
similar magnitude and direction. Overall, these effects appeared to be the strongest in women 
with luminal A or B disease [167, 168]. The other COX11 SNP, rs7222197, was in perfect 
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LD with rs6504950 in both HapMap CEU and YRI, and was inversely associated with breast 
cancer in Turnbull et al. (OR=0.89, 95% CI: 0.83-0.96, p=0.0009) [189].  
2.7.4 Summary of genetic risk factors  
 As shown by this literature review, the search for genetic risk factors for breast cancer 
has identified dozens of associated variants at a variety of chromosomal loci. Some of these 
polymorphisms or mutations are extremely rare, but have large effects on disease risk. This 
includes BRCA1, BRCA2, ATM, PTEN, and some of the other genes identified in linkage 
analyses or candidate gene studies. More common variants, such as rs13387042, or SNPs in 
FGFR2 or TNRC9/TOX3, tend to have weak associations with disease, especially because 
these polymorphisms are often proxies for nearby, correlated causal variants rather than 
contributory links themselves. Most of these variants have been replicated in several study 
populations, with each new analysis providing additional information on the form, 
magnitude, and direction of the association. 
 Despite heavy replication in women of European and Asian descent, far fewer studies 
include women of African descent. Studies that do include African Americans are often quite 
small, resulting in imprecise or inconsistent estimates. In many cases, it is not clear whether 
the failure to find and replicate associations is due to racial differences in genetic risk factors 
and linkage disequilibrium patterns [268-270], or if the study populations are simply too 
small to allow the detection of a weak association with sufficient precision. Subtype-specific 
analyses face the same methodological challenge. Differences in gene expression patterns, 
race and age distributions, prognoses, and risk factor profiles all imply that breast cancer 
subtypes have distinct etiologies and thus unique genetic origins, but results from subtype-
stratified analyses are thus far scant and generally inconclusive.  
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 If our ultimate goal is to improve breast cancer prevention, detection and treatment, 
we must first understand breast carcinogenesis, much of which is determined by individual 
variations in genetic make-up. Analyses within strata of race and subtype are of particular 
importance, as risk patterns vary according to these factors. Such analyses require either 
larger studies, which are expensive and logistically complicated, or the use of more powerful 
analysis methods within existing populations. The subsequent pages of this report describe 
the implementation, findings and conclusions of a Bayesian-based study of the effects of 
previously identified genetic risk factors on breast cancer and breast cancer subtypes. The use 
of Bayesian methods, which incorporate prior knowledge into effect estimation, generated 
more accurate and precise ORs than were possible with traditional frequentist techniques.    
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Figure 1: US breast cancer mortality rate by race, age group, and year
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Figure 2: ATM linkage disequilibrium map for HapMap CEU 
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Figure 3: ATM linkage disequilibrium map for HapMap YRI 
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Figure 4: CASP8 linkage disequilibrium map for HapMap CEU 
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Figure 5: CASP8 linkage disequilibrium map for HapMap YRI 
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Figure 6: TP53 linkage disequilibrium map for HapMap CEU 
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Figure 7: TP53 linkage disequilibrium map for HapMap YRI 
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Figure 8: CYP19A1 linkage disequilibrium map for HapMap CEU 
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Figure 9: CYP19A1 linkage disequilibrium map for HapMap YRI 
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Figure 10: PALB2 linkage disequilibrium map for HapMap CEU 
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Figure 11: PALB2 linkage disequilibrium map for HapMap YRI 
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Figure 12: ESR1 linkage disequilibrium map for HapMap CEU 
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Figure 13: ESR1 linkage disequilibrium map for HapMap YRI 
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Figure 14: CDKN2A/CDKN2B linkage disequilibrium map for HapMap CEU 
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Figure 15: CDKN2A/CDKN2B linkage disequilibrium map for HapMap YRI 
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Figure 16: FGFR2 linkage disequilibrium map for HapMap CEU 
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Figure 17: FGFR2 linkage disequilibrium map for HapMap YRI 
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Figure 18: TNRC9/TOX3 linkage disequilibrium map for HapMap CEU 
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Figure 19: TNRC9/TOX3 linkage disequilibrium map for HapMap YRI 
 
  67 
Table 1: Summary of risk factors by breast cancer subtype: Subtype vs. control 
 
  Subtype 
Risk Factor Luminal A Luminal B HER2+/ER- 
Basal-like or  
triple-negative 
Young vs. Old 
Age at Diagnosis inverse likely positive 
likely 
positive 
positive, 30-49 
year olds may 
have highest risk 
African 
American vs. 
non-Hispanic 
White 
inverse in one 
study 
null in one 
study 
positive in 
one study 
positive in one 
study 
Hispanic vs. non-
Hispanic White not assessed not assessed not assessed not assessed 
Asian vs. non-
Hispanic White not assessed not assessed not assessed not assessed 
Positive Family 
History of Breast 
Cancer 
positive positive positive positive 
Pre vs. 
Postmenopausal 
positive in one 
study 
positive in one 
study 
null in one 
study null in one study 
Later Age at 
Menopause positive likely null likely null inconsistent 
Early vs. Late 
Age at Menarche positive inconsistent inconsistent positive 
Parity vs. 
Nulliparity inverse inverse likely null inconsistent 
Lactation inverse inverse inverse inverse 
Parity and 
Lactation 
No interaction in 
one study not assessed not assessed 
increasing parity 
positively 
associated in non-
lactating women 
(1 study) 
Later Age at 
First Full Term 
Pregnancy 
any parity 
inversely 
associated with 
risk; later age 
riskier  
any parity 
inversely 
associated with 
risk; later age 
riskier  
inconsistent inconsistent 
Oral 
Contraceptive 
Use 
possibly inverse null null 
positively 
associated with 
long term use at 
younger age 
Hormone 
Replacement 
Therapy Use 
positive with 
current use 
positive with 
current use null 
possible positive 
association with 
current use 
Time Since Last 
Full Term 
Pregnancy 
Inverse 
association with 
recent pregnancy 
Inverse 
association 
with recent 
pregnancy 
possibly 
positive likely null 
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Spontaneous or 
Induced 
Abortion 
inconsistent inconsistent inconsistent inconsistent 
High Body Mass 
Index: Overall inconsistent 
inverse in one 
study 
null in one 
study positive 
High Body Mass 
Index: 
Premenopausal 
likely inverse possibly positive likely null positive 
Body Mass 
Index: 
Postmenopausal 
likely null null null null 
Waist to Hip 
Ratio 
positive 
association with 
greater WHR in 
premenopausal 
and 
postmenopausal 
women 
not assessed not assessed 
higher WHR 
increases risk of 
basal-like in pre 
and post 
menopausal 
women (1 study); 
null effect on 
triple-negative in 
postmenopausal 
women (1 study) 
Increased 
Physical Activity inverse 
null in one 
study 
inverse in 
one study inverse 
Increased 
Alcohol 
Consumption 
positive null positive inconsistent 
Increased 
Smoking 
Duration and 
intensity 
positively 
associated; 
former positively 
associated; 
current 
inconsistent 
former 
smoking 
positively 
associated (1 
study); current 
inversely 
associated (1 
study) 
former and 
current 
smoking 
positively 
associated (1 
study) 
null association 
with intensity and 
duration; 
inconsistent 
association with 
former and current 
smoking  
History of 
Benign Breast 
Disease 
positive positive null inconsistent 
High Breast 
Density 
positive in one 
study not assessed not assessed 
positive in one 
study 
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Table 2: Summary of risk factors by breast cancer subtype: Subtype vs. luminal A 
 
Risk Factor Luminal B HER2+/ER- 
Basal-like or  
triple-negative 
Young vs. Old 
Age at Diagnosis positive positive positive 
African American 
vs. non-Hispanic 
White 
null positive positive 
Hispanic vs. non-
Hispanic White positive positive inconsistent 
Asian vs. non-
Hispanic White positive positive inverse 
Positive Family 
History of Breast 
Cancer 
null null 
positive in pooled 
analysis; null in two 
other studies 
Pre vs. 
Postmenopausal inconsistent likely inverse null 
Later Age at 
Menopause not assessed not assessed not assessed 
Early vs. Late Age 
at Menarche null inconsistent positive 
Parity vs. 
Nulliparity null null 
possibly positive with a 
possible positive effect 
for increasing parity 
Lactation null null null 
Parity and 
Lactation 
parity positively 
associated in non-
lactating women in 
one study 
increasing parity 
positively associated 
in non-lactating 
women in one study 
increasing parity 
positively associated in 
non-lactating women in 
one study 
Later Age at First 
Full Term 
Pregnancy 
parity positively 
associated in younger 
mothers, effect 
attenuates with age 
parity positively 
associated in 
younger mothers, 
effect attenuates with 
age 
parity positively 
associated in younger 
mothers, effect 
attenuates with age 
Oral 
Contraceptive Use inconsistent null null 
Hormone 
Replacement 
Therapy Use 
inconsistent inconsistent null 
Time Since Last 
Full Term 
Pregnancy 
null in one study 
Shorter time 
associated with 
increased risk 
positive association in 
one study 
  70 
Spontaneous or 
Induced Abortion not assessed not assessed not assessed 
High Body Mass 
Index: Overall null 
likely null; inverse 
association in non-
Africans (1 study) 
positive 
High Body Mass 
Index: 
Premenopausal 
likely null likely positive positive 
Body Mass Index: 
Postmenopausal null null null 
Waist to Hip 
Ratio 
high WHR inversely 
associated in 
postmenopausal 
women, null in 
premenopausal  
(all from 1 study) 
high WHR inversely 
associated in 
postmenopausal 
women, null in 
premenopausal  
(all from 1 study) 
high WHR positively 
associated in pre and 
postmenopausal women 
(all from one study) 
Other Body Size 
Measurements not assessed not assessed not assessed 
Increased 
Physical Activity positive in one study null positive in one study 
Increased Alcohol 
Consumption inconsistent likely null likely null 
Increased 
Smoking 
null association with 
intensity and duration; 
positive association 
with former (1 study); 
null association with 
current (1 study) 
null association with 
intensity and 
duration; positive 
association with 
current (1 study); 
null association with 
former (1 study) 
inconsistent for duration 
and intensity; null for 
current smoking and 
former smoking (1 
study) 
History of Benign 
Breast Disease not assessed not assessed not assessed 
High Breast 
Density not assessed not assessed null in one study 
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Table 3: Summary of candidate genes by breast cancer subtype 
 
Chromosome Gene Summary of subtype findings 
2 
CASP8  
LD block 2 
One SNP assessed: associated with ER+/PR+ and ER-
/PR- disease 
CASP8  
LD block 3 
rs1045485 inversely associated with all subtypes; 
rs17468277 associated with triple-negative disease 
(pooled analysis) 
CTLA4 one study found an association between a SNP in the promoter region and ER+ and PR+ status 
LKB1 not assessed 
5 TERT Possible association with ER- and triple negative disease (pooled analysis) 
8 NBN not assessed 
10 PTEN not assessed 
11 ATM 
Several SNPs associated with PR+ status; 
Mostly null associations with ER status, though three 
SNPs associated with ER- disease 
14 XRCC3 No association with ER or PR status 
15 
CYP19A1 
LD block 1 
conflicting results regarding association between ER 
status and rs10046; possible association with HER2- 
status 
CYP19A1 
LD block 2 No association with ER, PR or HER2 status 
16 
PALB2 
LD block 1 Possible association with ER+ disease (1 study) 
PALB2 
1592delT Possible association with ER and PR- disease (1 study) 
17 
BRIP1 Mostly null associations with ER and PR status 
TP53 rs1042522 possibly associated with ER+ disease; no other associations observed 
22 
CHEK2 
any mutation 
possible positive association with ER+/Luminal A and B 
disease 
CHEK2 
1100delC (exon 
10) or del5395 
(exons 9 and 10) 
strong evidence of an association with ER+ disease; may 
also be associated with ER- disease  
CHEK2 
I157T and 
IVS2+IG>A 
possible positive association with ER+/Luminal A and B 
disease 
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Table 4: Breast cancer genome-wide association studies (GWAS) 
 
Study Study Initial Sample Size 
Replication 
Sample  Region 
Reported 
Gene(s) SNPs p-Value OR  
95% CI 
(text) 
Easton, 
June 
2007 
[194] 
Genome-wide 
association study 
identifies novel 
breast cancer 
susceptibility loci. 
390 cases,  
364 controls 
26646 cases,  
24889 
controls 
16q12.1 TNRC9 rs3803662 1.00E-36 1.2 [1.16-1.24]  
5p12 Intergenic rs981782 9.00E-06 1.04 [1.01-1.08]  
11p15.5 LSP1 rs3817198 3.00E-09 1.07 [1.04-1.11]  
5q11.2 MAP3K1 rs889312 7.00E-20 1.13 [1.10-1.16]  
10q26.13 FGFR2 rs2981582 2.00E-76 1.26 [1.23-1.30]  
8q24.21 Intergenic rs13281615 5.00E-12 1.08 [1.05-1.11]  
Hunter, 
July 2007 
[201] 
A genome-wide 
association study 
identifies alleles in 
FGFR2 associated 
with risk of sporadic 
postmenopausal 
breast cancer. 
1145 cases,  
1142 controls 
1176 cases,  
2072 controls 10q26.13 FGFR2 rs1219648 1.00E-10 1.2 [1.07-1.42]  
Stacey, 
July 2007 
[187] 
Common variants on 
chromosomes 2q35 
and 16q12 confer 
susceptibility to 
estrogen receptor-
positive breast 
cancer. 
1599 cases,  
11546 
controls 
2934 cases,  
5967 controls 
2q35 Intergenic rs13387042 1.00E-13 1.2 [1.14-1.26]  
16q12.1 TNRC9 rs3803662 6.00E-19 1.28 [1.21-1.35]  
Murabito
, July 
2007 
[188] 
A genome-wide 
association study of 
breast and prostate 
cancer in the 
NHLBI's 
Framingham Heart 
Study. 
723 cases  Not replicated 
5q34 Intergenic rs6556756 5.00E-07 NR NR 
15q21.1 FBN1 rs1876206 6.00E-06 NR NR 
13q32.1 ABCC4 rs1926657 2.00E-06 NR NR 
12q21.1 Intergenic rs1154865 7.00E-07 NR NR 
18q21.2 Intergenic rs1978503 1.00E-06 NR NR 
7q11.22 Intergenic rs10263639 3.00E-06 NR NR 
2p16.1 Intergenic rs10490113 5.00E-06 NR NR 
21q21.3 GRIK1 rs458685 6.00E-06 NR NR 
17q21.33 COL1A1 rs2075555 8.00E-08 NR NR 
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Gold,  
Mar 2008 
[196] 
Genome-wide 
association study 
provides evidence 
for a breast cancer 
risk locus at 6q22.33 
249 cases, 
299 controls 
(AJ, non-
BRCA1/2) 
1193 cases, 
1166 
controls 
(AJ, non-
BRCA1/2) 
6q22.33 ECHDC1 rs2180341 3.00E-08 1.41 [1.25-1.59]  
Zheng, 
Mar 2009 
[197] 
Genome-wide 
association study 
identifies a new 
breast cancer 
susceptibility locus 
at 6q25.1 
1505 CA 
cases, 1522 
CA controls 
1554 CA 
cases,  
1576 CA 
controls 
6q25.1 ESR1 rs2046210 2.00E-15 1.29 [1.21-1.37]  
Kibriya, 
April 
2009 
[204] 
A pilot genome-wide 
association study of 
early-onset breast 
cancer. 
30 cases,  
30 controls 
Not 
replicated 16q23.1 GLG1 rs10871290 4.00E-07 NR NR 
Thomas, 
May 
2009 
[186] 
A multistage 
genome-wide 
association study in 
breast cancer 
identifies two new 
risk alleles at 1p11.2 
and 14q24.1 
(RAD51L1). 
1145 cases,  
1142 controls 
8625 cases,  
9657 
controls 
2q35 Intergenic rs13387042 2.00E-08 1.25 [1.15-1.37]  
10q26.13 FGFR2 rs2981579 2.00E-10 1.17 [1.07-1.27]  
1p11.2 Intergenic rs11249433 7.00E-10 1.16 [1.09-1.24]  
16q12.1 TOX3 rs3803662 1.00E-09 1.16 [1.07-1.27]  
5q11.2 MAP3K1 rs16886165 5.00E-07 1.23 [1.12-1.35]  
14q24.1 RAD51L1 rs999737 2.00E-07 1.06 [1.01-1.14]  
Turnbull, 
June 
2010 
[189] 
Genome-wide 
association study 
identifies five new 
breast cancer 
susceptibility loci. 
3659 UK 
cases, 4897 
UK controls 
12576 EA 
cases, 12223 
EA controls 
8q24.21 Intergenic rs1562430 6.00E-07 1.17 [1.10-1.25]  
2q35 Intergenic rs13387042 2.00E-10 1.21 [1.14-1.29]  
10q21.2 ZNF365 rs10995190 5.00E-15 1.16 [1.10-1.22]  
9p21.3 CDKN2A rs1011970 3.00E-08 1.09 [1.04-1.14]  
11q13.3 MYEOV rs614367 3.00E-15 1.15 [1.10-1.20]  
3p24.1 SLC4A7 rs4973768 6.00E-07 1.16 [1.10-1.24]  
16q12.1 TOX3 rs3803662 3.00E-15 1.3 [1.22-1.39]  
10q26.13 FGFR2 rs2981579 4.00E-31 1.43 [1.35-1.53]  
5q11.2 MAP3K1 rs889312 5.00E-09 1.22 [1.14-1.30]  
10q22.3 ZMIZ1 rs704010 4.00E-09 1.07 [1.03-1.11]  
10p15.1 ANKRD16 rs2380205 5.00E-07 1.06 [1.02-1.10]  
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6q25.1 ESR1 rs3757318 3.00E-06 1.3 [1.17-1.46]  
11p15.5 LSP1 rs909116 7.00E-07 1.17 [1.10-1.24]  
Long,  
June 
2010 
[205] 
Identification of a 
functional genetic 
variant at 16q12.1 
for breast cancer 
risk: results from the 
Asia Breast Cancer 
Consortium. 
2073 CA 
cases, 2084 
CA controls 
10598 A 
cases, 8254 
A controls,  
2797 EA 
cases,  
2662 EA 
controls 
16q12.1 TOX3 rs4784227 1.00E-28 1.24 [1.20-1.29]  
Antoniou
, Oct 
2010 
[206] 
A locus on 19p13 
modifies risk of 
breast cancer in 
BRCA1 mutation 
carriers and is 
associated with 
hormone receptor-
negative breast 
cancer in the general 
population. 
1193 EA 
cases, 1190 
EA controls 
3012 EA 
cases, 2974 
EA controls 
19p13.11 ABHD8 rs8170 2.00E-09 1.26 [1.17-1.35]  
Gaudet, 
Oct 2010 
[202] 
Common genetic 
variants and 
modification of 
penetrance of 
BRCA2-associated 
breast cancer. 
899 BRCA2+ 
EA cases, 
804 BRCA2+ 
EA controls 
1264 cases,  
1222 
controls 
10q26.13 FGFR2 rs2981575 1.00E-08 1.28 [1.18-1.39]  
Li,  
Nov 
2010 
[207] 
A genome-wide 
association scan on 
estrogen receptor-
negative breast 
cancer. 
617 EA ER- 
cases, 4,583 
EA controls 
1001 EA 
ER- cases,  
7604 EA 
controls 
No SNPS met reporting requirements for statistical significance 
Fletcher, 
Mar 2011 
[190] 
Novel breast cancer 
susceptibility locus 
at 9q31.2: results of a 
genome-wide 
association study. 
1694 UK 
cases, 2365 
UK, 1145 EA 
cases, 1142 
EA controls 
7317 UK 
cases, 8124 
UK controls 
6q25.1 ESR1 rs3734805 1.00E-07 1.19 [1.11-1.27]  
5p12 Intergenic rs4415084 8.00E-11 1.17 [1.11-1.22]  
2q35 Intergenic rs13387042 2.00E-10 1.16 [1.11-1.22]  
3p24.1 SLC4A7 rs4973768 2.00E-08 1.14 [1.09-1.19]  
8q24.21 Intergenic rs1562430 3.00E-11 1.16 [1.11-1.22]  
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16q12.2 TOX3 rs3112612 4.00E-10 1.15 [1.10-1.21]  
10q26.13 FGFR2 rs1219648 1.00E-30 1.31 [1.25-1.37]  
10q26.13 FGFR2 rs10510102 2.00E-06 1.12 [1.07-1.17]  
9q31.2  RAD23B rs865686 2.00E-10 1.12 [1.09-1.18]  
Li,  
April 
2011 
[191] 
A combined analysis 
of genome-wide 
association studies in 
breast cancer. 
2702 EA 
women, 5726 
EA controls 
Up to 7386 
EA cases, 
7576 EA 
controls 
10q26.13 FGFR2 rs1219648 2.00E-13 1.32 [1.22-1.42]  
5p12 MRPS30 rs7716600 7.00E-07 1.24 [1.14-1.34]  
2q35 Intergenic rs13387042 9.00E-06 1.18 [1.10-1.27]  
16q12.1 TOX3 rs3803662 4.00E-07 1.22 [1.13-1.32]  
Cai,  
Sept 
2011 
[200] 
Genome-wide 
association study 
identifies breast 
cancer risk variant at 
10q21.2: results from 
the Asia Breast 
Cancer Consortium. 
2,062 EAA, 
2,066 EAA 
controls 
15091 EAA 
cases, 14877 
EAA 
controls 
10q21.2 ZNF365 rs10822013 6.00E-09 1.12 [1.06-1.18]  
7q32.3 NR rs2048672 6.00E-06 1.11 [1.05-1.17]  
Sehrawat
, Oct 
2011 
[195] 
Potential novel 
candidate 
polymorphisms 
identified in genome-
wide association 
study for breast 
cancer susceptibility. 
302 EA 
cases, 321 
EA controls 
1153 cases, 
1,215 
controls 
19q13.41 ZNF577 rs10411161 7.00E-06 1.42 [1.22-1.65]  
5p15.2 ROPN1L rs1092913 2.00E-06 1.45 [1.24-1.69]  
Haiman, 
Oct 2011 
[166] 
A common variant at 
the TERT-
CLPTM1L locus is 
associated with 
estrogen receptor-
negative breast 
cancer. 
1004 AA 
cases, 2745 
AA controls, 
1718 EA 
cases, 3670 
EA controls 
2222 EA 
cases,  
16363 EA 
controls 
5p15.33 TERT rs10069690 1.00E-10 1.18 [1.13-1.25]   
Long,  
Feb 2012 
[199] 
Genome-wide 
association study in 
east Asians identifies 
novel susceptibility 
loci for breast cancer 
2918 CA 
cases, 2324 
CA controls 
16173 A 
cases, 18282 
A controls 
6q25.1 TAB2 rs9485372 4.00E-12 1.11 [1.09-1.15] 
11q24.3 BARX2 rs7107217 5.00E-7 1.08 [1.05-1.11] 
6q25.1 ESR1 rs9383951 2.00E-6 1.14 [1.08-1.19] 
Kim,  A genome-wide 2273 KA 4049 KA 2q34 ERBB4 rs13393577 9.00E-14 1.53 [1.37-1.70] 
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Mar 2012 
[192] 
association study 
identifies a breast 
cancer risk variant in 
ERBB4 at 2q34: 
results from the 
Seoul Breast Cancer 
Study 
cases, 2052 
KA controls 
cases, 3845 
KA controls 
Chen,  
Jan 2013 
[203] 
A genome-wide 
association study of 
breast cancer in 
women of African 
ancestry 
3016 AA 
cases, 2745 
AA controls 
3533 AA 
cases, 11046 
AA controls 
14q31.3 GALC rs4322600 4.00E-6 1.18 [1.10-1.27] 
Elgazzar, 
Dec 2012 
[193] 
A genome-wide 
association study 
identifies a genetic 
variant in the SIAH2 
locus associated with 
hormonal receptor-
positive breast 
cancer in Japanese 
1086 JA 
cases,  
1816 JA 
controls 
1653 JA 
cases,  
2797 JA 
controls 
10q26.13 FGFR2 rs3750817 8.00E-8 1.22 NR 
3q25.1 SIAH2 rs6788895 9.00E-8 1.22 [1.13-1.31] 
Siddiq, 
Dec 2012 
[198] 
A meta-analysis of 
genome-wide 
association studies of 
breast cancer 
identifies two novel 
susceptibility loci at 
6q14 and 20q11 
3666 EA 
cases, 28864 
EA controls, 
1004 AA 
cases, 2744 
AA controls 
562 EA 
cases,  
6410 EA 
controls, 84 
JA cases, 
830 JA 
controls,  
300 H, 1164 
H controls 
6q25.1 ESR1 rs9383938 2.00E-10 1.28 NR 
20q11.22 RALY rs2284378 1.00E-8 1.16 [1.10-1.22] 
19p13.11 ANKLE1 rs8100241 4.00E-8 1.14 NR 
6q14.1 FAM46A rs17530068 3.00E-7 1.16 [1.10-1.23] 
Abbreviations: NR=Not reported, AA= African Ancestry, A=Asian, AJ= Ashkenazi Jewish, CA= Chinese ancestry, EA= European Ancestry, 
EAA= East Asian Ancestry, H=Hispanic, JA= Japanese Ancestry, KA= Korean ancestry, UK= United Kingdom  
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Table 5: Summary of effect estimates for GWAS-identified and other selected breast cancer SNPs among women of European 
(EA) and African American (AA) ancestry 
 
Chro
m-
osome 
Gene or 
gene 
region 
SNP Minor Allele 
MAF: 
CEU 
MAF: 
YRI 
MAF: 
ASW 
Number 
of studies 
(EA/AA)  
Range of estimates 
for log-additive 
genetic model 
Notes on subtype 
findings 
EA AA 
1 1p12 rs11249433 G 0.43 0.07 0.09 7 / 5 1.00 - 1.18 
0.93 - 
1.08 
strongest association in 
Luminal A and B cancers 
2 2p rs4666451 A 0.45 0.23 -- 5 / 0 0.93 - 1.01 NE 
evidence of association 
with ER+ and ER- disease 
2 2q35 rs13387042 G 0.44 0.22 0.25 15 / 7 0.83- 0.91 0.83- 1.07 some association with all subtypes 
3 SLC4A7 rs4973768 T 0.44 0.29 0.32 10 / 5 0.89- 1.16 0.92- 1.06 
strongest association in 
Luminal A cancers; no 
association in triple-
negative cancers 
4 4p rs12505080 C 0.29 0.10 0.17 1 / 0 0.99 NE NE 
4 TLR1 rs7696175 T 0.47 0.00 0.09 1 / 0  0.99 NE 
Associated with ER+, ER- 
and HER2- disease in 
Chinese 
5 MRPS30 rs4415084 T 0.38 0.66 0.68 8 / 6 1.01- 1.17 0.89- 1.13 
stronger associations with 
ER+ or PR+ disease; 
mostly null associations 
with ER- or PR- disease 
5 MRPS30 rs10941679 G 0.24 0.17 -- 7 / 6 1.11- 1.19 0.94 - 1.14 
strongest association in 
Luminal A and B cancers; 
null association in triple-
negative cancers 
5 5p12 rs981782 C 0.39 0.00 -- 5 / 0 0.90- 0.97 
not 
polymorp
hic 
strongest associations 
with ER- and HER2- 
disease 
5 5q rs30099 A 0.08 0.18 0.14 3 / 0  1.02- 1.05 NR possible associations with ER+, ER- and HER2+ 
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disease 
5 MAP3K1 rs889312 C 0.30 0.31 -- 16 / 7 1.01- 1.26 0.93- 1.33 evidence of association with all subtypes 
6 ECHDC1 rs2180341 G 0.26 0.36 0.25  4 / 5 0.96 - 1.41 
0.98 - 
1.09 
predominantly null 
associations with ER and 
PR status 
6 ESR1 rs2046210 A 0.29 0.68 0.60  5 / 8 0.94- 1.15 0.94 - 1.11 
some association with all 
subtypes 
6 ESR1 rs851974 G 0.47 0.14 0.24  1 / 1 0.92 1.13 NE 
6 ESR1 rs2077647 C 0.43 0.48 0.59 4 / 0 0.97* NE NE 
6 ESR1 rs2234693 C 0.41 0.53 0.54 10 / 1 0.97* 1.43# NE 
6 ESR1 rs1801132 G 0.17 0.07 0.08 5 / 0 0.95* NE NE 
6 ESR1 rs3020314 C 0.26 0.78 0.64 2 / 0 1.12* NE NE 
6 ESR1 rs3798577 C 0.44 0.45 0.47 4 / 0 0.98* NE evidence of association with ER- and PR- disease 
7 RELN rs17157903 T 0.12 0.11 0.08 1 / 0  1.11 NE NE 
8 8q24 rs13281615 G 0.45 0.42 -- 15 / 6 1.07- 1.31 0.94- 1.16 
strongest association in 
Luminal A and B; null 
association in triple-
negative  
8 8q24 rs1562430 C 0.35 0.50 0.45 4 / 0 0.85- 0.93 NE 
Associated with ER+, ER-
, PR+, and PR- disease in 
Chinese (one study) 
9 CDKN2A/B rs3731257 A 0.26 0.06 0.12 1 / 0 0.95
# NE NE 
9 CDKN2A/B rs3731249 T 0.02 0.00 0.01 1 / 0 1.5
& NE NE 
9 CDKN2A/B rs1011970 T 0.17 0.37 0.28 2 / 4 1.08- 1.09 0.9- 1.07 
some evidence of 
association with ER+ and 
triple-negative 
10 ANKRD16 rs2380205 T 0.48 0.64 0.60 2 / 4 0.94- 0.98 0.98- 1.03 
possible inverse 
association with ER+ 
disease, null association 
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with triple negative 
10 ZNF365 rs10995190 A 0.13 0.18 0.20 2 / 2 0.85- 0.86 1.03- 1.12 inversely associated with ER+ disease 
10 ZMIZ1 rs704010 T 0.43 0.02 0.07 1 / 2 1.07 0.90- 0.99 
positively associated with 
all ER/PR subtypes, but 
not triple-negative disease 
10 FGFR2 rs3750817 T 0.36 0.01 0.04 2 / 0 0.78- 0.86 NE 
GWAS hit in study of 
hormone receptor positive 
disease 
10 FGFR2 rs10736303 A 0.47 0.07 0.11 1 / 1 1.25 1.21# 
evidence of associations 
with ER+ and PR+ 
disease 
10 FGFR2 rs11200014 A 0.47 0.22 0.31 5  / 0 1.24- 1.31 NE 
Associated with ER+, 
PR+, HER2+ and HER2- 
in Chinese study 
10 FGFR2 rs2981579 A 0.47 0.64 0.63 7 / 3 1.20- 1.43 0.99- 1.08 
associated with ER+/PR+ 
in AA,and most subtypes 
in Chinese study 
10 FGFR2 rs1078806 G 0.46 0.21 0.31 1 / 1 1.26 0.95 NE 
10 FGFR2 rs2981578 C 0.49 0.94 -- 1 / 4 1.26 1.17- 1.24 
evidence of association 
with ER+, ER- and PR+ 
disease 
10 FGFR2 rs1219648 G 0.47 0.44 0.44 13 / 5 1.23- 1.33 0.84- 1.21 
evidence of association 
with ER+, PR+ and 
HER2- disease 
10 FGFR2 rs2912774 T 0.47 0.60 0.53 2 / 2 1.26 - 1.33 1.15- 1.19 
evidence of association 
with ER+ and ER- disease 
10 FGFR2 rs2936870 T 0.45 0.66 -- 1 / 0 1.26 NR NE 
10 FGFR2 rs2420946 T 0.47 0.58 0.48 7 / 1 1.21- 1.34 1.1 NE 
10 FGFR2 rs2981582 A 0.46 0.49 0.47 17 / 8 1.15- 1.59 0.80- 1.22 
strongest association in 
Luminal A and B; null 
association in 
HER2+/ER- and triple-
negative  
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10 FGFR2 rs3135718 G 0.43 0.37 -- 1 / 0 1.07 NE NE 
10 10q rs10510126 T 0.16 0.11 0.11 1 / 0 0.83 NE NE 
11 LSP1 rs3817198 C 0.33 0.09 0.07 16 / 6 0.96- 1.51 0.85- 1.21 
Generally imprecise and 
inconsistent findings, 
possible association with 
unclassified disease 
11 LSP1 rs909116 C 0.43 0.22 0.31 1 / 0 1.17 NE NE 
11 H19 rs2107425 T 0.30 0.58 0.51 1 / 0 0.96 NE NE 
11 MYEOV rs614367 T 0.19 0.13 0.08 2 / 4 1.15- 1.21 0.96- 1.13 possible association with ER+ and PR+ disease 
16 TNRC9 rs8051542 T 0.45 0.23 0.33 5 / 1 0.96- 1.15 0.98 evidence of association with ER+ disease 
16 TNRC9 rs12443621 A 0.47 0.49 -- 5 / 1 0.86 - 1.11 0.99 no evidence of association 
16 TNRC9 rs3803662 A 0.25 0.55 0.54 21 / 9 0.87- 1.33 0.75- 1.04 evidence of association with all subtypes 
16 TNRC9 rs4784227 T 0.23 0.05 0.08  2 / 3 1.17- 1.29 1.09- 1.23 
positively associated with 
all ER and PR subtypes in 
one Korean study 
16 TNRC9 rs3104746 A 0.05 0.24 -- 0 / 2 NE 1.17- 1.23 evidence of association with ER+ and ER- disease 
16 TNRC9 rs3112562 G 0.26 0.50 -- 0 / 1 NR 1.17 NE 
17 COX11 rs7222197 A 0.32 0.33 0.35 1 / 0 0.89 NE NE 
17 COX11 rs6504950 A 0.30 0.31 -- 6 / 5 0.80- 0.95 0.79- 1.06 
inverse association in 
Luminal A and B; null 
association in 
HER2+/ER- and triple-
negative 
NE= not evaluated; *= from Zhang et al. [20]meta-analysis; #=homozygous rare versus homozygous wildtype; &= dominant model 
 
  
  
3. Methods 
3.1 Study population 
3.1.1 Case and control ascertainment 
  The Carolina Breast Cancer Study (CBCS) is a population-based, case-control study 
of invasive and in situ breast cancer conducted in North Carolina between 1993 and 2001. 
Cases from 24 central and eastern North Carolina counties (see Figure 20) were identified 
using the North Carolina Central Cancer Registry’s Rapid Case Ascertainment program. This 
program offers registrars financial incentives for accelerated registration of new cancer 
diagnoses and thus provides investigators with more immediate access to pathology reports 
and contact information for potential study participants [271, 272]. Women were eligible for 
CBCS if they lived in one of the 24 counties, were diagnosed with invasive, primary breast 
cancer between 1993 and 2001, and were between the ages of 20 and 74 at the time of their 
diagnosis. Women diagnosed with in situ breast cancer between 1996 and 2001 were also 
eligible if they had ductal carcinoma in situ with microinvasion to a depth of 2 mm or lobular 
carcinoma in situ.  
 To ensure approximately equal representation of African Americans and non-African 
Americans, as well as pre and postmenopausal women, breast cancer cases were randomly 
sampled at disproportionate rates based on their age and race category. For Phase I of the 
study (1993-1996) these sampling proportions were as follows: 100% of African Americans 
under age 50, 75% of African Americans aged 50 or older, 67% of 
non-African Americans under age 50, and 20% of non-African Americans aged 50 or older. 
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For Phase II of the study (1996-2001), all African American invasive and in situ cases were 
recruited, as were all non-African American in situ cases. 50% of younger, non-African 
American, invasive breast cancer cases were recruited, as were 20% of older, non-African 
American cases. Although urban or rural status did not affect sampling probability, the 24 
selected counties included geographically and socioeconomically diverse regions of the state.  
 Controls aged 20-64 and 65-74 were selected from North Carolina Department of 
Motor Vehicle and Health Care Financing Administration records, respectively. Controls 
were approximately frequency-matched to cases on race and 5-year age groups using another 
set of predetermined sampling fractions. These ranged from 0.003% of non-African 
Americans aged 20-24 years to 2.1% of African Americans aged 70-74 years. Women who 
did not live in the study area or who had previous history of breast cancer were ineligible.  
3.1.2 Data collection 
 Once a newly diagnosed case was selected as a potential study participant, CBCS 
personnel contacted the woman’s treating physician, who had the right to refuse any further 
contact with the patient. All approved cases and randomly selected controls received an 
introductory letter followed by a telephone call, if a phone number was available. If a number 
was not available, as occurred with 5% of potential cases and 40% of potential controls, a 
study nurse visited the potential participant’s home [272]. Women who met all eligibility 
criteria and verbally consented to study participation were scheduled for a home interview 
with one of the study’s registered nurses.  
 After obtaining written informed consent, the study nurse administered a 
questionnaire about demographic information and known or suspected breast cancer risk 
factors. The nurse also took body measurements, including height, weight and waist and hip 
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girths, and drew a 30 ml blood sample. For cases, the nurse asked for permission to access 
medical records and paraffin-embedded tumor tissue blocks. Some participants opted to have 
their blood drawn at a physician’s office and sent into the study. Whenever possible, a 
University of North Carolina (UNC) pathologist used provided tumor tissue blocks to 
confirm the breast cancer diagnoses.  
 The overall response rate was 77% for cases and 57% for controls. Among cases, 
older African Americans had the lowest response rate, with 71% of initially contacted 
women successfully enrolled. Younger African American controls were the least likely to 
participate, with only 48% responding. The highest response rates for cases and controls 
were for younger non-African Americans (82%) and older non-African Americans (66%), 
respectively. Total enrollment included 1808 invasive cases (787 African American, 1016 
non-African American), and 1564 corresponding controls (718 African American, 846 non-
African American), as well as 503 in situ cases (107 African American, 401 non-African 
American) and 458 corresponding controls (70 African American, 388 non-African 
American).  
 Of those enrolled, 88% of cases (2039 of 2311) and 90% of controls (1817 of 2022) 
provided sufficient blood samples for genotype analysis (see Figure 21). Non- African 
Americans were more likely to provide blood samples than African Americans, but blood 
donation status did not differ by stage of disease or other breast cancer risk factors [273].   
 More than 98% of non-African Americans self-identified as white, with the remaining 
2% identifying as multi-racial, Hispanic, Native American, Asian-American, or other 
race/ethnicity. Aside from the expected differences in age and race distributions, the only 
observed discrepancy between Phase I CBCS cases and other North Carolina Central Cancer 
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Registry cases was that African Americans aged 40-59 with later stage disease were 
underrepresented in CBCS [274].  
3.1.3 SNP selection 
 I selected candidate single nucleotide polymorphisms (SNPs) for the proposed 
analysis from a list of SNPs already successfully genotyped in the CBCS population. As the 
purpose of my investigation is to evaluate the effect of previously established breast cancer 
risk variants within the CBCS population, I retained any SNPs identified as hits in genome-
wide association studies (GWAS) or that had strong and consistent evidence of an 
association in a candidate gene meta-analysis [20]. I also included any SNPs in the same 
gene as a selected risk variant.  
 As the most recent genotype analysis of CBCS participants was completed in mid-
2010, only some of the GWAS hits were included. In total, I selected 31 SNPs with genome-
wide significant or nearly genome-wide significant p-values in studies published before 
September 2010 [186, 187, 189, 194, 196, 197, 201, 205, 208, 209], 31 SNPs from the same 
genes as previous GWAS hits, and 21 SNPs from 3 critical candidate genes (ATM, CASP8, 
and TP53). I considered 41 of these SNPs to be ‘GWAS-identified’, which meant that they 
were either GWAS hits (n=22), near GWAS hits (n=9), or on the same gene as a GWAS hit 
and assessed in a GWAS study (n=10). Of the remaining 21 SNPs from GWAS-identified 
genes, nine had never before been evaluated in whites or African Americans with breast 
cancer.  The full list of included SNPs can be seen in Table 6. This table includes the SNPs 
discussed in sections 2.7.3, 5 ATM, CASP8, TP53 or ESR1 SNPs identified by Zhang et al. as 
having strong evidence of an association with breast cancer [20], and other ATM, CASP8, 
and TP53 SNPs. Given that the candidate gene hits and the GWAS-identified SNPs had a 
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concrete reference OR (from Zhang et al. or the original GWAS, respectively), these SNPs 
were eligible for replication. I considered a SNP to have replicated successfully if the OR 
was in the same direction as the reference OR and the 95% CI or 95% posterior interval (PI) 
excluded the null.  
3.1.4 Ancestry informative markers (AIMs)                           
 A panel of 144 ancestry informative markers (AIMs) was also genotyped in all CBCS 
participants with available blood samples. To be useful as an AIM, a genetic variant (usually 
a SNP) must have a widely discrepant MAF in the relevant parent populations and be highly 
informative of ancestry [275, 276]. In CBCS, we selected AIMs that could distinguish 
between European and African ancestry. More specifically, we selected SNPs with MAF 
differences of at least 60% between the International HapMap CEU and YRI populations that 
had high values for Fisher’s information criterion. This was completed for the following 
admixture proportions, all of which are likely scenarios in CBCS: 90% European/ 10% 
African, 90% African/ 10% European, and 50% European/ 50% African [210]. Fisher’s 
information criterion is the inverse of the variance of the maximum likelihood estimate of the 
ancestral contribution, and can therefore be interpreted as a measure of precision for the 
ancestral proportion estimate [277]. A more detailed account of the CBCS AIMs selection 
process and a table of selected markers can be found in Barnholtz-Sloan et al [210]. Of note, 
the ASW HapMap population (African Americans living in the Southwest USA) was not 
available when these AIMs were selected.  
3.1.5 Genotype analysis                          
 The SNPs included in this analysis were genotyped at two different times using two 
different genotyping platforms. Most SNPs were evaluated with a Custom GoldenGate 
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Genotyping assay from Illumina (Illumina, Inc., San Diego, CA). A few SNPs that failed 
Illumina genotyping analysis were reassessed using a Taqman panel. The Taqman analysis 
also included a number of GWAS hits identified in the time since the Illumina panel was 
performed.  
 These analyses are used to determine whether an individual has two copies of the 
common allele, two copies of the variant allele, or one copy of each. These three possible 
genotypes are also described as homozygous for the major allele, homozygous for the minor 
allele, or heterozygous. In some cases, the allele that is more common in whites was the rare 
allele in African Americans.  
3.1.5.1 Illumina assays 
 Initially, 1762 SNPs were submitted to Illumina for review and preliminary quality 
control assessment. Illumina validated each SNP according to its dbSNP identification 
number [278, 279], and provided designability scores to indicate the probability that each 
SNP would be genotyped successfully on their platform. 1365 SNPs passed this initial review 
process. To replace the failed SNPs, CBCS investigators selected the best possible substitutes 
and resubmitted the SNP panel to Illumina until a complete set of 1536 SNPs with passable 
design scores was identified.  
 Once the custom solid-phase bead assay was received from Illumina, the 3857 CBCS 
participants with available blood samples were genotyped for all 1536 SNPs in UNC’s 
Mammalian Genotyping Core lab. At UNC, 2 µg of participant DNA were extracted, then 
activated and combined with assay oligonucleotides, hybridization buffer, and paramagnetic 
particles [280]. Each assay contained three locus-specific oligonucleotides for each SNP, two 
of which bonded directly to the allele sites, and a third that hybridized downstream from the 
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other two. The third oligonucleotide contained a unique address sequence that corresponded 
to a particular bead type.  
 After several wash steps and the addition of DNA ligase, the oligonucleotide-tagged 
sequences formed double-stranded DNA fragments. These fragments were amplified with 
dyed polymerase chain reaction (PCR) primers such that each allele of a given SNP was 
uniquely labeled. Lastly, the finalized, single-stranded, dye-labeled DNA products were 
hybridized to the bead type specified by the address sequence contained in the third 
oligonucleotide. In this final form, the fluorescence signal of each bead, and thus the 
genotype of each SNP, could be measured using Illumina’s BeadArray Reader. 
3.1.5.2 Illumina Quality Control 
 CBCS investigators used several quality control techniques to measure and improve 
overall data accuracy. This included the use of blind duplicate samples, lab controls, the 
examination of individual call rates, and careful inspection of assay intensity data and 
genotype clustering images.    
 Roughly four percent (169 of 3857) of samples underwent duplicate, blinded 
genotyping. Of more then 200,000 possible discrepancies, 11 genotype miscalls were 
identified in these samples. DNA samples from the HapMap CEU population (provided by 
the Coriell Institute for Medical Research) were also repeatedly genotyped as lab controls, 
with only 2 discrepancies in 184 replications. As these error rates were well-within 
reasonable limits, no SNPs were excluded based on these results. However, closer inspection 
of assay intensity data and genotype clustering images did lead to the exclusion of 163 of the 
1536 genotyped SNPs (11%). Here, SNPs were excluded from further analyses if they 
showed low signal intensity or if genotype clusters were overlapping, as both are indications 
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of genotyping error.   
 Individuals were excluded from further analyses if they had call rates of less than 
95% for the 1383 remaining SNPs. 103 participants met this exclusion criteria. Six other 
subjects were omitted, including 5 genotyped as male and 1 with conflicting duplicate 
samples. Case, race, age, and stage distributions were similar for excluded and included 
subjects [273]. After exclusions, genotyping information was available for 3748 participants 
(1972 cases, 1776 controls) and 1373 SNPs, including 57 of the 83 candidate SNPs selected 
for this analysis and 144 AIMs.   
3.1.5.3 Taqman assays 
 The remaining 26 candidate SNPs were genotyped using Applied Biosystems’ (Foster 
City, CA) fluorogenic 5’ nuclease assay (‘TaqMan®’) and PRISM® 7900HT Sequence 
Detection System in UNC’s Mammalian Genotyping Core lab. As with the Illumina assays, 
the TaqMan assays were customized to target specific candidate SNPs. However, instead of 
oligonucleotides, TaqMan assays contain site-specific primers and fluorescently labeled 
probes for each selected SNP. TaqMan is more appropriate for genotyping a small number of 
SNPs in up to several thousand samples.  
 The genotyping process begins when activated DNA is combined with the custom-
designed SNP genotyping assay and the Taqman Universal PCR Master Mix. During the 
PCR process, which consists of 10 minutes at 95˚ C, followed by 40 cycles of 15 seconds at 
92˚ C and 1 minute at 60˚ C, the AmpliTaq Gold® DNA polymerase contained in the master 
mix amplifies genomic regions where the primers and probes have annealed [281]. As the 
probe is digested by the polymerase, it releases a unique fluorescence signal which is read 
using the PRISM® 7900HT Sequence Detection System. 
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3.1.5.4 Taqman Quality Control  
 Approximately 10% of the CBCS samples were run as blind duplicates, all of which 
were in agreement. Although several SNPs failed the initial design phase, all of the 
genotyped SNPs met quality controls standards. No additional participants were removed due 
to low call rates.  
3.1.5.5 SNP exclusions 
 I excluded six SNPs with MAFs less than 1% in white participants and ten SNPs with 
MAF less than 1% in African Americans, leaving a total of 77 evaluable SNPs in whites and 
73 in African Americans. 79 SNPs with MAF greater than 1% in the non-racially stratified 
CBCS population were evaluated in subtype analyses.  
3.1.6 IHC analysis        
 Tumor tissue was collected from 80% of all cases (1446 of 1808 invasive cases and 
399 of 503 in situ cases) and sent to the UNC Immunohistochemistry Core Laboratory for 
storage and assaying of three or more immunohistochemical (IHC) markers. This process has 
also been described in previous CBCS publications [3, 4, 89]. 
 When available, estrogen receptor (ER) and progesterone receptor (PR) status was 
abstracted from the patient’s medical records. This information was provided for 
approximately 80% of all invasive cases. For the remaining 11% of invasive cases with 
available tissue, ER and PR IHC assays were performed at the UNC core laboratory using 
archived tumor tissue [282]. Tumors with more than 5% of cells showing nuclei-specific 
staining were considered receptor positive [283]. A random 10% sample of tumors reported 
as ER+ in medical records were retested in the UNC lab, as were a random 10% sample of 
ER- tumors. With a concordance of 81% and a kappa statistic of 0.62 between the medical 
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records and the UNC-run assays, CBCS investigators decided that agreement was high 
enough to justify the continued reliance on medical records data [3].   
 All tissue samples with sufficient tissue were assayed for human epidermal growth 
factor receptor 2 (HER2), human epidermal growth factor receptor 1 (HER1 or EGFR), and 
cytokeratin 5/6 (CK 5/6) in the UNC Immunohistochemistry Core Laboratory. HER2 status 
was detected using the CB11 monoclonal antibody [284]. A case was considered HER2+ if at 
least 10% of observed cells showed signs of staining. This method had high concordance 
(81%) with PCR-based measures of HER2 gene expression. HER1 and CK 5/6 assays were 
conducted according to the methods developed by Nielsen et al [42]. Here, tissue with any 
sign of cytoplasmic or membranous staining was considered positive for CK 5/6 or HER1, 
respectively.  
 Due to the limited amount of available tissue, IHC analyses for in situ tumors were 
handled differently. The process is fully described in Livasy et al [89]. Briefly, tumor tissue 
was stained using antibodies for ER, HER2, HER1 and CK 5/6, then classified as positive or 
negative for each marker based on pre-established criteria. Tumors with an Allred score 
above 2 with nuclear staining were ER+. Tumors were HER2+ if more than 10% of visible 
cells demonstrated membranous staining with an intensity of 3+ using DAB chromogen or 
2+/3+ using SG chromogen. For CK 5/6 and HER1, any tissue with staining in the cytoplasm 
or membrane, respectively, was considered positive for expression. Given the high 
correlation between ER and PR expression [34-37] and the paucity of available tissue, PR 
status was not assessed in in situ tumors [4].  
 Upon completion of the IHC analyses, breast cancer cases were categorized according 
to their intrinsic subtype. As described in section 2.5, these subtypes are classified as follows: 
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luminal A (ER+ and/or PR+, HER2-), luminal B (ER+ and/or PR+, HER2+), HER2+/ER- 
(ER-, PR-, HER2+), and basal-like (ER-, PR-, HER2-, HER1+ and/or CK 5/6+), with those 
negative for all 5 markers considered “unclassified”. Altogether, 62% of cases were assigned 
subtypes, including 1149 invasive and 275 in situ cases. Compared to CBCS cases without 
IHC marker data, subtyped cases were more likely to be African American or have a higher 
stage of disease [4]. There were no differences between CBCS cases with and without IHC 
marker data in terms of age, menopausal status, or family history. 
 Of the 1972 cases with genotyping data, 1220 (62%) also had complete subtype 
information (Figure 21). Among individuals with both genotyping and subtype data, there 
were 700 luminal A cases (56%), 122 luminal B cases (10%), 98 HER2+/ER- cases (8%), 
207 basal-like cases (16%), and 133 unclassified cases (11%). This subtype distribution is 
virtually identical to the subtype distribution of all CBCS participants, as reported in Millikan 
et al [4]. In this regard, participants with genotyping and subtype information are well 
representative of all CBCS participants with subtype data.  
 
3.2 Other covariates 
3.2.1 Race and age  
 Prior to initial contact, potential participants’ race and age were abstracted from either 
the pathology report (cases) or Department of Motor Vehicle or Health Care Financing 
Administration records (controls). Each woman’s selection probability was based on this 
preliminary data. During the enrollment and eligibility confirmation phase of the study, each 
control was asked to verify her current age and each case her age at diagnosis. Additionally, 
nurse interviewers recorded each participant’s exact birth date during the in-home interviews 
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and confirmed that this date was consistent with prior reports. Nurse interviewers also asked 
participants to describe which racial group they belonged to – White, Black/African 
American, American Indian/ Eskimo, Asian/ Pacific Islander, or Other – and whether they 
considered themselves to be Hispanic.  
3.2.2 Stage at diagnosis 
 Breast cancer stage at diagnosis, as defined by the American Joint Committee on 
Cancer criteria, was abstracted from cases’ medical records. Briefly, women with in situ 
disease were classified as Stage 0 and women with progressively larger primary tumors 
and/or more lymph node involvement had Stages I, II or III breast cancer. Women with 
distant metastases were diagnosed with Stage IV disease [285].  
3.2.3 African and European ancestry  
 When examining how genetic variations affect disease status, I also had to account 
for differences in allele frequencies due to divergent ancestral origins. This phenomenon is 
known as population stratification. Self-identified race can capture some of the variability 
caused by population stratification, but many individuals cannot accurately classify their own 
ancestry. This is especially true with recently admixed populations, such as African 
Americans, who often have both African and European lineage.  
 In the CBCS, each participant’s proportion of European and African ancestry was 
estimated using maximum likelihood estimate (MLE) methods, 144 AIMs, and allele 
frequencies in HapMap CEU and YRI individuals. The HapMap populations served as 
proxies for the European and African parent populations, respectively. By including only 
these two parent populations, we assumed that each individual descended from one or both of 
these two groups, but no others. Individual ancestry proportions were estimated using the 
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equations described below [286]. 
  Given ancestral contributions m1 and m2, the probability of observing the kth allele at 
the gth locus in an admixed population A is:  !!"# = !!!!!! +!!!!!!. 
Based on our assumption that each population’s ancestry is limited to only two parent 
groups, we know that m1 + m2 =1. We can also define δ as the allele frequency difference in 
the two parent populations, such that δ = pg1k- pg2k. With these substitutions, we now have: !!"# = !!!!!! +!!!!!! = !!!! +!!!!!!. 
The likelihood of this function is equal to the product of each possible value of g and k: ! = !!"#!! = ! (!!!! +!!!!!!)!! ,  
and the log-likelihood is: 
 !ln(!) = ! ln !!"# = ln !!!! +!!!!!!!!!! .  
By maximizing this log-likelihood, we can obtain an equation that can be used to estimate the 
value of m1 that is most probable given the provided data:  
!!"(!)!!! = ! !!!!!!!!!!!!!!!!! = 0. 
The MLE of m1 was estimated using the Newton-Raphson method [286].  
 For our analysis, we treated each participant as a population with a sample size of one 
and estimated her proportion of European ancestry based on her genotype for each of the 144 
AIMs. Among African American CBCS participants, the median proportion of European 
ancestry was 0.19 (average= 0.22), with most women in the 0 to 0.50 range [210, 287]. The 
large majority of self-identified whites had between 80% and 100% European ancestry, with 
a median proportion of 0.94 (average = 0.93). The small proportion of women who self-
identified as mixed race, Hispanic, Asian/ Pacific Islander, or American Indian/ Eskimo had 
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median European ancestry estimates of 0.93, 0.75, 0.73 and 0.60 respectively.   
 
3.3 Statistical methods 
3.3.1 Descriptive statistics  
 Although previous publications have included detailed descriptions of the 
demographic and clinical characteristics of CBCS participants [3, 4, 282], I generated race-
stratified frequency estimates for the distribution of age, subtype, and stage at diagnosis for 
the women included in these analyses. To account for the unequal sampling and provide 
population-based estimates, frequency estimates were weighted by the inverse of the 
probability of being selected as a CBCS participant. I also provided weighted case- and race-
stratified genotype frequencies (Aim 1) and weighted race and subtype-stratified genotype 
frequencies (Aim 2). These descriptive statistics provided a preliminary account of the 
exposures and outcomes of interest and allowed comparisons between and across 
populations. Women who self-identified as a race other than non-Hispanic white or African 
American were excluded from race-stratified analyses, though they were included in some 
overall evaluations (Aim 2 only).  
3.3.2 Hardy-Weinberg equilibrium 
 In conjunction with the case and race-stratified genotype frequency analysis, I 
assessed whether the control population for each racial group was in Hardy-Weinberg 
equilibrium (HWE). According to the Hardy-Weinberg Law, “the genotype and allele 
frequencies in a large, randomly mating population remain stable over generations and there 
is a fixed relationship between allele and genotype frequencies” [288]. In practice, this means 
that the proportion of individuals with each genotype should directly correspond to the 
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overall allele frequencies for the population. In other words, if alleles A and B occur with 
frequencies pA and pB, then the relative frequencies of genotypes AA, AB and BB should be 
roughly equal to pA2, pApB and pB2, respectively.  Any violation of this relationship is a sign 
of non-random genotyping error, population stratification, natural selection, disease 
association, or chance. As the probability of natural selection within a single generation is 
quite minimal, the degree of disequilibrium due to either genotyping error or chance can be 
quantified by testing for HWE within racially restricted control populations.  
 I evaluated HWE using Pearson’s chi-square test. For each SNP I compared the 
number of individuals with genotype i expected under HWE (Ei) to the number of individuals 
observed with genotype i (Oi).  !! = (!!!!!)!!!!!! , with 1 degree of freedom (df) 
I conducted this analysis in African American and white control populations separately. Any 
SNP with a p-value less than 0.05 was considered in violation of HWE. Although violation 
of HWE may indicate genotyping error, the test has poor sensitivity and there is poor 
agreement on appropriate significance cut-points [289]. Therefore, rather than simply 
excluding those SNPs that were not in HWE, clustering images of those in Hardy-Weinberg 
disequilibrium were re-inspected for signs of poor genotype differentiation. SNPs were 
retained as long as their genotypes formed discrete clusters with minimal overlap and HWE 
was not violated in both population groups. As this strategy cannot rule out certain types of 
genotype misclassification, such as allelic drop-out, any SNPs not in HWE were noted and 
interpreted with caution [290].  
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3.3.3 Linkage disequilibrium 
 LD blocks were defined using Haploview (Haploview 4.2, Version 1.0, Broad 
Institute, Cambridge, MA, USA) [164] and haplotype block criteria established by Gabriel et 
al [165]. I assessed LD patterns in whites and African Americans separately. I used the 
ALLELE procedure in SAS v9.3 (SAS, Cary, NC) to calculate between SNP correlation 
measures r and D" [288].  
3.3.4 Confounding and other adjustment factors 
 Confounders are factors that are related to the exposure and disease of interest in such 
a way that the estimated effect of the exposure on the disease are difficult to separate out 
from the combined effect of the exposure and the confounder on the disease. To be a 
confounder, a factor must be (1) an extraneous risk factor for the disease, (2) associated with 
the exposure under study in the source population and (3) not be affected by the exposure or 
the disease [291]. In terms of the analyses proposed here, a true confounder must affect a 
woman’s genotype and her breast cancer incidence (Aim 1) or a woman’s genotype and her 
breast cancer subtype (Aim 2). As there are few factors that can affect genotype, the list of 
potential confounders is limited to ancestry, race, and age.  
3.3.4.1 Ancestry and Race  
 As discussed previously, allele frequency patterns vary across populations. These 
divergent patterns, known as population stratification, persist as long as populations remain 
isolated. However, if individuals from two previously isolated populations reproduce, as 
occurred with African Americans and, to a lesser extent, US whites, the populations become 
admixed and their offspring have allele frequencies somewhere between that of the two 
parent populations.  
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 Population stratification can induce confounding in genetic association studies if both 
the genotype frequency and underlying disease risk vary by ancestry [291, 292]. Given the 
racial disparities in breast cancer incidence and subtype distributions discussed in sections 
2.2 and 2.5.1, respectively, and the MAF discrepancies between the CEU, YRI and ASW 
populations presented in Table 5, population stratification likely confounds the association 
between genotype and breast cancer risk and between genotype and breast cancer subtype. 
Stratifying by self-reported race will partially address this concern, but because admixture 
has produced a great deal of variability within self-identified populations, I also adjusted for 
proportion of African ancestry. This proportion was centered at its overall mean for the 
subtype-specific analyses (Aim 2), but at the race-specific means for the overall breast cancer 
analysis (Aim 1) and the race-stratified subtype analyses (Aim 2). The causal directed acyclic 
graph (DAG) included as Figure 22 illustrates the relationship between these factors.  
 For Aim 1, I stratified by race as both a means to control confounding and to explore 
effect modification between African Americans and whites. In addition to affecting breast 
cancer incidence, breast cancer subtype, and allele frequencies, race also affects LD patterns. 
As most of the candidate SNPs are probably highly correlated with causal variants, rather 
than causal SNPs themselves, comparing results across populations may help to pinpoint the 
genomic region where the true causal SNP is located.  
 I also conducted some race-stratified analyses within the breast cancer subtype 
analysis (Aim 2), but because of within-strata sample size limitations, my primary analyses 
were completed using the entire CBCS population. This included women who identified as 
something other than non-Hispanic white or African American. In these overall analyses, I 
adjusted for race as a dichotomous variable (African American vs. non African American). 
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3.3.4.2 Age at selection 
 Older age is strongly associated with overall breast cancer incidence, and average age 
at diagnosis varies by breast cancer subtype. Although one’s genotype does not change with 
age, genotype can affect survival, and thus influences the probability that women with certain 
genotypes will be selected into the study. For this reason, I adjusted for age as a selection 
factor in both sets of analyses. In all analyses, I centered age at 50 years.  
3.3.4.3 Offset term 
 In addition to race, proportion European ancestry, and age, all models were adjusted 
for an offset term to account for the uneven sampling fractions utilized during study 
recruitment. Inclusion of this offset term, which was equal to the case versus control ratio of 
the log of the selection probability, eliminated the selection bias created by the distorted 
sampling [293]. This method is more efficient than traditional matched designs, and allows 
for simple, unbiased valuation of population-based point estimates and variances [294].  
3.3.5 Frequentist analysis 
  In addition to Bayesian statistical methods, which will be discussed in the following 
section, I estimated ORs and 95% CI using frequentist-based unconditional logistic 
regression models. Effect estimates obtained using these methods were directly comparable 
to previously published reports for the same SNPs and also served as reference points for the 
estimates obtained using Bayesian analysis methods. I did not adjust for multiple 
comparisons, as these were primarily candidate SNPs. Because they are calculated using 
maximum-likelihood estimation, I will herein refer to the frequentist estimates as the MLE 
ORs. 
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3.3.5.1 Genotype classification 
 For Aim 1, I estimated the association between each selected risk variant and incident 
breast cancer. For Aim 2, I estimated the association between each selected risk variant and 
breast cancer subtype. In both analyses, the risk allele for each SNP was selected a priori 
based on previously published results.  
 For whites, I selected risk alleles for SNPs in ATM, CASP8, ESR1 and TP53 based on 
the ORs reported by Zhang et al. in their comprehensive meta-analysis [20]. For the GWAS-
identified SNPs, I ascertained the risk allele in the original GWAS [186, 187, 189, 194, 196, 
197, 201, 205, 208, 209] and then compared these findings to subsequent replication studies 
[162, 163, 166, 168, 169, 188, 190, 191, 195, 199, 200, 202-207, 211-213, 216, 218-222, 
224, 225, 228-230, 232-237, 241-243, 245, 246, 250-256, 295-301]. As all of the statistically 
significant (p<0.05) ORs were in the same direction as the original GWAS, all designated 
risk alleles are identical to those indicated in the initial assessment (see Table 7). If a 
candidate SNP was not assessed in a GWAS or Zhang et al., I designated the minor variant as 
the risk variant, using the HapMap CEU population as a reference. The only exception to this 
rule was for the major allele of rs3750817 (FGFR2), which was associated with an increased 
risk of breast cancer in two large case-control studies and an increased risk of ER or PR+ 
disease in a later GWAS [169, 193, 252]. 
 I assumed the risk allele was the same for African Americans as it was for whites 
unless the majority of reported statistically significant associations were contradictory to 
those seen in whites. Two SNPs met these criteria (rs3803662 on TNRC9/TOX3 and 
rs1045485 on CASP8) [11, 12, 161, 169, 214-216, 220, 302-311]. 
 I estimated three MLE ORs for each SNP-outcome combination. Two of these ORs 
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were estimated assuming a general genetic model and the last was estimated assuming an 
additive genetic model. Either genetic model can be used to generate estimates for the 
relative effect of having one or two copies versus no copies of the risk allele, but the additive 
model makes the assumption that the relationship between the log ORs is linear. In other 
words, when assuming a general model, I treated genotype as a three-level categorical 
variable and estimated two ORs, one for the effect of being heterozygous versus homozygous 
for the risk allele, and one for the effect of being homozygous for the risk allele versus 
homozygous for the referent allele. With the additive model, I treated genotype as an ordinal 
variable with three levels corresponding to the number of copies of the risk allele (0, 1, or 2). 
The OR estimated using this model corresponded to the effect of being heterozygous versus 
homozygous for the referent allele, while e2*ln(OR) was the estimated effect of being 
homozygous for the risk allele versus homozygous for the referent allele. The additive model 
includes one less parameter than the general model, but it is also more restrictive and may 
fail to capture the relationship between the SNP and the outcome.  
 Alternatively, SNPs may follow dominant or recessive genetic patterns. Under either 
model assumption, two of the genotypes are grouped together, such that individuals with one 
or two copies of the risk allele have equal risk of the outcome (dominant model) or 
individuals with one or no copies of the risk allele have equal risk of the outcome (recessive 
model). These genetic models appear much less frequently in the literature, but are useful 
replacements for the general or additive model when the proportion of individuals 
homozygous for the risk allele is especially low or especially high. Accordingly, I estimated 
the OR using the dominant model for any SNPs with risk allele frequency (RAF) of less than 
5% in either cases or controls and used the recessive model when the RAF was greater than 
  101 
95%.   
3.3.5.2 Outcome classification 
 For my first aim, the outcome of interest was breast cancer, which included both 
invasive and in situ disease. This outcome was coded as a dichotomous variable, with each 
SNP-specific OR estimating the odds of being a case rather than a control among women of 
one genotype, relative to the odds of being a case rather than a control among women of the 
referent genotype.  
 To address my second aim, I treated breast cancer subtype as a categorical variable 
with six levels (control, luminal A, luminal B, HER2+/ER-, basal-like or unclassified) and 
modeled ORs using polytomous logistic regression models. With each polytomous model, I 
simultaneously estimated the effect of a given risk variant on the odds of having each 
subtype relative to being a control.  
3.3.5.3 Logistic regression  
 As this was a retrospective case-control study with unequal sampling of cases and 
controls, logistic regression was an appropriate method to model the effect of genotype on 
breast cancer risk in the presence of known and measured confounders and selection factors. 
Assuming a general genetic model and stratification by race, the estimated odds of having the 
outcome of interest (Y=1) given genotype g took the following form: Odds! Y = 1! G = g, race = r) = !exp!(! + !!!!! + !!!!! + !!!"# + !!!"#$%&'( +!""#$%), 
where x1=1 for heterozygotes, and 0 otherwise and x2 = 1 for risk allele homozygotes and 0 
otherwise. β1 and β2 estimated the log ORs for the effect of a heterozygous versus 
homozygous referent genotype and the homozygous risk genotype versus homozygous 
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referent genotype on breast cancer risk, respectively. The additive model took a similar form: Odds! Y = 1! G = g, race = r) = exp ! + !!!!! + !!!"# + !!!"#$%&!" + !""#$% , 
where x1 was equal to the number of copies of the risk allele and β1 was the log OR for the 
effect of each additional copy of the risk allele on the odds of having breast cancer. ORs and 
95% CIs were estimated using the LOGISTIC procedure in SAS v9.3 (SAS, Cary, NC).  
3.3.5.4 Polytomous logistic regression  
 To create the polytomous logistic regression model, I expanded the above binary 
form to include unique coefficients for each level of the outcome. This included a unique 
intercept and SNP, age, and ancestry parameter for each of the five subtypes. I selected this 
approach based on evidence that effect estimates generated using polytomous logistic 
regression models have lower standard errors than effect estimates fit using five separate 
binary logistic regression models [312]. I assessed the polytomous MLE ORs using the 
‘glogit’ link function in PROC LOGISTIC (SAS, Cary, NC). 
3.3.6 Bayesian analysis 
 At the cost of a few additional assumptions about the data and associations of interest, 
Bayesian statistical methods offer a powerful and more easily interpreted alternative to 
frequentist methods. Although many investigators avoid these methods because of added 
complexity and subjectivity, the added complexity is only moderate and frequentist analyses 
are also subjective. Moreover, my research questions could be addressed more effectively 
using Bayesian techniques, as such methods allowed me to use previous research to produce 
more accurate and precise effect estimates while implicitly controlling for false positive 
associations. 
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3.3.6.1 Bayes law 
 The difference between Bayesian and frequentist methods can best be described using 
Bayes’ Law, a principle of conditional probability:  
! ! ! = ! !(!)!(!) !!(!|!) 
Here θ is the parameter of interest, D are the observed data, and p(θ|D), the probability of 
observing an effect θ given the observed data, is the desired estimate. P(θ|D) is often referred 
to as the posterior probability and written in the form π(θ|D). Although the above form of 
Bayes’ Law only allows for a single parameter, it can easily be expanded to accommodate 
more variables.  
 As θ is an unknown random variable, the probability of observing data D given 
parameter θ, p(D|θ), is best estimated using a likelihood function, L(θ|D). Although the form 
of the function depends on the investigator’s research question and modeling assumptions, he 
or she would utilize the same likelihood function in a Bayesian or frequentist analysis.  
 Additional subjectivity is introduced into Bayesian analysis with the specification of 
p(θ), which is the probability of observing parameter θ independently of, or prior to, 
observing data D. As this quantity cannot be directly measured, it must be assigned by the 
investigator based on his or her prior knowledge about the nature of the association of 
interest. If the investigator is unwilling to assign an informed probability distribution to p(θ), 
the prior is given an infinite, uniform distribution. In this way, a frequentist analysis is 
equivalent to a Bayesian analysis where all values of θ, from - to + are equally likely.  
 The last term of Bayes’ Law is p(D), the marginal distribution of the data. This 
quantity is directly dependent on the values of p(θ) and p(D|θ) and takes the following form: 
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! ! ! ! ! !"!! . As this quantity is not dependent on θ, we can ignore its exact 
specifications and state Bayes’ Law as a simple proportional relationship between the 
posterior probability and the product of the prior probability and the likelihood function: ! !|! ∝ ! ! !(!|!). This proportion conveys the simple nature of the mathematical 
relationship between frequentist methods, which rely solely on the likelihood function, and 
Bayesian methods, which are additionally dependent on the specification of a prior 
probability estimate.  
3.3.6.2 Priors  
 A simple way to incorporate the prior is to add a second stage to the likelihood 
model. If the likelihood takes the form of a logistic regression, with the log OR of being a 
case given exposure Xj and covariates W modeled as: ln !!!! = !!! + !!!! +!", a second 
level can be added to the coefficient of the exposure !!: !! = !!! + !!!. Here, zj is a j×1 
matrix of 1’s, π is the prior log OR, T is a j×j identity matrix and the δj are assumed to be 
normally distributed with mean 0 and variance τ2T. The prior mean (π), variance (τ2T), or 
both can either be estimated directly from the data or assigned by the investigator. I use the 
term ‘full-Bayes’ to indicate that priors were assigned independently of the data at hand, 
‘empirical Bayes’ when both were estimated from the data, and ‘semi-Bayes’ when one prior 
was assigned and the other was estimated [14].  
3.3.6.3 General benefits of Bayesian analysis 
 Essentially, posterior probabilities are the result of shrinking the MLE towards the 
specified prior estimate, with the degree of shrinkage determined by the variance of the MLE 
relative to the variance of the prior [14, 313, 314]. In this way, including any prior with a 
finite variance will reduce the variance of the posterior probability relative to the MLE, 
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though the discrepancy will be minimal if the sample size is large and the prior is diffuse. If 
the MLE is between the true parameter value and the mean of the prior distribution, the 
shrinkage process will generate a biased effect measure. However, if the prior is well-
selected, any increase in bias due to shrinkage will be offset by an increase in precision, and, 
on average, allow more accurate effect estimation.  
 Bayesian effect estimates are also easier to interpret than frequentist estimates, as 
they can be phrased in terms of probability rather than the idea of repeated, unbiased 
sampling of the target population. For example, a frequentist 95% confidence interval refers 
to the region that will include the true parameter in 95% of infinite replications of unbiased 
data collection and measurement [291]. Alternatively, a 95% posterior interval (95% PI) is 
the region where the probability of covering the true estimate is 95% [315]. In terms of the 
actual effect estimates, a frequentist-determined estimate is the parameter that maximizes the 
likelihood of the observed data, while a Bayesian effect estimate reflects the odds that an 
investigator would place on the estimated parameter versus an alternative parameter, given 
his or her prior knowledge and the observed data.  
 Admittedly, the relative benefits of Bayesian analysis are dependent on the 
investigator’s choice of prior. While this requires a certain degree of subjectivity, prior 
selection is not arbitrary. The best priors are selected based on previously published findings 
or because of certain inherent properties. For example, null-centered priors will shrink all 
estimates towards 0, thereby attenuating the effect sizes of extreme observations and 
reducing overall type I error [14, 15]. If an investigator is concerned about the bias or 
generalizability of others’ results, he or she can accommodate this uncertainty by selecting a 
prior with a large variance. Additionally, while it is not possible to verify how a prior affects 
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the validity of an estimate, one can easily compare the relative influences of a variety of 
priors using sensitivity analyses. 
3.3.6.4 Application to replication of breast cancer susceptibility loci 
 For many of the reasons described above, Bayesian methods were well-suited to 
address the described research questions [316, 317]. First of all, most of the selected SNPs 
have been studied previously, many of them in 5 or more separate investigations. Nearly all 
of these replication studies were conducted using a case-control study designs and well-
defined, race-specific populations. While these studies may suffer from selection biases or 
other sources of error that affect generalizability or comparability, the assessment of both 
genotype and breast cancer status was extremely consistent across studies, with most 
previous studies of the association between known susceptibility variants and breast cancer 
producing ORs in the range of 1.1-1.3 [18, 20, 318]. 
 Additionally, Bayesian methods provide a means to advance research on the less 
studied topics of genetic risk factors for African Americans and breast cancer subtypes. 
Previous investigations have evaluated these SNPs in African Americans or within specific 
subtypes, but such analyses often have small sample sizes and thus produce only imprecise 
effect measures. By constructing priors based on previous knowledge about SNPs’ effects on 
overall breast cancer in previous studies of white or Asian populations, we can conduct 
better-informed statistical analyses and obtain valid and precise race-specific and subtype-
specific ORs.    
 When examining numerous SNPs in the same study, most investigators apply 
Bonferroni corrections to control for false positive associations and ensure that the overall α-
level remains at an acceptable level (usually 0.05). Because SNPs are often highly correlated 
  107 
with one another, multiple comparisons correction via Bonferroni methods are overly-
conservative and may fail to detect true associations [15, 291]. Alternatively, by applying 
Bayesian methods to genetic association studies and shrinking all effect estimates toward a 
well-justified, preconceived prior, we can limit the number of false positive associations [13-
16, 319-321]. As discussed previously, a null-centered prior should achieve this result.  
3.3.6.5 Bayes regression analysis 
 For both aims, I conducted full-Bayes analyses, where I assigned priors for the mean 
(π) and the variance (τ2T). For Aim 1 I also conducted semi-Bayes analyses, where I 
assigned a fixed τ2 but used LD-block (i.e. haplotype) level OR estimates to inform π. I did 
not use empirical Bayes methods, as the near-zero τ2 generated from this rich data set would 
cause over-shrinkage of the SNP-specific effects [322]. For all Bayesian analyses I assessed 
all SNP-outcome associations using additive genetic models. 
 All 83 candidate SNPs (Table 6) were individually assessed using Bayesian 
regression analysis methods with priors specified for the intercept, SNP, age, and ancestry 
parameters (Aim 1) or the intercept, SNP, age, ancestry and race parameters (Aim 2).  
3.3.6.5.1 Full Bayes analysis for Aim 1: Race-stratified estimates for SNP effects on overall 
breast cancer 
 Given the probable SNP-overall breast cancer OR range of 1.1-1.3, I assigned each 
SNP a null-centered, lognormal prior with a mean of 0 and variance τ2 ~ Γ-1(3, 0.2), such that 
95% of the prior mass for each SNP-breast cancer OR lay between 0.64 and 1.55 when τ2 
was equal to 0.05, the mode of the specified distribution. I also assigned null-centered, 
lognormal priors for age, ancestry and the intercept term. I assigned moderately strong priors 
to age and ancestry (τ2=0.68), both of which were mean-centered variables. Because the 
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intercept is difficult to define or interpret in a case-control study with weighted sampling, I 
assigned only a vague prior, with τ2=1000. I assumed that all priors were independent. 
 Bayesian ORs and 95% PIs were computed using the MCMC procedure in SAS v9.3 
(SAS, Cary, NC). PROC MCMC uses Markov-chain Monte Carlo (MCMC) methods with a 
random walk Metropolis algorithm to obtain posterior probability estimates [323]. This 
iterative, conditionally dependent stochastic process searches the space defined by the joint 
distribution of the specified parameters to find the region with the highest density [315]. I ran 
30,000 samples for each SNP model, discarding the first 1000 draws as a burn-in and 
retaining every fifth draw. I inspected autocorrelation, trace, and density plots for signs of 
poor mixing or non-convergence. 
3.3.6.5.2 Full Bayes analysis for Aim 2: SNP effects on breast cancer subtype 
 Given that subtype-specific SNP associations are poorly understood, I selected more 
diffuse hyperpriors when estimating subtype-specific effects. Each SNP was again assigned a 
null-centered, lognormal prior with a mean of 0, but this time the variance was τ2 ~ Γ-1(4, 
0.5). As such, 95% of the prior mass for each SNP-subtype OR lay between 0.54 and 1.86 
when τ2 was equal to its mode of 0.1. I used the same age, ancestry and intercept priors as I 
had in Aim 1, but also included a lognormal, null-centered prior for race (τ2=1.0). I opted for 
a more diffuse prior for race because it likely has a larger effect than the other mean-
centered, continuous covariates. As with the frequentist analysis, I used polytomous 
regression to model all five subtype versus control comparisons simultaneously.  
 For these complex models, I ran 50,000 samples, discarding the first 1000 draws as a 
burn-in and thinning by retaining every tenth sample, such that the results are based on 4990 
draws. I again inspected autocorrelation, trace, and density plots for signs of poor mixing or 
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non-convergence.  
3.3.6.6 Hierarchical models 
 Sixty-six of the 83 candidate SNPs were located in the same gene or gene region as at 
least one other candidate SNP (see Table 6). As many of the SNPs within these regions were 
highly correlated with one another, I implemented a different Bayesian approach, known as 
hierarchical modeling, in hopes of generating more informative and precise effect estimates 
than either the frequentist or full Bayes methods [324-332]. I used these semi-Bayesian 
methods to integrate linkage disequilibrium (LD) information into SNP-breast cancer 
association analyses. I did not evaluate SNP-subtype associations with these methods. 
 Like other Bayesian regression models, hierarchical models shrink MLEs towards a 
prior estimate, with the degree of shrinkage determined by the relative variances of the MLE 
and the prior. However, by selecting a semi-Bayes rather than a full Bayes approach, I was 
able to use the observed data to help inform prior selection. More specifically, I used the data 
to determine the mean of the prior for each SNP log OR (π) but selected priors for SNP 
variance parameters (τ2T) based on existing knowledge. This application of semi-Bayes 
methods did not require prior specification for all included parameters. 
 The prior mean was modeled using the joint effect of all of the SNPs in an LD block. 
In terms of the framework specified in Section 3.3.6.2, the first level of the hierarchy was 
used to model the joint association between the outcome and all of the SNPs included in each 
LD block, and the second level was used to model the association between the outcome and 
the haplotype [16, 328, 333, 334]. For example, if there were j=3 SNPs (x1, x2 and x3) in the 
LD block, the first level of the hierarchical model took the following form:  ln !!!! = !!! + !!!! +!" = !!! + !!!! + !!!! + !!!! +!". 
  110 
The second level was used to model !!: !! = !! !! !! ′ = !!! + !!!, where zj is a 3×1 
matrix of 1’s and π is both the haplotype effect and the prior log OR for each of the 
individual SNPs. In its simplest form, T is a 3x3 identity matrix and the δj are assumed to be 
normally distributed with mean 0 and variance τ2T. 
  I assigned fixed prior variances of 0.05 for each SNP log OR. As noted earlier, this 
variance corresponds to a prior OR with 95% mass between 0.64 and 1.55 when the prior 
mean is equal to 1. Although the estimated prior means were not set to zero in this scenario, 
this approximate range seemed reasonable given the usual size of individual SNP effects [18, 
20, 318]. Of note, if there was only one genotyped SNP in an LD block, π and βj were 
identical. 
 The above grouping approach is valid as long as an exchangeability assumption is 
met. This assumption states that before evaluating the relationship between the exposures 
(SNPs) and the outcome (breast cancer) in this study, there was no reason to suspect that any 
one SNP in an LD block had a true log OR different from the others in that LD block. As 
none of the included SNPs are known causal variants and all effects are evaluated in terms of 
risk alleles, I believe this assumption is acceptable in this setting. 
 Further specification of the correlation structure within the LD block may offer 
additional increases in precision. Here, I explored two such methods, both of which required 
alternative T matrices. For the first variation, I modeled correlation as an exponential decay 
function of the base pair distance between any two SNPs (dij). This takes the form of !!" = exp! − !!"!"""  [328]. I used their suggested values of 1000 and 1 for θ1 and θ2, 
respectively. For the second variation, I modeled the correlation structure directly, with tij = 
D′, a measure of LD. Only the 66 candidate SNPs located in the same gene or gene region as 
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at least one other candidate SNP were evaluated using these alternative T matrices. All 
hierarchical models were evaluated using the GLIMMIX procedure in SAS (Cary, NC).  
3.3.6.7 Sensitivity Analyses  
 Given that few studies have examined the effects of these previously established risk 
variants in breast cancer subtypes, I selected more diffuse priors for the SNP-subtype 
association analysis than I did for the SNP-overall breast cancer association analysis. 
However, I also conducted sensitivity analyses to explore the robustness of the SNP effect 
estimates under a variety of model assumptions. Therefore, in addition to the MLE and 
previously described Bayesian analysis [SNP~N(0, τ2), τ2 ~ Γ-1(4, 0.5), with mode at 0.1], I 
also estimated another set of Bayesian ORs and 95% PIs with more informative prior 
distributions [SNP~N(0, τ2),  τ2~Γ-1(3, 0.2), with mode at 0.05].   
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Figure 20: Carolina Breast Cancer Study (CBCS) Study area 
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Figure 21: Flow chart for Carolina Breast Cancer Study participants 
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Figure 22: Directed acyclic graph (DAG) for the relationship between genotype and 
breast cancer or breast cancer subtype 
 
 
  
  115 
Table 6: Included SNPs 
 
Chromosome Gene SNP 
1 1p12 rs11249433* 
2 CASP8 rs1045485§ and rs17468277 
2 2q35 rs13387042* 
2 2p rs4666451† 
3 SLC4A7 rs4973768* 
4 4p rs12505080† 
4 TLR1 rs7696175† 
5 MRPS30 rs4415084* and rs10941679† 
5 5p12 rs981782* 
5 5q rs30099† 
5 MAP3K1 rs889312* 
6 ESR1 rs2046210*, rs851974, rs2077647, rs2234693, rs1801132§, rs3020314§, and rs3798577 
6 ECHDC1 rs2180341* 
7 RELN rs17157903† 
8 8q24 rs13281615* and rs1562430* 
9 CDKN2A/ CDKN2B 
rs10757278, rs1011970*, rs3731249,  rs3731257, 
rs10811661, rs518394 and rs564398 
10 ANKRD16 rs2380205* 
10 ZNF365 rs10995190* 
10 ZMIZ1 rs704010* 
10 FGFR2 
rs2981579*, rs1219648*, rs2981582*, rs1896395, 
rs3750817‡, rs10736303‡, rs11200014, rs1078806‡, 
rs2981578‡, rs2912774‡, rs2936870‡, rs2420946‡, 
rs2162540, and rs3135718  
10 10q rs10510126† 
11 ATM 
rs3092992, rs664143, rs170548, rs3092993, rs1800054, 
rs4986761, rs1800056, rs1800057§, rs1800058, and 
rs1801516 
11 LSP1 rs3817198* and rs909116* 
11 MYEOV/CCND1 rs614367* 
11 H19 rs2107425† 
16 TNRC9/TOX3 
rs3803662*, rs4784227*, rs8049149, rs12443621‡, 
rs16951186, rs8051542‡, rs3104746, rs3112562, and 
rs9940048 
17 TP53 
rs1042522, rs9894946, rs1614984, rs4968187, 
rs12951053§, rs17880604, rs1800372, rs2909430, and 
rs8079544 
17 COX11 rs7222197‡ and rs6504950† 
*GWAS hit (p-value <1.0 x 10-5 in a GWAS) 
†near-GWAS hit (p-value <1.0 x 10-5 in preliminary GWAS or follow-up study) 
‡GWAS-identified SNP (OR estimated in one or more GWAS)  
§Strong evidence of an association with breast cancer in Zhang et al. meta-analysis 
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Table 7: Selection of risk variants among women of European (EA) and African 
American (AA) ancestry*  
 
Chrom-
osome 
Gene or gene 
region SNP 
Risk 
Allele 
Number 
of studies 
(EA/AA)  
Statistically 
significant 
studies 
(EA/AA) 
Proportion 
of consistent 
findings 
(EA/AA) 
1 1p12 rs11249433 G 7 / 5 4 / 0 1.00 / NA 
2 2p rs4666451 G 5 / 0 2 / 0 1.00 / NA 
2 2q35 rs13387042 A 15 / 7 12 / 2 1.00 / 1.00 
3 SLC4A7 rs4973768 T 10 / 5 7 / 0 1.00 / NA 
4 4p rs12505080 C 1 / 0 0 / 0 NA / NA 
4 TLR1 rs7696175 T 1 / 0  0 / 0 NA / NA 
5 MRPS30 rs4415084 T 8 / 6 4 / 0 1.00 / NA 
5 MRPS30 rs10941679 G 7 / 6 5 / 1 1.00 / 1.00 
5 5p12 rs981782 T 5 / 0 2 / 0 1.00 / NA 
5 5q rs30099 A 3 / 0  0 / 0 NA / NA 
5 MAP3K1 rs889312 C 16 / 7 9 / 0 1.00 / NA 
6 ECHDC1 rs2180341 G  4 / 5 1 / 0 1.00/ NA 
6 ESR1 rs2046210 A  5 / 8 2 / 0 1.00 / NA 
7 RELN rs17157903 T 1 / 0  0 / 0 NA / NA 
8 8q24 rs13281615 G 15 / 6 9 / 0 1.00 / NA 
8 8q24 rs1562430 T 4 / 0 2 / 0 1.00 / NA 
9 CDKN2A/B rs3731257 T 1 / 0 0 / 0 NA / NA 
9 CDKN2A/B rs3731249 A 1 / 0 1/ 0 1.00 / NA 
9 CDKN2A/B rs1011970 T 2 / 4 1 / 0 1.00 / NA 
10 ANKRD16 rs2380205 C 2 / 4 1 / 0 1.00 / NA 
10 ZNF365 rs10995190 G 2 / 2 2 / 0 1.00 / NA 
10 ZMIZ1 rs704010 T 1 / 2 1 / 1 1.00 / 1.00 
10 FGFR2 rs3750817 C 2 / 0 2 / 0 1.00 / NA 
10 FGFR2 rs10736303 G 1 / 1 0 / 0 NA / NA 
10 FGFR2 rs11200014 A 5 / 0 4 / 0 1.00 / NA 
10 FGFR2 rs2981579 T 7 / 3 5 / 0 1.00 / NA 
10 FGFR2 rs1078806 G 1 / 1 0 / 0 NA / NA 
10 FGFR2 rs2981578 C 1 / 4 0 / 3 NA / 1.00 
10 FGFR2 rs1219648 G 13 / 5 9 / 2 1.00 / 1.00 
10 FGFR2 rs2912774 T 2 / 2 1 / 0 1.00 / NA 
10 FGFR2 rs2936870 T 1 / 0 0 / 0 NA / NA 
10 FGFR2 rs2420946 T 7 / 1 5 / 0 NA / NA 
10 FGFR2 rs2981582 A 17 / 8 15 / 1 1.00 / 1.00 
10 FGFR2 rs3135718 G 1 / 0 0 / 0 NA / NA 
10 10q rs10510126 C 1 / 0 0 / 0 NA / NA 
11 LSP1 rs3817198 C 16 / 6 7 / 2 1.00 / 0.50 
11 LSP1 rs909116 T 1 / 0 0 / 0 NA / NA 
11 H19 rs2107425 C 1 / 0 0 / 0 NA / NA 
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11 MYEOV rs614367 T 2 / 4 1 / 0 1.00 / NA 
16 TNRC9 rs16951186 T 0 / 1 0 / 0 NA/ NA 
16 TNRC9 rs8051542 T 5 / 1 1 / 0 1.00 / NA 
16 TNRC9 rs12443621 G 5 / 1 2 / 0 1.00 / NA 
16 TNRC9 rs3803662 A 21 / 9 16 / 4 1.00 / 0.00 
16 TNRC9 rs4784227 T  2 / 3 1 / 0 1.00 / NA 
16 TNRC9 rs3104746 A 0 / 2 0 / 2 NA/ 1.00 
16 TNRC9 rs3112562 G 0 / 1 0 / 1 NA / 1.00 
17 COX11 rs7222197 G 1 / 1 0 / 0 NA / NA 
17 COX11 rs6504950 G 6 / 5 3 / 1 1.00 / 1.00 
*Excludes previously unstudied variants and CASP8, ESR1, ATM, and TP53 variants, which 
were assessed using the Zhang et al. meta-analysis. NA= not applicable 
 
  
4. Replication of Breast Cancer Susceptibility Loci in Whites and African Americans 
Using a Bayesian Approach 
 
4.1 Overview 
 Genome-wide association studies (GWAS) and candidate gene analyses have led to 
the discovery of several dozen genetic polymorphisms associated with breast cancer 
susceptibility, many of which are now considered well-established risk factors for the disease 
in women of European descent. Despite attempts to replicate these same variant-disease 
associations in African Americans, the evaluable populations are often too small to produce 
precise or consistent results. I estimated the association between 83 previously identified 
single nucleotide polymorphisms (SNPs) and breast cancer in whites and African Americans 
from the Carolina Breast Cancer Study (1993-2001) using maximum likelihood, Bayesian, 
and hierarchical modeling methods. The selected SNPs were previous GWAS hits (n=22) or 
near-hits (n=19), otherwise well-established risk loci (n=5), or in the same gene as another 
selected variant (n=37). I successfully replicated eighteen GWAS-identified SNPs in whites 
and ten GWAS-identified SNPs in African Americans. SNPs in FGFR2 and TNRC9/TOX3 
were strongly associated with breast cancer in both races. Additionally, SNPs in MRPS30, 
MAP3K1, CDKN2A/B, ZM1Z1, LSP1, H19, and TP53 were associated with breast cancer in 
whites and SNPs in TLR1, ESR1, and H19 were associated with breast cancer in African 
Americans. I provided precise and well-informed race-stratified ORs for several key breast 
cancer-related SNPs. My results demonstrate the utility of Bayesian methods in genetic 
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epidemiology and provide support for their application in relatively small, etiologically 
driven investigations. 
 
4.2 Introduction 
 As of January 2013, fifty-eight single nucleotide polymorphisms (SNPs) have met the 
criterion for genome-wide statistical significance of p<10-5 in at least one of twenty-three 
genome-wide association studies (GWAS) of breast cancer [18]. Most of these SNPs were 
consistently associated with the disease in subsequent investigations among women of 
European [162, 163, 166, 168, 169, 186-191, 193, 195, 198-207, 209, 211-213, 215, 216, 
218-225, 228-230, 232-237, 241-243, 245-247, 250-256, 258, 267, 295-301, 335] or Asian 
descent [168, 169, 187, 192, 194, 197, 199, 205, 209, 212, 217, 221, 225-227, 230, 232, 238, 
240-244, 246, 247, 262, 265, 336-339], but attempts to replicate these findings in African 
American women have been largely unsuccessful [11, 12, 169, 214-216, 231, 236, 243, 259, 
263]. In general, the search for African American specific risk variants has made slow 
progress, with few insights to explain the tendency for African Americans to have more 
aggressive, less-treatable disease subtypes [3, 4, 8, 50] and markedly higher breast-cancer 
specific mortality than whites (32.7 versus 23.7 deaths per 100,000 US women with breast 
cancer per year, 2000-2009) [2]. 
 Allele frequencies and linkage disequilibrium (LD) structure vary by race, with 
African Americans exhibiting generally weaker between-SNP correlations and smaller LD 
blocks [269, 270]. Because each SNP represents all 
correlated variants, SNPs associated with breast cancer in African Americans correspond to a 
narrower genomic region than SNPs associated with the disease in whites. Therefore, 
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studying African Americans can improve our understanding of disease etiology. 
Unfortunately, most of the existing studies of genetic risk factors for breast cancer in African 
Americans are small and therefore underpowered to reliably differentiate between null 
effects and ORs of 1.1-1.3, which is the typical range for GWAS-identified risk variants in 
other populations [18, 318]. 
 Given this existing knowledge about association size, as well as information about the 
genome’s physical structure, Bayesian statistical methods may be useful tools for enhancing 
the analysis of race-specific genetic risk factors for breast cancer. A variety of Bayesian-
based methods have been proposed for use in genetic epidemiology, but I focused on two of 
the most basic applications, namely hierarchical modeling and Bayesian regression. My goal 
was to obtain valid and precise effect estimates by capitalizing on existing information. 
 To further our understanding of genetic risk factors for the disease, I examined the 
association between breast cancer and several candidate SNPs using traditional maximum 
likelihood methods and both Bayesian approaches. All selected SNPs were located on genes 
with strong prior evidence of association with breast cancer, including both GWAS and 
candidate gene investigations. I assessed the relationship between these SNPs and breast 
cancer risk using the Carolina Breast Cancer Study, a population-based, case-control study 
with large samples of both white and African American women. 
 
4.3 Methods 
4.3.1 Study population 
 Cases were identified using the North Carolina Central Cancer Registry’s rapid case 
ascertainment program [271]. Women were eligible for the study if they were diagnosed with 
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invasive breast cancer between 1993 and 2001, were between 20 and 74 years of age at the 
time of their diagnosis, and were living in one of 24 selected North Carolina counties. 
Women diagnosed with in situ breast cancer between 1996 and 2001 were also eligible if 
they had ductal carcinoma in situ with microinvasion to a depth of 2 mm or lobular 
carcinoma in situ. To ensure approximately equal representation of African Americans and 
non African Americans, as well as pre- and postmenopausal women, breast cancer cases 
were randomly sampled at disproportionate rates based on race and age. 
 Controls aged 20-64 and 65-74 were selected from North Carolina Department of 
Motor Vehicles and Health Care Financing Administration records, respectively. Controls 
were probability-matched to cases on race and 5-year age group [293]. Women with a history 
of breast cancer were ineligible. All participants provided informed consent and all study 
procedures were approved by the Institutional Review Board at the University of North 
Carolina. 
 A study nurse administered a questionnaire to each participant during an in-home 
visit. The survey included questions on basic demographics, including age and self-reported 
race, known or suspected breast cancer risk factors, and medical and family history. 
Additionally, the nurse drew 30 ml of blood. The overall response rate was 77% for cases 
and 57% for controls. Of those enrolled, 88% of cases and 90% of controls provided 
sufficient blood samples for inclusion in genotype analyses, leaving a total sample size of 
2013 cases (1247 white, 766 African American) and 1786 controls (1105 white, 681 African 
American). I excluded 166 individuals who did not self-identify as African American or non-
Hispanic white. 
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4.3.2 SNP selection 
 Initially, I selected candidate SNPs with genome-wide significant p-values in any of 
eight early breast cancer GWAS or two GWAS follow-up studies [186, 187, 189, 194, 196, 
197, 201, 205, 208, 209]. I also evaluated several SNPs from these initial studies that had 
GWAS-significant p-values only in discovery phase analyses. Lastly, I retained any SNPs 
already genotyped in the study population that Zhang et al. [20] determined had “cumulative 
evidence of an association” with breast cancer, or that were in the same gene as a previously 
selected variant. In total, I selected 41 GWAS-identified SNPs, including 22 GWAS hits and 
19 other strongly associated SNPs, as wells as 5 SNPs from the Zhang et al. meta-analysis, 
and 37 SNPs from included genes. I later excluded six SNPs with minor allele frequencies 
(MAFs) less than 1% in white participants and ten SNPs with MAF<1% in African 
Americans, leaving a total of 77 SNPs in whites and 73 in African Americans. 
 All study participants were genotyped for 144 ancestry informative markers. I then 
estimated each participant’s proportion of African ancestry using maximum likelihood 
methods and allele frequency data from HapMap YRI and CEU populations. As ancestry can 
affect both allele frequency and breast cancer incidence, inclusion of this variable in 
regression models should reduce confounding due to population stratification [275, 292].  
4.3.3 Genotype analysis 
 The SNPs included in this analysis were genotyped using either a Custom 
GoldenGate Genotyping assay (Illumina, Inc., San Diego, CA) or a Taqman panel (Applied 
Biosystems, Inc., Foster City, CA). The Taqman panel included a few SNPs that failed the 
Illumina assay, as well as several more recently discovered GWAS hits. Both genotyping 
processes have been described previously [287, 340]. All of the SNPs included in this 
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analysis passed quality control evaluations, including the examination of individual call rates 
and inspection of assay intensity data and genotype clustering images. 109 women were 
assigned missing values for all of the Illumina SNPs due to poor genotyping quality, but were 
successfully genotyped on the Taqman SNPs. 
4.3.3 Statistical methods 
 I calculated risk allele frequencies (RAFs) and age and African ancestry distributions 
for whites and African Americans separately. To account for the sampling mechanism, I 
weighted these estimates by the inverse of the probability of being selected as a study 
participant. I tested for departures from Hardy-Weinberg equilibrium (HWE) in white and 
African American controls using Pearson’s chi-squared test. As low HWE p-values can 
indicate genotyping error, I re-inspected the genotype clustering images of SNPs with p<0.05 
in either population for signs of poor genotype differentiation. SNPs were retained if their 
genotypes formed discrete clusters with minimal overlap. 
 The relationship between each risk variant and incident breast cancer was assessed 
using logistic regression. I estimated ORs and 95% CIs assuming additive genetic models. I 
also assessed the ORs and 95% CIs for all SNPs under general genetic modeling 
assumptions. The risk allele for each SNP was selected a priori based on previously 
published results. For whites, I selected risk alleles for SNPs in ATM, CASP8, ESR1 and 
TP53 based on the ORs reported by Zhang et al [20]. For the remaining SNPs, I ascertained 
the risk alleles from the original GWAS [186, 187, 189, 194, 196, 197, 201, 205, 208, 209] 
and subsequent replication studies [11, 12, 162, 163, 166, 168, 169, 186-191, 193, 195, 198-
200, 202-209, 211-216, 218-225, 228-230, 232-237, 241-243, 245-247, 250-256, 258, 262, 
267, 295-301, 335]. As all of the statistically significant (p<0.05) ORs were in the same 
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direction, all designated risk alleles are identical to those indicated in the initial assessment. 
For novel SNPs and SNPs with no prior statistically significant findings, I designated the 
HapMap CEU minor variant as the risk variant.  
 I assumed the risk allele was the same for African Americans as it was for whites 
unless the majority of reported statistically significant associations were contradictory to 
those seen in whites. Two SNPs met these criteria (rs3803662 on TNRC9/TOX3 and 
rs1045485 on CASP8) [11, 12, 169, 214-216].  
 All models were stratified by race and adjusted for proportion of African ancestry and 
age at diagnosis or selection. I centered age at 50 years and ancestry at the race-specific 
means. An offset term was included to account for unequal sampling by race and age group. 
As these ORs were generated using maximum-likelihood estimation, I will herein refer to 
these frequentist estimates as the MLE ORs. GWAS-identified SNPs were considered 
successfully replicated if their entire 95% CI fell above the null, as were SNPs identified 
using the candidate gene meta-analysis. More formal homogeneity tests comparing my 
findings to the original GWAS studies or meta-analysis estimates were not appropriate, as 
these studies did not consistently report ORs from additive genetic models. 
4.3.4 Bayesian analysis 
 Bayes’s theorem states that the posterior probability distribution for the parameter of 
interest given the observed data, ƒ(β|D), is proportional to the likelihood of the observed data, 
L(β|D), multiplied by the prior probability distribution ƒ(β) [314, 315].  Here, the likelihood 
function is the same as the MLE likelihood, with the log OR of being a case given exposure 
Xj and covariates W modeled as: ln !!!! = !!! + !!!! +!", where p is the probability of 
being a case. In this application, βj is the estimated log OR of being a breast cancer case for 
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each copy of the risk allele at SNP j and γ is a vector of estimated log ORs for age and 
ancestry.  
 To incorporate the priors, I added a second stage to the model: !! = !!! + !!!, where 
zj is a j×1 matrix of 1’s, π is the prior log OR, T is a j×j identity matrix and the δj are 
assumed to be normally distributed with mean 0 and variance τ2T. The prior mean (π), 
variance (τ2T), or both can either be estimated directly from the data or assigned by the 
investigator. I use the term ‘full-Bayes’ to indicate that priors were assigned independently of 
the data at hand, ‘empirical Bayes’ when both were estimated from the data, and ‘semi-
Bayes’ when one prior was assigned and the other was estimated [14]. 
 I conducted both a full-Bayes analysis, where I assigned priors for the mean and τ2, 
and a semi-Bayes analysis, where I assigned a fixed τ2 but used LD-block (i.e. haplotype) 
level OR estimates to inform π. I did not use empirical Bayes methods, as the near-zero τ2 
generated from this rich data set caused over-shrinkage of the SNP-specific effects [322]. 
 To obtain Bayesian (i.e. full-Bayes) log OR estimates, I assigned a null-centered, 
lognormal prior with a mean of 0 and variance τ2 ~ Γ-1(3, 0.2) to each SNP, such that 95% of 
the prior mass for each SNP-breast cancer OR lay between 0.64 and 1.55 when τ2 was equal 
to 0.05, the mode of the specified distribution. As discussed previously, this range likely 
includes the true value for any single SNP-breast cancer association. Each Bayesian model 
included exactly one SNP (j=1).  
 I also assigned null-centered, lognormal priors for both age and ancestry, giving both 
parameters prior variances of 0.68. These priors reflect my belief, with moderate uncertainty, 
that these mean-centered covariates are weakly associated with breast cancer. Because 
standard implementation of MCMC requires prior distributions for every parameter, I placed 
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a β0 ~ N(0,1000) prior on the intercept. In the absence of other information, this vague prior 
should generate posterior intercept estimates nearly identical to the MLE intercept parameter 
estimate. I assumed that all priors were independent.  
 Additionally, I used semi-Bayes analysis (i.e. hierarchical modeling) to integrate 
haplotype information [13, 326, 328, 333]. Specifically, I used the estimated joint effect of 
all of the SNPs in an LD block to inform the prior mean (π). If there was only one genotyped 
SNP in an LD block, π and βj were identical. I assigned fixed prior variances of 0.05 for each 
SNP, but did not assign priors for the intercept, age, or ancestry.  
 The above grouping approach is valid as long as an exchangeability assumption is 
met. This assumption states that before evaluating the relationship between the exposures 
(SNPs) and the outcome (breast cancer), there was no reason to suspect that any one SNP in 
an LD block had a true log OR different from the others in that LD block. As none of the 
included SNPs are known causal variants and all effects are evaluated in terms of risk alleles, 
I believe this assumption is acceptable in this setting. 
 Further specification of the correlation structure within the LD block may offer 
additional increases in precision. Here, I explored two such methods, both of which required 
alternative T matrices. For the first variation, I modeled correlation as an exponential decay 
function of the base pair distance between any two SNPs (dij). This takes the form of !!" = exp! − !!"!"""  [328]. For the second variation, I modeled the correlation structure 
directly, with tij = D′, a measure of LD.  
 For Bayes methods I presented posterior geometric mean ORs (i.e., antilogs of 
posterior mean log ORs) and 95% posterior intervals (PIs). For the Bayesian analyses I ran 
30,000 samples for each SNP model, discarding the first 1000 draws as a burn-in and 
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retaining every fifth draw. I inspected autocorrelation, trace and density plots to verify that 
all posterior estimates converged appropriately. 
 LD blocks were determined using methods proposed by Gabriel et al. [165] and 
conducted in Haploview (Haploview 4.2, Version 1.0, Broad Institute, Cambridge, MA, 
USA) [164]. Bayesian models were analyzed using PROC MCMC or PROC GLIMMIX 
(SAS v9.3, Cary, NC). Example code is provided in the appendix. 
 
4.4 Results 
 As expected, age distributions were similar for cases and controls, regardless of race 
(Table 8). White cases and controls were 52 and 53 years old at time of selection, on average, 
and African American cases and controls were both 52 years old. Whites had approximately 
7% African ancestry and African Americans had 77%. More detailed descriptions of the 
study population, without the exclusions for missing SNP data, can be found in previous 
Carolina Breast Cancer Study publications [282]. 
 Table 9 shows the RAFs for white and African American cases and controls and 
HWE p-values for white and African American controls. Seven SNPs were not in HWE by 
the established criterion (p<0.05). I retained 6 of the 7 SNPs, as their clustering images 
indicated good differentiation with no overlap between genotypes and none failed HWE tests 
in both races. I excluded the seventh SNP, rs614367 (MYEOV), after observing disparate 
clusters for the homozygous rare genotype and finding evidence of allelic dropout.  
 MLE ORs and 95% CIs for general and additive models for whites and African 
Americans can be seen in Tables 10 and 11, respectively. Tables 12 and 13 show the MLE 
ORs and confidence limit ratios (CLRs) for the additive models, as well as the ORs and 
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posterior limit ratios (PLRs) for the Bayesian models. The CLRs and PLRs are displayed to 
facilitate comparisons of model precision.  
 Among study whites, 18 of the GWAS-identified SNPs successfully replicated 
according to both MLE CIs and Bayesian PIs. Notably, all the FGFR2 SNPs had relatively 
strong, positive associations with breast cancer (ORs>1.15), as did both of the MRPS30 
SNPs, two of the TNRC9/TOX3 SNPs (rs3803662 and rs4784227), rs889312 in MAP3K1, 
rs704010 in ZMIZ1, and rs2107425 in H19. rs909116 in LSP1 replicated in MLE, but not 
Bayesian assessments. Three other FGFR2 SNPs (rs3750817, rs11200014, and rs2162540) 
were strongly associated with breast cancer (OR>1.2) in study whites.  
 None of the SNPs selected from the candidate gene meta-analysis replicated, though 
several SNPs in ATM and TP53 were strongly associated with disease (|ln OR| > 0.15). The 
original GWAS and meta-analysis ORs are provided in Table 2 for further reference.  
 The most extreme example of the difference between MLE and Bayesian estimates in 
study whites was for rs3104746 in TNRC9/TOX3, the SNP with the highest MLE OR (1.66, 
95% CI: 1.10, 2.51). Here, the Bayesian estimate was closer to the null (OR=1.42, 95% PI: 
0.97, 1.94) and more precise (MLE CLR=2.29 vs. Bayesian PLR=2.01).   
 Ten of the GWAS-identified SNPs successfully replicated in African Americans 
(Table 3). This included nine FGFR2 SNPs (ORs >1.15) and rs2046210 in ESR1. Two other 
TNRC9/TOX3 SNPs (rs3104746 and rs3112562) had ORs >1.25 via either analysis method. 
rs7696175 in TLR1 replicated when MLE methods were used, but not when Bayesian 
methods were used.  
 Two other SNPs, rs2107425 (H19) and rs12443621 (TNRC9/TOX3), were statistically 
significant, but the SNPs were inversely associated with breast cancer and thus inconsistent 
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with the original reports. Some of the ATM and ESR1 MLE ORs were relatively strong, but 
none of the SNPs from the candidate gene meta-analysis successfully replicated.  
 The 77 SNPs evaluable in whites separated into 55 unique LD blocks. The thirteen 
SNPs in FGFR2 formed the largest block (Figure 23), followed by ATM (5 SNPs) (Figure 
24) and TP53 (3 SNPs) (Figure 25). LD blocks consisting of two highly correlated SNPs 
were also genotyped in CASP8, CDKN2A/B (Figure 26), TNRC9/TOX3 (Figure 27) and 
COX11. In African Americans the FGFR2 SNPs formed three separate blocks of 5, 4, and 2 
SNPs respectively (Figure 23), while the other 3 SNPs were not strongly linked. One of the 
unlinked SNPs, rs1896395, was not evaluable in whites (RAF=0%). TNRC9/TOX3 contained 
two 2-SNP LD-blocks (Figure 27) and TP53 (Figure 25) contained a single 3-SNP block. 
The two SNPs within CASP8, CDKN2A (Figure 26), and COX11 were again in high LD. 
None of the ATM SNPs were strongly correlated in African Americans (Figure 24). None of 
the MRPS30, ESR1, 8q24, or LSP1 SNPs were in LD in either race. In total, the 73 SNPs 
evaluable in African Americans formed 58 LD blocks.  
 Semi-Bayes ORs and 95% PIs for the identity matrix-based hierarchical models are 
also presented in Tables 12 and 13. For both African Americans and whites, the hierarchical-
based estimates had comparable or slightly lower precision than the MLE ORs, and 
consistently lower precision than the Bayesian estimates. According to hierarchically derived 
estimates, many of the SNPs in the larger LD blocks were not associated with breast cancer. 
For example, MLE and Bayesian ORs indicated that all thirteen of the highly correlated 
FGFR2 SNPs were strongly associated with breast cancer among whites, while the 
hierarchical model generated mostly near-null estimates for these SNPs. Of the thirteen, 
rs2981579 had the strongest effect (OR=1.20, 95% PI: 0.85, 1.72). Similarly, MLE and 
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Bayesian models indicated that 10 of the 14 FGFR2 SNPs were associated with breast cancer 
in African Americans, while hierarchical modeling produced elevated associations for one 
SNP in each of the three LD blocks (rs3750817: OR=1.38, 95% CI: 1.05, 1.83, rs2981578: 
OR=1.23, 95% CI: 0.99, 1.53, and rs2420946: OR=1.27, 95% CI: 0.96, 1.66) and for 2 of the 
3 independent SNPs.  
 Direct comparisons of all 3 hierarchical models (identity, exponential decay by spatial 
distance, and correlation) for both races are shown in Figures 28 and 29. Further specification 
of the T covariance matrix did not substantially affect estimates or model precision, though 
PLRs were consistently smaller when the correlation structure was incorporated in some 
form (Tables 14 and 15). Haplotype ORs are also captured in these figures. 
 
4.5 Discussion   
 As several of the SNPs analyzed here were previously reported for this study 
population [210], I will limit my discussion to novel findings. Among whites, statistically 
significant associations for rs10757278 in CDKN2A/B and rs3104746 in TNRC9/TOX3 have 
never before been reported. I also corroborated previously observed associations between 
breast cancer and several well-validated GWAS-identified SNPs, including two MRPS30 
SNPs (rs4415084 and rs10941679) [169, 186, 190, 191, 208, 211, 220, 223, 228, 230], 
rs1562430 in 8q24 [186, 189, 190], and rs4784227 in TNRC9/TOX3 [205, 262]. Additionally, 
I replicated several less-established GWAS-identified SNPs, including rs704010 in ZMIZ1 
[189], and rs3750817, rs10736303, rs1078806, and rs2981578 in FGFR2 [194, 196]. The 
only CASP8, ATM, or TP53 SNP to demonstrate a statistically significant association 
(rs9894986 in TP53) was not associated with disease in Zhang et al [20]. 
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 I am the first to report a statistically significant association for rs3750817 in FGFR2 
in African Americans. Previous investigations of rs2046210 (ESR1) in African Americans 
produced mostly near-null ORs [11, 12, 169, 214, 216, 242, 243], but several of the FGFR2 
and TNRC9/TOX3 SNPs were associated with breast cancer in one or more prior 
investigations. This includes rs10736303 and rs2981578 (FGFR2) [12, 259] and rs3104746 
and rs3112562 (TNRC9/TOX3) [231]. rs2981578 and rs3104746 were both positively 
associated with disease in a pooled analysis by Chen et al. [214], but approximately 20% of 
these participants were drawn from the CBCS population.  
 Because the hierarchical models included more parameters than the MLE or Bayesian 
models, they did not improve precision. However, my results do lend support to previous 
claims that these methods can help differentiate individual effects of highly correlated SNPs 
[326, 328, 330].  
 The closely linked FGFR2 SNPs provide the best example of these potential benefits. 
Even though all thirteen evaluable SNPs were strongly associated with breast cancer in 
whites, it is implausible that each association is independent. A more likely explanation is 
that one or two causal variants within the LD block drive all of the observed associations. In 
this scenario, models that evaluate all the SNPs simultaneously in a single-level model will 
often produce unstable estimates. Rather than limiting analyses to haplotype effects, 
hierarchical models can effectively accommodate correlated exposures and provide stable 
SNP and haplotype-level ORs.  
 Unfortunately, even though the estimated OR for one FGFR2 SNP, rs2981579, was 
notably higher than the rest, I did not have sufficient precision to reliably differentiate 
between its relatively weak OR and the null when so many SNPs were assessed 
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simultaneously. Analyses of SNPs in the other multi-SNP LD blocks were relatively more 
precise, but also largely inconclusive. 
 The hierarchical models performed better in African Americans, with rs3750817, 
rs2981578, rs2420946, and rs3104746 demonstrating notably stronger associations than the 
other SNP(s) in FGFR2 block 1, FGFR2 block 2, FGFR2 block 3, and TNRC9/TOX3 block 
2, respectively. This performance improvement is likely attributable to the anticipated racial 
differences in LD block size. More explicit specifications of the incorporated covariance 
matrices had little impact on point estimates or precision in either racial group. 
 I believe my specifications of prior means and variances are reasonable. First, aside 
from mutations in BRCA1/2, it is unlikely that a single SNP has a large effect on breast 
cancer risk [318]. Second, as long as the covariate priors are appropriately specified, Bayes 
analysis with null-centered priors should bias effect estimates towards the null [17]. In this 
way, Bayesian analysis also reduces the probability of observing a false positive association. 
Lastly, I believe that correlated SNPs within an LD-block meet the criteria for 
exchangeability.  
 After accounting for the sampling mechanisms, the only observed discrepancy 
between study cases and other North Carolina cases was that African Americans with later 
stage disease were underrepresented in CBCS [274]. Therefore, ORs could be biased if the 
evaluated SNP is related to disease aggressiveness or medical care utilization. With regard to 
genotyping, whites were more likely to provide blood samples than African Americans, but 
blood donation status did not differ by stage of disease or other breast cancer risk factors. 
Case, race, age, and stage distributions were similar for genotyped and non-genotyped 
subjects.  
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 The inclusion of in situ cases could bias estimates of SNPs associated with disease 
aggressiveness or progression. However, given the strong evidence that in situ tumors have 
similar risk profiles to invasive cases [4, 341], I chose to retain these cases and corresponding 
controls. 
 A major strength of this study is the population itself, which is a large, racially 
diverse, population-based sample with well-validated data. The inclusion of a large sample of 
African American women allowed me to investigate racial differences in genetic risk factors 
and, accordingly, provide information that may help pinpoint causal variants. Both age and 
case status should be accurately captured and I had information on both self-reported race 
and proportion of African ancestry. While factors such as allelic dropout cannot be ruled out 
for SNPs demonstrating Hardy-Weinberg disequilibrium, the quality control measures 
employed during the genotyping process should have reduced the number and impact of 
genotype misclassification. Nonetheless, results for SNPs that violated HWE should be 
interpreted with caution.  
 In this analysis I replicated several previously identified breast cancer susceptibility 
loci in whites and African Americans using both MLE and Bayesian methods. My findings 
offer additional evidence that the regions containing these replicated SNPs play an important 
role in breast cancer etiology. The SNPs that replicated in African Americans are especially 
instructive, as they narrow or refine the genomic region containing the causal variant. My use 
of Bayesian methods to incorporate external information about the likely effect size and 
correlation structure further augments the utility of these results. I believe that fine-mapping 
studies and smaller etiologically-driven investigations may derive even greater benefit from 
these better-informed, more stable approaches.
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Table 8: Descriptive statistics for Whites and African Americans in  
the Carolina Breast Cancer Study (1993-2001) 
 
 Cases Controls 
 
Whites (%)* 
N=1247 
African 
Americans 
(%)* N=766 
Whites (%)* 
N=1105 
African 
Americans 
(%)* N=681 
Age (years); mean 
(std) 
52.2 (11.7) 51.6 (11.7) 53.0 (11.2) 51.9 (11.3) 
Proportion African 
Ancestry; mean 
(std) 
0.06 (0.07) 0.78 (0.13) 0.07 (0.07) 0.77 (0.14) 
Postmenopausal; N 
(%) 
686 (69) 430 (58) 640 (37) 377 (41) 
Stage of Disease; N 
(%) 
    In situ 356 (12) 89 (12)   Stage I 405 (46) 224 (31)   Stage II 346 (34) 309 (43)   Stage III 72 (6) 79 (11)   Stage IV 16 (1) 27 (4)   missing 52 38   Subtype; N (%)     Luminal A 453 (64) 242 (49)   Luminal B 82 (11) 38 (8)   HER2+/ER- 59 (6) 39 (8)   Basal-like 94 (11) 112 (22)   Unclassified 60 (8) 71 (14)   Missing 499 264   ER status; N (%)     Positive 697 (69) 334 (50)   Negative 359 (31) 352 (50)   Missing 191 80   PR status; N (%)     Positive 515 (64) 272 (44)   Negative 312 (36) 356 (56)   Missing 420 138   HER2 status; N 
(%) 
    Positive 180 (18) 94 (16)   Negative 746 (82) 514 (84)   Missing 321 158   *weighted by inverse sampling probability 
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Table 9: Risk allele frequencies (RAF) by race and case status, whites and African Americans in 
the Carolina Breast Cancer Study 
 
 
Whites  
(1247 cases, 1105 controls) 
African Americans  
(766 cases, 681 controls) 
Gene Locus Risk allele 
RAF 
casesa 
RAF 
controlsa 
HWE 
p-value 
Risk 
allele 
RAF 
casesa 
RAF 
controlsa 
HWE 
p-value 
1p12 rs11249433 G 0.44 0.41 0.54 G 0.14 0.10 0.01 
CASP8 rs1045485 G 0.88 0.87 0.63 C 0.06 0.05 0.74 
CASP8 rs17468277 C 0.87 0.87 0.63 C 0.95 0.95 0.95 
2q35 rs13387042 A 0.54 0.47 0.83 A 0.74 0.73 1.00 
2p rs4666451 G 0.60 0.63 0.30 G 0.78 0.77 0.12 
SLC4A rs4973768 T 0.48 0.42 0.22 T 0.36 0.40 0.05 
4p rs12505080 C 0.29 0.24 0.80 C 0.17 0.17 0.64 
TLR1 rs7696175 T 0.45 0.45 0.91 T 0.08 0.06 0.54 
MRPS30 rs4415084 T 0.43 0.42 0.18 T 0.64 0.58 0.70 
MRPS30 rs10941679 G 0.29 0.30 0.76 G 0.19 0.19 0.17 
5p12 rs981782 T 0.53 0.59 0.26 T 0.92 0.91 0.60 
5q rs30099 T 0.10 0.10 0.40 T 0.16 0.12 0.75 
MAP3K rs889312 C 0.32 0.34 0.85 C 0.33 0.36 0.08 
ESR1 rs2046210 A 0.36 0.35 0.48 A 0.64 0.61 0.15 
ESR1 rs851974 G 0.42 0.43 0.28 G 0.17 0.17 0.46 
ESR1 rs2077647 A 0.51 0.49 0.64 A 0.52 0.51 0.16 
ESR1 rs2234693 T 0.53 0.57 0.45 T 0.47 0.48 0.63 
ESR1 rs1801132 C 0.76 0.76 0.43 C 0.90 0.88 0.36 
ESR1 rs3020314 C 0.36 0.34 0.15 C 0.69 0.71 0.75 
ESR1 rs3798577 T 0.52 0.53 0.43 T 0.57 0.54 0.27 
ECHDC rs2180341 G 0.25 0.27 0.55 G 0.31 0.33 0.83 
RELN rs17157903 T 0.13 0.12 0.06 T 0.11 0.10 0.08 
8q24 rs13281615 G 0.43 0.42 0.17 G 0.44 0.43 0.58 
8q24 rs1562430 T 0.59 0.57 0.78 T 0.54 0.53 0.61 
CDKN2A/B rs3731257 T 0.23 0.23 0.24 T 0.09 0.11 0.89 
CDKN2A/B rs3731249 A 0.03 0.03 0.90 A 0.01 0.00 0.95 
CDKN2A/B rs518394 G 0.44 0.48 0.17 G 0.08 0.08 0.06 
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CDKN2A/B rs564398 G 0.42 0.47 0.29 G 0.08 0.08 0.02 
CDKN2A/B rs1011970 T 0.19 0.15 0.62 T 0.33 0.34 0.14 
CDKN2A/B rs10757278 A 0.54 0.55 0.18 A 0.81 0.82 0.77 
CDKN2A/B rs10811661 C 0.17 0.20 0.02 C 0.07 0.07 0.24 
ANKRD rs2380205 C 0.56 0.60 0.88 C 0.42 0.46 0.72 
ZNF365 rs10995190 G 0.86 0.82 0.76 G 0.83 0.83 0.90 
ZMIZ1 rs704010 T 0.43 0.42 0.93 T 0.11 0.08 0.82 
FGFR2 rs1896395 A 0.00 0.00 0.96 A 0.20 0.20 0.04 
FGFR2 rs3750817 C 0.65 0.60 0.16 C 0.91 0.88 0.83 
FGFR2 rs10736303 G 0.54 0.49 0.19 G 0.87 0.84 0.75 
FGFR2 rs11200014 A 0.46 0.41 0.65 A 0.20 0.21 0.75 
FGFR2 rs2981579 T 0.47 0.41 0.51 T 0.62 0.61 0.10 
FGFR2 rs1078806 G 0.45 0.41 0.53 G 0.21 0.21 0.99 
FGFR2 rs2981578 C 0.54 0.49 0.09 C 0.87 0.84 0.45 
FGFR2 rs1219648 G 0.45 0.39 0.35 G 0.44 0.41 0.57 
FGFR2 rs2912774 A 0.45 0.40 0.26 A 0.59 0.55 0.07 
FGFR2 rs2936870 T 0.45 0.40 0.25 T 0.60 0.56 0.14 
FGFR2 rs2420946 T 0.44 0.39 0.21 T 0.54 0.52 0.03 
FGFR2 rs2162540 G 0.44 0.39 0.28 G 0.54 0.52 0.41 
FGFR2 rs2981582 T 0.44 0.39 0.30 T 0.49 0.49 0.96 
FGFR2 rs3135718 G 0.44 0.39 0.23 G 0.58 0.54 0.65 
10q rs10510126 C 0.89 0.89 0.38 C 0.89 0.90 0.21 
ATM rs1800054 G 0.02 0.02 0.34 G 0.00 0.00 0.94 
ATM rs4986761 C 0.02 0.01 0.68 C 0.00 0.00 0.98 
ATM rs1800056 C 0.02 0.01 0.67 C 0.00 0.00 0.95 
ATM rs1800057 G 0.03 0.02 0.90 G 0.01 0.01 0.91 
ATM rs1800058 T 0.02 0.02 0.06 T 0.01 0.01 0.91 
ATM rs1801516 A 0.15 0.14 0.17 A 0.03 0.02 0.48 
ATM rs3092992 C 0.06 0.04 0.13 C 0.01 0.01 0.77 
ATM rs664143 C 0.58 0.57 0.70 C 0.66 0.66 0.45 
ATM rs170548 G 0.31 0.37 0.88 G 0.09 0.12 0.07 
ATM rs3092993 A 0.15 0.14 0.19 A 0.03 0.02 0.48 
LSP1 rs3817198 C 0.33 0.34 0.18 C 0.17 0.17 0.16 
LSP1 rs909116 T 0.54 0.52 0.20 T 0.71 0.72 0.96 
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MYEOV rs614367 T 0.18 0.11 0.05 T 0.13 0.15 0.33 
H19 rs2107425 C 0.71 0.68 0.74 C 0.48 0.53 0.42 
TNRC9/TOX3 rs8049149 T 0.00 0.00 0.98 T 0.02 0.02 0.32 
TNRC9/TOX3 rs16951186 T 0.01 0.01 0.75 T 0.17 0.19 0.95 
TNRC9/TOX3 rs8051542 T 0.46 0.44 0.43 T 0.35 0.30 0.12 
TNRC9/TOX3 rs12443621 G 0.51 0.41 0.39 G 0.47 0.51 1.00 
TNRC9/TOX3 rs3803662 T 0.32 0.24 0.73 C 0.48 0.46 0.65 
TNRC9/TOX3 rs4784227 T 0.29 0.22 0.62 T 0.08 0.07 0.59 
TNRC9/TOX3 rs3104746 A 0.03 0.02 0.48 A 0.26 0.18 0.87 
TNRC9/TOX3 rs3112562 G 0.22 0.20 0.45 G 0.52 0.46 0.88 
TNRC9/TOX3 rs9940048 A 0.26 0.24 0.50 A 0.31 0.30 0.64 
TP53 rs9894946 G 0.82 0.84 0.48 G 0.95 0.95 0.25 
TP53 rs1614984 T 0.41 0.39 0.22 T 0.40 0.40 0.03 
TP53 rs4968187 T 0.00 0.00 0.93 T 0.01 0.00 0.92 
TP53 rs12951053 C 0.07 0.06 0.47 C 0.11 0.11 0.09 
TP53 rs17880604 C 0.02 0.01 0.21 C 0.00 0.00 0.95 
TP53 rs1800372 G 0.02 0.02 0.54 G 0.00 0.00 0.98 
TP53 rs2909430 G 0.15 0.13 0.66 G 0.27 0.24 0.64 
TP53 rs1042522 C 0.75 0.77 0.64 C 0.39 0.43 0.77 
TP53 rs8079544 C 0.95 0.95 1.00 C 0.89 0.89 0.83 
COX11 rs7222197 G 0.71 0.75 0.60 G 0.66 0.65 0.70 
COX11 rs6504950 G 0.71 0.75 0.59 G 0.67 0.65 0.66 
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Table 10: SNP genotype distributions and associations with incident breast cancer for 
White women in the Carolina Breast Cancer Study (1993-2000) 
 
Gene SNP genotype 
Cases 
(%)* 
n=1247 
Controls (%)* 
n=1105   
General model:  
OR (95% CI)† 
Additive model: 
OR (95% CI)† 
1p12 rs11249433 
A/A 382 (31.7) 361 (36.8)  1.00 1.00 A/G 601 (47.7) 547 (43.8)  0.99 (0.81-1.21) 1.09 (0.96-1.24) G/G 251 (20.6) 192 (19.4)  1.22 (0.95-1.58) P-trend= 0.2 missing 13 5     
CASP8 rs1045485 
C/C 20 (2.0) 23 (1.6)  1.00 1.00 C/G 264 (21.0) 257 (23.2)  1.21 (0.63-2.32) 1.13 (0.94-1.35) G/G 919 (77.0) 809 (75.2)  1.34 (0.71-2.54) P-trend= 0.2 missing 44 16     
CASP8 rs17468277 
T/T 20 (2.0) 23 (1.6)  1.00 1.00 C/T 266 (21.2) 257 (23.2)  1.22 (0.63-2.34) 1.12 (0.93-1.34) C/C 918 (76.8) 809 (75.2)  1.34 (0.71-2.53) P-trend= 0.2 missing 43 16     
2q35 rs13387042 
G/G 245 (21.2) 242 (29.7)  1.00 1.00 A/G 590 (49.2) 546 (46.6)  1.04 (0.83-1.30) 1.08 (0.96-1.22) A/A 369 (29.6) 300 (23.7)  1.16 (0.91-1.49) P-trend= 0.2 missing 43 17     
2p rs4666451 
A/A 188 (15.7) 186 (14.3)  1.00 1.00 A/G 582 (49.5) 508 (45.7)  1.10 (0.85-1.41) 1.02 (0.90-1.16) G/G 432 (34.8) 395 (39.9)  1.07 (0.82-1.38) P-trend= 0.8 missing 45 16     
SLC4A7 rs4973768 
C/C 326 (27.4) 309 (33.6)  1.00 1.00 C/T 636 (49.9) 526 (47.9)  1.17 (0.95-1.44) 1.04 (0.92-1.17) T/T 271 (22.8) 260 (18.5)  1.07 (0.83-1.37) P-trend= 0.5 missing 14 10     
4p rs12505080 
T/T 600 (49.4) 569 (58.5)  1.00 1.00 C/T 520 (42.6) 421 (34.4)  1.15 (0.96-1.39) 1.06 (0.92-1.23) C/C 92 (7.9) 81 (7.1)  0.99 (0.70-1.40) P-trend= 0.4 missing 35 34     TLR1 rs7696175 C/C 376 (32.0) 347 (28.1)  1.00 1.00 
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C/T 565 (46.7) 537 (54.8)  0.97 (0.80-1.19) 1.09 (0.96-1.23) T/T 262 (21.3) 205 (17.1)  1.22 (0.95-1.56) P-trend= 0.2 missing 44 16     
MRPS30 rs4415084 
C/C 391 (32.5) 410 (34.9)  1.00 1.00 C/T 631 (49.9) 535 (46.4)  1.22 (1.00-1.48) 1.23 (1.08-1.40) T/T 207 (17.7) 147 (18.7)  1.52 (1.16-2.00) P-trend= 0.002 missing 18 13     
MRPS30 rs10941679 
A/A 634 (50.7) 608 (51.9)  1.00 1.00 A/G 507 (41.0) 417 (35.5)  1.20 (1.00-1.44) 1.18 (1.03-1.36) G/G 98 (8.3) 68 (12.5)  1.37 (0.96-1.95) P-trend= 0.02 missing 8 12     
5p12 rs981782 
G/G 254 (22.5) 224 (15.7)  1.00 1.00 G/T 611 (49.4) 560 (50.7)  0.92 (0.73-1.15) 0.98 (0.86-1.11) T/T 339 (28.2) 305 (33.5)  0.95 (0.74-1.22) P-trend= 0.7 missing 43 16     
5q rs30099 
C/C 975 (81.3) 896 (81.4)  1.00 1.00 C/T 219 (18.0) 181 (17.8)  1.08 (0.86-1.36) 1.04 (0.85-1.28) T/T 10 (0.8) 12 (0.8)  0.83 (0.34-2.05) P-trend= 0.7 missing 43 16     
MAP3K1 rs889312 
A/A 559 (47.4) 551 (45.9)  1.00 1.00 A/C 512 (41.4) 449 (39.4)  1.09 (0.91-1.31) 1.19 (1.04-1.35) C/C 132 (11.1) 89 (14.8)  1.56 (1.15-2.13) P-trend= 0.01 missing 44 16     
ESR1 rs2046210 
G/G 507 (39.4) 480 (40.9)  1.00 1.00 A/G 581 (48.3) 482 (47.7)  1.19 (0.99-1.44) 1.09 (0.96-1.24) A/A 144 (12.3) 133 (11.4)  1.10 (0.82-1.46) P-trend= 0.2 missing 15 10     
ESR1 rs851974 
A/A 404 (32.5) 338 (29.6)  1.00 1.00 A/G 611 (50.6) 557 (54.1)  0.93 (0.76-1.13) 0.91 (0.80-1.03) G/G 217 (16.9) 201 (16.3)  0.82 (0.63-1.06) P-trend= 0.1 missing 15 9     
ESR1 rs2077647 
A/A 277 (23.0) 239 (28.4)  1.00 1.00 A/G 602 (51.1) 550 (45.5)  0.98 (0.78-1.22) 0.97 (0.86-1.10) A/A 325 (25.9) 299 (26.2)  0.94 (0.74-1.21) P-trend= 0.6 missing 43 17     
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ESR1 rs2234693 
C/C 264 (22.6) 214 (18.3)  1.00 1.00 C/T 579 (48.3) 551 (50.2)  0.85 (0.67-1.06) 0.95 (0.84-1.07) T/T 361 (29.1) 323 (31.5)  0.88 (0.69-1.13) P-trend= 0.4 missing 43 17     
ESR1 rs1801132 
G/G 78 (6.9) 51 (3.8)  1.00 1.00 C/G 423 (35.0) 390 (39.6)  0.66 (0.45-0.99) 0.92 (0.80-1.06) C/C 703 (58.1) 648 (56.6)  0.68 (0.46-1.00) P-trend= 0.3 missing 43 16     
ESR1 rs3020314 
T/T 519 (42.6) 460 (40.3)  1.00 1.00 C/T 512 (41.8) 512 (51.3)  0.81 (0.67-0.97) 1.05 (0.92-1.19) C/C 173 (15.6) 117 (8.5)  1.37 (1.03-1.81) P-trend= 0.5 missing 43 16     
ESR1 rs3798577 
C/C 271 (22.3) 264 (21.4)  1.00 1.00 C/T 598 (50.6) 531 (51.1)  1.12 (0.90-1.39) 1.03 (0.91-1.17) T/T 334 (27.0) 294 (27.5)  1.07 (0.84-1.37) P-trend= 0.6 missing 44 16     
ECHDC1 rs2180341 
A/A 698 (56.1) 642 (49.8)  1.00 1.00 A/G 462 (37.8) 399 (45.4)  1.03 (0.86-1.24) 1.04 (0.90-1.20) G/G 67 (6.0) 56 (4.8)  1.10 (0.74-1.63) P-trend= 0.6 missing 20 8     
RELN rs17157903 
C/C 924 (76.1) 806 (77.8)  1.00 1.00 C/T 252 (21.9) 252 (20.0)  0.88 (0.71-1.08) 0.87 (0.73-1.04) T/T 27 (2.0) 30 (2.2)  0.76 (0.43-1.33) P-trend= 0.1 missing 44 17     
8q24 rs13281615 
A/A 383 (32.0) 398 (32.0)  1.00 1.00 A/G 594 (49.4) 502 (51.4)  1.19 (0.98-1.45) 1.11 (0.98-1.26) G/G 221 (18.5) 188 (16.6)  1.21 (0.94-1.56) P-trend= 0.1 missing 49 17     
8q24 rs1562430 
C/C 192 (15.8) 204 (15.7)  1.00 1.00 C/T 602 (49.4) 543 (54.8)  1.14 (0.89-1.46) 1.13 (0.99-1.28) T/T 435 (34.8) 349 (29.5)  1.28 (0.98-1.65) P-trend= 0.1 missing 18 9     
CDKN2A/B rs3731257 
C/C 710 (60.3) 621 (61.2)  1.00 1.00 C/T 412 (33.3) 393 (32.4)  0.90 (0.75-1.09) 0.93 (0.81-1.07) T/T 82 (6.4) 75 (6.4)  0.92 (0.65-1.31) P-trend= 0.3 
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missing 43 16     
CDKN2A/B rs3731249c 
G/G 1134 (94.5) 1020 (94.1)  1.00 1.00 A/G or A/A 70 (5.5) 69 (5.9)  0.00 (0.00-0.00) 0.90 (0.63-1.28) missing 43 16     
CDKN2A/B rs518394 
C/C 402 (32.3) 371 (30.4)  1.00 1.00 C/G 572 (46.6) 510 (42.3)  1.04 (0.85-1.26) 1.03 (0.91-1.16) G/G 229 (21.1) 208 (27.3)  1.05 (0.82-1.35) P-trend= 0.7 missing 44 16     
CDKN2A/B rs564398 
A/A 429 (34.8) 395 (32.1)  1.00 1.00 G/A 566 (45.7) 507 (42.4)  1.02 (0.84-1.24) 1.04 (0.92-1.17) G/G 207 (19.5) 186 (25.5)  1.08 (0.84-1.40) P-trend= 0.6 missing 45 17     
CDKN2A/B rs1011970 
G/G 832 (66.6) 752 (72.3)  1.00 1.00 G/T 344 (29.4) 299 (25.4)  1.07 (0.88-1.30) 1.13 (0.96-1.33) T/T 47 (4.1) 33 (2.2)  1.51 (0.92-2.45) P-trend= 0.1 missing 24 21     
CDKN2A/B rs10757278 
G/G 268 (20.9) 260 (20.2)  1.00 1.00 A/G 604 (50.1) 567 (49.6)  0.98 (0.79-1.22) 1.17 (1.04-1.33) A/A 351 (29.0) 263 (30.1)  1.36 (1.06-1.74) P-trend= 0.01 missing 24 15     
CDKN2A/B rs10811661 
T/T 844 (69.7) 773 (64.9)  1.00 1.00 C/T 325 (27.5) 276 (30.7)  1.07 (0.88-1.31) 1.00 (0.85-1.18) C/C 35 (2.8) 40 (4.4)  0.79 (0.49-1.30) P-trend= 0.99 missing 43 16     
ANKRD16 rs2380205 
T/T 247 (20.3) 203 (16.6)  1.00 1.00 C/T 579 (46.5) 532 (46.0)  0.92 (0.73-1.16) 1.01 (0.89-1.14) C/C 394 (33.2) 355 (37.3)  1.00 (0.78-1.29) P-trend= 0.9 missing 27 15     
ZNF365 rs10995190 
A/A 24 (2.0) 21 (1.7)  1.00 1.00 A/G 303 (24.6) 270 (31.6)  0.82 (0.43-1.58) 1.00 (0.84-1.20) G/G 909 (73.4) 804 (66.7)  0.85 (0.45-1.61) P-trend= 1 missing 11 10     
ZMIZ1 rs704010 
C/C 406 (31.9) 426 (36.6)  1.00 1.00 C/T 601 (50.7) 510 (42.1)  1.30 (1.07-1.57) 1.24 (1.09-1.41) T/T 211 (17.3) 151 (21.4)  1.50 (1.15-1.96) P-trend= 0.001 
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missing 29 18     
FGFR2 rs3750817 
T/T 142 (11.1) 180 (14.5)  1.00 1.00 C/T 576 (47.5) 500 (51.3)  1.56 (1.19-2.03) 1.24 (1.09-1.40) C/C 513 (41.4) 414 (34.1)  1.68 (1.28-2.20) P-trend= 0.001 missing 16 11     
FGFR2 rs10736303 
A/A 258 (20.5) 313 (23.5)  1.00 1.00 A/G 627 (51.2) 523 (54.9)  1.46 (1.18-1.82) 1.33 (1.17-1.50) G/G 351 (28.3) 256 (21.6)  1.76 (1.37-2.26) P-trend= 1 x 10
-5 
missing 11 13     
FGFR2 rs11200014 
G/G 358 (29.2) 406 (32.8)  1.00 1.00 A/G 593 (50.0) 512 (52.2)  1.31 (1.08-1.60) 1.30 (1.15-1.48) A/A 253 (20.9) 171 (14.9)  1.70 (1.31-2.19) P-trend= 3 x 10
-5 
missing 43 16     
FGFR2 rs2981579 
C/C 346 (28.2) 401 (32.4)  1.00 1.00 C/T 594 (50.1) 511 (52.3)  1.36 (1.11-1.65) 1.33 (1.18-1.51) T/T 264 (21.7) 177 (15.3)  1.77 (1.38-2.28) P-trend= 1 x 10
-5 
missing 43 16     
FGFR2 rs1078806 
A/A 376 (30.0) 411 (33.0)  1.00 1.00 A/G 596 (49.1) 514 (51.9)  1.29 (1.06-1.57) 1.29 (1.14-1.46) G/G 258 (20.9) 174 (15.1)  1.67 (1.29-2.16) P-trend= 1 x 10
-4 
missing 17 6     
FGFR2 rs2981578 
T/T 261 (20.6) 321 (24.4)  1.00 1.00 C/T 625 (51.0) 520 (53.4)  1.49 (1.20-1.85) 1.32 (1.17-1.50) C/C 354 (28.3) 259 (22.1)  1.76 (1.37-2.25) P-trend= 1 x 10
-5 
missing 7 5     
FGFR2 rs1219648 
A/A 374 (30.9) 425 (36.2)  1.00 1.00 A/G 588 (49.0) 499 (49.1)  1.34 (1.11-1.63) 1.31 (1.16-1.48) G/G 241 (20.0) 165 (14.7)  1.69 (1.31-2.19) P-trend= 2 x 10
-5 
missing 44 16     
FGFR2 rs2912774 
C/C 366 (30.4) 420 (35.9)  1.00 1.00 A/C 594 (49.7) 497 (48.9)  1.37 (1.13-1.67) 1.30 (1.15-1.47) A/A 242 (19.9) 170 (15.2)  1.65 (1.28-2.13) P-trend= 4 x 10
-5 
missing 45 18     
FGFR2 rs2936870 C/C 366 (30.3) 420 (35.8)  1.00 1.00 C/T 594 (49.5) 498 (49.0)  1.37 (1.13-1.66) 1.30 (1.15-1.47) 
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T/T 244 (20.1) 171 (15.2)  1.66 (1.29-2.14) P-trend= 3 x 10
-5 
missing 43 16     
FGFR2 rs2420946 
C/C 380 (31.6) 433 (36.7)  1.00 1.00 C/T 587 (49.0) 490 (48.8)  1.37 (1.13-1.66) 1.30 (1.15-1.48) T/T 235 (19.4) 163 (14.6)  1.66 (1.28-2.15) P-trend= 3 x 10
-5 
missing 45 19     
FGFR2 rs2162540 
A/A 385 (32.0) 436 (36.8)  1.00 1.00 A/G 583 (48.5) 493 (49.1)  1.34 (1.11-1.63) 1.31 (1.15-1.48) G/G 234 (19.4) 160 (14.2)  1.69 (1.30-2.18) P-trend= 3 x 10
-5 
missing 45 16     
FGFR2 rs2981582 
C/C 385 (31.9) 437 (36.8)  1.00 1.00 C/T 587 (48.9) 493 (49.1)  1.35 (1.12-1.64) 1.30 (1.15-1.48) T/T 232 (19.2) 159 (14.1)  1.67 (1.29-2.17) P-trend= 3 x 10
-5 
missing 43 16     
FGFR2 rs3135718 
A/A 376 (31.2) 432 (36.5)  1.00 1.00 A/G 592 (49.2) 493 (48.8)  1.38 (1.14-1.67) 1.31 (1.16-1.48) G/G 236 (19.6) 164 (14.6)  1.68 (1.30-2.17) P-trend= 2 x 10
-5 
missing 43 16     
10q rs10510126 
T/T 16 (1.5) 13 (0.9)  1.00 1.00 C/T 231 (19.4) 239 (19.4)  0.70 (0.31-1.55) 1.11 (0.91-1.35) C/C 957 (79.1) 837 (79.7)  0.82 (0.38-1.79) P-trend= 0.3 missing 43 16     
ATM rs1800054c 
C/C 1160 (96.3) 1048 (96.9)  1.00 1.00 C/G or G/G 43 (3.7) 41 (3.1)  1.04 (0.66-1.64) 1.01 (0.65-1.58) missing 44 16     
ATM rs1800057c 
C/C 1130 (93.9) 1028 (95.4)  1.00 1.00 C/G or G/G 74 (6.1) 61 (4.6)  1.10 (0.76-1.60) 1.09 (0.76-1.56) missing 43 16     
ATM rs1800058c 
C/C 1160 (96.2) 1040 (96.2)  1.00 1.00 C/T or T/T 44 (3.8) 49 (3.8)  0.82 (0.53-1.28) 0.82 (0.54-1.25) missing 43 16     
ATM rs1801516 
G/G 877 (71.4) 792 (72.8)  1.00 1.00 A/G 310 (27.2) 279 (26.1)  0.98 (0.80-1.19) 0.98 (0.82-1.17) A/A 17 (1.4) 17 (1.2)  0.98 (0.48-1.99) P-trend= 0.8 missing 43 17     
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ATM rs3092992c 
A/A 1081 (89.1) 993 (91.7)  1.00 1.00 A/C or C/C 123 (10.9) 96 (8.3)  1.17 (0.87-1.58) 1.19 (0.89-1.60) missing 43 16     
ATM rs664143 
T/T 213 (17.2) 203 (18.4)  1.00 1.00 C/T 578 (50.0) 527 (43.3)  1.07 (0.84-1.36) 1.02 (0.90-1.15) C/C 412 (32.9) 359 (38.3)  1.05 (0.82-1.36) P-trend= 0.8 missing 44 16     
ATM rs170548 
T/T 538 (45.5) 499 (44.6)  1.00 1.00 G/T 553 (46.6) 478 (36.9)  1.10 (0.91-1.32) 0.98 (0.86-1.12) G/G 113 (7.9) 112 (18.5)  0.83 (0.61-1.13) P-trend= 0.7 missing 43 16     
ATM rs3092993 
C/C 877 (71.4) 793 (72.9)  1.00 1.00 A/C 310 (27.2) 278 (26.0)  0.98 (0.80-1.20) 0.98 (0.82-1.18) A/A 17 (1.4) 17 (1.2)  0.98 (0.48-1.99) P-trend= 0.8 missing 43 17     
LSP1 
rs3817198 
T/T 537 (45.3) 502 (40.7)  1.00 1.00 C/T 529 (43.9) 488 (50.3)  1.01 (0.84-1.22) 1.08 (0.95-1.24) C/C 136 (10.8) 98 (9.0)  1.26 (0.93-1.71) P-trend= 0.2 missing 45 17     
rs909116 
C/C 257 (21.1) 251 (19.7)  1.00 1.00 C/T 608 (50.5) 566 (56.0)  1.03 (0.83-1.29) 1.14 (1.01-1.30) T/T 358 (28.3) 273 (24.4)  1.30 (1.01-1.66) P-trend= 0.04 missing 24 15     
H19 rs2107425 
T/T 101 (7.6) 111 (8.5)  1.00 1.00 C/T 505 (42.7) 466 (46.7)  1.24 (0.90-1.70) 1.15 (1.00-1.31) C/C 593 (49.7) 512 (44.7)  1.38 (1.01-1.89) P-trend= 0.04 missing 48 16     
TNRC9/ 
TOX3 rs8051542 
C/C 372 (31.8) 350 (30.4)  1.00 1.00 C/T 580 (44.9) 546 (51.9)  0.95 (0.78-1.15) 1.12 (0.99-1.26) T/T 252 (23.3) 193 (17.7)  1.30 (1.01-1.67) P-trend= 0.1 missing 43 16     
TNRC9/ 
TOX3 rs12443621 
A/A 306 (25.0) 296 (33.9)  1.00 1.00 A/G 563 (48.2) 557 (49.2)  1.01 (0.82-1.25) 1.17 (1.04-1.33) G/G 335 (26.8) 236 (16.9)  1.38 (1.08-1.77) P-trend= 0.01 missing 43 16     
  
145 
TNRC9/ 
TOX3 rs3803662 
C/C 572 (47.5) 579 (58.4)  1.00 1.00 C/T 502 (41.2) 427 (35.1)  1.22 (1.01-1.46) 1.27 (1.11-1.46) T/T 130 (11.4) 83 (6.5)  1.73 (1.26-2.37) P-trend= 4 x 10
-3 
missing 43 16     
TNRC9/ 
TOX3 rs4784227 
C/C 637 (52.0) 631 (61.6)  1.00 1.00 C/T 486 (38.4) 398 (32.9)  1.20 (1.00-1.44) 1.26 (1.09-1.44) T/T 103 (9.6) 68 (5.5)  1.70 (1.21-2.41) P-trend= 0.001 missing 21 8     
TNRC9/ 
TOX3 rs3104746
c 
T/T 1160 (94.6) 1039 (96.9)  1.00 1.00 A/T or A/A 69 (5.4) 46 (3.1)  1.66 (1.10-2.51) 1.66 (1.10-2.51) missing 18 16     
TNRC9/ 
TOX3 rs3112562 
C/C 741 (61.0) 644 (64.0)  1.00 1.00 C/G 416 (33.9) 398 (32.5)  0.90 (0.75-1.08) 0.99 (0.86-1.15) G/G 70 (5.1) 54 (3.5)  1.22 (0.82-1.81) P-trend= 0.9 missing 20 9     
TNRC9/ 
TOX3 rs9940048 
G/G 656 (54.0) 602 (57.1)  1.00 1.00 A/G 483 (40.5) 421 (37.6)  1.04 (0.87-1.25) 1.03 (0.89-1.19) A/A 65 (5.5) 66 (5.3)  1.02 (0.70-1.49) P-trend= 0.7 missing 43 16     
TP53 rs9894946 
A/A 44 (3.5) 31 (2.3)  1.00 1.00 A/G 346 (32.0) 286 (24.3)  0.76 (0.46-1.27) 0.84 (0.72-0.99) G/G 814 (64.5) 770 (73.4)  0.66 (0.40-1.07) P-trend= 0.04 missing 43 18     
TP53 rs1614984 
C/C 418 (35.1) 354 (36.4)  1.00 1.00 C/T 564 (47.0) 551 (49.0)  0.84 (0.69-1.02) 1.03 (0.91-1.17) T/T 221 (17.9) 184 (14.6)  1.15 (0.89-1.48) P-trend= 0.6 missing 44 16     
TP53 rs12951053 
A/A 1047 (86.9) 953 (87.7)  1.00 1.00 A/C 146 (12.5) 133 (12.2)  1.01 (0.77-1.32) 1.09 (0.85-1.39) C/C 10 (0.5) 3 (0.2)  2.71 (0.71-10.34) P-trend= 0.5 missing 44 16     
TP53 rs17880604c 
G/G 1168 (97.0) 1053 (97.1)  1.00 1.00 C/G or C/C 36 (3.0) 36 (2.9)  0.82 (0.49-1.35) 0.82 (0.51-1.33) missing 43 16     TP53 rs1800372c A/A 1165 (97.1) 1044 (97.0)  1.00 1.00 
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A/G or G/G 38 (2.9) 40 (3.0)  0.84 (0.52-1.35) 0.88 (0.55-1.40) missing 44 21     
TP53 rs2909430 
A/A 887 (72.4) 814 (76.1)  1.00 1.00 A/G 291 (25.5) 257 (22.6)  1.04 (0.85-1.28) 1.11 (0.93-1.33) G/G 26 (2.2) 18 (1.3)  1.67 (0.89-3.14) P-trend= 0.2 missing 43 16     
TP53 rs1042522 
G/G 90 (7.8) 73 (6.5)  1.00 1.00 C/G 445 (35.1) 406 (33.7)  0.98 (0.68-1.41) 0.98 (0.85-1.13) C/C 680 (57.2) 608 (59.8)  0.96 (0.68-1.37) P-trend= 0.8 missing 32 18     
TP53 rs8079544d 
T/T or C/T 123 (9.0) 128 (9.7)  1.00 1.00 CC 1081 (91.0) 961 (90.3)  1.21 (0.92-1.60) 1.24 (0.95-1.63) missing 43 16     A/A 95 (7.4) 85 (6.1)  1.00 1.00 
COX11 rs7222197 
A/G 525 (43.2) 454 (37.2)  1.07 (0.76-1.51) 0.98 (0.85-1.12) G/G 613 (49.4) 560 (56.6)  1.01 (0.72-1.42) P-trend= 0.7 missing 14 6     A/A 94 (7.4) 86 (6.2)  1.00 1.00 
COX11 rs6504950 
A/G 522 (43.1) 457 (37.3)  1.08 (0.77-1.52) 0.98 (0.85-1.12) G/G 614 (49.5) 560 (56.5)  1.02 (0.73-1.43) P-trend= 0.8 missing 17 2       
aweighted by inverse sampling probability 
badjusted for age at diagnosis (cases) or selection (controls) and proportion of African ancestry 
cAssessed using dominant and additive model (MAF<5%) 
dAssessed using recessive and additive model (MAF>95%) 
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Table 11: SNP genotype distributions and associations with incident breast cancer for 
African American women in the Carolina Breast Cancer Study (1993-2000) 
 
Gene SNP genotype Cases (%)* n=742 
Controls (%)* 
n=681   
General model:  
OR (95% CI)† 
Additive model: 
OR (95% CI)† 
1p12 rs11249433 
A/A 565 (74.0) 536 (81.4)   1.00 1.00 
A/G 190 (25.0) 121 (16.9)  1.51 (1.15-1.99) 1.26 (0.99-1.60) G/G 8 (1.0) 16 (1.7)  0.58 (0.24-1.44) P-trend= 0.1 missing 3 8     
CASP8 rs1045485 
G/G 660 (89.0) 579 (89.2)  1.00 1.00 C/G 80 (10.7) 77 (10.6)  0.96 (0.68-1.35) 0.93 (0.67-1.29) C/C 2 (0.3) 2 (0.2)  0.45 (0.05-3.74) P-trend= 0.7 missing 24 23     
CASP8 rs17468277 
T/T 1 (0.1) 2 (0.2)  1.00 1.00 C/T 74 (9.8) 70 (10.0)  3.97 (0.29-54.81) 1.09 (0.78-1.54) C/C 667 (90.0) 586 (89.9)  4.14 (0.31-56.07) P-trend= 0.6 missing 24 23     
2q35 rs13387042 
G/G 47 (6.2) 45 (8.4)  1.00 1.00 A/G 292 (39.3) 254 (37.0)  1.10 (0.70-1.75) 1.02 (0.86-1.22) A/A 403 (54.4) 358 (54.6)  1.10 (0.70-1.73) P-trend= 0.8 missing 24 24     
2p rs4666451 
A/A 26 (3.5) 43 (8.6)  1.00 1.00 A/G 267 (36.1) 221 (29.6)  2.16 (1.25-3.72) 1.15 (0.96-1.39) G/G 449 (60.5) 394 (61.9)  2.10 (1.23-3.57) P-trend= 0.1 missing 24 23     
SLC4A7 rs4973768 
C/C 322 (42.6) 250 (36.2)  1.00 1.00 C/T 334 (43.8) 340 (46.6)  0.77 (0.61-0.97) 0.90 (0.77-1.06) T/T 103 (13.7) 83 (17.2)  0.91 (0.65-1.29) P-trend= 0.2 missing 7 8     
4p rs12505080 
T/T 514 (68.1) 461 (68.2)  1.00 1.00 C/T 218 (28.9) 184 (30.0)  1.09 (0.86-1.39) 1.09 (0.88-1.34) C/C 22 (3.0) 16 (1.7)  1.17 (0.58-2.37) P-trend= 0.4 missing 12 20     
TLR1 rs7696175 C/C 630 (85.0) 573 (88.0)  1.00 1.00 C/T 99 (13.3) 81 (11.6)  1.22 (0.87-1.71) 1.39 (1.04-1.86) 
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T/T 13 (1.7) 4 (0.4)  4.11 (1.27-13.24) P-trend= 0.03 missing 24 23     
MRPS30 rs4415084 
C/C 97 (12.8) 100 (19.7)  1.00 1.00 C/T 343 (45.9) 312 (44.0)  1.33 (0.95-1.86) 1.13 (0.97-1.33) T/T 310 (41.3) 259 (36.3)  1.37 (0.97-1.94) P-trend= 0.1 missing 16 10     
MRPS30 rs10941679 
A/A 497 (65.5) 436 (65.5)  1.00 1.00 A/G 234 (30.8) 219 (31.7)  0.95 (0.75-1.20) 1.00 (0.82-1.22) G/G 28 (3.7) 19 (2.8)  1.24 (0.67-2.30) P-trend= 1 missing 7 7     
5p12 rs981782 
G/G 11 (1.4) 7 (1.0)  1.00 1.00 G/T 105 (14.1) 110 (15.0)  0.78 (0.27-2.26) 1.11 (0.84-1.46) T/T 625 (84.5) 540 (84.0)  0.91 (0.32-2.59) P-trend= 0.5 missing 25 24     
5q rs30099 
C/C 527 (70.9) 493 (76.2)  1.00 1.00 C/T 199 (26.9) 152 (22.7)  1.26 (0.98-1.62) 1.22 (0.98-1.52) T/T 16 (2.2) 13 (1.1)  1.28 (0.59-2.74) P-trend= 0.1 missing 24 23     
MAP3K1 rs889312 
A/A 316 (42.7) 281 (37.9)  1.00 1.00 A/C 364 (49.2) 313 (53.1)  1.00 (0.79-1.25) 0.95 (0.80-1.13) C/C 62 (8.2) 64 (9.0)  0.84 (0.57-1.25) P-trend= 0.5 missing 24 23     
ESR1 rs2046210 
G/G 96 (12.7) 99 (13.4)  1.00 1.00 A/G 350 (46.1) 340 (50.9)  1.06 (0.76-1.48) 1.22 (1.04-1.43) A/A 312 (41.2) 231 (35.6)  1.40 (1.00-1.98) P-trend= 0.02 missing 8 11     
ESR1 rs851974 
A/G 523 (69.3) 444 (68.0)  1.00 1.00 A/G 208 (27.5) 208 (29.4)  0.87 (0.68-1.11) 0.93 (0.76-1.14) G/G 25 (3.2) 20 (2.6)  1.06 (0.57-2.00) P-trend= 0.5 missing 10 9     
ESR1 rs2077647 
A/A 170 (22.9) 155 (24.6)  1.00 1.00 A/G 372 (50.2) 346 (48.2)  0.97 (0.74-1.27) 1.07 (0.92-1.25) A/A 200 (26.9) 155 (27.2)  1.14 (0.84-1.56) P-trend= 0.4 missing 24 25     ESR1 rs2234693 C/C 198 (26.8) 182 (26.1)  1.00 1.00 
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C/T 396 (53.3) 334 (52.2)  1.09 (0.84-1.41) 0.96 (0.82-1.13) T/T 148 (19.9) 142 (21.7)  0.91 (0.66-1.25) P-trend= 0.6 missing 24 23     
ESR1 rs1801132 
G/G 8 (1.0) 7 (0.9)  1.00 1.00 C/G 134 (18.4) 144 (23.0)  0.76 (0.26-2.19) 1.19 (0.93-1.52) C/C 599 (80.6) 507 (76.1)  0.95 (0.33-2.68) P-trend= 0.2 missing 25 23     
ESR1 rs3020314 
T/T 63 (8.5) 65 (7.8)  1.00 1.00 C/T 339 (45.5) 278 (43.2)  1.20 (0.81-1.77) 1.00 (0.84-1.19) C/C 339 (46.0) 315 (49.0)  1.11 (0.75-1.65) P-trend= 1 missing 25 23     
ESR1 rs3798577 
C/C 140 (19.0) 130 (22.7)  1.00 1.00 C/T 367 (49.0) 309 (46.6)  1.18 (0.88-1.58) 1.02 (0.88-1.19) T/T 235 (32.0) 219 (30.7)  1.08 (0.79-1.47) P-trend= 0.8 missing 24 23     
ECHDC1 rs2180341 
A/A 354 (47.7) 317 (42.5)  1.00 1.00 A/G 321 (42.6) 288 (48.8)  0.94 (0.75-1.19) 0.98 (0.83-1.15) G/G 75 (9.7) 68 (8.7)  1.00 (0.68-1.46) P-trend= 0.8 missing 16 8     
RELN rs17157903 
C/C 599 (80.7) 523 (79.4)  1.00 1.00 C/T 129 (17.4) 132 (20.3)  0.87 (0.66-1.16) 1.07 (0.83-1.37) T/T 14 (1.9) 3 (0.3)  5.21 (1.48-18.29) P-trend= 0.6 missing 24 23     
8q24 rs13281615 
A/A 219 (29.2) 204 (33.1)  1.00 1.00 A/G 387 (53.1) 331 (48.7)  1.14 (0.89-1.46) 1.00 (0.86-1.18) G/G 130 (17.7) 123 (18.2)  0.97 (0.70-1.34) P-trend= 1 missing 30 23     
8q24 rs1562430 
C/C 158 (20.7) 147 (23.5)  1.00 1.00 C/T 375 (50.3) 327 (47.4)  1.11 (0.84-1.47) 1.00 (0.86-1.17) T/T 219 (29.1) 197 (29.1)  1.02 (0.75-1.39) P-trend= 1 missing 14 10     
CDKN2A/B rs3731257 
C/C 617 (83.3) 535 (79.2)  1.00 1.00 C/T 119 (15.9) 117 (19.8)  0.87 (0.65-1.16) 0.88 (0.67-1.15) T/T 6 (0.8) 6 (1.1)  0.86 (0.26-2.82) P-trend= 0.3 missing 24 23     
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CDKN2A/B rs518394 
C/C 623 (84.1) 559 (84.4)  1.00 1.00 C/G 112 (14.9) 91 (14.4)  1.05 (0.77-1.45) 1.01 (0.76-1.35) G/G 7 (1.0) 8 (1.2)  0.81 (0.27-2.42) P-trend= 0.9 missing 24 23     
CDKN2A/B rs564398 
A/A 628 (84.7) 566 (85.5)  1.00 1.00 G/A 109 (14.5) 84 (13.3)  1.11 (0.80-1.54) 1.01 (0.75-1.35) G/G 5 (0.7) 8 (1.2)  0.52 (0.16-1.74) P-trend= 0.9 missing 24 23     
CDKN2A/B rs1011970 
G/G 349 (46.6) 314 (47.6)  1.00 1.00 G/T 307 (40.9) 277 (37.1)  0.92 (0.73-1.16) 0.95 (0.81-1.11) T/T 93 (12.5) 79 (15.3)  0.93 (0.65-1.32) P-trend= 0.5 missing 17 11     
CDKN2A/B rs10757278 
G/G 27 (3.7) 22 (3.3)  1.00 1.00 A/G 241 (31.2) 192 (29.0)  0.96 (0.52-1.79) 0.91 (0.75-1.12) A/A 490 (65.1) 452 (67.7)  0.87 (0.47-1.59) P-trend= 0.4 missing 8 15     
ANKRD16 rs2380205 
T/T 259 (34.1) 226 (29.9)  1.00 1.00 C/T 360 (48.1) 329 (48.9)  0.95 (0.74-1.21) 0.97 (0.83-1.13) C/C 132 (17.8) 113 (21.2)  0.95 (0.69-1.31) P-trend= 0.7 missing 15 13     
ZNF365 rs10995190 
A/A 28 (3.6) 22 (3.9)  1.00 1.00 A/G 206 (27.0) 202 (26.6)  0.75 (0.41-1.38) 1.06 (0.87-1.29) G/G 526 (69.4) 449 (69.5)  0.86 (0.48-1.55) P-trend= 0.6 missing 6 8     
ZMIZ1 rs704010 
C/C 601 (79.5) 532 (85.4)  1.00 1.00 C/T 148 (19.4) 128 (13.7)  1.07 (0.80-1.42) 1.05 (0.80-1.36) T/T 8 (1.0) 7 (0.9)  0.94 (0.32-2.75) P-trend= 0.7 missing 9 14     
FGFR2 rs1896395 
C/C 474 (63.9) 408 (61.4)  1.00 1.00 A/C 235 (31.6) 231 (36.4)  0.87 (0.69-1.10) 1.01 (0.83-1.23) A/A 33 (4.5) 19 (2.2)  1.69 (0.94-3.07) P-trend= 0.9 missing 24 23     
FGFR2 rs3750817 
T/T 6 (0.9) 11 (1.9)  1.00 1.00 C/T 120 (15.9) 155 (20.7)  1.83 (0.59-5.73) 1.74 (1.34-2.26) C/C 635 (83.2) 506 (77.4)  3.16 (1.03-9.71) P-trend= 3x10
-5 
  
151 
missing 5 9     
FGFR2 rs10736303 
A/A 15 (2.1) 20 (3.8)  1.00 1.00 A/G 168 (22.1) 186 (23.7)  1.29 (0.62-2.72) 1.39 (1.12-1.74) G/G 580 (75.8) 471 (72.5)  1.83 (0.89-3.77) P-trend= 0.003 missing 3 4     
FGFR2 rs11200014 
G/G 476 (64.3) 425 (61.4)  1.00 1.00 A/G 232 (31.2) 206 (35.1)  1.00 (0.79-1.27) 1.04 (0.86-1.26) A/A 34 (4.5) 27 (3.5)  1.23 (0.71-2.11) P-trend= 0.7 missing 24 23     
FGFR2 rs2981579 
C/C 110 (14.9) 129 (18.1)  1.00 1.00 C/T 341 (46.1) 301 (42.4)  1.39 (1.02-1.90) 1.22 (1.04-1.42) T/T 291 (39.0) 228 (39.5)  1.54 (1.12-2.13) P-trend= 0.01 missing 24 23     
FGFR2 rs1078806 
A/A 480 (63.5) 433 (61.3)  1.00 1.00 A/G 240 (31.8) 216 (35.6)  1.01 (0.80-1.28) 1.06 (0.88-1.29) G/G 36 (4.7) 27 (3.1)  1.30 (0.75-2.25) P-trend= 0.5 missing 10 5     
FGFR2 rs2981578 
T/T 15 (2.1) 22 (3.9)  1.00 1.00 C/T 165 (21.8) 184 (23.7)  1.42 (0.68-2.93) 1.42 (1.14-1.77) C/C 580 (76.1) 470 (72.4)  2.02 (0.99-4.09) P-trend= 0.002 missing 6 5     
FGFR2 rs1219648 
A/A 230 (31.2) 227 (32.9)  1.00 1.00 A/G 363 (48.8) 325 (52.0)  1.13 (0.89-1.45) 1.19 (1.02-1.39) G/G 149 (20.0) 106 (15.1)  1.45 (1.05-1.99) P-trend= 0.03 missing 24 23     
FGFR2 rs2912774 
C/C 134 (18.0) 131 (19.6)  1.00 1.00 A/C 347 (46.7) 350 (50.4)  1.05 (0.78-1.41) 1.27 (1.09-1.49) A/A 261 (35.3) 176 (30.0)  1.55 (1.13-2.13) P-trend= 0.003 missing 24 24     
FGFR2 rs2936870 
C/C 129 (17.4) 126 (18.8)  1.00 1.00 C/T 340 (45.9) 345 (50.2)  1.05 (0.78-1.41) 1.27 (1.09-1.48) T/T 272 (36.7) 187 (31.0)  1.53 (1.11-2.11) P-trend= 0.003 missing 25 23     
FGFR2 rs2420946 C/C 158 (21.3) 146 (21.6)  1.00 1.00 C/T 366 (49.4) 356 (52.3)  1.02 (0.77-1.35) 1.17 (1.00-1.37) 
  
152 
T/T 218 (29.4) 156 (26.1)  1.36 (0.99-1.86) P-trend= 0.05 missing 24 23     
FGFR2 rs2162540 
A/A 161 (21.7) 166 (24.0)  1.00 1.00 A/G 367 (49.5) 339 (48.8)  1.19 (0.91-1.56) 1.23 (1.05-1.44) G/G 214 (28.8) 152 (27.2)  1.51 (1.11-2.06) P-trend= 0.01 missing 24 24     
FGFR2 rs2981582 
C/C 186 (25.1) 200 (27.7)  1.00 1.00 C/T 382 (51.3) 325 (47.6)  1.30 (1.00-1.68) 1.19 (1.02-1.39) T/T 174 (23.6) 133 (24.7)  1.40 (1.02-1.91) P-trend= 0.03 missing 24 23     
FGFR2 rs3135718 
A/A 147 (19.7) 148 (24.3)  1.00 1.00 A/G 326 (44.0) 321 (44.3)  1.11 (0.83-1.47) 1.26 (1.08-1.46) G/G 269 (36.3) 187 (31.4)  1.54 (1.14-2.10) P-trend= 0.003 missing 24 25     
10q rs10510126 
T/T 16 (2.2) 6 (0.6)  1.00 1.00 C/T 133 (18.2) 145 (18.5)  0.33 (0.12-0.88) 1.04 (0.82-1.32) C/C 593 (79.6) 507 (80.9)  0.40 (0.15-1.05) P-trend= 0.8 missing 24 23     
ATM rs1801516‡ 
G/G 700 (94.3) 623 (95.2)  1.00 1.00 A/G or A/A 42 (5.7) 35 (4.8)  1.16 (0.72-1.88) 1.22 (0.77-1.95) missing 24 23     
ATM rs664143 
T/T 96 (13.0) 70 (9.6)  1.00 1.00 C/T 316 (42.6) 302 (44.9)  0.77 (0.54-1.10) 0.95 (0.81-1.11) C/C 330 (44.4) 285 (45.5)  0.81 (0.57-1.16) P-trend= 0.5 missing 24 24     
ATM rs170548 
T/T 622 (84.0) 535 (78.5)  1.00 1.00 G/T 105 (14.1) 112 (19.9)  0.78 (0.57-1.05) 0.86 (0.67-1.11) G/G 14 (1.9) 11 (1.6)  1.13 (0.49-2.58) P-trend= 0.3 missing 25 23     
ATM rs3092993‡ 
C/C 700 (94.3) 623 (95.2)  1.00 1.00 A/C or A/A 42 (5.7) 35 (4.8)  1.16 (0.72-1.88) 1.22 (0.77-1.95) missing 24 23     
LSP1 rs3817198 
T/T 506 (68.2) 459 (69.7)  1.00 1.00 C/T 224 (30.1) 175 (26.3)  1.19 (0.93-1.52) 1.01 (0.82-1.24) C/C 12 (1.7) 24 (4.0)  0.47 (0.23-0.99) P-trend= 0.9 
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missing 24 23     
LSP1 rs909116 
C/C 59 (7.8) 54 (9.4)  1.00 1.00 C/T 309 (41.5) 271 (36.4)  1.13 (0.74-1.73) 1.00 (0.84-1.19) T/T 381 (50.7) 343 (54.2)  1.08 (0.71-1.65) P-trend= 1.00 missing 17 13     
H19 rs2107425 
T/T 186 (25.1) 149 (21.1)  1.00 1.00 C/T 390 (53.1) 339 (52.3)  0.92 (0.70-1.20) 0.84 (0.71-0.98) C/C 161 (21.8) 170 (26.6)  0.70 (0.51-0.96) P-trend= 0.03 missing 29 23     
TNRC9/TOX3 rs8049149‡ 
C/C 712 (96.0) 627 (95.5)  1.00 1.00 C/T or T/T 30 (4.0) 31 (4.5)  0.92 (0.54-1.56) 0.92 (0.54-1.56) missing 24 23     
TNRC9/TOX3 rs16951186 
C/C 511 (69.3) 438 (64.8)  1.00 1.00 C/T 202 (26.9) 198 (32.5)  0.81 (0.63-1.03) 0.90 (0.74-1.09) T/T 29 (3.8) 22 (2.7)  1.10 (0.61-1.97) P-trend= 0.3 missing 24 23     
TNRC9/TOX3 rs8051542 
C/C 313 (42.5) 295 (46.0)  1.00 1.00 C/T 342 (45.8) 304 (47.6)  1.04 (0.83-1.31) 1.14 (0.97-1.35) T/T 87 (11.7) 59 (6.5)  1.45 (0.99-2.11) P-trend= 0.1 missing 24 23     
TNRC9/TOX3 rs12443621 
A/A 208 (28.3) 164 (25.7)  1.00 1.00 A/G 370 (49.8) 329 (47.1)  0.90 (0.69-1.16) 0.86 (0.74-1.01) G/G 164 (21.9) 165 (27.2)  0.74 (0.55-1.01) P-trend= 0.1 missing 24 23     
TNRC9/TOX3 rs3803662 
T/T 196 (26.2) 182 (29.5)  1.00 1.00 C/T 378 (51.3) 333 (49.6)  1.08 (0.84-1.40) 1.06 (0.90-1.23) C/C 166 (22.4) 142 (21.0)  1.11 (0.81-1.52) P-trend= 0.5 missing 26 24     
TNRC9/TOX3 rs4784227 
C/C 636 (84.2) 580 (86.6)  1.00 1.00 C/T 112 (14.6) 83 (13.0)  1.17 (0.85-1.62) 1.25 (0.93-1.67) T/T 9 (1.2) 4 (0.4)  2.70 (0.69-10.65) P-trend= 0.1 missing 9 14     
TNRC9/TOX3 rs3104746 
T/T 411 (54.3) 432 (66.4)  1.00 1.00 A/T 297 (39.5) 208 (30.4)  1.58 (1.25-2.00) 1.54 (1.27-1.86) A/A 46 (6.2) 24 (3.2)  2.22 (1.31-3.76) P-trend= 1 x 10
-5 
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missing 12 17     
TNRC9/TOX3 rs3112562 
C/C 166 (21.6) 187 (29.6)  1.00 1.00 C/G 391 (52.1) 332 (48.8)  1.39 (1.06-1.81) 1.28 (1.09-1.50) G/G 199 (26.3) 144 (21.6)  1.64 (1.19-2.25) P-trend= 0.002 missing 10 18     
TNRC9/TOX3 rs9940048 
G/G 352 (47.4) 341 (47.5)  1.00 1.00 A/G 327 (44.1) 262 (45.2)  1.20 (0.96-1.51) 1.10 (0.93-1.31) A/A 63 (8.6) 55 (7.3)  1.07 (0.71-1.61) P-trend= 0.3 missing 24 23     
TP53 rs9894946d 
A/A or A/G 71 (9.6) 62 (7.9)  1.00 1.00 G/G 670 (90.4) 596 (92.1)  0.94 (0.65-1.36) 0.96 (0.68-1.36) missing 25 23     
TP53 rs1614984 
C/C 271 (36.4) 264 (38.1)  1.00 1.00 C/T 347 (46.7) 285 (43.0)  1.21 (0.95-1.53) 1.07 (0.92-1.25) T/T 124 (16.9) 109 (18.9)  1.07 (0.78-1.48) P-trend= 0.4 missing 24 23     
TP53 rs12951053 
A/A 581 (78.2) 526 (80.2)  1.00 1.00 A/C 158 (21.5) 119 (18.3)  1.24 (0.94-1.63) 1.03 (0.80-1.32) C/C 2 (0.3) 12 (1.5)  0.16 (0.04-0.72) P-trend= 0.8 missing 25 24     
TP53 rs2909430 
A/A 404 (54.1) 354 (59.8)  1.00 1.00 A/G 273 (37.2) 254 (32.7)  1.00 (0.79-1.26) 1.06 (0.89-1.25) G/G 65 (8.7) 50 (7.5)  1.22 (0.81-1.83) P-trend= 0.5 missing 24 23     
TP53 rs1042522 
G/G 282 (37.8) 247 (34.7)  1.00 1.00 C/G 353 (46.9) 310 (44.8)  0.95 (0.74-1.20) 0.98 (0.83-1.15) C/C 117 (15.3) 102 (20.5)  0.97 (0.69-1.36) P-trend= 0.8 missing 14 22     
TP53 rs8079544 
T/T 8 (1.0) 7 (1.0)  1.00 1.00 C/T 142 (19.1) 117 (20.0)  1.09 (0.36-3.27) 0.89 (0.69-1.15) C/C 592 (79.9) 534 (79.0)  0.95 (0.32-2.79) P-trend= 0.4 missing 24 23     
COX11 rs7222197 
A/A 93 (12.3) 87 (12.8)  1.00 1.00 A/G 324 (42.5) 305 (45.1)  1.02 (0.72-1.45) 1.14 (0.97-1.33) G/G 343 (45.3) 285 (42.1)  1.23 (0.87-1.75) P-trend= 0.1 
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missing 6 4     
COX11 rs6504950 
A/A 94 (12.3) 87 (12.8)  1.00 1.00 A/G 325 (42.3) 305 (44.8)  1.01 (0.71-1.43) 1.13 (0.96-1.32) G/G 346 (45.4) 288 (42.4)  1.21 (0.86-1.71) P-trend= 0.1 missing 1 1       
aweighted by inverse sampling probability 
badjusted for age at diagnosis (cases) or selection (controls) and proportion of African ancestry 
cAssessed using dominant and additive model (MAF<5%) 
dAssessed using recessive and additive model (MAF>95%) 
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Table 12: Comparison of odds ratios (ORs) and confidence limit ratios (CLRs) or posterior limit ratios (PLRs) for MLE, 
Bayesian and hierarchical regression models among white 
 
Gene and 
 LD block SNP Reference OR
a MLE OR
b  
(95% CI) 
MLE 
CLR 
Bayesian ORb  
(95% PI) 
Bayes 
PLR 
Hierarchical 
ORe (95% PI) 
Hierar
chical 
PLR 
1p12 rs11249433d 1.14 (1.10, 1.19) [186] 1.09 (0.96, 1.24) 1.28 1.09 (0.96, 1.22) 1.28 1.09 (0.96, 1.24) 1.28 
CASP8 block1 rs1045485f 1.12 (1.08, 1.18) [20] 1.13 (0.94, 1.35) 1.43 1.11 (0.93, 1.29) 1.39 1.08 (0.78, 1.49) 1.90 
CASP8 block1 rs17468277  1.12 (0.93, 1.34) 1.43 1.11 (0.93, 1.29) 1.38 1.04 (0.76, 1.44) 1.90 
2q35 rs13387042d 1.20 (1.14, 1.26) [187] 1.08 (0.96, 1.22) 1.28 1.08 (0.96, 1.21) 1.27 1.08 (0.96, 1.22) 1.28 
2p rs4666451e 1.03 (1.00, 1.06) [194] 1.02 (0.90, 1.16) 1.28 1.02 (0.90, 1.14) 1.27 1.02 (0.90, 1.16) 1.28 
SLC4A7 rs4973768d 1.16 (1.10, 1.24) [189] 1.04 (0.92, 1.17) 1.28 1.04 (0.92, 1.17) 1.28 1.04 (0.92, 1.17) 1.28 
4p rs12505080e 1.15 (1.03, 1.28)g [201] 1.06 (0.92, 1.23) 1.33 1.06 (0.92, 1.21) 1.31 1.06 (0.92, 1.23) 1.33 
TLR1 rs7696175e 1.12 (1.00, 1.26)g [201] 1.09 (0.96, 1.23) 1.28 1.09 (0.96, 1.22) 1.27 1.09 (0.96, 1.23) 1.28 
MRPS30 rs4415084d 1.16 (1.10, 1.21) [208] 1.23 (1.08, 1.40) 1.30 1.22 (1.07, 1.37) 1.28 1.23 (1.08, 1.40) 1.30 
MRPS30 rs10941679e 1.19 (1.13, 1.26) [208] 1.18 (1.03, 1.36)  1.32 1.17 (1.01, 1.33) 1.31 1.18 (1.03, 1.36) 1.32 
5p12 rs981782d 1.04 (1.01, 1.08) [194] 0.98 (0.86, 1.11) 1.28 0.98 (0.87, 1.10) 1.27 0.98 (0.86, 1.11) 1.28 
5q rs30099e 1.05 (1.01, 1.10) [194] 1.04 (0.85, 1.28) 1.52 1.04 (0.84, 1.24) 1.48 1.04 (0.85, 1.28) 1.52 
MAP3K1 rs889312d 1.13 (1.10, 1.16) [194] 1.19 (1.04, 1.35) 1.30 1.18 (1.03, 1.32) 1.29 1.19 (1.04, 1.35) 1.30 
ESR1 rs2046210d 1.29 (1.21, 1.37) [197] 1.09 (0.96, 1.24) 1.30 1.08 (0.95, 1.22) 1.28 1.09 (0.96, 1.24) 1.30 
ESR1 rs851974  0.91 (0.80, 1.03) 1.29 0.91 (0.81, 1.03) 1.27 0.91 (0.80, 1.03) 1.29 ESR1 rs2077647  0.97 (0.86, 1.10) 1.28 0.97 (0.86, 1.10) 1.27 0.97 (0.86, 1.10) 1.28 ESR1 rs2234693  0.95 (0.84, 1.07) 1.28 0.95 (0.84, 1.06) 1.27 0.95 (0.84, 1.07) 1.28 
ESR1 rs1801132f 1.05 (1.00, 1.11) [20] 0.92 (0.80, 1.06) 1.34 0.93 (0.80, 1.05) 1.31 0.92 (0.80, 1.06) 1.34 
ESR1 rs3020314f 1.12 (1.06,1.18) [20] 1.05 (0.92, 1.19) 1.29 1.05 (0.93, 1.18) 1.27 1.05 (0.92, 1.19) 1.29 
ESR1 rs3798577  1.03 (0.91, 1.17) 1.28 1.03 (0.91, 1.16) 1.27 1.03 (0.91, 1.17) 1.28 
ECHDC1 rs2180341d 1.41 (1.25, 1.59) [196] 1.04 (0.90, 1.20) 1.34 1.04 (0.89, 1.19) 1.33 1.04 (0.90, 1.20) 1.34 
RELN rs17157903e 1.11 (1.00, 1.23) [201] 0.87 (0.73, 1.04) 1.42 0.89 (0.75, 1.05) 1.40 0.87 (0.73, 1.04) 1.42 
8q24 rs13281615d 1.08 (1.05, 1.11) [194] 1.11 (0.98, 1.26) 1.28 1.11 (0.98, 1.24) 1.26 1.11 (0.98, 1.26) 1.28 
8q24 rs1562430d 1.17 (1.10, 1.25) [189] 1.13 (0.99, 1.28) 1.29 1.12 (0.99, 1.26) 1.27 1.13 (0.99, 1.28) 1.29 
CDKN2A/B rs3731257  0.93 (0.81, 1.07) 1.32 0.94 (0.81, 1.07) 1.31 0.93 (0.81, 1.07) 1.32 
CDKN2A/B rs3731249  0.90 (0.63, 1.28) 2.04 0.94 (0.68, 1.20) 1.78 0.90 (0.63, 1.29) 2.04 CDKN2A/B 
block 1 rs518394  1.03 (0.91, 1.16) 1.28 1.03 (0.91, 1.15) 1.26 1.03 (0.91, 1.16) 1.28 
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CDKN2A/B 
block 1 rs564398  1.04 (0.92, 1.17) 1.28 1.04 (0.91, 1.17) 1.28 1.05 (0.82, 1.36) 1.67 
CDKN2A/B rs1011970d 1.20 (1.11, 1.30) [189] 1.13 (0.96, 1.33) 1.38 1.12 (0.95, 1.30) 1.36 1.13 (0.96, 1.33) 1.38 
CDKN2A/B rs10757278  1.17 (1.04, 1.33) 1.28 1.16 (1.01, 1.30) 1.28 1.17 (1.04, 1.33) 1.28 CDKN2A/B rs10811661  1.00 (0.85, 1.18) 1.38 1.01 (0.85, 1.16) 1.36 1.00 (0.85, 1.18) 1.38 ANKRD16 rs2380205d 1.06 (1.02, 1.10) [189] 1.01 (0.89, 1.14) 1.28 1.01 (0.89, 1.14) 1.27 1.01 (0.89, 1.14) 1.28 
ZNF365 rs10995190d 1.16 (1.10, 1.22) [189] 1.00 (0.84, 1.20) 1.43 1.00 (0.85, 1.17) 1.38 1.00 (0.84, 1.20) 1.43 
ZMIZ1 rs704010d 1.07 (1.03, 1.11) [189] 1.24 (1.09, 1.41) 1.29 1.23 (1.08, 1.39) 1.28 1.24 (1.09, 1.41) 1.29 
FGFR2 block 1 rs3750817  1.24 (1.09, 1.40) 1.29 1.22 (1.08, 1.37) 1.28 0.96 (0.81, 1.15) 1.43 
FGFR2 block 1 rs10736303e 1.25 (1.18, 1.32) [194] 1.33 (1.17, 1.50) 1.28 1.31 (1.15, 1.47) 1.28 1.08 (0.79, 1.48) 1.88 
FGFR2 block 1 rs11200014  1.30 (1.15, 1.48) 1.28 1.29 (1.13, 1.44) 1.27 0.94 (0.66, 1.35) 2.05 
FGFR2 block 1 rs2981579d 1.17 (1.07, 1.27)g [186] 1.33 (1.18, 1.51) 1.28 1.31 (1.16, 1.48) 1.27 1.20 (0.85, 1.72) 2.03 
FGFR2 block 1 rs1078806e 1.26 (1.13, 1.40) [196] 1.29 (1.14, 1.46) 1.28 1.28 (1.14, 1.44) 1.26 0.95 (0.67, 1.34) 1.99 
FGFR2 block 1 rs2981578e 1.26 (1.19, 1.34) [194] 1.32 (1.17, 1.50) 1.28 1.30 (1.15, 1.45) 1.26 1.11 (0.81, 1.51) 1.86 
FGFR2 block 1 rs1219648d 1.27 (1.18, 1.36) [201] 1.31 (1.16, 1.48) 1.28 1.29 (1.14, 1.45) 1.27 1.04 (0.72, 1.51) 2.10 
FGFR2 block 1 rs2912774e 1.26 (1.19, 1.34) [194] 1.30 (1.15, 1.47) 1.28 1.28 (1.13, 1.44) 1.27 0.96 (0.66, 1.40) 2.13 
FGFR2 block 1 rs2936870e 1.26 (1.19, 1.34) [194] 1.30 (1.15, 1.47) 1.28 1.29 (1.13, 1.44) 1.28 0.98 (0.67, 1.43) 2.14 
FGFR2 block 1 rs2420946e 1.25 (1.18, 1.36) [201] 1.30 (1.15, 1.48) 1.28 1.28 (1.14, 1.45) 1.27 0.99 (0.67, 1.46) 2.16 
FGFR2 block 1 rs2162540  1.31 (1.15, 1.48) 1.28 1.29 (1.13, 1.44) 1.27 1.04 (0.72, 1.50) 2.10 
FGFR2 block 1 rs2981582d 1.26 (1.23, 1.30) [194] 1.30 (1.15, 1.48) 1.28 1.29 (1.13, 1.44) 1.28 1.01 (0.70, 1.46) 2.09 
FGFR2 block 1 rs3135718e 1.15 (1.07, 1.23) [194] 1.31 (1.16, 1.48) 1.28 1.29 (1.14, 1.45) 1.27 1.04 (0.73, 1.49) 2.04 
10q rs10510126e 1.20 (1.08, 1.35) [201] 1.11 (0.91, 1.35) 1.47 1.10 (0.91, 1.31) 1.43 1.11 (0.91, 1.35) 1.47 
ATM rs1800054  1.01 (0.65, 1.58) 2.45 1.03 (0.70, 1.42) 2.03 1.01 (0.65, 1.58) 2.45 
ATM rs1800057f 1.20 (1.01, 1.44)h [20]  1.09 (0.76, 1.56) 2.06 1.08 (0.78, 1.39) 1.79 1.09 (0.76, 1.56) 2.06 
ATM rs1800058  0.82 (0.54, 1.25) 2.33 0.90 (0.62, 1.18) 1.90 0.82 (0.54, 1.25) 2.34 ATM block 1 rs1801516  0.98 (0.82, 1.17) 1.43 0.99 (0.84, 1.16) 1.39 0.94 (0.68, 1.31) 1.94 ATM block 1 rs3092992  1.19 (0.89, 1.60) 1.80 1.16 (0.87, 1.46) 1.67 1.13 (0.87, 1.46) 1.68 ATM block 1 rs664143  1.02 (0.90, 1.15) 1.28 1.02 (0.90, 1.14) 1.27 1.10 (0.92, 1.31) 1.42 ATM block 1 rs170548  0.98 (0.86, 1.12) 1.31 0.98 (0.86, 1.11) 1.29 0.91 (0.74, 1.11) 1.50 ATM block 1 rs3092993  0.98 (0.82, 1.18) 1.43 0.99 (0.83, 1.15) 1.39 0.96 (0.69, 1.34) 1.94 
LSP1 rs3817198d 1.07 (1.04, 1.11) [194] 1.08 (0.95, 1.24) 1.30 1.08 (0.95, 1.22) 1.28 1.08 (0.95, 1.24) 1.30 
LSP1 rs909116d 1.17 (1.10, 1.24) [189] 1.14 (1.01, 1.30) 1.28 1.13 (0.99, 1.27) 1.28 1.14 (1.01, 1.30) 1.28 
H19 rs2107425e 1.04 (1.01, 1.08) [194] 1.15 (1.00, 1.31) 1.31 1.14 (1.01, 1.30) 1.29 1.15 (1.00, 1.31) 1.31 
TNRC9/TOX3 rs16951186  1.17 (0.62, 2.18) 3.49 1.10 (0.69, 1.56) 2.26 1.17 (0.62, 2.18) 3.49 
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TNRC9/TOX3 rs8051542e 1.09 (1.06, 1.13) [194] 1.12 (0.99, 1.26) 1.28 1.11 (0.97, 1.23) 1.27 1.12 (0.99, 1.26) 1.28 
TNRC9/TOX3 rs1244362e 1.11 (1.08, 1.14) [194] 1.17 (1.04, 1.33) 1.28 1.16 (1.03, 1.31) 1.27 1.17 (1.04, 1.33) 1.28 
TNRC9/TOX3 
block 1 rs3803662
d 1.20 (1.16, 1.24) [194] 1.27 (1.11, 1.46) 1.31 1.25 (1.10, 1.42) 1.29 1.14 (0.91, 1.43) 1.58 
TNRC9/TOX3 
block 1 rs4784227
d 1.25 (1.20, 1.31) [199] 1.26 (1.09, 1.44) 1.32 1.23 (1.07, 1.41) 1.31 1.11 (0.88, 1.41) 1.60 
TNRC9/TOX3 rs3104746  1.66 (1.10, 2.51) 2.29 1.42 (0.97, 1.94) 2.01 1.66 (1.10, 2.51) 2.29 
TNRC9/TOX3 rs3112562  0.99 (0.86, 1.15) 1.34 0.99 (0.86, 1.13) 1.32 0.99 (0.86, 1.15) 1.34 
TNRC9/TOX3 rs9940048  1.03 (0.89, 1.19) 1.33 1.03 (0.89, 1.17) 1.32 1.03 (0.89, 1.19) 1.33 
TP53 rs9894946  0.84 (0.72, 0.99) 1.38 0.86 (0.73, 1.00) 1.36 0.84 (0.72, 0.99) 1.38 
TP53 rs1614984  1.03 (0.91, 1.17) 1.28 1.03 (0.92, 1.15) 1.26 1.03 (0.91, 1.17) 1.28 
TP53 rs12951053f 1.15 (1.04, 1.26) [20] 1.09 (0.85, 1.39) 1.63 1.08 (0.83, 1.32) 1.58 1.09 (0.85, 1.39) 1.63 
TP53 rs17880604  0.82 (0.51, 1.33) 2.62 0.92 (0.61, 1.26) 2.06 0.82 (0.51, 1.33) 2.62 
TP53 block 1 rs1800372  0.88 (0.55, 1.40) 2.57 0.95 (0.64, 1.30) 2.03 1.01 (0.72, 1.40) 1.94 
TP53 block 1 rs2909430  1.11 (0.93, 1.33) 1.43 1.10 (0.92, 1.29) 1.41 1.10 (0.89, 1.35) 1.51 
TP53 block 1 rs1042522  0.98 (0.85, 1.13) 1.33 0.99 (0.85, 1.12) 1.31 1.09 (0.92, 1.29) 1.40 
TP53 rs8079544  1.24 (0.95, 1.63) 1.72 1.19 (0.92, 1.50) 1.63 1.24 (0.95, 1.63) 1.72 
COX11 block 1 rs7222197e 1.12 (1.04, 1.20) [189] 0.98 (0.85, 1.12) 1.32 0.98 (0.86, 1.12) 1.29 0.99 (0.72, 1.36) 1.89 
COX11 block 1 rs6504950e 1.05 (1.03, 1.09) [209] 0.98 (0.85, 1.12) 1.32 0.98 (0.84, 1.11) 1.31 0.99 (0.72, 1.36) 1.89 
aOR from initial GWAS or candidate gene meta-analysis (if met criteria for cumulative evidence of association); all ORs for log-additive genetic 
models, unless otherwise specified 
badjusted for age at diagnosis (case) or selection (controls) and proportion of African ancestry 
cadjusted for age at diagnosis (case) or selection (controls), proportion of African ancestry and other SNPs in LD block 
dprevious GWAS hit 
eOther GWAS-identified gene 
fcumulative evidence of an association in Zhang et al. meta-analysis 
gOR estimated using general genetic model 
hOR estimated using dominant genetic model 
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Table 13: Comparison of odds ratios (ORs) and confidence limit ratios (CLRs) or posterior limit ratios (PLRs) for frequentist, 
basic hierarchical and Bayesian regression models among African American women in the Carolina Breast Cancer Study 
 
Gene and 
 LD block SNP Reference OR
a MLE OR
b 
(95% CI) 
MLE 
CLR 
Bayesian ORb  
(95% PI) 
Bayes 
PLR 
Hierarchical 
ORc  (95% PI) 
Hierar
chical 
PLR 
1p12 rs11249433d 1.14 (1.10, 1.19) [186] 1.26 (0.99, 1.60) 1.61 1.22 (0.96, 1.48) 1.53 1.26 (0.99, 1.60) 1.61 
CASP8 block 1 rs1045485f 1.12 (1.08, 1.18) [20] 0.93 (0.67, 1.29) 1.93 0.96 (0.69, 1.22) 1.77 1.12 (0.39, 3.17) 8.05 
CASP8 block 1 rs17468277  1.09 (0.78, 1.54) 1.99 1.07 (0.78, 1.38) 1.78 1.20 (0.41, 3.53) 8.68 2q35 rs13387042d 1.20 (1.14, 1.26) [187] 1.02 (0.86, 1.22) 1.43 1.02 (0.86, 1.20) 1.39 1.02 (0.86, 1.22) 1.43 
2p rs4666451e 1.03 (1.00, 1.06) [194] 1.15 (0.96, 1.39) 1.45 1.13 (0.95, 1.34) 1.41 1.15 (0.96, 1.39) 1.45 
SLC4A7 rs4973768d 1.16 (1.10, 1.24) [189] 0.90 (0.77, 1.06) 1.38 0.91 (0.77, 1.04) 1.35 0.90 (0.77, 1.06) 1.38 
4p rs12505080e 1.15 (1.03, 1.28)g [201] 1.09 (0.88, 1.34) 1.52 1.08 (0.88, 1.30) 1.48 1.09 (0.88, 1.34) 1.52 
TLR1 rs7696175e 1.12 (1.00, 1.26)g [201] 1.39 (1.04, 1.86) 1.79 1.29 (0.99, 1.66) 1.68 1.39 (1.04, 1.86) 1.80 
MRPS30 rs4415084d 1.16 (1.10, 1.21) [208] 1.13 (0.97, 1.33) 1.38 1.13 (0.96, 1.30) 1.35 1.13 (0.97, 1.33) 1.38 
MRPS30 rs10941679e 1.19 (1.13, 1.26) [208] 1.00 (0.82, 1.22) 1.49 1.01 (0.83, 1.19) 1.43 1.00 (0.82, 1.22) 1.49 
5p12 rs981782d 1.04 (1.01, 1.08) [194] 1.11 (0.84, 1.46) 1.74 1.09 (0.84, 1.36) 1.61 1.11 (0.84, 1.46) 1.74 
5q rs30099e 1.05 (1.01, 1.10) [194] 1.22 (0.98, 1.52) 1.55 1.19 (0.96, 1.44) 1.50 1.22 (0.98, 1.52) 1.55 
MAP3K1 rs889312d 1.13 (1.10, 1.16) [194] 0.95 (0.80, 1.13) 1.41 0.96 (0.81, 1.11) 1.37 0.95 (0.80, 1.13) 1.41 
ESR1 rs2046210d 1.29 (1.21, 1.37) [197] 1.22 (1.04, 1.43) 1.38 1.20 (1.03, 1.39) 1.35 1.22 (1.04, 1.43) 1.38 
ESR1 rs851974  0.93 (0.76, 1.14) 1.50 0.94 (0.78, 1.13) 1.45 0.93 (0.75, 1.14) 1.50 ESR1 rs2077647  1.07 (0.92, 1.25) 1.37 1.07 (0.92, 1.23) 1.34 1.07 (0.92, 1.25) 1.37 ESR1 rs2234693  0.96 (0.82, 1.13) 1.37 0.97 (0.83, 1.12) 1.35 0.96 (0.82, 1.13) 1.37 ESR1 rs1801132f 1.05 (1.00, 1.11) [20] 1.19 (0.93, 1.52) 1.64 1.16 (0.91, 1.42) 1.55 1.19 (0.93, 1.52) 1.64 
ESR1 rs3020314f 1.12 (1.06,1.18) [20] 1.00 (0.84, 1.19) 1.41 1.01 (0.85, 1.17) 1.37 1.00 (0.84, 1.19) 1.41 
ESR1 rs3798577  1.02 (0.88, 1.19) 1.36 1.02 (0.89, 1.18) 1.33 1.02 (0.87, 1.19) 1.36 ECHDC1 rs2180341d 1.41 (1.25, 1.59) [196] 0.98 (0.83, 1.15) 1.39 0.98 (0.84, 1.14) 1.36 0.98 (0.83, 1.15) 1.39 
RELN rs17157903e 1.11 (1.00, 1.23) [201] 1.07 (0.83, 1.37) 1.64 1.07 (0.85, 1.31) 1.54 1.07 (0.83, 1.37) 1.64 
8q24 rs13281615d 1.08 (1.05, 1.11) [194] 1.00 (0.86, 1.18) 1.38 1.01 (0.85, 1.17) 1.37 1.00 (0.86, 1.18) 1.38 
8q24 rs1562430d 1.17 (1.10, 1.25) [189] 1.00 (0.86, 1.17) 1.36 1.00 (0.87, 1.16) 1.34 1.00 (0.86, 1.17) 1.36 
CDKN2A/B rs3731257  0.88 (0.67, 1.15) 1.71 0.91 (0.71, 1.14) 1.60 0.88 (0.67, 1.15) 1.71 CDKN2A/B 
block 1 rs518394  1.01 (0.76, 1.35) 1.76 1.02 (0.78, 1.28) 1.64 1.01 (0.76, 1.35) 1.76 
CDKN2A/B 
block 1 rs564398  1.01 (0.75, 1.35) 1.79 1.01 (0.77, 1.27) 1.66 1.00 (0.72, 1.40) 1.96 
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CDKN2A/B rs1011970d 1.20 (1.11, 1.30) [189] 0.95 (0.81, 1.11) 1.38 0.96 (0.82, 1.10) 1.34 0.95 (0.81, 1.11) 1.38 
CDKN2A/B rs10757278  0.91 (0.75, 1.12) 1.50 0.93 (0.76, 1.09) 1.44 0.91 (0.75, 1.12) 1.50 CDKN2A/B rs10811661  1.00 (0.74, 1.35) 1.83 1.01 (0.76, 1.28) 1.67 1.00 (0.74, 1.35) 1.83 
ANKRD16 rs2380205d 1.06 (1.02, 1.10) [189] 0.97 (0.83, 1.13) 1.37 0.98 (0.84, 1.13) 1.34 0.97 (0.83, 1.13) 1.37 
ZNF365 rs10995190d 1.16 (1.10, 1.22) [189] 1.06 (0.87, 1.29) 1.49 1.05 (0.86, 1.23) 1.44 1.06 (0.87, 1.29) 1.49 
ZMIZ1 rs704010d 1.07 (1.03, 1.11) [189] 1.05 (0.80, 1.36) 1.69 1.04 (0.80, 1.28) 1.61 1.05 (0.80, 1.36) 1.69 
FGFR2 rs1896395  1.01 (0.83, 1.23) 1.48 1.02 (0.84, 1.20) 1.44 1.01 (0.83, 1.23) 1.48 
FGFR2 block 1 rs3750817  1.74 (1.34, 2.26) 1.69 1.61 (1.22, 2.02) 1.66 1.38 (1.05, 1.83) 1.74 FGFR2 block 1 rs10736303e 1.25 (1.18, 1.32) [194] 1.39 (1.12, 1.74) 1.56 1.33 (1.07, 1.61) 1.51 1.08 (0.83, 1.39) 1.67 
FGFR2 block 1 rs11200014  1.04 (0.86, 1.26) 1.47 1.04 (0.85, 1.23) 1.45 0.97 (0.70, 1.34) 1.92 FGFR2 block 1 rs2981579d 1.17 (1.07, 1.27)g [186] 1.22 (1.04, 1.42) 1.36 1.19 (1.03, 1.37) 1.33 1.10 (0.93, 1.31) 1.41 
FGFR2 block 1 rs1078806e 1.26 (1.13, 1.40) [196] 1.06 (0.88, 1.29) 1.47 1.06 (0.87, 1.25) 1.43 1.00 (0.72, 1.38) 1.92 
FGFR2 block 2 rs2981578e 1.26 (1.19, 1.34) [194] 1.42 (1.14, 1.77) 1.56 1.36 (1.10, 1.65) 1.51 1.23 (0.99, 1.53) 1.54 
FGFR2 block 2 rs1219648d 1.27 (1.18, 1.36) [201] 1.19 (1.02, 1.39) 1.37 1.18 (1.01, 1.35) 1.33 1.01 (0.82, 1.24) 1.51 
FGFR2 block 2 rs2912774e 1.26 (1.19, 1.34) [194] 1.27 (1.09, 1.49) 1.37 1.25 (1.06, 1.43) 1.35 1.09 (0.80, 1.49) 1.85 
FGFR2 block 2 rs2936870e 1.26 (1.19, 1.34) [194] 1.27 (1.09, 1.48) 1.37 1.25 (1.07, 1.44) 1.34 1.09 (0.80, 1.48) 1.84 
FGFR2 block 3 rs2420946e 1.25 (1.18, 1.36) [201] 1.17 (1.00, 1.37) 1.37 1.16 (1.00, 1.35) 1.35 0.95 (0.72, 1.25) 1.73 
FGFR2 block 3 rs2162540  1.23 (1.05, 1.44) 1.36 1.21 (1.04, 1.40) 1.34 1.23 (1.05, 1.44) 1.37 FGFR2 rs2981582d 1.26 (1.23, 1.30) [194] 1.19 (1.02, 1.39) 1.37 1.18 (1.00, 1.35) 1.35 1.19 (1.02, 1.39) 1.37 
FGFR2 rs3135718e 1.15 (1.07, 1.23) [194] 1.26 (1.08, 1.46) 1.35 1.24 (1.07, 1.43) 1.33 1.26 (1.08, 1.46) 1.35 
10q rs10510126e 1.20 (1.08, 1.35) [201] 1.04 (0.82, 1.32) 1.61 1.04 (0.82, 1.25) 1.53 1.04 (0.82, 1.32) 1.61 
ATM rs1801516  1.22 (0.77, 1.95) 2.54 1.14 (0.76, 1.58) 2.08 1.22 (0.77, 1.95) 2.54 ATM rs664143  0.95 (0.81, 1.11) 1.38 0.96 (0.82, 1.10) 1.35 0.95 (0.81, 1.11) 1.38 ATM rs170548  0.86 (0.67, 1.11) 1.66 0.90 (0.70, 1.10) 1.57 0.86 (0.67, 1.11) 1.66 ATM rs3092993  1.22 (0.77, 1.95) 2.54 1.14 (0.76, 1.58) 2.08 1.22 (0.77, 1.95) 2.54 LSP1 rs3817198d 1.07 (1.04, 1.11) [194] 1.01 (0.82, 1.24) 1.52 1.01 (0.82, 1.24) 1.47 1.01 (0.82, 1.24) 1.52 
LSP1 rs909116d 1.17 (1.10, 1.24) [189] 1.00 (0.84, 1.19) 1.42 1.01 (0.84, 1.17) 1.39 1.00 (0.84, 1.19) 1.42 
H19 rs2107425e 1.04 (1.01, 1.08) [194] 0.84 (0.71, 0.98) 1.38 0.86 (0.73, 0.98) 1.35 0.84 (0.71, 0.98) 1.38 
TNRC9/TOX3 rs8049149  0.92 (0.54, 1.56) 2.87 0.98 (0.64, 1.35) 2.10 0.92 (0.54, 1.56) 2.87 TNRC9/TOX3 rs16951186  0.90 (0.74, 1.09) 1.49 0.92 (0.76, 1.10) 1.45 0.90 (0.74, 1.09) 1.49 TNRC9/TOX3 rs8051542e 1.09 (1.06, 1.13) [194] 1.14 (0.97, 1.35) 1.39 1.13 (0.97, 1.30) 1.35 1.14 (0.97, 1.35) 1.39 
TNRC9/TOX3 rs12443621e 1.11 (1.08, 1.14) [194] 0.86 (0.74, 1.01) 1.36 0.88 (0.75, 1.00) 1.34 0.86 (0.74, 1.01) 1.36 
TNRC9/TOX3 
block 1 rs3803662
d 1.20 (1.16, 1.24) [194] 1.06 (0.90, 1.23) 1.37 1.05 (0.91, 1.21) 1.34 1.11 (0.94, 1.31) 1.39 
TNRC9/TOX3 
block 1 rs4784227
d 1.25 (1.20, 1.31) [199] 1.25 (0.93, 1.67) 1.80 1.19 (0.90, 1.51) 1.67 1.28 (0.96, 1.71) 1.77 
TNRC9/ TOX3 rs3104746  1.54 (1.27, 1.86) 1.46 1.49 (1.22, 1.75) 1.43 1.39 (1.14, 1.71) 1.50 
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block 2 
TNRC9/ TOX3 
block 2 rs3112562  1.28 (1.09, 1.50) 1.37 1.26 (1.09, 1.46) 1.35 1.12 (0.94, 1.33) 1.41 
TNRC9/TOX3 rs9940048  1.10 (0.93, 1.31) 1.40 1.10 (0.92, 1.29) 1.39 1.10 (0.93, 1.31) 1.41 TP53 rs9894946  0.96 (0.68, 1.36) 2.01 0.93 (0.70, 1.28) 1.82 0.96 (0.68, 1.37) 2.01 TP53 rs1614984  1.07 (0.92, 1.25) 1.36 1.07 (0.91, 1.22) 1.34 1.07 (0.92, 1.25) 1.36 
TP53 block 1 rs12951053f 1.15 (1.04, 1.26) [20] 1.03 (0.80, 1.32) 1.64 1.03 (0.81, 1.25) 1.55 1.01 (0.77, 1.32) 1.71 
TP53 block 1 rs2909430  1.06 (0.89, 1.25) 1.40 1.06 (0.89, 1.22) 1.37 1.04 (0.84, 1.28) 1.52 TP53 block 1 rs1042522  0.98 (0.83, 1.15) 1.38 0.98 (0.83, 1.13) 1.36 1.00 (0.82, 1.22) 1.50 TP53 rs8079544  0.89 (0.69, 1.15) 1.66 0.92 (0.72, 1.12) 1.57 0.89 (0.69, 1.15) 1.66 COX 11 block 1 rs7222197e 1.12 (1.04, 1.20) [189] 1.14 (0.97, 1.33) 1.38 1.12 (0.95, 1.29) 1.36 1.07 (0.77, 1.47) 1.90 
COX 11 block 1 rs6504950e 1.05 (1.03, 1.09) [209] 1.13 (0.96, 1.32) 1.37 1.12 (0.95, 1.28) 1.35 1.07 (0.77, 1.47) 1.90 
aOR from initial GWAS or candidate gene meta-analysis (if met criteria for cumulative evidence of association); all ORs for log-additive genetic 
models, unless otherwise specified badjusted for age at diagnosis (case) or selection (controls) and proportion of African ancestry cadjusted for age at diagnosis (case) or selection (controls), proportion of African ancestry and other SNPs in the LD block 
dprevious GWAS hit 
eOther GWAS-identified gene 
fcumulative evidence of an association in Zhang et al. meta-analysis 
gOR estimated using general genetic model 
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Figure 23: FGFR2 linkage disequilibrium (LD) patterns, CBCS whites (A) and African 
Americans (B) 
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Figure 24: ATM linkage disequilibrium (LD) patterns, CBCS whites (A) and African 
Americans (B) 
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Figure 25: TP53 linkage disequilibrium (LD) patterns, CBCS whites (A) and African 
Americans (B) 
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Figure 26: CDNK2A/B linkage disequilibrium (LD) patterns, CBCS whites (A) and 
African Americans (B) 
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Figure 27: TNRC9/TOX3 linkage disequilibrium (LD) patterns, CBCS whites (A) and 
African Americans (B) 
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Figure 28: Comparison of point estimates and 95% PIs for hierarchical models with 
investigator specified covariance matrices, CBCS whites 
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Figure 29: Comparison of point estimates and 95% PIs for hierarchical models with 
investigator specified covariance matrices, CBCS African Americans 
 
 
  
  169 
Table 14: Comparison of posterior limit ratios (PLRs) for hierarchical regression 
models among white women in the Carolina Breast Cancer Study  
 
Gene and 
 LD block SNP 
Identity 
Covariance 
Matrix 
Exponential Decay 
by Spatial Distance 
Covariance Matrix 
Correlation-based 
Covariance Matrix 
CASP8 block1 rs1045485 1.90 1.90 1.84 
CASP8 block1 rs17468277 1.90 1.90 1.84 
CDKN2A/B block 1 rs518394 1.66 1.66 1.59 
CDKN2A/B block 1 rs564398 1.67 1.67 1.60 
FGFR2 block 1 rs3750817 1.43 1.43 1.42 
FGFR2 block 1 rs10736303 1.88 1.82 1.76 
FGFR2 block 1 rs11200014 2.05 1.94 1.89 
FGFR2 block 1 rs2981579 2.03 1.96 1.89 
FGFR2 block 1 rs1078806 1.99 1.94 1.85 
FGFR2 block 1 rs2981578 1.86 1.86 1.75 
FGFR2 block 1 rs1219648 2.10 2.12 1.94 
FGFR2 block 1 rs2912774 2.14 1.79 1.96 
FGFR2 block 1 rs2936870 2.15 1.80 1.97 
FGFR2 block 1 rs2420946 2.16 1.97 1.97 
FGFR2 block 1 rs2162540 2.15 1.67 1.96 
FGFR2 block 1 rs2981582 2.13 1.70 1.96 
FGFR2 block 1 rs3135718 2.09 2.08 1.93 
ATM block 1 rs1801516 1.93 1.73 1.86 
ATM block 1 rs3092992 1.68 1.69 1.69 
ATM block 1 rs664143 1.42 1.43 1.41 
ATM block 1 rs170548 1.45 1.45 1.44 
ATM block 1 rs3092993 1.93 1.76 1.86 
TNRC9/ TOX3 block 1 rs3803662 1.58 1.58 1.55 
TNRC9/ TOX3 block 1 rs4784227 1.60 1.60 1.56 
TP53 block 1 rs1800372 1.93 1.87 2.06 
TP53 block 1 rs2909430 1.63 1.55 1.58 
TP53 block 1 rs1042522 1.41 1.43 1.44 
COX11 block 1 rs7222197 1.89 1.89 1.77 
COX11 block 1 rs6504950 1.89 1.89 1.77 
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Table 15: Comparison of posterior limit ratios (PLRs) for hierarchical regression 
models among African American women in the Carolina Breast Cancer Study  
 
Gene and 
 LD block SNP 
Identity 
Covariance 
Matrix 
Exponential Decay 
by Spatial Distance 
Covariance Matrix 
Correlation-based 
Covariance Matrix 
CASP8 block 1 rs1045485 8.05 8.05 8.05 
CASP8 block 1 rs1746827
7 
8.68 8.68 8.69 
CDKN2A/B block 1 rs518394 1.93 1.93 1.93 
CDKN2A/B block 2 rs564398 1.96 1.96 1.96 
FGFR2 block 1 rs3750817 1.74 1.72 1.74 
FGFR2 block 1 rs1073630
3 
1.67 1.62 1.66 
FGFR2 block 1 rs1120001
4 
1.92 1.81 1.87 
FGFR2 block 1 rs2981579 1.41 1.41 1.41 
FGFR2 block 1 rs1078806 1.92 1.85 1.87 
FGFR2 block 2 rs2981578 1.54 1.55 1.54 
FGFR2 block 2 rs1219648 1.51 1.52 1.51 
FGFR2 block 2 rs2912774 1.85 1.44 1.83 
FGFR2 block 2 rs2936870 1.84 1.44 1.83 
FGFR2 block 3 rs2420946 1.73 1.57 1.73 
FGFR2 block 3 rs2162540 1.72 1.56 1.72 
TNRC9/ TOX3 block 1 rs3803662 1.39 1.39 1.39 
TNRC9/ TOX3 block 1 rs4784227 1.77 1.77 1.77 
TNRC9/ TOX3 block 2 rs3104746 1.50 1.50 1.50 
TNRC9/ TOX3 block 2 rs3112562 1.41 1.41 1.41 
TP53 block 1 rs1295105
3 
1.71 1.71 1.71 
TP53 block 1 rs2909430 1.52 1.52 1.52 
TP53 block 1 rs1042522 1.50 1.50 1.50 
COX 11 block 1 rs7222197 1.90 1.90 1.77 
COX 11 block 1 rs6504950 1.90 1.90 1.77 
 
 
  
  
5. Breast Cancer Subtypes and Previously Established Genetic Risk Factors: A 
Bayesian Approach 
 
5.1 Overview 
 Gene expression analyses indicate that breast cancer is a heterogeneous disease with 
at least five immunohistologic subtypes. Despite growing evidence that these subtypes are 
etiologically and prognostically distinct, few studies have investigated whether they have 
divergent genetic risk factors. To help fill in this gap in our understanding, I examined 
associations between breast cancer subtypes and previously established susceptibility loci 
among white and African American women in the Carolina Breast Cancer Study. I used 
Bayesian polytomous logistic regression to estimate odds ratios (ORs) and 95% posterior 
intervals (PIs) for the association between each of 78 single nucleotide polymorphisms 
(SNPs) and 5 breast cancer subtypes. Subtypes were defined using 5 immunohistochemical 
markers: estrogen receptors (ER), progesterone receptors (PR), human epidermal growth 
factor receptors 1 and 2 (HER1/2) and cytokeratin (CK) 5/6. Several SNPs in TNRC9/TOX3 
were associated with luminal A (ER/PR+, HER2-) or basal-like breast cancer (ER-, PR-, 
HER2-, HER1 or CK 5/6+), and one SNP (rs3104746) was associated with both. SNPs in 
FGFR2 were associated with luminal A, luminal B (ER/PR+, HER2+), or HER2+/ER- 
disease, but none were associated with basal-like disease. I also observed subtype differences 
in the effects of SNPs in 2q35, 4p, TLR1, MAP3K1, ESR1, CDKN2A/B, ANKRD16, and 
ZM1Z1. I found evidence that genetic risk factors for breast cancer vary by subtype and 
further clarified the role of several key susceptibility genes. 
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5.2 Introduction 
 Researchers have long recognized that breast cancer is a heterogeneous disease with 
variable prognoses and clinical characteristics. Further, epidemiologic investigations have 
discovered evidence of divergent etiologic processes [29, 89], with some key differences in 
risk factors across disease subgroups [4, 101-103]. While these findings have led to 
advancements in our understanding of the disease, inconsistent subtype definitions and 
imprecise estimates have hampered progress. Attempts to identify subtype-specific genetic 
risk factors have been especially discouraging, with little consistency across study 
populations [167, 168, 226].   
 Most investigators rely on immunohistochemical (IHC) analysis of estrogen receptors 
(ER), progesterone receptors (PR) and human epidermal growth factor receptors-2 (HER2) to 
define breast cancer subtypes. These markers are included in most routine clinical 
evaluations of breast tumors, as they are predictive of response to targeted therapies such as 
tamoxifen and trastuzumab. Based on concerns that these three markers did not adequately 
capture disease heterogeneity, researchers turned to gene expression analysis for more in-
depth assessments. In one of the first large-scale gene expression analyses of breast tissue, 
Perou et al. [39] observed that tumors with similar expression patterns also had similar IHC 
subtypes. The only major exception was triple-negative tumors (i.e. ER-, PR- and HER2-), 
which clustered into two separate groups with different cytokeratin 5/6 (CK 5/6) and human 
epidermal growth factor receptor-1 (HER1) expression patterns.  
 This research led to a new classification system with 5 IHC markers serving as 
adequate, inexpensive surrogates for more complex gene expression profiles [3, 41, 42]. 
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Because the CK 5/6 protein is usually present in basal epithelial cells but not in more 
differentiated luminal epithelial cells, the subtypes were designated as follows: Luminal A 
(ER or PR+, HER2-), Luminal B (ER/PR+, HER2+), HER2+/ER-, and Basal-like (ER-, PR-, 
HER2-, HER1+ or CK 5/6+).  
 This subtype classification system has led to insights into racial disparities and 
furthered understanding of etiologic and prognostic differences between disease subgroups. 
Luminal A is the most common subtype, but subtype prevalence varies according to the age 
and race of the population [3, 5, 50, 53]. Notably, basal-like and other triple-negative tumors 
are more common in women of African descent [3, 4, 8, 50, 53, 63, 64]. For women 
diagnosed before 2000, those with HER2+/ER- and basal-like breast cancers had the poorest 
prognoses [3, 5, 53, 58]. The development and FDA approval of trastuzumab has since 
improved survival rates for women with HER2+ disease, but women with basal-like or other 
types of triple-negative disease still experience high short-term mortality [60, 86, 95]. This 
phenomenon likely explains some of the racial disparity in mortality between US African 
Americans and whites (30.5 versus 21.6 deaths per 100,000 women with breast cancer per 
year, 2009) [2]. 
 In previous studies of subtype-specific determinants, luminal A breast cancer was 
associated with most established breast cancer risk factors, including family history of breast 
cancer, reproductive factors, decreased physical activity, increased alcohol consumption and 
high breast density [4, 62, 65, 66, 79, 82, 83, 103, 108, 109, 110, 111, 114, 115, 117, 118, 
122, 342]. In case-only risk ratio analyses, women with a family history of the disease, a 
younger age at diagnosis, or an earlier age at menarche were more likely to have triple-
negative than luminal A tumors. Triple-negative tumors were also relatively more common 
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in African Americans and in women who had more children but did not breastfeed. Risk 
factors for the rarer luminal B and HER2+/ER- subtypes are less well-established, but 
evidence suggests that African American race, family history of breast cancer, lack of 
breastfeeding and high alcohol consumption are risk factors for HER2+/ER- disease. 
Luminal B breast cancers are more common in younger women, but otherwise have similar 
risk profiles to luminal A tumors.  
 The ground-breaking discovery of the rare but highly penetrant BRCA1 and BRCA2 
genes [130, 132] opened a floodgate of linkage analyses, candidate gene studies, and later, 
genome-wide association studies (GWAS). Since then, 52 single nucleotide polymorphisms 
(SNPs) have met the criteria for genome-wide “discovery” [18] and variants on six candidate 
genes (ATM, CASP8, CHEK2, CTLA4, NBN, and TP53) have “cumulative evidence of an 
association” [20]. Of the aforementioned variants, only BRCA1 has been consistently linked 
to a particular subtype, with numerous studies observing associations between BRCA1 
mutations and triple-negative disease [41, 140, 141, 143] or increased basal marker 
expression [41, 148].  
 In an attempt to elucidate subtype-specific genetic risk factors for breast cancer and 
further our understanding of disease etiology, I estimated associations between breast cancer 
subtypes and several previously identified candidate gene and GWAS hits using women from 
the Carolina Breast Cancer Study (CBCS). This population is well-suited to answer this 
research question, as it is one of the few studies to have both a large proportion of African 
American participants and information on basal IHC markers. This evaluation is further 
enhanced by the use of Bayesian statistical methods, which improve effect estimate accuracy 
through the incorporation of prior information. 
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5.3 Methods 
5.3.1 Study population 
 The CBCS is a population-based, case-control study of invasive and in situ breast 
cancer. The study was conducted in 24 North Carolina counties between 1993 and 2001. To 
be eligible, cases had to be between 20 and 74 years of age at the time of their diagnosis, 
with no prior history of breast cancer. Women with in situ breast cancer were eligible if they 
were diagnosed with ductal carcinoma in situ with microinvasion to a depth of 2 mm or 
lobular carcinoma in situ between 1996 and 2001.   
 Both invasive and in situ cases were identified using the North Carolina Central 
Cancer Registry’s rapid case ascertainment program [272]. A main objective of the CBCS 
was to collect information on traditionally under-researched populations. Therefore, cases 
were randomly sampled at disproportionate rates based on race and age. This sampling 
strategy ensured approximately equal representation of African American and non-African 
American women, as well as younger (age<50) and older women (age 50+). 
 Throughout the study period, controls aged 20-64 years were selected from North 
Carolina Department of Motor Vehicles records and were probability matched to cases based 
on race and age group [293]. Controls aged 65-74 were selected form Health Care Financing 
Administration records in a similar fashion. Women with a history of breast cancer were 
excluded.  
 A study nurse conducted detailed in-home interviews of all cases and controls. 
During the interview, each participant answered questions about her reproductive, medical, 
and family history, and her exposure to several known or suspected breast cancer risk factors. 
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Each participant was also asked to confirm her age and race and provide a 30 ml blood 
sample. All participants provided written informed consent and cases were asked to release 
their medical records and tumor tissue. The Institutional Review Board at the University of 
North Carolina (UNC) approved this study. 
 The overall response rate was 77% for cases and 57% for controls. 90% of controls, 
or 1816 women, provided sufficient blood samples for inclusion in genotype analyses (1105 
whites, 681 African Americans, 30 other race). 88% of cases provided blood samples (2039 
women), but only 55% of cases provided both blood and tumor samples (748 whites, 502 
African Americans, 10 other race). This included 247 in situ cases. Individuals who self-
identified as a race other than white or African American were included in overall analyses 
but excluded from race-specific assessments because of small numbers.  
5.3.2 IHC analysis        
 Tumor tissue and medical records were collected from area hospitals and sent to 
UNC. ER and PR status was abstracted from the patient’s medical records, when available. If 
not available, ER and PR IHC assays were performed at the UNC Immunohistochemistry 
Core Laboratory. Tumors with more than 5% of cells showing nuclei-specific staining were 
considered receptor positive [283]. Agreement between medical records reports and UNC-
run assays in 10% random samples of ER+ and ER- tumors was high (concordance = 81%, 
kappa = 0.62) [3].  
 All tumor samples with sufficient tissue were assayed for HER2, HER1 and CK 5/6. 
A case was considered HER2+ if at least 10% of observed cells showed signs of CB11 
monoclonal antibody staining [284]. Tissue with any sign of cytoplasmic or membranous 
staining was considered positive for CK 5/6 or HER1, respectively [4, 42]. Due to the limited 
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amount of available tissue, in situ tumors were not evaluated for PR status and staining 
techniques for ER, HER2, HER1 and CK 5/6 status were slightly modified (see Livasy et al. 
[89]).  
 As described above, these subtypes were classified as follows: luminal A (ER+ and/or 
PR+, HER2-), luminal B (ER+ and/or PR+, HER2+), HER2+/ER- (ER-, PR-, HER2+), and 
basal-like (ER-, PR-, HER2-, HER1+ and/or CK 5/6+). Additionally, tumors negative for all 
five markers were grouped together as the ‘unclassified’ subtype. 
5.3.3 SNP selection 
 Single nucleotide polymorphisms (SNPs) from ten early breast cancer GWAS [186, 
187, 189, 194, 196, 197, 201, 205] or GWAS follow-up studies [208, 209] were selected for 
inclusion in this subtype evaluation study. I included SNPs from these studies that had 
genome-wide p-values below 10-5 in preliminary or pooled analyses. I also retained SNPs in 
CASP8, ATM, and TP53, some of the key genes identified in a recent comprehensive meta-
analysis [20]. Lastly, I included a number of SNPs in the same gene as GWAS selected 
variants, most of which were originally selected to enhance coverage of these regions. In 
total, this analysis included 22 GWAS hits, 19 other GWAS-identified variants that fell short 
of genome-wide significance criteria, 21 SNPs from CASP8, ATM, or TP53, and 21 tag SNPs 
from select GWAS genes.  
 Each CBCS participant was genotyped at 144 ancestry informative markers. This 
genotype information was used to estimate each participant’s proportion of African ancestry. 
When included in regression models, this ancestry proportion estimate should control 
confounding due to population stratification [275, 292].  
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5.3.4 Genotype analysis 
 The included SNPs were genotyped using either a Taqman panel (Applied 
Biosystems, Inc., Foster City, CA) or a Custom GoldenGate Genotyping assay (Illumina, 
Inc., San Diego, CA). The majority of SNPs were genotyped on the Illumina panel, as 
described previously [287]. The Taqman panel [340] included SNPs that had low Illumina 
design scores, failed the Illumina assay, or were identified as GWAS hits after the Illumina 
assays were performed. Eighty-one women with poor genotyping quality on the Illumina 
panel were assigned missing values for those SNPs. All of the SNPs selected for inclusion in 
this subtype analysis passed quality control tests, including those for call rate, assay intensity, 
and genotype clustering. 
 For each SNP I examined published studies to determine which allele was associated 
with an increased risk of breast cancer in previous analyses. This allele was designated as the 
risk allele. For whites, I selected risk alleles for all ATM, CASP8, and TP53 SNPs based on 
the Zhang et al. meta-analysis [20]. For the remaining SNPs, I ascertained the risk allele in 
the initial GWAS [186, 187, 189, 194, 196, 197, 201, 205, 208, 209] and subsequent 
replication studies [11, 12, 162, 163, 166, 168, 169, 186-191, 193, 195, 198-200, 202-209, 
211-216, 218-225, 228-230, 232-237, 241-243, 245-247, 250-256, 258, 262, 267, 295-301, 
335]. In each case, if the 95% CI limits excluded the null, the OR for the specified allele was 
in the same direction as the initial study. Despite some minor discrepancies in the direction of 
the ORs in African American only studies, I assigned the same risk allele for both racial 
groups to allow pooling and facilitate comparisons. For novel SNPs and SNPs with no prior 
statistically significant findings, I designated the minor variant as the risk variant, using the 
HapMap CEU population as a reference. 
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5.3.5 Statistical methods 
 I calculated case-stratified descriptive statistics for age, proportion of African 
ancestry, and menopausal status, and then repeated these analyses for white and African 
American participants separately. I also examined overall and race-stratified distributions of 
stage at diagnosis, breast cancer subtype, and ER, PR, and HER2 status. Participants were 
weighted according to their inverse sampling probability. Similarly, all regression models 
included an offset term to account for the weighted sampling procedures.  
 For all SNPs, I calculated overall and race-stratified risk allele frequencies (RAFs). I 
tested for departures from Hardy-Weinberg equilibrium (HWE) separately in white and 
African American controls using Pearson’s chi-squared test. If a SNP had a HWE p-value 
less than 0.05 in either population, I re-inspected the SNP’s genotype clustering images for 
indications of poor genotype differentiation or other lab error.   
 I calculated ORs and 95% posterior intervals (PIs) for the association between each 
subtype and SNP using Bayesian polytomous logistic regression models. I assumed additive 
genetic models and adjusted for self-reported race (African American or non-African 
American), proportion of African ancestry, and age at diagnosis or selection. I centered age 
at 50 years and ancestry at its mean value. I also calculated race-specific ORs and 95% PIs, 
adjusting for age and ancestry.  
 Previous studies of the association between known susceptibility variants and breast 
cancer have produced ORs in the range of 1.1-1.3 [18, 20, 318], but subtype-specific 
associations are less well characterized. Bearing this in mind, I assigned each SNP log OR a 
null-centered prior with a mean of 0, but selected a variance of τ2 ~ 1/Γ(4, 0.5) to reflect the 
likely effect size. These parameters correspond to prior SNP-subtype ORs with 95% mass 
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between 0.54 and 1.86 when τ2 is equal to the mode of the distribution (0.1). As a full Bayes 
approach requires priors for all parameters, I also assigned null-centered, lognormal priors 
for age, ancestry, race and the intercept term. I assigned relatively informative priors to age 
and ancestry (τ2=0.68), which were both mean-centered variables, but a larger variance to 
race (τ2=1.0). Because the intercept is difficult to define or interpret in a case-control study 
with weighted sampling, I assigned a vague prior, with τ2=1000. I assumed that all priors 
were independent. 
 Priors were incorporated into regression models using Bayes’ theorem. Briefly, 
Bayes’ theorem states the posterior probability distribution for the parameter of interest given 
the observed data, ƒ(β|D), is proportional to the likelihood of the observed data, L(β;D), 
multiplied by the prior probability distribution ƒ(β) [14, 315, 343]. The aforementioned 
likelihood is identical to the likelihood used to obtain the maximum likelihood estimate 
(MLE) in a standard frequentist logistic regression model. Put another way, the posterior OR 
is essentially an inverse-variance weighted combination of the likelihood and prior 
distribution. Further, the variance of the resulting, normal posterior distribution is the inverse 
of the sum of the weights.  
 I also conducted sensitivity analyses, estimating MLE of ORs and 95% CIs and 
another set of Bayesian ORs and 95% PIs given a more informative, but still null-centered 
prior [SNP~N(0, τ2),  τ2~1/Γ (3, 0.2), with mode at 0.05]. For each Bayesian model, I took 
50,000 samples, discarding the first 1000 draws as a burn in, and thinning by retaining every 
tenth draw, such that the results are based on 4990 samples. Autocorrelation, trace, and 
density plots indicated adequate mixing and model convergence. All analyses were 
conducted using the SAS procedure MCMC (v9.3, Cary, NC). Example code is provided in 
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the appendix.  
 
5.4 Results 
 As seen in Table 16, white and African American participants in the CBCS 
population differed in a few key ways. African Americans were more likely to have later 
stage disease, with 63% presenting at stage II or higher, relative to 48% of whites. African 
Americans were also less likely to be postmenopausal at the time of their diagnosis and were 
more likely to have basal-like (22% vs. 11%), unclassified (14% vs. 8%) or HER2+/ER- 
disease (8% vs. 6%). Luminal A breast cancer was the most common breast cancer subtype 
overall (60%). Seven SNPs had HWE p-values<0.05 (Table 17), though no SNPs failed 
HWE tests in both whites and African Americans. Upon re-inspection of genotype clustering 
images, I found that six of the seven SNPs showed good differentiation with no overlap 
between genotypes. I excluded the seventh SNP, rs614367 (MYEOV), after discovering 
evidence of allelic dropout and observing disparate clustering within the homozygous rare 
genotype. I also excluded SNPs with minor allele frequencies less than 1% in this sample. 
This left me with 78 SNPs in the overall analysis, 76 in the white only analysis and 73 in the 
African American only analysis.  
 Subtype-specific ORs and 95% PIs for all participants are presented in Table 18. 
Several SNPs were associated with luminal A breast cancer, including 13 of 14 evaluated 
FGFR2 SNPs (ORs1.25) and several SNPs in TNRC9/TOX3 (see Figure 30). The strongest 
association was seen for rs3104746 on TNRC9/TOX3 (OR=1.58, 95% PI: 1.24, 1.94). Other 
noteworthy associations included rs13387042 (2q35), rs12505080 (4p), rs7696175 (TLR1), 
rs889312 (MAP3K1), rs851974 (ESR1), rs1011970 (CDKN2A/B), and rs9894946 (TP53).   
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 HER2+/ER- disease and unclassified disease were also strongly associated with 
several FGFR2 and TNRC9/TOX3 SNPs. For both subtypes the OR estimates for the FGFR2 
SNPs were high, with many at or near 1.4. Beyond these key genes, HER2+/ER- disease was 
positively correlated with the designated risk variant at rs2046210 on ESR1, and rs704010 on 
ZMIZ1, but negatively correlated with the risk variant at rs7696175 on TLR1, rs3798577 on 
ESR1, and rs518394 on CDKN2A/B. The C allele at rs2380205 (ANKRD16) was inversely 
associated with the risk of unclassified breast cancer.  
 I identified relatively few susceptibility variants for luminal B breast cancer. All but 
one FGFR2 SNP was associated with increased disease risk, but the observed effects were 
weaker than the other non basal-like subtype ORs and only one had a posterior interval that 
excluded the null (rs2981578). The risk allele at rs704010 on ZMIZ1 was also associated 
with luminal B disease (OR=1.34, 95% PI: 0.96, 1.70). 
 None of the FGFR2 SNPs were associated with an increased risk of basal-like breast 
cancer. In fact, most of the FGFR2 ORs for basal-like disease were less than one. Risk 
variants at two TNRC9/TOX3 SNPs (rs3014746 and rs3112562) were positively associated 
with basal-like disease, as were risk variants at rs704010 on ZMIZ1 and rs2046210 on ESR1. 
Additionally, rs7696175 on TLR1 and rs10941679 on MRPS30 each had ORs greater than 
1.2 for basal-like breast cancer, relative to controls.  
 Race-stratified subtype analyses revealed a few additional insights (Tables 19 and 
20). The most striking was for rs10757278 on CDKN2A/B, where the A allele was positively 
associated with basal-like disease in whites (OR=1.19, 95% PI: 1.02, 1.39) but negatively 
associated with disease in African Americans (OR=0.75, 95% PI: 0.58, 0.94). Race-specific 
FGFR2 and TNRC9/TOX3 results can be seen in Figure 31. 
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 The two 8q24 SNPs were strongly associated with luminal A breast cancer only 
among whites (OR=1.16, 95% PI: 0.98, 1.35 and OR=1.17, 95% PI: 1.00, 1.37 for 
rs13281615 and rs1562430, respectively). The same was true for a TNRC9/TOX3 SNP 
(rs8051542 OR=1.16, 95% PI: 0.99, 1.35) and a LSP1 SNP (rs909116 OR=1.17, 95% PI: 
0.99, 1.37). As for the other subtypes, rs3112562 and rs12443621 (TNRC9/TOX3) were 
strongly associated with luminal B (OR=0.64, 95% PI: 0.39, 0.89) and HER2+/ER- breast 
cancer (OR=1.53, 95% PI: 1.05, 2.09), respectively, only among whites. I observed no 
noteworthy findings in the African American only analyses.  
 Results from the MLE analysis and alternate Bayes analysis are presented in Tables 
21 and 22. Compared with the MLE results, the ORs and PIs presented here are attenuated 
towards the null and are more precise. The ORs from the Bayesian analysis with more 
informative priors were further attenuated. The SNP-subtype association patterns were 
consistent across all methods.  
  
5.5 Discussion 
 In this study of breast cancer subtypes and previously established susceptibility 
variants, I observed critical differences in subtype-specific genetic risk factors. The most 
conspicuous differences involved the FGFR2 gene, where most of the 14 evaluated SNPs 
were associated with luminal A, HER2+/ER- and unclassified disease, but not basal-like 
disease. I also found evidence that SNPs on or near TNRC9/TOX3 are differentially related to 
breast cancer subtype and that rs10757278 (CDKN2A/B) is differentially related to basal-like 
disease by race. SNPs in 2q35, 4p, TLR1, MRPS30, MAP3K1, ESR1, ANKRD16, ZM1Z1, and 
TP53 may also be related to subtype-specific etiology. 
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 As few other studies have employed these enhanced subtype definitions, it is difficult 
to compare my results with previous reports.  Most prior investigations of this topic were 
limited to comparisons of a single hormone receptor, usually ER+ versus ER- disease [162, 
169, 187, 192, 208, 216, 217, 222, 232, 236, 247, 259]. A few have looked at risk factors for 
combined ER, PR, HER2 status [166, 167, 226, 344], but to my knowledge, only one other 
study by Broeks et al. [168] has examined genetic risk factors according to all five IHC 
markers. Broeks et al. [168], Stevens et al. [167], and Han et al. [226] examined some of the 
SNPs included in this analysis, with some consistencies across populations. 
 The only FGFR2 SNP examined by Broeks et al. [168] was rs2981582. They also 
observed positive associations between the T allele and luminal A disease and no association 
between the SNP and basal-like breast cancer. Their luminal B OR was in the same direction 
I observed, but of much greater magnitude. Stevens et al. and Han et al. also found near-null 
associations between rs2981582 and triple negative disease. Contrary to my findings, 
however, rs2981582 was not associated with HER2+/ER- disease in either study, nor was it 
associated with unclassified disease in Stevens et al. The effect estimates for rs2981582 and 
luminal A and B disease reported by Han et al. are similar to those seen in my study. I am the 
first to report subtype-specific estimates for any other FGFR2 SNPs. 
 Broeks et al., Stevens et al., and Han et al. also evaluated one TNRC9/TOX3 SNP, 
rs3803662. Both Broeks et al. and Han et al. observed a positive association with the T allele 
and luminal A breast cancer, as I did. However, these authors also observed associations 
between the T allele and luminal B and HER2+/ER- disease, where I found only a weak 
association with Luminal B and a near-null association with HER2+/ER- disease. Lastly, 
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Broeks et al. observed an association between rs3803662 and basal-like disease, which I did 
not observe.  
 These three study groups also assessed other SNPs included in this panel. While it is 
difficult to draw clear inferences from individual SNP-subtype analyses, these studies, 
together with mine, suggest that some important differences by subtype do exist. In addition 
to FGFR2 and TNRC9/TOX3, the effects of rs2046210 (ESR1), rs13387042 (2q35), and 
rs889312 (MAP3K1) seem to vary according to subtype. Additional studies are needed to 
further clarify the role of these SNPs and the other potentially important genes identified in 
my investigation.   
 While this is one of the first studies to look at genetic risk factors for specific 
subtypes, breast cancer susceptibility loci are a commonly studied topic. Bayesian methods 
allowed me to use this plethora of prior information to generate more precise estimates. 
Assuming I selected reasonable priors, the results presented here will also be more accurate, 
on average, than those produced using frequentist methods that do not incorporate the wealth 
of information from prior studies. Further, by selecting null-centered, highly informative 
priors, bias resulting from these methods is likely to be towards the null [17]. In this way, this 
application of Bayesian methods also reduces the probability of observing false positive 
associations. I believe the priors specified here are reasonable given existing knowledge of 
breast cancer susceptibility variants, but I also provide alternate analyses that demonstrate the 
influence of my assumptions. 
 Within the CBCS population, African Americans were less likely than non-African 
Americans to provide blood for genotyping, but were more likely to have tumor tissue 
available for IHC analysis. Women with advanced disease were also more likely to provide 
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tumor tissue. These trends may result in biased effect estimates for SNPs related to race or 
disease aggressiveness. Controlling for self-reported race and ancestry should alleviate some 
of this bias. Though not included in this analysis, I could have used inverse-probability of 
selection weighting or Bayesian imputation methods to further address this issue.   
 There is some disagreement in the field as to how best to classify breast cancer 
subtypes. As discussed, the IHC markers used here are only proxies for more complex gene 
expression profiles, and thus may not sufficiently capture tumor heterogeneity [44-47]. While 
my approach is likely more informative than one using three or fewer markers, poor subtype 
specification may attenuate effects and underestimate subtype differences. Misclassification 
due to inaccurate medical records or IHC evaluations could also bias effects. Other potential 
sources of misclassification include allelic drop-out and other genotyping errors, though 
thorough quality control checks likely limited the impact of such errors.  
 I included in situ cases to increase sample size and improve precision. While this 
could bias effect estimates of SNPs associated with disease aggressiveness or progression, 
shared risk profiles [4, 341, 345] and subtype distributions [4, 89, 346] suggest this bias 
would be small.  
 The diverse composition of the CBCS population is a major strength of this study. By 
recruiting a large proportion of African Americans, study investigators generated a 
population uniquely suited to answer questions about race and subtype differences in risk 
factors. To date, this is the largest study to evaluate breast cancer subtypes using a five-
marker panel and one of the largest population-based studies of breast cancer in African 
Americans.  
  187 
 This analysis of previously established breast cancer susceptibility loci provides 
strong evidence of etiologic heterogeneity across breast cancer subtypes. Though likely only 
a small part of the carcinogenic process, the risk variants identified here offer valuable clues 
about the nature of these diverse pathways. In turn, this vital information may help to 
advance disease prevention and control efforts. 
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Table 16: Descriptive statistics for Carolina Breast Cancer Study participants included 
in subtype analysis 
 
  Cases  Controls 
  
Overall 
(%)* 
N=1260** 
White 
(%)* 
N=748 
African 
Americans 
(%)* 
N=502 
Overall 
(%)* 
N=1816** 
White 
(%)* 
N=1105 
African 
Americans 
(%)* 
N=681 
Age (years); mean 
(std) 51.5 (11.6) 52.1 (11.8) 50.8 (11.4) 52.5 (11.3) 53.0 (11.2) 51.9 (11.3) 
Proportion African 
Ancestry; mean (std) 
0.35 (0.36) 0.06 (0.06) 0.77 (0.13) 0.33 (0.36) 0.07 (0.09) 0.77 (0.14) 
Postmenopausal; N 
(%) 
691 (67) 417 (70) 269 (56) 1032 (38) 640 (37) 377 (41) 
Stage of Disease; N 
(%)      
  
In situ 247 (10) 192 (10) 52 (10) 
  
  
Stage I 369 (39) 232 (42) 136 (28) 
    
Stage II 492 (42) 250 (40) 237 (50) 
    
Stage III 100 (7) 46 (6) 54 (11) 
    
Stage IV 24 (2) 12 (2) 11 (2) 
    
missing 28 16 12 
    
Subtype; N (%)        
Luminal A 700 (60) 453 (64) 242 (49) 
    
Luminal B 122 (11) 82 (11) 38 (8) 
    
HER2+/ER- 98 (6) 59 (6) 39 (8) 
    
Basal-like 207 (13) 94 (11) 112 (22) 
    
Unclassified 133 (9) 60 (8) 71 (14) 
    
ER+; N (%) 745 (66) 497 (70) 243 (50) 
    
PR+; N (%) 543 (60) 341 (64) 197 (45) 
    
missing 247 192 52 
    
HER2+; N (%) 220 (17) 141 (17) 77 (16)       
*percentages weighted by inverse sampling probability 
**includes those who self-identified as a race other than white or African American  
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Table 17: Risk allele frequencies (RAF) by race and case status, African Americans and non African Americans in the 
Carolina Breast Cancer Study 
 
     
All (1260 cases,  
1817 controls)** 
Whites  
(748 cases, 1105 controls) 
African Americans  
(502 cases, 681 controls) 
Gene Locus Risk allele 
RAF 
cases* 
RAF 
controls* 
RAF 
cases* 
RAF 
controls* 
HWE p-
value 
RAF 
cases* 
RAF 
controls* 
HWE p-
value 
1p12 rs11249433 G 0.37 0.36 0.44 0.41 0.54 0.14 0.10 0.01 
CASP8 rs1045485 G 0.89 0.88 0.88 0.87 0.63 0.94 0.95 0.74 
CASP8 rs17468277 C 0.89 0.88 0.88 0.87 0.63 0.95 0.95 0.95 
2q35 rs13387042 A 0.59 0.52 0.55 0.47 0.83 0.73 0.73 1.00 
2p rs4666451 G 0.64 0.65 0.60 0.63 0.30 0.78 0.77 0.12 
SLC4A7 rs4973768 T 0.44 0.42 0.47 0.42 0.22 0.35 0.40 0.05 
4p rs12505080 C 0.27 0.23 0.30 0.24 0.80 0.18 0.17 0.64 
TLR1 rs7696175 T 0.38 0.38 0.46 0.45 0.91 0.09 0.06 0.54 
MRPS30 rs4415084 T 0.46 0.45 0.42 0.42 0.18 0.64 0.58 0.70 
MRPS30 rs10941679 G 0.27 0.28 0.29 0.30 0.76 0.19 0.19 0.17 
5p12 rs981782 T 0.60 0.65 0.51 0.59 0.26 0.91 0.91 0.60 
5q rs30099 T 0.11 0.10 0.10 0.10 0.40 0.15 0.12 0.75 
MAP3K1 rs889312 C 0.33 0.35 0.33 0.34 0.85 0.33 0.36 0.08 
ESR1 rs2046210 A 0.43 0.40 0.38 0.35 0.48 0.62 0.61 0.15 
ESR1 rs851974 G 0.36 0.39 0.41 0.43 0.28 0.18 0.17 0.46 
ESR1 rs2077647 A 0.50 0.49 0.50 0.49 0.64 0.51 0.51 0.16 
ESR1 rs2234693 T 0.50 0.55 0.51 0.57 0.45 0.46 0.48 0.63 
ESR1 rs1801132 C 0.79 0.78 0.76 0.76 0.43 0.90 0.88 0.36 
ESR1 rs3020314 C 0.44 0.41 0.38 0.34 0.15 0.68 0.71 0.75 
ESR1 rs3798577 T 0.52 0.53 0.50 0.53 0.43 0.58 0.54 0.27 
ECHDC1 rs2180341 G 0.26 0.28 0.24 0.27 0.55 0.32 0.33 0.83 
RELN rs17157903 T 0.14 0.12 0.14 0.12 0.06 0.11 0.10 0.08 
8q24 rs13281615 G 0.43 0.42 0.43 0.42 0.17 0.43 0.43 0.58 
8q24 rs1562430 T 0.59 0.56 0.60 0.57 0.78 0.53 0.53 0.61 
CDKN2A/B rs3731257 T 0.20 0.21 0.23 0.23 0.24 0.08 0.11 0.89 
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CDKN2A/B rs3731249 A 0.02 0.02 0.03 0.03 0.90 0.01 0.00 0.95 
CDKN2A/B rs518394 G 0.36 0.41 0.44 0.48 0.17 0.09 0.08 0.06 
CDKN2A/B rs564398 G 0.35 0.40 0.42 0.47 0.29 0.08 0.08 0.02 
CDKN2A/B rs1011970 T 0.22 0.18 0.19 0.15 0.62 0.33 0.34 0.14 
CDKN2A/B rs10757278 A 0.60 0.60 0.55 0.55 0.18 0.80 0.82 0.77 
CDKN2A/B rs10811661 C 0.14 0.18 0.16 0.20 0.02 0.07 0.07 0.24 
ANKRD16 rs2380205 C 0.54 0.58 0.57 0.60 0.88 0.41 0.46 0.72 
ZNF365 rs10995190 G 0.85 0.83 0.86 0.82 0.76 0.82 0.83 0.90 
ZMIZ1 rs704010 T 0.35 0.36 0.42 0.42 0.93 0.11 0.08 0.82 
FGFR2 rs1896395 A 0.05 0.04 0.00 0.00 0.96 0.21 0.20 0.04 
FGFR2 rs3750817 C 0.71 0.65 0.65 0.60 0.16 0.91 0.88 0.83 
FGFR2 rs10736303 G 0.61 0.55 0.54 0.49 0.19 0.86 0.84 0.75 
FGFR2 rs11200014 A 0.40 0.38 0.45 0.41 0.65 0.22 0.21 0.75 
FGFR2 rs2981579 T 0.49 0.45 0.46 0.41 0.51 0.61 0.61 0.10 
FGFR2 rs1078806 G 0.40 0.38 0.45 0.41 0.53 0.22 0.21 0.99 
FGFR2 rs2981578 C 0.61 0.55 0.54 0.49 0.09 0.86 0.84 0.45 
FGFR2 rs1219648 G 0.44 0.40 0.44 0.39 0.35 0.47 0.41 0.57 
FGFR2 rs2912774 A 0.47 0.42 0.44 0.40 0.26 0.58 0.55 0.07 
FGFR2 rs2936870 T 0.47 0.43 0.44 0.40 0.25 0.59 0.56 0.14 
FGFR2 rs2420946 T 0.45 0.41 0.43 0.39 0.21 0.54 0.52 0.03 
FGFR2 rs2162540 G 0.45 0.41 0.42 0.39 0.28 0.54 0.52 0.41 
FGFR2 rs2981582 T 0.44 0.40 0.42 0.39 0.30 0.50 0.49 0.96 
FGFR2 rs3135718 G 0.46 0.42 0.43 0.39 0.23 0.58 0.54 0.65 
10q rs10510126 C 0.89 0.90 0.89 0.89 0.38 0.89 0.90 0.21 
ATM rs1800054 G 0.02 0.01 0.02 0.02 0.34 0.00 0.00 0.94 
ATM rs4986761 C 0.01 0.01 0.01 0.01 0.68 0.00 0.00 0.98 
ATM rs1800056 C 0.02 0.01 0.02 0.01 0.67 0.00 0.00 0.95 
ATM rs1800057 G 0.03 0.02 0.04 0.02 0.90 0.01 0.01 0.91 
ATM rs1800058 T 0.02 0.02 0.02 0.02 0.06 0.01 0.01 0.91 
ATM rs1801516 A 0.12 0.12 0.15 0.14 0.17 0.03 0.02 0.48 
ATM rs3092992 C 0.04 0.04 0.05 0.04 0.13 0.01 0.01 0.77 
ATM rs664143 C 0.60 0.61 0.58 0.60 0.70 0.67 0.68 0.45 
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ATM rs170548 G 0.27 0.33 0.32 0.37 0.88 0.09 0.12 0.07 
ATM rs3092993 A 0.12 0.12 0.15 0.14 0.19 0.03 0.02 0.48 
LSP1 rs3817198 C 0.29 0.31 0.32 0.34 0.18 0.17 0.17 0.16 
LSP1 rs909116 T 0.57 0.56 0.53 0.52 0.20 0.72 0.72 0.96 
MYEOV rs614367 T 0.16 0.12 0.17 0.11 0.05 0.14 0.15 0.33 
H19 rs2107425 C 0.65 0.65 0.70 0.68 0.74 0.50 0.53 0.42 
TNRC9/TOX3 rs8049149 T 0.00 0.00 0.00 0.00 0.98 0.01 0.02 0.32 
TNRC9/TOX3 rs16951186 T 0.05 0.04 0.01 0.01 0.75 0.17 0.19 0.95 
TNRC9/TOX3 rs8051542 T 0.43 0.41 0.46 0.44 0.43 0.33 0.30 0.12 
TNRC9/TOX3 rs12443621 G 0.50 0.43 0.51 0.41 0.39 0.48 0.51 1.00 
TNRC9/TOX3 rs3803662 T 0.36 0.29 0.32 0.24 0.73 0.52 0.54 0.65 
TNRC9/TOX3 rs4784227 T 0.24 0.19 0.29 0.22 0.62 0.09 0.07 0.59 
TNRC9/TOX3 rs3104746 A 0.08 0.05 0.03 0.02 0.48 0.26 0.18 0.87 
TNRC9/TOX3 rs3112562 G 0.28 0.25 0.22 0.20 0.45 0.51 0.46 0.88 
TNRC9/TOX3 rs9940048 A 0.26 0.25 0.25 0.24 0.50 0.31 0.30 0.64 
TP53 rs9894946 G 0.84 0.87 0.81 0.86 0.48 0.96 0.96 0.25 
TP53 rs1614984 T 0.41 0.39 0.41 0.39 0.22 0.39 0.40 0.03 
TP53 rs4968187 T 0.00 0.00 0.00 0.00 0.93 0.01 0.00 0.92 
TP53 rs12951053 C 0.08 0.07 0.08 0.06 0.47 0.11 0.11 0.09 
TP53 rs17880604 C 0.01 0.01 0.01 0.01 0.21 0.00 0.00 0.95 
TP53 rs1800372 G 0.01 0.01 0.02 0.02 0.54 0.01 0.00 0.98 
TP53 rs2909430 G 0.17 0.14 0.14 0.13 0.66 0.28 0.24 0.64 
TP53 rs1042522 C 0.67 0.71 0.75 0.77 0.64 0.40 0.43 0.77 
TP53 rs8079544 C 0.94 0.94 0.96 0.95 1.00 0.89 0.89 0.83 
COX11 rs7222197 G 0.70 0.73 0.72 0.75 0.60 0.66 0.65 0.70 
COX11 rs6504950 G 0.70 0.73 0.72 0.75 0.59 0.66 0.65 0.66 
*Weighted by inverse sampling probability  
**Includes individuals who identified as a race other than white or African American  
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Table 18: Odds ratios and 95% posterior intervals for the association between the selected single nucleotide polymorphisms 
(SNPs) and each breast cancer subtype, relative to controls [SNP log OR~N(0,τ2), τ2 ~ Γ-1(4, 0.5) with mode=0.10]* 
 
Gene  SNP Luminal A N=700 
Luminal B 
N=122 
HER2+/ER- 
N=98 
Unclassified 
N=133 
Basal-like 
N=207 
1p12 rs11249433 1.09 (0.94, 1.25) 1.04 (0.78, 1.33) 1.11 (0.79, 1.45) 1.24 (0.93, 1.58) 1.09 (0.85, 1.35) 
CASP8 rs1045485 1.10 (0.88, 1.32) 1.00 (0.67, 1.35) 0.97 (0.62, 1.33) 1.24 (0.80, 1.73) 1.15 (0.80, 1.56) 
CASP8 rs17468277 1.11 (0.89, 1.35) 0.96 (0.64, 1.34) 0.94 (0.60, 1.32) 1.29 (0.84, 1.82) 1.10 (0.79, 1.47) 
2q35 rs13387042 1.18 (1.04, 1.35) 0.99 (0.76, 1.25) 0.98 (0.69, 1.25) 1.10 (0.85, 1.40) 0.92 (0.73, 1.12) 
2p rs4666451 0.97 (0.85, 1.11) 1.03 (0.76, 1.29) 1.14 (0.84, 1.48) 1.24 (0.93, 1.56) 1.16 (0.91, 1.41) 
SLC4A7 rs4973768 0.98 (0.86, 1.09) 1.01 (0.78, 1.27) 0.91 (0.68, 1.17) 0.93 (0.70, 1.15) 0.99 (0.78, 1.19) 
4p rs12505080 1.18 (1.02, 1.36) 1.14 (0.84, 1.45) 1.15 (0.82, 1.54) 0.88 (0.61, 1.13) 0.98 (0.75, 1.21) 
TLR1 rs7696175 1.20 (1.02, 1.38) 0.99 (0.74, 1.29) 0.79 (0.54, 1.04) 1.08 (0.77, 1.38) 1.27 (0.96, 1.59) 
MRPS30 rs4415084 1.11 (0.96, 1.25) 1.06 (0.80, 1.32) 1.15 (0.85, 1.49) 1.08 (0.84, 1.35) 1.17 (0.93, 1.41) 
MRPS30 rs10941679 1.10 (0.93, 1.27) 0.94 (0.69, 1.22) 1.04 (0.73, 1.36) 0.95 (0.69, 1.23) 1.21 (0.95, 1.45) 
5p12 rs981782 0.90 (0.78, 1.03) 0.88 (0.64, 1.12) 1.08 (0.78, 1.41) 0.99 (0.72, 1.28) 1.07 (0.82, 1.33) 
5q rs30099 1.09 (0.89, 1.31) 1.03 (0.66, 1.37) 1.13 (0.75, 1.56) 0.91 (0.60, 1.20) 0.99 (0.73, 1.28) 
MAP3K1 rs889312 1.17 (1.02, 1.33) 1.04 (0.80, 1.32) 1.00 (0.74, 1.30) 1.08 (0.82, 1.35) 0.89 (0.70, 1.09) 
ESR1 rs2046210 1.03 (0.90, 1.16) 1.07 (0.82, 1.36) 1.29 (0.97, 1.67) 1.15 (0.88, 1.44) 1.29 (1.01, 1.55) 
ESR1 rs851974 0.89 (0.77, 1.02) 1.13 (0.84, 1.43) 0.86 (0.62, 1.12) 0.88 (0.64, 1.10) 0.96 (0.76, 1.18) 
ESR1 rs2077647 0.95 (0.83, 1.08) 1.00 (0.76, 1.25) 0.98 (0.72, 1.26) 0.94 (0.71, 1.16) 0.96 (0.76, 1.17) 
ESR1 rs2234693 0.91 (0.79, 1.04) 0.96 (0.75, 1.20) 1.02 (0.75, 1.27) 0.86 (0.67, 1.08) 0.99 (0.79, 1.18) 
ESR1 rs1801132 1.09 (0.92, 1.28) 0.91 (0.66, 1.20) 0.98 (0.67, 1.31) 1.02 (0.74, 1.32) 0.85 (0.64, 1.05) 
ESR1 rs3020314 1.02 (0.89, 1.17) 1.23 (0.93, 1.54) 1.08 (0.80, 1.37) 0.99 (0.77, 1.23) 1.12 (0.90, 1.34) 
ESR1 rs3798577 0.97 (0.86, 1.10) 1.05 (0.79, 1.32) 0.82 (0.62, 1.02) 1.10 (0.85, 1.35) 1.00 (0.82, 1.21) 
ECHDC1 rs2180341 0.99 (0.84, 1.13) 1.01 (0.75, 1.31) 1.04 (0.74, 1.36) 0.95 (0.70, 1.20) 1.01 (0.80, 1.23) 
RELN rs17157903 1.00 (0.83, 1.18) 1.07 (0.74, 1.41) 0.77 (0.48, 1.09) 0.99 (0.70, 1.32) 1.09 (0.78, 1.39) 
8q24 rs13281615 1.04 (0.90, 1.17) 0.99 (0.75, 1.25) 1.13 (0.85, 1.43) 1.08 (0.85, 1.35) 0.98 (0.79, 1.17) 
8q24 rs1562430 1.06 (0.93, 1.19) 0.96 (0.72, 1.22) 1.20 (0.90, 1.55) 1.06 (0.83, 1.32) 1.07 (0.85, 1.28) 
CDKN2A/B rs3731257 0.92 (0.78, 1.06) 0.89 (0.64, 1.17) 0.96 (0.66, 1.26) 0.91 (0.66, 1.19) 0.91 (0.70, 1.16) 
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CDKN2A/B rs3731249 0.99 (0.65, 1.33) 1.08 (0.55, 1.68) 1.11 (0.56, 1.76) 0.95 (0.49, 1.46) 0.96 (0.51, 1.48) 
CDKN2A/B rs518394 0.99 (0.86, 1.13) 1.00 (0.73, 1.26) 0.77 (0.52, 1.00) 1.04 (0.76, 1.34) 1.14 (0.88, 1.38) 
CDKN2A/B rs564398 1.01 (0.85, 1.15) 1.01 (0.76, 1.28) 0.81 (0.56, 1.08) 1.08 (0.80, 1.40) 1.09 (0.83, 1.36) 
CDKN2A/B rs1011970 1.12 (0.96, 1.29) 0.91 (0.65, 1.15) 0.90 (0.63, 1.15) 0.87 (0.63, 1.10) 1.12 (0.86, 1.38) 
CDKN2A/B rs10757278 1.05 (0.90, 1.18) 1.06 (0.80, 1.35) 1.02 (0.75, 1.31) 1.22 (0.93, 1.52) 1.10 (0.86, 1.34) 
CDKN2A/B rs10811661 0.95 (0.78, 1.13) 1.01 (0.71, 1.35) 0.82 (0.54, 1.15) 0.84 (0.56, 1.12) 1.10 (0.81, 1.39) 
ANKRD16 rs2380205 1.03 (0.90, 1.15) 1.05 (0.79, 1.30) 1.10 (0.82, 1.40) 0.80 (0.61, 0.99) 0.94 (0.77, 1.13) 
ZNF365 rs10995190 1.03 (0.84, 1.22) 0.83 (0.59, 1.09) 0.83 (0.59, 1.11) 1.24 (0.88, 1.64) 0.95 (0.74, 1.21) 
ZMIZ1 rs704010 1.09 (0.94, 1.25) 1.34 (0.96, 1.70) 1.36 (0.97, 1.77) 0.96 (0.70, 1.25) 1.34 (1.03, 1.66) 
FGFR2 rs1896395 1.05 (0.80, 1.30) 0.92 (0.54, 1.33) 1.31 (0.73, 1.89) 1.06 (0.70, 1.44) 1.06 (0.71, 1.40) 
FGFR2 rs3750817 1.33 (1.13, 1.53) 1.27 (0.92, 1.64) 1.22 (0.86, 1.60) 1.26 (0.92, 1.64) 1.01 (0.79, 1.25) 
FGFR2 rs10736303 1.32 (1.14, 1.52) 1.31 (0.98, 1.65) 1.26 (0.90, 1.64) 1.37 (0.99, 1.77) 0.99 (0.78, 1.22) 
FGFR2 rs11200014 1.26 (1.10, 1.43) 1.05 (0.80, 1.31) 1.19 (0.86, 1.52) 1.41 (1.08, 1.77) 0.88 (0.70, 1.07) 
FGFR2 rs2981579 1.26 (1.10, 1.42) 1.11 (0.84, 1.41) 1.34 (1.00, 1.68) 1.44 (1.11, 1.80) 0.92 (0.74, 1.10) 
FGFR2 rs1078806 1.24 (1.08, 1.42) 1.07 (0.79, 1.36) 1.19 (0.86, 1.53) 1.40 (1.06, 1.76) 0.87 (0.68, 1.07) 
FGFR2 rs2981578 1.33 (1.15, 1.51) 1.31 (1.01, 1.67) 1.34 (0.98, 1.76) 1.38 (1.03, 1.84) 1.01 (0.79, 1.25) 
FGFR2 rs1219648 1.29 (1.13, 1.47) 1.10 (0.83, 1.37) 1.24 (0.89, 1.59) 1.62 (1.24, 2.04) 0.95 (0.76, 1.15) 
FGFR2 rs2912774 1.26 (1.10, 1.41) 1.11 (0.84, 1.39) 1.42 (1.06, 1.80) 1.47 (1.14, 1.85) 0.92 (0.73, 1.09) 
FGFR2 rs2936870 1.26 (1.09, 1.41) 1.13 (0.86, 1.43) 1.38 (1.02, 1.76) 1.50 (1.16, 1.89) 0.91 (0.72, 1.09) 
FGFR2 rs2420946 1.22 (1.06, 1.38) 1.06 (0.80, 1.32) 1.40 (1.04, 1.79) 1.46 (1.12, 1.83) 0.89 (0.71, 1.07) 
FGFR2 rs2162540 1.28 (1.11, 1.45) 1.08 (0.82, 1.36) 1.42 (1.05, 1.83) 1.52 (1.17, 1.90) 0.91 (0.72, 1.10) 
FGFR2 rs2981582 1.27 (1.09, 1.43) 1.10 (0.87, 1.40) 1.39 (1.02, 1.76) 1.28 (1.00, 1.57) 0.92 (0.73, 1.10) 
FGFR2 rs3135718 1.26 (1.10, 1.42) 1.13 (0.85, 1.40) 1.35 (1.01, 1.71) 1.51 (1.17, 1.90) 0.91 (0.73, 1.09) 
10q rs10510126 1.09 (0.88, 1.30) 1.07 (0.73, 1.46) 1.08 (0.72, 1.49) 0.94 (0.63, 1.26) 1.14 (0.81, 1.48) 
ATM rs1800054 1.10 (0.66, 1.59) 1.10 (0.54, 1.76) 1.12 (0.51, 1.78) 1.00 (0.49, 1.62) 1.20 (0.58, 1.91) 
ATM rs1800057 1.19 (0.81, 1.64) 0.95 (0.49, 1.48) 1.33 (0.68, 2.13) 1.01 (0.50, 1.60) 1.10 (0.56, 1.67) 
ATM rs1800058 1.05 (0.67, 1.44) 0.94 (0.45, 1.46) 1.03 (0.51, 1.67) 0.98 (0.47, 1.56) 0.98 (0.49, 1.56) 
ATM rs1801516 1.03 (0.82, 1.24) 1.05 (0.70, 1.43) 0.97 (0.64, 1.37) 0.95 (0.63, 1.32) 0.99 (0.70, 1.32) 
ATM rs3092992 0.97 (0.68, 1.30) 0.99 (0.57, 1.49) 1.19 (0.62, 1.85) 1.05 (0.61, 1.57) 1.38 (0.79, 1.97) 
ATM rs664143 1.09 (0.95, 1.23) 1.00 (0.77, 1.25) 1.06 (0.79, 1.35) 0.94 (0.74, 1.17) 0.98 (0.79, 1.19) 
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ATM rs170548 0.98 (0.84, 1.13) 0.90 (0.66, 1.16) 1.00 (0.72, 1.31) 0.94 (0.69, 1.22) 1.00 (0.77, 1.24) 
ATM rs3092993 1.03 (0.83, 1.25) 1.06 (0.69, 1.48) 0.94 (0.60, 1.35) 0.96 (0.61, 1.29) 1.03 (0.73, 1.37) 
LSP1 rs3817198 1.02 (0.88, 1.18) 0.87 (0.62, 1.10) 1.19 (0.86, 1.52) 1.21 (0.92, 1.55) 1.02 (0.79, 1.26) 
LSP1 rs909116 1.09 (0.94, 1.23) 0.92 (0.69, 1.15) 1.23 (0.90, 1.58) 1.03 (0.79, 1.30) 1.09 (0.86, 1.32) 
H19 rs2107425 1.03 (0.90, 1.17) 0.93 (0.71, 1.17) 0.99 (0.74, 1.24) 0.94 (0.72, 1.18) 1.00 (0.81, 1.19) 
TNRC9/TOX3 rs16951186 1.02 (0.78, 1.25) 1.30 (0.79, 1.88) 0.84 (0.48, 1.21) 0.83 (0.52, 1.12) 0.97 (0.67, 1.31) 
TNRC9/TOX3 rs8051542 1.10 (0.97, 1.24) 0.96 (0.74, 1.20) 1.12 (0.84, 1.43) 1.31 (1.02, 1.64) 0.84 (0.66, 1.03) 
TNRC9/TOX3 rs12443621 1.06 (0.94, 1.20) 0.93 (0.71, 1.16) 1.21 (0.92, 1.55) 0.95 (0.74, 1.18) 1.00 (0.82, 1.21) 
TNRC9/TOX3 rs3803662 1.16 (1.01, 1.33) 1.09 (0.83, 1.35) 1.01 (0.77, 1.29) 1.13 (0.88, 1.41) 0.96 (0.78, 1.16) 
TNRC9/TOX3 rs4784227 1.32 (1.13, 1.54) 1.09 (0.76, 1.43) 1.10 (0.76, 1.46) 1.29 (0.94, 1.67) 0.90 (0.66, 1.17) 
TNRC9/TOX3 rs3104746 1.58 (1.24, 1.94) 1.05 (0.60, 1.50) 1.31 (0.80, 1.85) 1.12 (0.76, 1.58) 1.49 (1.06, 1.98) 
TNRC9/TOX3 rs3112562 1.07 (0.93, 1.22) 0.88 (0.62, 1.14) 1.46 (1.06, 1.87) 0.80 (0.60, 1.03) 1.33 (1.06, 1.62) 
TNRC9/TOX3 rs9940048 1.13 (0.97, 1.28) 0.84 (0.61, 1.08) 1.17 (0.86, 1.50) 0.98 (0.72, 1.25) 0.91 (0.72, 1.11) 
TP53 rs9894946 0.86 (0.72, 1.02) 0.83 (0.59, 1.12) 1.01 (0.65, 1.36) 1.05 (0.71, 1.43) 1.12 (0.81, 1.49) 
TP53 rs1614984 1.01 (0.88, 1.13) 0.94 (0.71, 1.16) 1.01 (0.78, 1.28) 1.04 (0.79, 1.30) 1.13 (0.92, 1.36) 
TP53 rs12951053 0.95 (0.75, 1.18) 1.32 (0.86, 1.84) 1.16 (0.71, 1.62) 1.25 (0.82, 1.73) 0.99 (0.70, 1.30) 
TP53 rs17880604 0.87 (0.49, 1.24) 0.84 (0.35, 1.38) 1.21 (0.54, 1.94) 0.96 (0.46, 1.57) 1.12 (0.57, 1.76) 
TP53 rs1800372 0.97 (0.55, 1.38) 1.24 (0.57, 2.00) 0.93 (0.39, 1.53) 1.34 (0.59, 2.22) 1.04 (0.46, 1.71) 
TP53 rs2909430 1.12 (0.96, 1.31) 1.09 (0.78, 1.45) 1.06 (0.73, 1.38) 0.88 (0.63, 1.13) 1.10 (0.85, 1.37) 
TP53 rs1042522 1.03 (0.89, 1.18) 0.99 (0.73, 1.26) 0.82 (0.61, 1.06) 0.94 (0.70, 1.17) 0.97 (0.77, 1.18) 
TP53 rs8079544 0.98 (0.78, 1.23) 1.38 (0.83, 2.07) 0.76 (0.45, 1.07) 0.87 (0.59, 1.20) 1.05 (0.71, 1.44) 
COX11 rs7222197 1.06 (0.92, 1.22) 1.08 (0.80, 1.35) 1.01 (0.74, 1.29) 1.09 (0.82, 1.37) 1.05 (0.85, 1.27) 
COX11 rs6504950 1.05 (0.91, 1.20) 1.07 (0.80, 1.37) 1.00 (0.73, 1.28) 1.08 (0.81, 1.35) 1.05 (0.84, 1.28) 
*Estimates generated using polytomous logistic regression adjusting for age at diagnosis/selection, proportion African ancestry and self-
reported race. 
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Figure 30: Odds ratios and 95% posterior intervals for FGFR2 and TNRC9/TOX3 
SNPs, All CBCS participants 
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Table 19: Odds ratios and 95% posterior intervals for SNP-subtype associations in Carolina Breast Cancer Study whites, 
[SNP log OR~N(0,τ2), τ2 ~ Γ-1(4, 0.5) with mode=0.10]* 
 
Gene  SNP Luminal A N=453 
Luminal B 
N=82 
HER2+/ER- 
N=59 
Unclassified 
N=60 
Basal-like 
N=94 
1p12 rs11249433 1.04 (0.87, 1.20) 1.10 (0.81, 1.44) 0.98 (0.69, 1.30) 1.21 (0.83, 1.63) 1.05 (0.76, 1.35) 
CASP8 rs1045485 1.13 (0.90, 1.40) 0.95 (0.62, 1.32) 0.93 (0.57, 1.30) 1.13 (0.70, 1.62) 1.39 (0.89, 1.99) 
CASP8 rs17468277 1.12 (0.87, 1.39) 0.94 (0.60, 1.29) 0.94 (0.58, 1.33) 1.16 (0.70, 1.71) 1.36 (0.87, 1.94) 
2q35 rs13387042 1.18 (1.00, 1.37) 1.07 (0.76, 1.37) 1.02 (0.72, 1.36) 1.02 (0.71, 1.36) 1.05 (0.78, 1.37) 
2p rs4666451 0.98 (0.83, 1.14) 1.12 (0.79, 1.47) 1.05 (0.72, 1.39) 1.11 (0.76, 1.46) 1.13 (0.81, 1.47) 
SLC4A7 rs4973768 1.04 (0.87, 1.20) 1.10 (0.80, 1.43) 0.91 (0.62, 1.20) 0.97 (0.68, 1.27) 0.93 (0.67, 1.19) 
4p rs12505080 1.17 (0.97, 1.37) 1.04 (0.72, 1.37) 1.20 (0.80, 1.63) 0.91 (0.60, 1.25) 1.06 (0.75, 1.37) 
TLR1 rs7696175 1.17 (0.99, 1.35) 0.98 (0.71, 1.27) 0.81 (0.53, 1.07) 1.11 (0.77, 1.45) 1.21 (0.89, 1.53) 
MRPS30 rs4415084 1.19 (0.99, 1.39) 0.88 (0.62, 1.15) 1.28 (0.88, 1.71) 1.00 (0.68, 1.35) 1.16 (0.83, 1.50) 
MRPS30 rs10941679 1.18 (0.99, 1.40) 0.93 (0.65, 1.26) 1.17 (0.77, 1.62) 0.97 (0.63, 1.32) 1.19 (0.88, 1.54) 
5p12 rs981782 0.87 (0.73, 1.01) 0.80 (0.58, 1.05) 1.15 (0.81, 1.54) 0.94 (0.65, 1.26) 1.08 (0.77, 1.37) 
5q rs30099 1.05 (0.80, 1.31) 0.99 (0.61, 1.41) 0.95 (0.55, 1.42) 0.91 (0.52, 1.32) 0.94 (0.59, 1.33) 
MAP3K1 rs889312 1.25 (1.04, 1.47) 1.19 (0.86, 1.60) 1.07 (0.73, 1.47) 1.21 (0.84, 1.64) 0.97 (0.70, 1.26) 
ESR1 rs2046210 1.03 (0.87, 1.20) 1.12 (0.83, 1.47) 1.07 (0.75, 1.42) 1.18 (0.79, 1.56) 1.25 (0.91, 1.58) 
ESR1 rs851974 0.88 (0.75, 1.03) 1.07 (0.74, 1.36) 0.86 (0.58, 1.16) 0.85 (0.58, 1.15) 0.94 (0.69, 1.20) 
ESR1 rs2077647 0.97 (0.82, 1.13) 0.96 (0.69, 1.25) 0.97 (0.70, 1.29) 0.87 (0.61, 1.16) 0.93 (0.69, 1.19) 
ESR1 rs2234693 0.88 (0.74, 1.02) 0.95 (0.69, 1.23) 1.05 (0.70, 1.40) 0.80 (0.54, 1.06) 1.01 (0.74, 1.28) 
ESR1 rs1801132 1.05 (0.86, 1.25) 0.90 (0.62, 1.20) 0.88 (0.58, 1.21) 0.85 (0.58, 1.15) 0.82 (0.59, 1.08) 
ESR1 rs3020314 1.02 (0.86, 1.19) 1.10 (0.77, 1.43) 1.16 (0.79, 1.57) 1.06 (0.74, 1.41) 1.34 (0.97, 1.73) 
ESR1 rs3798577 0.96 (0.81, 1.09) 0.99 (0.73, 1.30) 0.77 (0.52, 1.04) 1.11 (0.78, 1.44) 0.97 (0.72, 1.26) 
ECHDC1 rs2180341 0.94 (0.77, 1.13) 1.00 (0.67, 1.35) 0.95 (0.61, 1.34) 1.24 (0.80, 1.67) 0.90 (0.62, 1.21) 
RELN rs17157903 0.92 (0.74, 1.14) 0.97 (0.64, 1.37) 0.78 (0.43, 1.12) 1.12 (0.74, 1.59) 1.15 (0.78, 1.54) 
8q24 rs13281615 1.16 (0.98, 1.35) 0.97 (0.70, 1.26) 1.11 (0.76, 1.47) 1.04 (0.73, 1.38) 0.99 (0.75, 1.28) 
8q24 rs1562430 1.17 (1.00, 1.37) 0.95 (0.69, 1.23) 1.17 (0.79, 1.59) 1.34 (0.89, 1.79) 1.02 (0.76, 1.32) 
CDKN2A/B rs3731257 0.99 (0.82, 1.16) 0.94 (0.64, 1.24) 1.07 (0.74, 1.44) 0.95 (0.63, 1.29) 0.93 (0.63, 1.22) 
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CDKN2A/B rs3731249 0.86 (0.53, 1.19) 1.11 (0.55, 1.72) 1.14 (0.59, 1.77) 0.97 (0.47, 1.53) 0.88 (0.44, 1.36) 
CDKN2A/B rs518394 1.00 (0.84, 1.16) 0.99 (0.71, 1.29) 0.76 (0.53, 1.01) 1.11 (0.78, 1.49) 1.17 (0.87, 1.50) 
CDKN2A/B rs564398 1.02 (0.86, 1.18) 1.04 (0.76, 1.33) 0.82 (0.53, 1.09) 1.16 (0.79, 1.54) 1.10 (0.82, 1.40) 
CDKN2A/B rs1011970 1.10 (0.89, 1.32) 0.99 (0.62, 1.37) 1.08 (0.66, 1.54) 0.98 (0.62, 1.40) 1.19 (0.82, 1.63) 
CDKN2A/B rs10757278 1.19 (1.02, 1.39) 1.07 (0.79, 1.41) 1.03 (0.71, 1.35) 1.08 (0.78, 1.45) 1.13 (0.85, 1.45) 
CDKN2A/B rs10811661 0.91 (0.73, 1.11) 1.01 (0.68, 1.38) 0.91 (0.58, 1.28) 0.89 (0.56, 1.28) 1.12 (0.78, 1.51) 
ANKRD16 rs2380205 1.12 (0.94, 1.30) 1.08 (0.76, 1.39) 1.00 (0.70, 1.33) 0.81 (0.57, 1.08) 1.01 (0.73, 1.29) 
ZNF365 rs10995190 1.03 (0.81, 1.28) 0.91 (0.58, 1.27) 0.80 (0.51, 1.14) 1.17 (0.73, 1.66) 1.10 (0.70, 1.53) 
ZMIZ1 rs704010 1.12 (0.95, 1.32) 1.37 (0.96, 1.79) 1.33 (0.89, 1.77) 0.95 (0.64, 1.27) 1.26 (0.92, 1.61) 
FGFR2 rs3750817 1.29 (1.08, 1.49) 1.26 (0.89, 1.65) 1.10 (0.78, 1.49) 1.11 (0.77, 1.50) 0.92 (0.69, 1.19) 
FGFR2 rs10736303 1.36 (1.14, 1.57) 1.36 (0.91, 1.75) 1.08 (0.72, 1.45) 1.31 (0.92, 1.78) 0.90 (0.65, 1.16) 
FGFR2 rs11200014 1.30 (1.10, 1.52) 1.24 (0.88, 1.62) 1.14 (0.76, 1.50) 1.55 (1.06, 2.06) 0.84 (0.61, 1.08) 
FGFR2 rs2981579 1.36 (1.14, 1.57) 1.21 (0.85, 1.57) 1.15 (0.79, 1.53) 1.53 (1.06, 2.08) 0.84 (0.60, 1.06) 
FGFR2 rs1078806 1.29 (1.09, 1.51) 1.23 (0.89, 1.58) 1.14 (0.75, 1.54) 1.51 (1.04, 2.02) 0.83 (0.61, 1.08) 
FGFR2 rs2981578 1.38 (1.17, 1.62) 1.36 (0.96, 1.76) 1.20 (0.83, 1.58) 1.32 (0.88, 1.75) 0.90 (0.66, 1.17) 
FGFR2 rs1219648 1.32 (1.13, 1.54) 1.21 (0.85, 1.58) 1.13 (0.74, 1.49) 1.42 (0.97, 1.92) 0.82 (0.61, 1.07) 
FGFR2 rs2912774 1.31 (1.11, 1.51) 1.18 (0.83, 1.54) 1.14 (0.76, 1.51) 1.39 (0.96, 1.85) 0.81 (0.59, 1.05) 
FGFR2 rs2936870 1.31 (1.11, 1.52) 1.18 (0.86, 1.57) 1.15 (0.81, 1.58) 1.36 (0.94, 1.78) 0.83 (0.61, 1.08) 
FGFR2 rs2420946 1.31 (1.10, 1.51) 1.14 (0.82, 1.49) 1.14 (0.79, 1.53) 1.32 (0.90, 1.74) 0.83 (0.62, 1.08) 
FGFR2 rs2162540 1.32 (1.10, 1.52) 1.13 (0.81, 1.46) 1.14 (0.78, 1.53) 1.34 (0.94, 1.78) 0.80 (0.58, 1.04) 
FGFR2 rs2981582 1.32 (1.11, 1.53) 1.16 (0.83, 1.49) 1.16 (0.78, 1.56) 1.32 (0.89, 1.74) 0.82 (0.60, 1.07) 
FGFR2 rs3135718 1.31 (1.10, 1.51) 1.13 (0.83, 1.46) 1.12 (0.76, 1.47) 1.31 (0.90, 1.71) 0.83 (0.61, 1.06) 
10q rs10510126 1.17 (0.89, 1.45) 1.09 (0.67, 1.51) 0.98 (0.58, 1.40) 0.97 (0.61, 1.37) 1.11 (0.71, 1.57) 
ATM rs1800054 1.01 (0.62, 1.45) 1.15 (0.55, 1.90) 1.19 (0.50, 1.99) 0.94 (0.42, 1.47) 1.31 (0.66, 2.07) 
ATM rs1800057 1.12 (0.75, 1.55) 0.89 (0.43, 1.42) 1.40 (0.68, 2.26) 0.99 (0.44, 1.60) 1.22 (0.67, 1.95) 
ATM rs1800058 1.08 (0.67, 1.53) 0.90 (0.43, 1.42) 1.01 (0.45, 1.62) 1.09 (0.52, 1.76) 1.00 (0.52, 1.59) 
ATM rs1801516 0.98 (0.77, 1.19) 1.07 (0.69, 1.49) 0.89 (0.54, 1.27) 0.91 (0.54, 1.29) 1.05 (0.69, 1.43) 
ATM rs3092992 0.93 (0.64, 1.25) 1.07 (0.57, 1.61) 1.17 (0.60, 1.85) 1.05 (0.54, 1.65) 1.37 (0.77, 2.04) 
ATM rs664143 1.07 (0.91, 1.24) 1.05 (0.77, 1.34) 1.25 (0.88, 1.66) 0.89 (0.63, 1.17) 1.00 (0.75, 1.26) 
ATM rs170548 1.03 (0.87, 1.22) 1.01 (0.72, 1.32) 1.17 (0.77, 1.57) 0.90 (0.61, 1.22) 0.98 (0.72, 1.29) 
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ATM rs3092993 0.98 (0.76, 1.20) 1.06 (0.68, 1.46) 0.89 (0.54, 1.30) 0.90 (0.54, 1.28) 1.04 (0.70, 1.43) 
LSP1 rs3817198 1.07 (0.90, 1.25) 0.84 (0.60, 1.10) 1.20 (0.81, 1.63) 1.07 (0.71, 1.43) 1.07 (0.79, 1.39) 
LSP1 rs909116 1.17 (0.99, 1.37) 0.90 (0.65, 1.15) 1.06 (0.75, 1.43) 1.08 (0.72, 1.45) 1.07 (0.79, 1.38) 
H19 rs2107425 1.11 (0.93, 1.31) 0.96 (0.68, 1.25) 1.10 (0.76, 1.48) 1.02 (0.67, 1.38) 1.19 (0.82, 1.54) 
TNRC9/TOX3 rs8051542 1.16 (0.99, 1.35) 1.05 (0.75, 1.34) 1.07 (0.75, 1.42) 1.10 (0.76, 1.49) 0.91 (0.67, 1.16) 
TNRC9/TOX3 rs12443621 1.22 (1.02, 1.40) 0.86 (0.62, 1.09) 1.53 (1.05, 2.09) 0.89 (0.61, 1.18) 1.18 (0.86, 1.51) 
TNRC9/TOX3 rs3803662 1.34 (1.14, 1.59) 1.12 (0.79, 1.47) 1.16 (0.79, 1.58) 0.99 (0.67, 1.34) 0.99 (0.72, 1.28) 
TNRC9/TOX3 rs4784227 1.30 (1.08, 1.53) 1.15 (0.80, 1.54) 1.13 (0.75, 1.56) 1.12 (0.76, 1.53) 1.00 (0.70, 1.32) 
TNRC9/TOX3 rs3104746 1.41 (0.86, 2.01) 0.97 (0.40, 1.55) 1.15 (0.55, 1.90) 1.02 (0.44, 1.68) 1.08 (0.50, 1.75) 
TNRC9/TOX3 rs3112562 0.96 (0.78, 1.15) 0.64 (0.39, 0.89) 1.58 (1.03, 2.16) 0.75 (0.45, 1.07) 1.32 (0.92, 1.75) 
TNRC9/TOX3 rs9940048 1.07 (0.89, 1.26) 0.85 (0.59, 1.14) 1.04 (0.66, 1.41) 0.86 (0.57, 1.19) 0.97 (0.69, 1.27) 
TP53 rs9894946 0.85 (0.68, 1.02) 0.91 (0.61, 1.27) 1.05 (0.66, 1.51) 1.05 (0.63, 1.46) 1.01 (0.69, 1.36) 
TP53 rs1614984 1.03 (0.87, 1.19) 0.93 (0.67, 1.23) 1.09 (0.77, 1.49) 1.04 (0.71, 1.38) 1.10 (0.83, 1.42) 
TP53 rs12951053 0.94 (0.70, 1.20) 1.19 (0.66, 1.73) 1.51 (0.83, 2.32) 1.04 (0.55, 1.54) 1.28 (0.74, 1.89) 
TP53 rs17880604 0.83 (0.49, 1.23) 0.86 (0.32, 1.42) 1.25 (0.56, 2.13) 0.92 (0.31, 1.53) 1.10 (0.51, 1.84) 
TP53 rs1800372 0.88 (0.51, 1.31) 1.25 (0.57, 2.07) 0.96 (0.41, 1.65) 1.12 (0.47, 1.87) 1.09 (0.48, 1.75) 
TP53 rs2909430 1.15 (0.91, 1.41) 0.85 (0.49, 1.17) 0.96 (0.56, 1.38) 0.94 (0.60, 1.37) 1.09 (0.69, 1.51) 
TP53 rs1042522 0.97 (0.81, 1.15) 1.25 (0.85, 1.69) 0.86 (0.59, 1.17) 1.10 (0.74, 1.52) 0.93 (0.67, 1.22) 
TP53 rs8079544 1.01 (0.73, 1.33) 1.46 (0.76, 2.38) 1.03 (0.51, 1.61) 1.18 (0.60, 1.80) 1.21 (0.69, 1.88) 
COX11 rs7222197 1.03 (0.85, 1.21) 1.01 (0.72, 1.33) 1.01 (0.67, 1.37) 1.22 (0.83, 1.66) 0.92 (0.66, 1.18) 
COX11 rs6504950 1.02 (0.85, 1.20) 0.99 (0.69, 1.31) 1.02 (0.69, 1.37) 1.24 (0.84, 1.72) 0.92 (0.64, 1.19) 
*Estimates generated using polytomous logistic regression adjusting for age at diagnosis/selection and proportion African ancestry. 
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Table 20: Odds ratios and 95% posterior intervals for SNP-subtype associations in Carolina Breast Cancer Study African 
Americans [SNP log OR~N(0,τ2), τ2 ~ Γ-1(4, 0.5) with mode=0.10]* 
 
Gene  SNP Luminal A N=242 
Luminal B 
N=38 
HER2+/ER- 
N=39 
Unclassified 
N=71 
Basal-like 
N=112 
1p12 rs11249433 1.23 (0.89, 1.61) 0.79 (0.41, 1.25) 1.36 (0.71, 2.07) 1.38 (0.86, 1.97) 1.16 (0.74, 1.58) 
CASP8 rs1045485 1.04 (0.68, 1.43) 1.18 (0.58, 1.89) 1.08 (0.57, 1.71) 1.27 (0.69, 1.96) 0.83 (0.50, 1.21) 
CASP8 rs17468277 1.12 (0.72, 1.56) 1.15 (0.60, 1.88) 1.06 (0.51, 1.67) 1.37 (0.71, 2.13) 0.82 (0.49, 1.22) 
2q35 rs13387042 1.16 (0.89, 1.43) 0.92 (0.55, 1.32) 0.91 (0.57, 1.28) 1.15 (0.78, 1.56) 0.80 (0.59, 1.04) 
2p rs4666451 0.98 (0.76, 1.20) 0.84 (0.51, 1.22) 1.35 (0.82, 1.98) 1.32 (0.83, 1.81) 1.18 (0.85, 1.57) 
SLC4A7 rs4973768 0.89 (0.71, 1.08) 0.87 (0.55, 1.26) 0.95 (0.61, 1.35) 0.92 (0.64, 1.21) 1.06 (0.78, 1.35) 
4p rs12505080 1.18 (0.91, 1.51) 1.25 (0.78, 1.81) 1.09 (0.64, 1.57) 0.95 (0.61, 1.32) 0.93 (0.65, 1.24) 
TLR1 rs7696175 1.43 (0.95, 1.94) 1.09 (0.57, 1.69) 0.88 (0.39, 1.38) 1.07 (0.59, 1.58) 1.39 (0.86, 2.05) 
MRPS30 rs4415084 1.01 (0.81, 1.22) 1.36 (0.88, 1.95) 1.01 (0.66, 1.42) 1.12 (0.79, 1.48) 1.18 (0.89, 1.52) 
MRPS30 rs10941679 0.97 (0.74, 1.23) 0.95 (0.55, 1.39) 0.87 (0.50, 1.27) 0.96 (0.63, 1.32) 1.23 (0.87, 1.59) 
5p12 rs981782 1.16 (0.79, 1.53) 1.23 (0.66, 1.88) 0.95 (0.53, 1.43) 1.00 (0.62, 1.49) 1.05 (0.67, 1.47) 
5q rs30099 1.08 (0.80, 1.36) 1.10 (0.64, 1.59) 1.30 (0.78, 1.90) 0.96 (0.63, 1.36) 1.07 (0.71, 1.46) 
MAP3K1 rs889312 1.08 (0.85, 1.32) 0.79 (0.46, 1.13) 0.98 (0.60, 1.39) 0.94 (0.62, 1.29) 0.87 (0.63, 1.12) 
ESR1 rs2046210 0.99 (0.78, 1.20) 1.05 (0.68, 1.48) 1.52 (0.95, 2.16) 1.10 (0.75, 1.46) 1.26 (0.93, 1.64) 
ESR1 rs851974 0.96 (0.73, 1.20) 1.13 (0.66, 1.60) 0.96 (0.57, 1.40) 1.05 (0.66, 1.42) 1.03 (0.74, 1.38) 
ESR1 rs2077647 0.96 (0.77, 1.14) 1.08 (0.69, 1.48) 0.99 (0.65, 1.36) 1.08 (0.73, 1.40) 1.00 (0.75, 1.28) 
ESR1 rs2234693 0.96 (0.79, 1.16) 0.99 (0.64, 1.35) 1.00 (0.64, 1.37) 0.98 (0.71, 1.31) 0.96 (0.71, 1.21) 
ESR1 rs1801132 1.21 (0.86, 1.60) 1.00 (0.56, 1.56) 1.26 (0.67, 1.99) 1.36 (0.81, 2.04) 0.95 (0.61, 1.34) 
ESR1 rs3020314 0.98 (0.77, 1.20) 1.50 (0.85, 2.15) 0.96 (0.60, 1.34) 0.87 (0.61, 1.16) 0.88 (0.65, 1.14) 
ESR1 rs3798577 1.02 (0.81, 1.22) 1.22 (0.77, 1.68) 0.97 (0.61, 1.32) 1.16 (0.84, 1.53) 1.05 (0.77, 1.33) 
ECHDC1 rs2180341 1.03 (0.82, 1.26) 1.06 (0.69, 1.50) 1.13 (0.73, 1.61) 0.79 (0.55, 1.06) 1.13 (0.85, 1.48) 
RELN rs17157903 1.16 (0.83, 1.50) 1.23 (0.63, 1.84) 0.92 (0.45, 1.40) 0.91 (0.54, 1.35) 1.06 (0.67, 1.47) 
8q24 rs13281615 0.85 (0.68, 1.03) 1.02 (0.63, 1.43) 1.09 (0.71, 1.51) 1.07 (0.77, 1.40) 0.99 (0.74, 1.26) 
8q24 rs1562430 0.90 (0.72, 1.08) 0.97 (0.62, 1.37) 1.20 (0.78, 1.62) 0.85 (0.62, 1.12) 1.10 (0.81, 1.38) 
CDKN2A/B rs3731257 0.76 (0.49, 1.02) 0.91 (0.45, 1.38) 0.88 (0.45, 1.33) 1.02 (0.60, 1.47) 0.95 (0.62, 1.35) 
CDKN2A/B rs518394 0.98 (0.65, 1.28) 0.97 (0.51, 1.45) 0.94 (0.49, 1.42) 0.96 (0.54, 1.37) 1.10 (0.70, 1.55) 
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CDKN2A/B rs564398 0.97 (0.67, 1.30) 1.02 (0.58, 1.61) 0.90 (0.43, 1.38) 0.95 (0.53, 1.36) 1.11 (0.68, 1.56) 
CDKN2A/B rs1011970 1.15 (0.92, 1.38) 0.92 (0.59, 1.28) 0.79 (0.48, 1.11) 0.80 (0.57, 1.07) 1.07 (0.80, 1.38) 
CDKN2A/B rs10757278 0.75 (0.58, 0.94) 1.11 (0.65, 1.68) 1.05 (0.62, 1.51) 1.35 (0.82, 1.91) 0.99 (0.69, 1.32) 
CDKN2A/B rs10811661 1.09 (0.74, 1.44) 1.00 (0.49, 1.58) 0.79 (0.37, 1.25) 0.91 (0.48, 1.33) 1.08 (0.67, 1.52) 
ANKRD16 rs2380205 0.91 (0.72, 1.10) 1.08 (0.64, 1.49) 1.23 (0.80, 1.70) 0.85 (0.60, 1.09) 0.90 (0.67, 1.14) 
ZNF365 rs10995190 1.04 (0.78, 1.30) 0.85 (0.49, 1.21) 0.92 (0.59, 1.36) 1.25 (0.79, 1.75) 0.87 (0.62, 1.15) 
ZMIZ1 rs704010 0.90 (0.64, 1.20) 0.96 (0.50, 1.49) 1.19 (0.63, 1.84) 1.00 (0.57, 1.44) 1.40 (0.96, 1.95) 
FGFR2 rs1896395 1.01 (0.77, 1.27) 0.93 (0.54, 1.35) 1.32 (0.79, 1.90) 1.03 (0.67, 1.38) 1.05 (0.73, 1.37) 
FGFR2 rs3750817 1.38 (0.93, 1.87) 1.36 (0.67, 2.16) 1.53 (0.70, 2.54) 1.44 (0.81, 2.23) 1.29 (0.82, 1.84) 
FGFR2 rs10736303 1.13 (0.83, 1.47) 1.14 (0.63, 1.75) 1.60 (0.82, 2.53) 1.27 (0.77, 1.81) 1.14 (0.75, 1.56) 
FGFR2 rs11200014 1.16 (0.89, 1.44) 0.83 (0.49, 1.21) 1.25 (0.79, 1.76) 1.19 (0.77, 1.63) 0.96 (0.66, 1.28) 
FGFR2 rs2981579 1.10 (0.90, 1.33) 1.02 (0.68, 1.44) 1.59 (0.96, 2.27) 1.29 (0.91, 1.72) 1.00 (0.74, 1.24) 
FGFR2 rs1078806 1.18 (0.89, 1.44) 0.83 (0.50, 1.21) 1.26 (0.79, 1.80) 1.21 (0.82, 1.66) 0.98 (0.68, 1.28) 
FGFR2 rs2981578 1.15 (0.86, 1.48) 1.18 (0.67, 1.82) 1.62 (0.84, 2.60) 1.34 (0.82, 1.91) 1.13 (0.76, 1.53) 
FGFR2 rs1219648 1.19 (0.95, 1.45) 0.95 (0.60, 1.35) 1.38 (0.87, 1.96) 1.71 (1.17, 2.32) 1.09 (0.81, 1.39) 
FGFR2 rs2912774 1.14 (0.91, 1.41) 1.04 (0.66, 1.47) 1.80 (1.15, 2.71) 1.44 (1.00, 1.93) 1.01 (0.74, 1.30) 
FGFR2 rs2936870 1.15 (0.93, 1.38) 1.09 (0.69, 1.55) 1.73 (1.01, 2.56) 1.49 (1.04, 2.02) 0.97 (0.73, 1.23) 
FGFR2 rs2420946 1.06 (0.85, 1.29) 0.99 (0.62, 1.39) 1.70 (1.04, 2.44) 1.50 (1.00, 1.98) 0.95 (0.71, 1.21) 
FGFR2 rs2162540 1.14 (0.90, 1.37) 1.03 (0.65, 1.48) 1.71 (1.04, 2.48) 1.58 (1.08, 2.11) 1.02 (0.75, 1.28) 
FGFR2 rs2981582 1.16 (0.94, 1.42) 1.05 (0.67, 1.46) 1.65 (1.08, 2.33) 1.19 (0.82, 1.60) 1.00 (0.75, 1.28) 
FGFR2 rs3135718 1.14 (0.92, 1.38) 1.18 (0.73, 1.66) 1.64 (1.00, 2.36) 1.58 (1.11, 2.13) 1.00 (0.75, 1.26) 
10q rs10510126 0.97 (0.71, 1.25) 1.15 (0.58, 1.74) 1.24 (0.70, 1.92) 0.94 (0.60, 1.32) 1.17 (0.78, 1.69) 
ATM rs1801516 1.19 (0.69, 1.79) 0.88 (0.38, 1.43) 1.16 (0.52, 1.89) 1.16 (0.51, 1.82) 0.94 (0.49, 1.47) 
ATM rs664143 1.15 (0.91, 1.39) 0.99 (0.61, 1.34) 0.85 (0.54, 1.18) 1.03 (0.73, 1.37) 0.95 (0.71, 1.22) 
ATM rs170548 0.92 (0.62, 1.20) 0.78 (0.39, 1.28) 0.73 (0.36, 1.16) 1.07 (0.63, 1.56) 1.01 (0.65, 1.44) 
ATM rs3092993 1.19 (0.69, 1.79) 0.88 (0.38, 1.43) 1.16 (0.52, 1.89) 1.16 (0.51, 1.82) 0.94 (0.49, 1.47) 
LSP1 rs3817198 0.87 (0.65, 1.11) 0.97 (0.56, 1.43) 1.13 (0.69, 1.61) 1.30 (0.90, 1.79) 1.00 (0.66, 1.35) 
LSP1 rs909116 0.91 (0.72, 1.12) 0.98 (0.58, 1.40) 1.47 (0.88, 2.16) 0.95 (0.65, 1.26) 1.10 (0.77, 1.43) 
H19 rs2107425 0.94 (0.75, 1.15) 0.92 (0.60, 1.30) 0.88 (0.57, 1.22) 0.93 (0.64, 1.22) 0.87 (0.65, 1.11) 
TNRC9/TOX3 rs8049149 0.98 (0.49, 1.52) 1.10 (0.44, 1.89) 1.11 (0.47, 1.90) 0.73 (0.23, 1.20) 0.81 (0.34, 1.33) 
TNRC9/TOX3 rs16951186 1.00 (0.74, 1.27) 1.32 (0.77, 1.87) 0.85 (0.48, 1.27) 0.75 (0.44, 1.05) 0.93 (0.64, 1.24) 
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TNRC9/TOX3 rs8051542 1.05 (0.81, 1.29) 0.90 (0.56, 1.28) 1.21 (0.74, 1.69) 1.44 (1.03, 1.96) 0.81 (0.57, 1.06) 
TNRC9/TOX3 rs12443621 0.88 (0.70, 1.05) 1.17 (0.72, 1.65) 0.88 (0.57, 1.23) 1.01 (0.73, 1.34) 0.88 (0.65, 1.12) 
TNRC9/TOX3 rs3803662 0.94 (0.76, 1.15) 1.10 (0.68, 1.53) 0.87 (0.56, 1.23) 1.19 (0.84, 1.58) 0.96 (0.73, 1.24) 
TNRC9/TOX3 rs4784227 1.36 (0.92, 1.81) 0.89 (0.43, 1.43) 1.02 (0.49, 1.61) 1.65 (0.92, 2.47) 0.77 (0.43, 1.12) 
TNRC9/TOX3 rs3104746 1.52 (1.14, 1.90) 1.12 (0.65, 1.64) 1.26 (0.73, 1.83) 1.16 (0.77, 1.60) 1.51 (1.02, 1.96) 
TNRC9/TOX3 rs3112562 1.21 (0.93, 1.47) 1.27 (0.80, 1.75) 1.17 (0.77, 1.63) 0.87 (0.60, 1.14) 1.31 (0.96, 1.68) 
TNRC9/TOX3 rs9940048 1.21 (0.94, 1.46) 0.93 (0.60, 1.33) 1.38 (0.88, 1.97) 1.14 (0.79, 1.54) 0.89 (0.64, 1.15) 
TP53 rs9894946 1.03 (0.64, 1.44) 0.88 (0.42, 1.40) 0.99 (0.47, 1.67) 1.18 (0.57, 1.82) 1.32 (0.67, 2.11) 
TP53 rs1614984 0.97 (0.77, 1.16) 1.03 (0.66, 1.41) 0.93 (0.60, 1.28) 1.00 (0.70, 1.30) 1.15 (0.84, 1.45) 
TP53 rs12951053 0.97 (0.69, 1.29) 1.34 (0.73, 2.06) 0.81 (0.40, 1.26) 1.31 (0.82, 1.86) 0.85 (0.51, 1.21) 
TP53 rs2909430 1.05 (0.82, 1.28) 1.29 (0.84, 1.79) 1.10 (0.69, 1.54) 0.89 (0.59, 1.18) 1.07 (0.79, 1.36) 
TP53 rs1042522 1.16 (0.92, 1.41) 0.77 (0.48, 1.08) 0.87 (0.55, 1.23) 0.84 (0.57, 1.11) 1.03 (0.76, 1.31) 
TP53 rs8079544 0.95 (0.69, 1.26) 1.12 (0.60, 1.75) 0.70 (0.37, 1.04) 0.75 (0.44, 1.05) 0.99 (0.61, 1.37) 
COX11 rs7222197 1.08 (0.87, 1.32) 1.19 (0.76, 1.68) 1.05 (0.69, 1.45) 1.02 (0.71, 1.35) 1.17 (0.86, 1.49) 
COX11 rs6504950 1.08 (0.87, 1.29) 1.21 (0.77, 1.71) 1.06 (0.70, 1.46) 0.99 (0.69, 1.30) 1.16 (0.87, 1.51) 
*Estimates generated using polytomous logistic regression adjusting for age at diagnosis/selection and proportion African ancestry. 
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Figure 31: Odds ratios and 95% posterior intervals for FGFR2 and TNRC9/TOX3 
SNPs for CBCS whites (left) and African Americans (right) 
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Table 21: Maximum likelihood odds ratios and 95% confidence intervals for the association between the selected single 
nucleotide polymorphisms (SNPs) and each breast cancer subtype, relative to controls* 
 
Gene SNP Luminal A N=700 
Luminal B 
N=122 
HER2+/ER- 
N=98 
Unclassified 
N=133 
Basal-like 
N=207 
1p12 rs11249433 1.10 (0.95, 1.28) 1.05 (0.78, 1.42) 1.15 (0.82, 1.61) 1.35 (1.00, 1.82) 1.12 (0.87, 1.44) 
CASP8 rs1045485 1.12 (0.91, 1.39) 0.98 (0.64, 1.49) 0.92 (0.58, 1.45) 1.38 (0.85, 2.24) 1.16 (0.80, 1.69) 
CASP8 rs17468277 1.14 (0.92, 1.41) 0.93 (0.61, 1.40) 0.89 (0.56, 1.42) 1.41 (0.86, 2.33) 1.13 (0.78, 1.65) 
2q35 rs13387042 1.19 (1.04, 1.37) 0.98 (0.74, 1.29) 0.96 (0.70, 1.30) 1.10 (0.84, 1.45) 0.91 (0.73, 1.14) 
2p rs4666451 0.98 (0.85, 1.12) 1.03 (0.77, 1.37) 1.18 (0.85, 1.64) 1.28 (0.96, 1.72) 1.19 (0.94, 1.51) 
SLC4A7 rs4973768 0.97 (0.85, 1.11) 1.01 (0.77, 1.32) 0.88 (0.65, 1.19) 0.91 (0.70, 1.18) 0.97 (0.78, 1.20) 
4p rs12505080 1.20 (1.03, 1.39) 1.18 (0.87, 1.60) 1.22 (0.87, 1.72) 0.86 (0.62, 1.20) 0.99 (0.76, 1.28) 
TLR1 rs7696175 1.21 (1.04, 1.41) 0.99 (0.73, 1.36) 0.72 (0.49, 1.05) 1.10 (0.79, 1.53) 1.33 (1.02, 1.73) 
MRPS30 rs4415084 1.12 (0.98, 1.29) 1.06 (0.80, 1.40) 1.20 (0.88, 1.64) 1.10 (0.84, 1.43) 1.20 (0.96, 1.51) 
MRPS30 rs10941679 1.11 (0.95, 1.30) 0.91 (0.66, 1.27) 1.04 (0.73, 1.49) 0.95 (0.69, 1.31) 1.24 (0.97, 1.59) 
5p12 rs981782 0.89 (0.77, 1.04) 0.83 (0.61, 1.13) 1.09 (0.76, 1.56) 0.93 (0.67, 1.29) 1.08 (0.82, 1.41) 
5q rs30099 1.08 (0.88, 1.33) 1.05 (0.69, 1.61) 1.17 (0.75, 1.83) 0.85 (0.56, 1.30) 0.99 (0.71, 1.38) 
MAP3K1 rs889312 1.18 (1.03, 1.36) 1.04 (0.78, 1.40) 1.00 (0.72, 1.39) 1.09 (0.82, 1.44) 0.88 (0.69, 1.12) 
ESR1 rs2046210 1.04 (0.90, 1.19) 1.09 (0.82, 1.44) 1.36 (1.00, 1.86) 1.18 (0.90, 1.54) 1.33 (1.07, 1.67) 
ESR1 rs851974 0.89 (0.77, 1.02) 1.16 (0.87, 1.55) 0.81 (0.58, 1.14) 0.86 (0.64, 1.16) 0.93 (0.73, 1.19) 
ESR1 rs2077647 0.95 (0.83, 1.08) 0.99 (0.75, 1.30) 0.95 (0.71, 1.29) 0.92 (0.71, 1.20) 0.95 (0.77, 1.18) 
ESR1 rs2234693 0.89 (0.78, 1.02) 0.94 (0.72, 1.24) 1.01 (0.75, 1.36) 0.81 (0.62, 1.05) 0.96 (0.78, 1.20) 
ESR1 rs1801132 1.09 (0.92, 1.29) 0.86 (0.62, 1.20) 0.93 (0.64, 1.37) 1.00 (0.70, 1.41) 0.81 (0.62, 1.06) 
ESR1 rs3020314 1.02 (0.89, 1.17) 1.26 (0.95, 1.68) 1.09 (0.79, 1.50) 0.98 (0.74, 1.29) 1.13 (0.90, 1.42) 
ESR1 rs3798577 0.97 (0.85, 1.10) 1.04 (0.80, 1.36) 0.77 (0.57, 1.03) 1.10 (0.86, 1.42) 0.99 (0.81, 1.23) 
ECHDC1 rs2180341 0.98 (0.85, 1.14) 0.99 (0.73, 1.36) 1.03 (0.73, 1.44) 0.94 (0.70, 1.26) 1.01 (0.79, 1.29) 
RELN rs17157903 0.99 (0.82, 1.21) 1.07 (0.73, 1.58) 0.65 (0.39, 1.10) 0.98 (0.66, 1.45) 1.13 (0.83, 1.54) 
8q24 rs13281615 1.04 (0.91, 1.18) 0.98 (0.75, 1.29) 1.14 (0.84, 1.54) 1.08 (0.84, 1.40) 0.99 (0.79, 1.22) 
8q24 rs1562430 1.06 (0.93, 1.22) 0.93 (0.71, 1.22) 1.24 (0.92, 1.68) 1.09 (0.84, 1.41) 1.08 (0.87, 1.34) 
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CDKN2A/B rs3731257 0.92 (0.77, 1.08) 0.85 (0.60, 1.21) 0.96 (0.66, 1.41) 0.89 (0.62, 1.26) 0.88 (0.66, 1.18) 
CDKN2A/B rs3731249 0.97 (0.61, 1.53) 1.14 (0.49, 2.65) 1.30 (0.52, 3.27) 0.69 (0.22, 2.20) 0.89 (0.38, 2.07) 
CDKN2A/B rs518394 0.98 (0.84, 1.14) 1.00 (0.74, 1.36) 0.69 (0.48, 1.00) 1.05 (0.76, 1.45) 1.16 (0.89, 1.51) 
CDKN2A/B rs564398 1.00 (0.86, 1.16) 1.03 (0.75, 1.40) 0.73 (0.50, 1.06) 1.09 (0.79, 1.52) 1.11 (0.85, 1.45) 
CDKN2A/B rs1011970 1.12 (0.96, 1.30) 0.88 (0.63, 1.24) 0.87 (0.60, 1.25) 0.82 (0.60, 1.12) 1.13 (0.89, 1.44) 
CDKN2A/B rs10757278 1.05 (0.91, 1.21) 1.07 (0.80, 1.44) 1.02 (0.74, 1.41) 1.26 (0.93, 1.70) 1.11 (0.87, 1.42) 
CDKN2A/B rs10811661 0.93 (0.77, 1.13) 1.00 (0.68, 1.48) 0.71 (0.43, 1.17) 0.77 (0.50, 1.18) 1.10 (0.80, 1.51) 
ANKRD16 rs2380205 1.02 (0.90, 1.17) 1.07 (0.81, 1.40) 1.10 (0.82, 1.48) 0.76 (0.59, 0.98) 0.93 (0.75, 1.16) 
ZNF365 rs10995190 1.02 (0.85, 1.22) 0.76 (0.54, 1.08) 0.75 (0.52, 1.09) 1.30 (0.89, 1.90) 0.92 (0.70, 1.22) 
ZMIZ1 rs704010 1.11 (0.95, 1.29) 1.46 (1.08, 1.97) 1.49 (1.06, 2.08) 0.98 (0.71, 1.35) 1.41 (1.09, 1.82) 
FGFR2 rs1896395 1.05 (0.80, 1.39) 0.82 (0.44, 1.54) 1.53 (0.89, 2.62) 1.05 (0.68, 1.63) 1.08 (0.74, 1.56) 
FGFR2 rs3750817 1.37 (1.17, 1.59) 1.34 (0.98, 1.83) 1.29 (0.90, 1.85) 1.31 (0.94, 1.81) 1.04 (0.80, 1.34) 
FGFR2 rs10736303 1.35 (1.17, 1.57) 1.38 (1.02, 1.86) 1.33 (0.95, 1.86) 1.45 (1.07, 1.98) 1.00 (0.78, 1.27) 
FGFR2 rs11200014 1.28 (1.11, 1.47) 1.09 (0.82, 1.45) 1.25 (0.91, 1.72) 1.51 (1.15, 1.98) 0.87 (0.68, 1.11) 
FGFR2 rs2981579 1.28 (1.12, 1.46) 1.13 (0.86, 1.48) 1.42 (1.05, 1.91) 1.54 (1.19, 1.99) 0.92 (0.75, 1.14) 
FGFR2 rs1078806 1.26 (1.10, 1.45) 1.09 (0.82, 1.46) 1.26 (0.92, 1.73) 1.50 (1.14, 1.97) 0.87 (0.68, 1.11) 
FGFR2 rs2981578 1.37 (1.18, 1.58) 1.39 (1.03, 1.87) 1.44 (1.03, 2.03) 1.48 (1.09, 2.01) 1.01 (0.79, 1.29) 
FGFR2 rs1219648 1.31 (1.15, 1.50) 1.12 (0.85, 1.46) 1.31 (0.98, 1.77) 1.76 (1.36, 2.28) 0.96 (0.78, 1.20) 
FGFR2 rs2912774 1.28 (1.12, 1.46) 1.13 (0.86, 1.47) 1.51 (1.12, 2.04) 1.55 (1.19, 2.00) 0.91 (0.73, 1.13) 
FGFR2 rs2936870 1.28 (1.12, 1.46) 1.15 (0.88, 1.50) 1.49 (1.10, 2.00) 1.58 (1.22, 2.05) 0.90 (0.73, 1.12) 
FGFR2 rs2420946 1.24 (1.09, 1.41) 1.07 (0.82, 1.40) 1.48 (1.10, 1.99) 1.54 (1.19, 2.00) 0.88 (0.71, 1.09) 
FGFR2 rs2162540 1.29 (1.13, 1.47) 1.09 (0.83, 1.43) 1.50 (1.11, 2.01) 1.60 (1.24, 2.06) 0.90 (0.73, 1.12) 
FGFR2 rs2981582 1.28 (1.12, 1.46) 1.13 (0.86, 1.47) 1.49 (1.11, 2.00) 1.33 (1.03, 1.72) 0.91 (0.73, 1.12) 
FGFR2 rs3135718 1.28 (1.13, 1.46) 1.15 (0.88, 1.51) 1.44 (1.08, 1.94) 1.58 (1.23, 2.04) 0.91 (0.74, 1.13) 
10q rs10510126 1.11 (0.90, 1.36) 1.09 (0.71, 1.68) 1.11 (0.69, 1.79) 0.91 (0.62, 1.34) 1.18 (0.83, 1.68) 
ATM rs1800054 1.19 (0.69, 2.06) 1.37 (0.49, 3.88) 1.41 (0.43, 4.60) 0.81 (0.20, 3.40) 1.57 (0.66, 3.75) 
ATM rs1800057 1.31 (0.86, 2.01) 0.86 (0.31, 2.37) 2.02 (0.91, 4.46) 0.99 (0.36, 2.75) 1.24 (0.59, 2.64) 
ATM rs1800058 1.02 (0.62, 1.68) 0.76 (0.24, 2.43) 1.00 (0.31, 3.23) 0.85 (0.26, 2.75) 0.88 (0.35, 2.26) 
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ATM rs1801516 1.01 (0.81, 1.26) 1.04 (0.66, 1.64) 0.89 (0.51, 1.53) 0.92 (0.55, 1.52) 1.00 (0.67, 1.49) 
ATM rs3092992 1.01 (0.70, 1.46) 1.04 (0.49, 2.21) 1.45 (0.68, 3.09) 1.23 (0.58, 2.62) 1.74 (1.00, 3.01) 
ATM rs664143 1.09 (0.95, 1.24) 1.00 (0.76, 1.31) 1.04 (0.77, 1.41) 0.93 (0.72, 1.20) 0.97 (0.78, 1.20) 
ATM rs170548 0.97 (0.83, 1.14) 0.87 (0.63, 1.21) 1.01 (0.71, 1.45) 0.93 (0.67, 1.30) 0.98 (0.75, 1.28) 
ATM rs3092993 1.01 (0.81, 1.27) 1.05 (0.67, 1.64) 0.89 (0.51, 1.53) 0.92 (0.56, 1.52) 1.00 (0.67, 1.49) 
LSP1 rs3817198 1.02 (0.88, 1.19) 0.84 (0.61, 1.16) 1.25 (0.90, 1.75) 1.28 (0.96, 1.72) 1.04 (0.81, 1.35) 
LSP1 rs909116 1.09 (0.95, 1.25) 0.88 (0.67, 1.17) 1.27 (0.92, 1.74) 1.02 (0.78, 1.34) 1.10 (0.88, 1.39) 
H19 rs2107425 1.03 (0.89, 1.18) 0.90 (0.68, 1.19) 0.97 (0.71, 1.32) 0.92 (0.71, 1.21) 0.99 (0.79, 1.24) 
TNRC9/TOX3 rs16951186 1.01 (0.77, 1.31) 1.47 (0.88, 2.45) 0.66 (0.34, 1.27) 0.70 (0.43, 1.13) 0.94 (0.64, 1.37) 
TNRC9/TOX3 rs8051542 1.11 (0.97, 1.27) 0.95 (0.72, 1.26) 1.16 (0.85, 1.57) 1.36 (1.05, 1.77) 0.82 (0.65, 1.03) 
TNRC9/TOX3 rs12443621 1.07 (0.94, 1.22) 0.91 (0.70, 1.20) 1.26 (0.94, 1.70) 0.93 (0.72, 1.20) 1.00 (0.81, 1.23) 
TNRC9/TOX3 rs3803662 1.17 (1.02, 1.35) 1.10 (0.83, 1.46) 1.00 (0.73, 1.36) 1.12 (0.86, 1.47) 0.97 (0.77, 1.21) 
TNRC9/TOX3 rs4784227 1.35 (1.15, 1.59) 1.12 (0.80, 1.58) 1.15 (0.79, 1.69) 1.42 (1.01, 1.98) 0.88 (0.65, 1.21) 
TNRC9/TOX3 rs3104746 1.71 (1.35, 2.16) 1.08 (0.63, 1.84) 1.49 (0.90, 2.47) 1.20 (0.79, 1.82) 1.66 (1.20, 2.29) 
TNRC9/TOX3 rs3112562 1.08 (0.94, 1.25) 0.82 (0.60, 1.13) 1.56 (1.13, 2.14) 0.75 (0.56, 1.01) 1.37 (1.09, 1.72) 
TNRC9/TOX3 rs9940048 1.13 (0.98, 1.31) 0.81 (0.58, 1.12) 1.24 (0.89, 1.72) 0.97 (0.72, 1.30) 0.90 (0.70, 1.15) 
TP53 rs9894946 0.85 (0.70, 1.03) 0.76 (0.52, 1.11) 0.97 (0.61, 1.55) 1.06 (0.68, 1.65) 1.11 (0.77, 1.61) 
TP53 rs1614984 1.01 (0.88, 1.15) 0.92 (0.70, 1.21) 1.01 (0.75, 1.37) 1.03 (0.80, 1.34) 1.14 (0.93, 1.41) 
TP53 rs12951053 0.96 (0.75, 1.22) 1.48 (0.96, 2.29) 1.28 (0.78, 2.10) 1.39 (0.92, 2.08) 1.01 (0.69, 1.49) 
TP53 rs17880604 0.75 (0.40, 1.40) 0.31 (0.04, 2.29) 1.71 (0.60, 4.85) 0.77 (0.18, 3.22) 1.22 (0.47, 3.15) 
TP53 rs1800372 0.96 (0.52, 1.77) 1.81 (0.69, 4.79) 0.48 (0.06, 3.57) 2.27 (0.86, 6.02) 1.14 (0.39, 3.30) 
TP53 rs2909430 1.13 (0.96, 1.34) 1.09 (0.77, 1.55) 1.06 (0.73, 1.54) 0.85 (0.61, 1.18) 1.10 (0.85, 1.42) 
TP53 rs1042522 1.02 (0.88, 1.18) 0.99 (0.73, 1.33) 0.78 (0.57, 1.07) 0.91 (0.69, 1.20) 0.95 (0.75, 1.19) 
TP53 rs8079544 0.96 (0.75, 1.23) 1.71 (0.89, 3.30) 0.63 (0.39, 1.03) 0.80 (0.52, 1.23) 1.03 (0.69, 1.53) 
COX11 rs7222197 1.06 (0.92, 1.22) 1.09 (0.81, 1.47) 1.01 (0.73, 1.39) 1.11 (0.84, 1.47) 1.05 (0.84, 1.32) 
COX11 rs6504950 1.05 (0.91, 1.22) 1.08 (0.80, 1.45) 1.01 (0.73, 1.39) 1.08 (0.82, 1.42) 1.04 (0.83, 1.31) 
*Estimates generated using polytomous logistic regression adjusting for age at diagnosis/selection, proportion African ancestry and self-
reported race. 
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Table 22: Odds ratios and 95% posterior intervals for the association between the selected single nucleotide polymorphisms 
(SNPs) and each breast cancer subtype, relative to controls [SNP log OR~N(0,τ2), τ2 ~ Γ-1(3, 0.2) with mode=0.05]* 
 
Gene SNP Luminal A N=700 
Luminal B 
N=122 
HER2+/ER- 
N=98 
Unclassified 
N=133 
Basal-like 
N=207 
1p12 rs11249433 1.08 (0.93, 1.22) 1.03 (0.77, 1.28) 1.09 (0.82, 1.40) 1.21 (0.90, 1.50) 1.09 (0.84, 1.32) 
CASP8 rs1045485 1.09 (0.89, 1.30) 0.98 (0.71, 1.30) 0.97 (0.64, 1.27) 1.17 (0.82, 1.55) 1.11 (0.79, 1.40) 
CASP8 rs17468277 1.11 (0.91, 1.33) 0.97 (0.68, 1.26) 0.97 (0.66, 1.28) 1.21 (0.83, 1.65) 1.07 (0.78, 1.39) 
2q35 rs13387042 1.17 (1.02, 1.31) 1.00 (0.76, 1.24) 0.98 (0.73, 1.20) 1.09 (0.86, 1.34) 0.93 (0.75, 1.11) 
2p rs4666451 0.96 (0.85, 1.10) 1.02 (0.80, 1.28) 1.11 (0.83, 1.42) 1.19 (0.92, 1.50) 1.14 (0.92, 1.39) 
SLC4A7 rs4973768 0.98 (0.86, 1.10) 1.01 (0.80, 1.24) 0.94 (0.70, 1.18) 0.94 (0.72, 1.15) 1.00 (0.82, 1.18) 
4p rs12505080 1.17 (1.00, 1.34) 1.11 (0.83, 1.42) 1.13 (0.81, 1.48) 0.89 (0.68, 1.14) 0.98 (0.77, 1.20) 
TLR1 rs7696175 1.19 (1.03, 1.37) 1.01 (0.76, 1.25) 0.82 (0.59, 1.06) 1.04 (0.77, 1.33) 1.23 (0.96, 1.54) 
MRPS30 rs4415084 1.10 (0.96, 1.24) 1.04 (0.80, 1.29) 1.14 (0.85, 1.46) 1.07 (0.84, 1.32) 1.15 (0.93, 1.39) 
MRPS30 rs10941679 1.10 (0.95, 1.27) 0.94 (0.71, 1.17) 1.03 (0.77, 1.33) 0.96 (0.70, 1.21) 1.17 (0.94, 1.45) 
5p12 rs981782 0.91 (0.78, 1.04) 0.91 (0.68, 1.12) 1.08 (0.81, 1.40) 0.98 (0.74, 1.23) 1.07 (0.85, 1.33) 
5q rs30099 1.09 (0.90, 1.29) 1.04 (0.76, 1.38) 1.08 (0.75, 1.44) 0.93 (0.64, 1.24) 1.01 (0.74, 1.26) 
MAP3K1 rs889312 1.16 (1.00, 1.31) 1.03 (0.80, 1.31) 1.00 (0.75, 1.27) 1.06 (0.81, 1.33) 0.90 (0.73, 1.10) 
ESR1 rs2046210 1.02 (0.89, 1.14) 1.06 (0.82, 1.33) 1.26 (0.94, 1.59) 1.13 (0.87, 1.39) 1.25 (0.99, 1.51) 
ESR1 rs851974 0.91 (0.79, 1.03) 1.11 (0.85, 1.39) 0.88 (0.63, 1.11) 0.91 (0.71, 1.15) 0.95 (0.76, 1.15) 
ESR1 rs2077647 0.95 (0.83, 1.06) 1.00 (0.78, 1.22) 0.98 (0.75, 1.20) 0.96 (0.76, 1.16) 0.97 (0.80, 1.16) 
ESR1 rs2234693 0.91 (0.79, 1.03) 0.97 (0.77, 1.21) 1.01 (0.76, 1.25) 0.86 (0.65, 1.04) 0.97 (0.80, 1.16) 
ESR1 rs1801132 1.09 (0.93, 1.27) 0.94 (0.71, 1.20) 0.97 (0.69, 1.25) 1.02 (0.73, 1.30) 0.87 (0.66, 1.07) 
ESR1 rs3020314 1.01 (0.88, 1.13) 1.18 (0.92, 1.48) 1.06 (0.80, 1.37) 0.98 (0.76, 1.20) 1.10 (0.88, 1.31) 
ESR1 rs3798577 0.97 (0.85, 1.10) 1.05 (0.84, 1.29) 0.84 (0.63, 1.05) 1.09 (0.87, 1.33) 1.00 (0.82, 1.18) 
ECHDC1 rs2180341 0.98 (0.86, 1.12) 1.01 (0.78, 1.25) 1.03 (0.75, 1.31) 0.97 (0.76, 1.19) 1.01 (0.81, 1.22) 
RELN rs17157903 1.01 (0.83, 1.19) 1.06 (0.76, 1.37) 0.83 (0.57, 1.10) 0.99 (0.73, 1.30) 1.10 (0.86, 1.36) 
8q24 rs13281615 1.03 (0.91, 1.16) 0.99 (0.77, 1.23) 1.09 (0.82, 1.36) 1.06 (0.84, 1.30) 0.98 (0.81, 1.18) 
8q24 rs1562430 1.05 (0.93, 1.18) 0.96 (0.76, 1.19) 1.15 (0.87, 1.44) 1.05 (0.83, 1.29) 1.06 (0.88, 1.27) 
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CDKN2A/B rs3731257 0.94 (0.80, 1.09) 0.92 (0.67, 1.15) 0.99 (0.70, 1.28) 0.94 (0.68, 1.19) 0.93 (0.71, 1.16) 
CDKN2A/B rs3731249 0.99 (0.67, 1.31) 1.06 (0.56, 1.55) 1.13 (0.67, 1.70) 0.93 (0.54, 1.38) 0.97 (0.60, 1.42) 
CDKN2A/B rs518394 0.99 (0.86, 1.12) 1.01 (0.76, 1.27) 0.81 (0.60, 1.06) 1.03 (0.77, 1.30) 1.13 (0.90, 1.38) 
CDKN2A/B rs564398 1.00 (0.87, 1.14) 1.02 (0.78, 1.27) 0.83 (0.59, 1.07) 1.06 (0.81, 1.35) 1.08 (0.84, 1.34) 
CDKN2A/B rs1011970 1.11 (0.95, 1.28) 0.93 (0.70, 1.17) 0.93 (0.66, 1.20) 0.88 (0.67, 1.11) 1.11 (0.88, 1.35) 
CDKN2A/B rs10757278 1.04 (0.90, 1.18) 1.06 (0.82, 1.34) 1.02 (0.77, 1.29) 1.17 (0.90, 1.46) 1.07 (0.86, 1.30) 
CDKN2A/B rs10811661 0.96 (0.80, 1.13) 1.01 (0.72, 1.31) 0.88 (0.61, 1.17) 0.87 (0.63, 1.14) 1.08 (0.83, 1.36) 
ANKRD16 rs2380205 1.03 (0.90, 1.16) 1.05 (0.82, 1.29) 1.08 (0.83, 1.35) 0.82 (0.63, 1.00) 0.95 (0.78, 1.13) 
ZNF365 rs10995190 1.03 (0.86, 1.21) 0.86 (0.61, 1.12) 0.85 (0.58, 1.13) 1.21 (0.90, 1.59) 0.94 (0.74, 1.20) 
ZMIZ1 rs704010 1.08 (0.93, 1.23) 1.29 (0.97, 1.62) 1.26 (0.91, 1.64) 0.97 (0.72, 1.24) 1.30 (1.02, 1.60) 
FGFR2 rs1896395 1.02 (0.79, 1.26) 0.95 (0.61, 1.30) 1.22 (0.79, 1.67) 1.05 (0.73, 1.37) 1.05 (0.74, 1.36) 
FGFR2 rs3750817 1.30 (1.12, 1.51) 1.23 (0.90, 1.58) 1.18 (0.87, 1.52) 1.22 (0.91, 1.57) 1.02 (0.78, 1.26) 
FGFR2 rs10736303 1.29 (1.13, 1.48) 1.26 (0.95, 1.59) 1.20 (0.90, 1.54) 1.31 (0.98, 1.68) 0.99 (0.79, 1.21) 
FGFR2 rs11200014 1.24 (1.08, 1.41) 1.06 (0.83, 1.34) 1.17 (0.86, 1.48) 1.35 (1.04, 1.69) 0.88 (0.70, 1.06) 
FGFR2 rs2981579 1.25 (1.09, 1.41) 1.11 (0.86, 1.39) 1.31 (0.97, 1.67) 1.41 (1.09, 1.74) 0.92 (0.75, 1.10) 
FGFR2 rs1078806 1.23 (1.08, 1.39) 1.07 (0.83, 1.36) 1.17 (0.87, 1.48) 1.36 (1.04, 1.71) 0.89 (0.70, 1.08) 
FGFR2 rs2981578 1.32 (1.13, 1.51) 1.27 (0.94, 1.62) 1.27 (0.95, 1.66) 1.35 (1.01, 1.75) 1.00 (0.81, 1.21) 
FGFR2 rs1219648 1.28 (1.12, 1.45) 1.08 (0.83, 1.35) 1.24 (0.92, 1.59) 1.58 (1.22, 1.97) 0.96 (0.77, 1.16) 
FGFR2 rs2912774 1.25 (1.08, 1.40) 1.08 (0.85, 1.35) 1.38 (1.03, 1.74) 1.41 (1.10, 1.74) 0.91 (0.74, 1.09) 
FGFR2 rs2936870 1.25 (1.08, 1.41) 1.12 (0.85, 1.42) 1.35 (1.01, 1.72) 1.44 (1.12, 1.80) 0.91 (0.73, 1.09) 
FGFR2 rs2420946 1.22 (1.07, 1.37) 1.05 (0.80, 1.31) 1.36 (1.02, 1.71) 1.42 (1.11, 1.77) 0.89 (0.71, 1.06) 
FGFR2 rs2162540 1.26 (1.10, 1.41) 1.07 (0.82, 1.32) 1.36 (1.01, 1.75) 1.47 (1.14, 1.83) 0.90 (0.75, 1.08) 
FGFR2 rs2981582 1.24 (1.08, 1.40) 1.08 (0.83, 1.35) 1.33 (1.01, 1.68) 1.25 (0.99, 1.55) 0.91 (0.75, 1.09) 
FGFR2 rs3135718 1.25 (1.10, 1.41) 1.12 (0.87, 1.40) 1.31 (0.97, 1.66) 1.44 (1.12, 1.82) 0.91 (0.74, 1.08) 
10q rs10510126 1.08 (0.90, 1.29) 1.07 (0.73, 1.39) 1.06 (0.75, 1.43) 0.95 (0.68, 1.24) 1.12 (0.81, 1.43) 
ATM rs1800054 1.10 (0.74, 1.49) 1.09 (0.61, 1.59) 1.09 (0.52, 1.72) 0.97 (0.54, 1.45) 1.12 (0.64, 1.68) 
ATM rs1800057 1.15 (0.83, 1.54) 0.97 (0.56, 1.39) 1.20 (0.67, 1.80) 0.99 (0.58, 1.46) 1.08 (0.63, 1.54) 
ATM rs1800058 1.04 (0.70, 1.40) 0.96 (0.57, 1.42) 1.03 (0.58, 1.58) 1.02 (0.58, 1.50) 1.00 (0.59, 1.46) 
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ATM rs1801516 1.02 (0.83, 1.22) 1.02 (0.71, 1.34) 0.96 (0.64, 1.30) 0.95 (0.64, 1.28) 1.01 (0.73, 1.29) 
ATM rs3092992 0.96 (0.70, 1.26) 1.00 (0.55, 1.42) 1.10 (0.65, 1.58) 1.08 (0.66, 1.53) 1.26 (0.80, 1.75) 
ATM rs664143 1.08 (0.94, 1.22) 1.00 (0.80, 1.26) 1.03 (0.78, 1.30) 0.96 (0.75, 1.16) 0.99 (0.80, 1.17) 
ATM rs170548 0.98 (0.85, 1.12) 0.92 (0.70, 1.18) 1.02 (0.79, 1.33) 0.95 (0.70, 1.19) 1.00 (0.78, 1.22) 
ATM rs3092993 1.01 (0.81, 1.20) 1.04 (0.72, 1.38) 0.95 (0.66, 1.27) 0.96 (0.66, 1.26) 1.01 (0.71, 1.32) 
LSP1 rs3817198 1.01 (0.88, 1.15) 0.89 (0.66, 1.12) 1.15 (0.85, 1.47) 1.18 (0.92, 1.46) 1.02 (0.82, 1.26) 
LSP1 rs909116 1.08 (0.93, 1.22) 0.93 (0.72, 1.14) 1.17 (0.87, 1.48) 1.03 (0.79, 1.27) 1.08 (0.87, 1.30) 
H19 rs2107425 1.04 (0.91, 1.17) 0.94 (0.73, 1.18) 0.98 (0.75, 1.25) 0.96 (0.76, 1.18) 1.00 (0.81, 1.19) 
TNRC9/TOX3 rs16951186 1.01 (0.78, 1.24) 1.23 (0.77, 1.74) 0.87 (0.55, 1.22) 0.84 (0.55, 1.11) 0.96 (0.69, 1.26) 
TNRC9/TOX3 rs8051542 1.11 (0.98, 1.25) 0.97 (0.74, 1.23) 1.11 (0.83, 1.42) 1.26 (0.99, 1.56) 0.84 (0.68, 1.00) 
TNRC9/TOX3 rs12443621 1.06 (0.94, 1.18) 0.94 (0.74, 1.14) 1.19 (0.90, 1.47) 0.95 (0.76, 1.17) 1.00 (0.81, 1.19) 
TNRC9/TOX3 rs3803662 1.14 (0.99, 1.30) 1.09 (0.85, 1.36) 0.99 (0.74, 1.23) 1.10 (0.85, 1.36) 0.97 (0.79, 1.16) 
TNRC9/TOX3 rs4784227 1.30 (1.11, 1.51) 1.07 (0.76, 1.37) 1.08 (0.78, 1.41) 1.24 (0.88, 1.61) 0.90 (0.66, 1.12) 
TNRC9/TOX3 rs3104746 1.54 (1.20, 1.89) 1.02 (0.68, 1.38) 1.23 (0.80, 1.74) 1.11 (0.75, 1.50) 1.43 (1.02, 1.85) 
TNRC9/TOX3 rs3112562 1.07 (0.92, 1.22) 0.88 (0.67, 1.13) 1.38 (0.99, 1.80) 0.81 (0.61, 1.01) 1.31 (1.05, 1.60) 
TNRC9/TOX3 rs9940048 1.13 (0.98, 1.27) 0.87 (0.66, 1.10) 1.15 (0.86, 1.47) 0.98 (0.78, 1.22) 0.93 (0.74, 1.12) 
TP53 rs9894946 0.87 (0.73, 1.03) 0.87 (0.62, 1.15) 1.01 (0.69, 1.34) 1.06 (0.75, 1.39) 1.08 (0.80, 1.39) 
TP53 rs1614984 1.01 (0.89, 1.14) 0.96 (0.75, 1.18) 1.01 (0.79, 1.27) 1.02 (0.81, 1.24) 1.12 (0.91, 1.33) 
TP53 rs12951053 0.94 (0.74, 1.16) 1.21 (0.84, 1.62) 1.12 (0.74, 1.51) 1.20 (0.85, 1.58) 1.00 (0.70, 1.30) 
TP53 rs17880604 0.91 (0.56, 1.28) 0.90 (0.48, 1.38) 1.16 (0.59, 1.79) 0.99 (0.53, 1.46) 1.08 (0.59, 1.57) 
TP53 rs1800372 0.97 (0.61, 1.35) 1.13 (0.62, 1.68) 0.95 (0.54, 1.45) 1.22 (0.66, 1.92) 1.02 (0.60, 1.51) 
TP53 rs2909430 1.11 (0.95, 1.29) 1.07 (0.78, 1.36) 1.04 (0.76, 1.33) 0.91 (0.68, 1.14) 1.09 (0.87, 1.33) 
TP53 rs1042522 1.04 (0.90, 1.19) 1.00 (0.76, 1.26) 0.85 (0.63, 1.07) 0.95 (0.74, 1.17) 0.97 (0.77, 1.18) 
TP53 rs8079544 0.97 (0.75, 1.20) 1.26 (0.81, 1.79) 0.80 (0.53, 1.10) 0.90 (0.61, 1.24) 1.04 (0.74, 1.39) 
COX11 rs7222197 1.05 (0.92, 1.19) 1.07 (0.81, 1.33) 1.00 (0.76, 1.26) 1.07 (0.84, 1.30) 1.04 (0.85, 1.24) 
COX11 rs6504950 1.05 (0.91, 1.19) 1.06 (0.83, 1.32) 1.02 (0.77, 1.29) 1.05 (0.83, 1.32) 1.04 (0.84, 1.26) 
*Estimates generated using polytomous logistic regression adjusting for age at diagnosis/selection, proportion African ancestry and self-
reported race. 
 
  
6. Discussion 
6.1 Summary of findings 
 In this study of race and subtype differences in the effects of previously established 
susceptibility variants on breast cancer risk, I replicated several SNPs in white or African 
American CBCS participants and observed notable differences in subtype-specific genetic 
risk factors. I used Bayesian methods to incorporate prior information and obtain more 
precise effect estimates than would be possible with standard approaches, such as maximum 
likelihood. 
6.1.1 Racial differences in breast cancer susceptibility loci  
 According to the ORs and 95% PIs estimated using Bayesian methods, 18 of 41 
GWAS-identified SNPs replicated in whites and ten of 41 replicated in African Americans. 
None of the candidate gene hits replicated in either race. These findings are summarized in 
Table 23. This table also includes information on whether the ORs reported for CBCS were 
in the same direction as previous studies, regardless of their confidence limits. Because I 
evaluated all SNPs using the a priori risk variant as the index variant, any SNPs with ORs 
greater than one were consistent with previous findings.  
 In whites, I found evidence of positive associations between breast cancer and several 
well-validated GWAS-identified risk variants, including two MRPS30 SNPs (rs4415084 and 
rs10941679) [169, 186, 190, 191, 208, 211, 220, 223, 228, 230], rs889312 on MAP3K1 [162, 
168, 169, 189, 194, 213, 218, 220, 232, 235, 239], several FGFR2 SNPs [162, 168, 169, 186, 
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189-191, 194, 196, 201, 208, 213, 218-220, 222, 223, 229, 232-234, 236, 237, 251-258, 339, 
347, 348], and several TNRC9/TOX3 SNPs [11, 162, 163, 168, 169, 186, 187, 189, 191, 194, 
202, 205, 217-220, 222, 229, 232, 234, 235, 237, 262]. Additionally, I replicated two less-
established GWAS-identified SNPs, rs704010 in ZMIZ1 [189, 247], and rs2107425 on H19 
[194]. As for the remaining SNPs, the large majority of estimated ORs were positive, 
indicating general agreement with the existing literature. This included rs909116 (LSP1) and 
rs1562430 (8q24), two GWAS-identified SNPs that fell just short of replication criteria in 
CBCS whites (Table 23).  
 A few of the non-GWAS, non-candidate gene SNPs were positively associated with 
breast cancer in CBCS whites (Table 24). This included rs10757278 in CDKN2A/B, 
rs3750817, rs11200014, and rs2162540 in FGFR2 and rs3104746 in TNRC9/TOX3. Of these, 
rs2162540, rs10757278 and rs3104746 were novel findings, though rs2162540 was reported 
in a previous CBCS paper [210]. Results for rs3750817 agreed with those from two previous 
case-controls studies [169, 252]. The only CASP8, ATM, or TP53 SNP associated with breast 
cancer was rs9894986 in TP53, which was negatively associated with the disease. The same 
variant allele had a near-null, positive association with disease in Zhang et al [20]. 
 Nine of the ten SNPs that replicated in CBCS African Americans were in FGFR2 
(Table 23). This included rs1219648 [11, 12, 201, 215, 216, 236, 257] and rs2981578 [12, 
214, 215, 258, 259], both of which were associated with the disease in several previous 
studies of African Americans. I also replicated rs2981579, rs2981582 and rs2420946. These 
three variants are known to increase breast cancer susceptibility in whites, but have rarely 
replicated in African Americans [11, 12, 169, 186, 194, 201, 214-216, 236, 257, 258, 259]. 
Barnholtz-Sloan et al. [210] previously reported the associations between breast cancer and 
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rs1219648, rs2981579, rs2981582 and rs2420946 in CBCS African Americans. Barnholtz-
Sloan et al. were also the first to report ORs for rs2912774, rs2936870, and rs3135718, three 
FGFR2 SNPs identified in a GWAS by Easton et al [194]. The ninth FGFR2 SNP to 
replicate in CBCS African Americans was rs10736303. This SNP was also identified in 
Easton et al., but was not included in the previous CBCS analysis. It was positively 
associated with disease in one previously studied African American population [259]. 
 The only other SNP to replicate in African Americans was rs2046210 in ESR1. Most 
previous evaluations of this SNP in African Americans generated near-null ORs for log-
additive models [11, 12, 169, 214-216, 242, 243]. Two other SNPs, rs2107425 (H19) and 
rs12443621 (TNRC9/TOX3), had 95% PIs that excluded the null, but were inversely 
associated with breast cancer and thus inconsistent with the original reports. The ORs for the 
remaining GWAS-identified or candidate gene SNPs were again predominantly positive 
(Table 23), indicating concordance with previous findings. This included both of the SNPs 
with a priori racial differences in risk alleles (rs1045485 on CASP8 and rs3803662 on 
TNRC9/TOX3) and a few SNPs that fell just short of the selected cut-point for replication 
(rs7696175 on TLR1 and rs30099 on chromosome 5q). 
 CBCS is the first study to report statistically significant associations for rs3750817 
and rs2162540 (FGFR2) in African Americans. rs2162540 was previously reported by 
Barnholtz-Sloan et al. [210], but I am the first to do so for rs3750817. I also corroborated 
previous evidence that rs3104746 and rs3112562 (TNRC9/TOX3) are associated with breast 
cancer in African Americans [214, 231] (Table 24).  
 Despite their relative imprecision in this application, the results from the hierarchical 
models support previous claims that these methods can help differentiate individual effects of 
  212 
highly correlated SNPs [326, 328, 330]. Single-level models with the same number of 
parameters will often produce unstable estimates, but hierarchical models can simultaneously 
and stably estimate both haplotype-level and single-SNP effect estimates. 
 For example, even though none of the hierarchically-estimated FGFR2 met the 
criteria for replication, the OR for rs2981579 in whites was notably higher than the rest of the 
SNPs in the 13-SNP FGFR2 LD block. As it is unlikely that each of the FGFR2 SNPs is 
independently associated with disease, the hierarchical results better reflect the presence of 
one or two causal variants in high LD with the other evaluated SNPs.  
 The FGFR2 hierarchical models performed slightly better in African Americans, with 
rs3750817, rs2981578, and rs2420946 demonstrating notably stronger associations than the 
other SNP(s) in block 1, 2 and 3, respectively. This performance improvement may be 
attributable to the anticipated racial differences in LD block size. ORs for SNPs in the other, 
smaller LD blocks were relatively more precise, but contributed little new information. More 
explicit specifications of the incorporated covariance matrices had little impact on point 
estimates or precision in either racial group.  
6.1.2 Subtype differences in breast cancer susceptibility loci 
 I observed some crucial differences in subtype-specific genetic risk factors. The most 
conspicuous differences involved the FGFR2 gene, where most of the 14 evaluated SNPs 
were strongly associated with luminal A, HER2+/ER- and unclassified disease, but none 
were associated with basal-like breast cancer. In the only other study to examine the 
relationship between any FGFR2 SNP and all five IHC subtypes, Broeks et al. [168] also 
observed a null association between rs2981582-T and basal-like disease and a positive 
association between rs2981582-T and luminal A disease. Their luminal B OR was in the 
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same direction as CBCS, but of much greater magnitude. Stevens et al. [167] and Han et al. 
[226] also found near-null associations between rs2981582 and triple negative disease, and 
Han et al. estimated ORs for luminal A and B disease similar to those seen in CBCS. 
Contrary to my findings, however, rs2981582 was not associated with HER2+/ER- disease in 
either study, nor was it associated with unclassified disease in Stevens et al. 
 None of the other FGFR2 SNPs were evaluated using a 5-marker or even a 3-marker 
IHC panel, but many were assessed within categories of a single marker (e.g. ER+ cases 
relative to controls). In general, these studies reported positive associations between the 
FGFR2 SNPs and ER+, ER-, PR+ and HER2- disease [162, 163, 168, 169, 192, 193, 198, 
205, 208, 214, 216, 219, 222, 227, 232, 236, 244, 253, 255, 259, 349] 
 (Table 23 and 24). This included rs3750817, which met the criteria for genome-wide 
significance among women with hormone receptor positive disease [193].  
 Broeks et al. [168], Stevens et al. [167], and Han et al. [226] also evaluated 
rs3803662 in TNRC9/TOX3. This SNP had a positive association with luminal A breast 
cancer in CBCS, which was consistent with the ORs reported by Broeks et al. and Han et al. 
However, these authors also observed associations between rs3803662-T and luminal B and 
HER2+/ER- disease, where I found only a weak association with Luminal B and a near-null 
association with HER2+/ER- disease. Broeks et al. observed an association between 
rs3803662 and basal-like disease, which I did not replicate.  
 I also observed a positive association between rs4784227 (TNRC9/TOX3) and luminal 
A disease, which was consistent with Kim et al.’s [192] assessment of disease risk by ER and 
PR status. Similarly, I found that rs3104746 (TNRC9/TOX3) was associated with luminal A 
and basal-like disease, while Chen et al. [214] observed positive associations between 
  214 
rs3104746-A and both ER+ and ER- breast cancer, relative to controls. The only other 
TNRC9/TOX3 SNP with prior evidence of an association with a particular breast cancer 
subtype was rs8051542. This SNP was positively associated with unclassified disease in 
CBCS, but was not associated with ER- disease in any of three previous studies [205, 266, 
349]. In contrast, all three reported positive associations between rs8051542 and ER+ breast 
cancer. 
  I found a positive association between rs2046210 (ESR1) and triple-negative breast 
cancer. This association was previously reported by Han et al [226]. I also replicated Han et 
al.’s finding that rs889312 (MAP3K1) was associated with luminal A breast cancer, but not 
their findings that rs2046210 and rs4973768 (SLC4A7) were associated with luminal A 
disease. Similarly, I did not replicate their finding that rs2046210 was associated with 
HER2+/ER- disease.  
 Broeks et al. [168] found that rs3817198 (LSP1) was associated with triple-negative 
breast cancer, but the same SNP was not associated with any subtype in the CBCS 
population. Further, where Broeks et al. found that rs13387042 (2q35) and rs889312 
(MAP3K1) were associated with triple-negative breast cancer and that rs13387042 was 
associated with basal-like breast cancer, I found that these two SNPs were associated with 
luminal A breast cancer only. None of the susceptibility loci for triple-negative breast cancer 
highlighted by Stevens et al. were genotyped in CBCS [167].  
 According to my results, SNPs in 4p, TLR1, ANKRD16, and ZM1Z1 may also be 
related to subtype-specific etiology. However, as with the majority of FGFR2 and 
TNRC9/TOX3 SNPs, it is difficult to compare my results with previous reports, as most prior 
investigations of this topic were limited to single hormone receptor comparisons [189, 192, 
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193, 198, 214, 216, 227, 247]. I have attempted to summarize the findings for all included 
SNPs in Tables 23 and 24. In general, those associated with luminal A breast cancer in CBCS 
were associated with ER+ disease in previous investigations. Few previous studies found 
SNPs associated with triple-negative or ER- disease, and those that did were not replicated in 
this investigation.   
 In the race-stratified subtype analyses, I found evidence that rs10757278 
(CDKN2A/B) was differentially related to basal-like disease by race and that a few other 
SNP-subtype associations were much stronger when the analysis was limited to whites. This 
included rs1562430 (8q24) and rs3112562 and rs12443621 (TNRC9/TOX3). These findings 
support the hypothesis that there are both race and subtype differences in breast cancer 
susceptibility variants. Additional studies are needed to further clarify the role of these SNPs 
and the other potentially important genes identified in my investigation.  
 
6.2 Strengths and limitations  
 The CBCS has some inherent limitations. These include selection bias, exposure and 
outcome misclassification, and informative missing data. Inappropriately specified genetic 
models and the inclusion of in situ breast cancer cases may also limit the validity of these 
particular analyses.   
 Differences in response rates by case-control status, race, and age may have 
introduced selection bias. Further, non African Americans were more likely than African 
Americans to provide blood for genotyping, but were less likely to have tumor tissue 
available for IHC analysis. Women with early stage disease were also less likely to provide 
tumor tissue. 
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 Including race and age as model covariates should limit the bias resulting from this 
potentially informative missing data. However, given that women with more advanced 
disease were more likely to provide tumor tissue, the subtype-specific analyses may still be 
biased if one or more of the included SNPs is related to disease aggressiveness or medical 
care utilization. Though not included here, the extent of this bias could be explored further 
using inverse-probability of selection weighting or Bayesian imputation methods. 
 Despite quality control checks, some genotyping errors may be present. My decision 
to retain SNPs that violated HWE may have exacerbated this issue, but I only did so after 
verifying genotype clustering images and considering other potential threats to validity. This 
process led me to drop rs614367 (MYEOV). This particular SNP was not in HWE in white 
controls (p=0.05) and closer inspection of the TaqMan genotype results plots revealed 
disparate clusters for the homozygous rare genotype. I also discovered that the primer used 
for the analysis included a second polymorphic site. As this could result in failed 
amplification and allelic drop-out, I compared the CBCS MAFs for rs614367 to the MAFs in 
HapMap CEU and ASW populations. After finding these incompatible, I decided to exclude 
the SNP from further analysis. The genotype clusters for the remaining six SNPs that failed 
HWE tests formed three distinct clusters with no overlap and were therefore retained.  
 Age and self-identified race were collected and validated for all CBCS participants. I 
accounted for additional variation within self-identified racial groups by adjusting for 
proportion of African ancestry.  
 Classification of incident and in situ breast cancer cases is likely accurate, as disease 
status was first identified using a cancer registry and then confirmed by the participant. 
However, breast cancer subtypes are much more difficult to classify accurately. First of all, 
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as each tumor was stained and interpreted by a pathologist, there may have been inaccuracies 
due to human error. Additionally, even though CBCS investigators decided 81% 
concordance between medical record reports and UNC-run assays of ER and PR status was 
sufficiently high [273], additional misclassification due to inter-laboratory discrepancies in 
staining techniques or positivity cut-points was clearly present. Lastly, there is some 
disagreement in the field as to how best to classify breast cancer subtypes. The 
immunhistochemical markers are themselves proxies for gene expression patterns [39, 40] 
and while the majority of investigators support the subtype definitions described here, many 
authors do not differentiate between basal-like and unclassified breast cancer [8, 79, 85, 117], 
while others note that additional markers, such as claudin or Ki-67, may also be important 
[43- 46, 57, 350].  
 I included in situ cases to increase sample size and improve precision. Because most 
studies of genetic risk factors for breast cancer are limited to invasive breast cancer cases it is 
unclear whether the findings are generalizable to in situ cases. The inclusion of in situ cases 
could be particularly problematic if any of the included SNPs are associated with disease 
aggressiveness or if genotype affects the probability that an in situ case progresses into an 
invasive case. However, there is strong evidence that in situ tumors have similar subtype [4, 
89, 346] and risk profiles [4, 341, 345] to invasive cases, and can therefore be included in the 
proposed analysis as early stage cases without substantially biasing the results.  
 Although I included MLE ORs estimated using co-dominant modeling assumptions, I 
assumed additive models for all Bayesian analyses and drew inferences from additive models 
only. This approach is consistent with the existing literature, as most of the GWAS and 
replication studies cited in this report provided effects for additive models. If the true effect 
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of the causal variant did not follow an additive pattern, the reported OR estimates would be 
biased and my inferences would be incorrect. While it is possible to do statistical tests to 
compare model fit under different assumptions (e.g. Akaike Information Criteria [AIC]), 
such global tests are underpowered to detect subtle differences in fit [291] and are rarely 
used. Alternatively, I could have incorporated model uncertainty using Bayesian methods, as 
proposed by Stephens et al [15]. However, because the quality and quantity of a priori 
information varied widely among the selected SNPs, it would have been difficult to construct 
priors for many of the included SNPs. 
 The SNPs selected for this analysis were both a strength and a limitation. I was able 
to evaluate the role of a number of important GWAS and candidate gene hits, but the panel 
was incomplete and I was not able to include any new discoveries. Additionally, while I 
believe that the inclusion of more finely mapped regions augmented theses analyses, only a 
few of the selected regions included tag SNPs in addition to the variant of interest. In 
particular, this limited my ability to fully explore the performance of the hierarchical 
methods within high LD regions.  
 The diverse composition of CBCS is a major strength of this study. Study 
investigators originally chose to include large numbers of African American women so they 
could explore racial differences in breast cancer risk factors and breast cancer related 
outcomes. Because subtype distributions vary by race, this recruitment scheme inadvertently 
ensured that all five intrinsic subtypes were well represented in the CBCS population. In this 
way, the study is uniquely suited to answer questions about both race and subtype differences 
in etiology and prognosis. Studying the disease in racial groups with unique LD patterns also 
provided information that may help pinpoint causal variants. To date, this is one of the 
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largest population-based studies of African Americans and also one of the largest studies to 
evaluate breast cancer subtypes using a five-marker IHC panel. 
 A strength of these particular analyses was the use of Bayesian methods. Breast 
cancer susceptibility loci are a commonly studied topic and Bayesian methods offered a way 
to make use of the plethora of prior information to generate more precise estimates. I believe 
the priors specified here were reasonable given our existing knowledge of breast cancer 
susceptibility variants and linkage disequilibrium patterns.  Therefore, the results presented 
here should be more accurate, on average, than those produced using traditional frequentist 
methods. Further, by selecting only null-centered, informative priors for the full Bayes 
analysis, any bias resulting from these methods should be towards the null [17]. In this way, 
this application of Bayesian methods also reduces the probability of observing false positive 
associations. Similarly, hierarchical models shrink everything towards the group-level mean, 
which should also help control type I error.  
 Lastly, while I do believe that my prior assumptions were reasonable, I provided a 
sensitivity analysis that included the MLE estimates as well as Bayesian estimates given 
more informative priors. These supplementary analyses demonstrated the relative influence 
of the prior assumptions.  
 
6.3 Public health implications 
 While I did not identify any completely new susceptibility loci, I replicated several 
previously established risk variants and explored some of the potentially causal regions more 
thoroughly. For some SNPs, I reported novel race- or subtype-specific effect estimates. As 
most previous attempts to isolate effects within African Americans or for individual subtypes 
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have produced mostly imprecise and inconsistent findings, my work may help advance our 
understanding of breast cancer etiology.  
 Additionally, since LD patterns vary by race, these race-stratified analyses may help 
to narrow down the specific region or regions of the candidate genes that are most strongly 
associated with the disease of interest. Improved understanding of genetic risk factors and 
disease etiology can ultimately improve breast cancer control and prevention by identifying 
potential targets for directed therapies and for locating high-risk individuals. Subsequent 
research on environmental or treatment-related factors that interact with these genes could 
contribute further public health benefit.  
 This research also has potential methodological impacts. For both manuscripts, I 
provided a simple, yet descriptive discussion of the merits of Bayesian analysis and how to 
implement the selected methods. This included SAS code for hierarchical models and 
Bayesian polytomous logistic regression, both of which are sparsely documented. As these 
methods are well accepted but rarely used in the applied epidemiology literature, I hope that 
my work will encourage others to consider them for similar investigations.  
 
6.4 Future research 
 The breast cancer genetic epidemiology field is large and evolves quickly. The 21 
GWAS hits selected for this analysis were from the first 8 GWAS. Since then, another 15 
GWAS have been published, bringing the total count to 58 hits [183]. It would be interesting 
to see how these more recently identified SNPs replicate, especially within different racial 
groups and disease subtypes. There were also several other candidate genes in Zhang et al. 
[20] that merit further study.  
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 This ever-expanding body of literature could also be used to formulate more 
informative, SNP-specific priors than were selected for the analysis presented here. For 
example, one could conduct meta-analyses of each of the selected SNPs and use these results 
to choose tailored prior distributions. Such an approach would further improve the precision 
and overall accuracy of the estimated effects, as long as the chosen priors more accurately 
reflected the true effect and the selected variances were at least as informative as those 
specified in the previously described analyses. However, such an approach would require 
extensive literature reviews of each of the candidate SNPs, with careful consideration of all 
potential biases, including publication bias, selection bias, and population stratification.  
 Our understanding of breast cancer subtypes is quickly evolving. While my use of the 
five IHC marker definition is more refined than most previous investigations, it does not 
capture the true heterogeneity of the disease [47]. As these subtype definitions improve, I 
hope that we will start to see even more convincing evidence of etiologic differences between 
tumor types.  
 In terms of methodological pursuits, I can see myself applying Bayesian methods in 
several other genetic epidemiology scenarios, including further replication studies, gene-
environment or gene-gene interaction studies, and fine-mapping investigations. While it 
might be more difficult to define and justify priors for environmental factors, which may 
have larger or less predictable effects than SNPs, the breast cancer literature includes copious 
investigations and meta-analyses from which to draw informative priors. As both gene-
environment and gene-gene interaction analyses are often vastly underpowered, the field 
would benefit from the improved precision of Bayesian approaches. Similarly, I think that 
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fine-mapping investigations would benefit from hierarchical approaches, as standard MLE 
methods cannot accurately accommodate high between-SNP correlations.  
 The ultimate goal of any of these proposed directions is to learn more about breast 
cancer etiology so that we may better prevent, detect, and treat the disease. My main 
aspiration is to do what I can to contribute to this worthy endeavor.  
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Table 23: Summary of replication results and subtype-specific findings for GWAS-identified and candidate gene SNP hits 
 
Chrom
-osome 
Gene or 
gene 
region 
SNP 
EA AA 
Previous subtype findings CBCS subtype findings  Replica
tion?* OR>1.0? 
Replica
tion?* 
OR>1.0
? 
1 1p12 rs11249433 No Yes No Yes strongest association in Luminal A and B cancers null 
2 CASP8 rs1045485 No Yes No Yes Equally associated with all subtypes null 
2 2p rs4666451 No Yes No Yes evidence of association with ER+ and ER- disease null 
2 2q35 rs13387042 No Yes No Yes some association with all subtypes 
positively associated 
with luminal A 
3 SLC4A7 rs4973768 No Yes No No 
strongest association in 
Luminal A cancers; no 
association in triple-
negative  
null 
4 4p rs12505080 No Yes No Yes NE positively associated with luminal A 
4 TLR1 rs7696175 No Yes No Yes 
Associated with ER+, ER- 
and HER2- disease in 
Chinese 
positively associated 
with luminal A and 
basal-like, inversely 
associated with 
HER2+/ER- 
5 MRPS30 rs4415084 Yes Yes No Yes 
stronger associations with 
ER+ or PR+ disease; 
mostly null associations 
with ER- or PR- disease 
null 
5 MRPS30 rs10941679 Yes Yes No Yes 
strongest association in 
Luminal A and B cancers; 
null association in triple-
negative cancers 
positively associated 
with basal-like  
5 5p12 rs981782 No No No Yes strongest associations with ER- and HER2- disease null 
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5 5q rs30099 No Yes No Yes 
possible associations with 
ER+, ER- and HER2+ 
disease 
null 
5 MAP3K1 rs889312 Yes Yes No No evidence of association with all subtypes 
positively associated 
with luminal A 
6 ECHDC1 rs2180341 No Yes No No 
predominantly null 
associations with ER and 
PR status 
null 
6 ESR1 rs2046210 No Yes Yes Yes some association with all subtypes 
positively associated 
with basal-like and 
HER2+/ER- 
6 ESR1 rs1801132 No No No Yes NE null 
6 ESR1 rs3020314 No Yes No Yes NE null 
7 RELN rs17157903 No No No Yes NE null 
8 8q24 rs13281615 No Yes No Yes 
strongest association in 
Luminal A and B; null 
association in triple-
negative 
null 
8 8q24 rs1562430 No Yes No Null 
Associated with ER+, ER-, 
PR+, and PR- disease in 
Chinese (one study) 
Positively associated 
with luminal A in whites 
only 
9 CDKN2A/B rs1011970 No Yes No No 
some evidence of 
association with ER+ and 
triple-negative 
null 
10 ANKRD16 rs2380205 No Yes No No 
possible inverse 
association with ER+ 
disease, null association 
with triple negative 
negatively associated 
with unclassified 
10 ZNF365 rs10995190 No Yes No Yes inversely associated with ER+ disease null 
10 ZMIZ1 rs704010 Yes Yes No Yes 
positively associated with 
all ER/PR subtypes, but 
not triple-negative disease 
positively associated 
with basal-like, luminal 
B and HER2+/ER- 
10 FGFR2 rs10736303 Yes Yes Yes Yes evidence of associations positively associated 
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with ER+ and PR+ disease with luminal A, luminal 
B and unclassified 
10 FGFR2 rs2981579 Yes Yes Yes Yes 
associated with ER+/PR+ 
in AA,and most subtypes 
in Chinese study 
positively associated 
with luminal A, 
HER2+/ER- and 
unclassified 
10 FGFR2 rs1078806 Yes Yes No Yes NE 
positively associated 
with luminal A and 
unclassified 
10 FGFR2 rs2981578 Yes Yes Yes Yes 
evidence of association 
with ER+, ER- and PR+ 
disease 
positively associated 
with luminal A, luminal 
B, HER2+/ER- and 
unclassified 
10 FGFR2 rs1219648 Yes Yes Yes Yes evidence of association with ER+, PR+ and HER2-  
positively associated 
with luminal A and 
unclassified 
10 FGFR2 rs2912774 Yes Yes Yes Yes evidence of association with ER+ and ER- disease 
positively associated 
with luminal A, 
HER2+/ER- and 
unclassified 
10 FGFR2 rs2936870 Yes Yes Yes Yes NE 
positively associated 
with luminal A, 
HER2+/ER- and 
unclassified 
10 FGFR2 rs2420946 Yes Yes Yes Yes NE 
positively associated 
with luminal A, 
HER2+/ER- and 
unclassified 
10 FGFR2 rs2981582 Yes Yes Yes Yes 
strongest association in 
Luminal A and B; null 
association in HER2+/ER- 
and triple-negative 
positively associated 
with luminal A, 
HER2+/ER- and 
unclassified 
10 FGFR2 rs3135718 Yes Yes Yes Yes NE 
positively associated 
with luminal A, 
HER2+/ER- and 
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unclassified 
10 10q rs1051012 No Yes No Yes NE null 
10 ATM rs1800057 No Yes NE NE NE null 
11 LSP1 rs3817198 No Yes No Yes 
Generally imprecise and 
inconsistent findings, 
possible association with 
unclassified disease 
null 
11 LSP1 rs909116 No Yes No Yes NE null 
11 H19 rs2107425 Yes Yes No No NE null 
11 MYEOV rs614367 NE NE NE NE possible association with ER+ and PR+ disease NE  
16 TNRC9 rs8051542 No Yes No Yes evidence of association with ER+ disease 
positively associated 
with unclassified  
16 TNRC9 rs1244362 Yes Yes No No no evidence of association 
Positively associated 
with HER2+/ER- in 
whites 
16 TNRC9 rs3803662 Yes Yes No Yes evidence of association with all subtypes 
positively associated 
with luminal A 
16 TNRC9 rs4784227 Yes Yes No Yes 
positively associated with 
all ER and PR subtypes in 
one Korean study 
positively associated 
with luminal A and 
unclassified 
17 TP53 rs12951053 No Yes No Yes NE null 
17 COX11 rs7222197 No No No Yes NE null 
17 COX11 rs6504950 No No No Yes 
inverse association in 
Luminal A and B; null 
association in HER2+/ER- 
and triple-negative 
null 
*Based on Bayesian posterior mean and 95% PI 
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Table 24: Comparison of previous findings and CBCS results for less established (non-GWAS, non-candidate) SNPs 
 
 
Chrom-
osome 
Gene or 
gene 
region 
SNP 
Range of estimates 
in previous studies 
CBCS effect 
estimates 
Summary of previous 
subtype findings CBCS subtype findings 
EA AA EA AA 
2 CASP8 rs17468277 1.05-1.06 NE 1.11 1.07 NE null 
6 ESR1 rs851974 1.09 0.88 0.91 0.94 NE inversely associated with luminal A 
6 ESR1 rs2077647 1.03* NE 0.97 1.07 NE null 
6 ESR1 rs2234693 1.03* 0.90# 0.95 0.97 NE null 
6 ESR1 rs3798577 1.02* NE 1.03 1.02 evidence of association with ER- and PR- disease 
inversely associated with 
HER2+/ER- 
9 CDKN2A/B rs3731257 1.1
# NE 0.94 0.91 NE null 
9 CDKN2A/B rs3731249 1.5
& NE 0.94 NE NE null 
9 CDKN2A/B rs518394 NE NE 1.03 1.02 NE 
Inversely associated with 
HER2+/ER- 
9 CDKN2A/B rs564398 NE NE 1.04 1.01 NE null 
9 CDKN2A/B rs10757278 NE NE 1.16 0.93 NE 
Positively associated with 
unclassified in whites, 
inversely associated in 
African Americans 
9 CDKN2A/B rs10811661 NE NE 1.01 1.01 NE null 
10 FGFR2 rs1896395 NE NE NE 1.02 NE null 
10 FGFR2 rs3750817 1.16-1.28 NE 1.22 1.61 
GWAS hit in Japanese 
study of hormone receptor 
positive disease (inverse 
association) 
positively associated with 
luminal A 
10 FGFR2 rs11200014 1.24- 1.31 NE 1.29 1.04 Associated with ER+, PR+, Positively associated with 
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HER2+ and HER2- in 
Chinese study 
luminal A and unclassified 
10 FGFR2 rs2162540 NE NE 1.29 1.21 NE 
Positively associated with 
luminal A, HER2+/ER- and 
unclassified 
10 ATM rs1800054 1.16*& 2.02 1.03 NE associated with PR+ tumors null 
10 ATM rs4986761 1.08*& NE NE NE not associated with any subtype NE 
10 ATM rs1800056 1.27*& NE NE NE NE NE 
10 ATM rs1800058 1.25*& NE 0.90 NE not associate with ER or PR status null 
10 ATM rs1801516 1.09* 1.14-1.27 0.99 1.14 
ER+ inversely associated, 
relative to ER- null 
10 ATM rs3092992 NE NE 1.16 NE NE null 
10 ATM rs664143 1.02* NE 1.02 0.96 associated with PR+ null 
10 ATM rs170548 0.94 NE 0.98 0.90 not associated with ER+ or PR+ null 
10 ATM rs3092993 NE NE 0.99 1.14 NE null 
16 TNRC9 rs8049149 NE NE NE 0.98 NE NE 
16 TNRC9 rs16951186 NE NE 1.10 0.92 NE null 
16 TNRC9 rs3104746 NE 1.17-1.23 1.42 1.49 
evidence of association 
with ER+ and ER- disease 
positively associated with 
luminal A and basal-like 
16 TNRC9 rs3112562 NE 1.17 0.99 1.26 NE 
positively associated with 
HER2+/ER- and basal-like, 
inversely associated with 
unclassified; inversely 
associated with luminal B 
in whites 
16 TNRC9 rs9940048 NE NE 1.03 1.10 NE positively associated with luminal A 
17 TP53 rs9894946 1.07* NE 0.86 0.93 NE inversely associated with luminal A 
17 TP53 rs1614984 1.01* NE 1.03 1.07 NE null 
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17 TP53 rs4968187 NE NE NE NE NE null 
17 TP53 rs17880604 NE NE 0.92 NE NE null 
17 TP53 rs1800372 NE NE 0.95 NE NE null 
17 TP53 rs2909430 1.00* NE 1.10 1.06 NE null 
17 TP53 rs1042522 1.02* NE 0.99 0.98 associated with ER+  null 
17 TP53 rs8079544 1.11* NE 1.19 0.92 NE null 
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Appendix 1: SAS code 
Bayesian model, dichotomous outcome 
PROC MCMC DATA=DATA NMC=30000 NBI=1000 THIN=5 
MONITOR=(OR1 beta0 beta1 beta2 beta3 var) SEED =6544; 
WHERE RACE=1; 
PARMS beta0 beta1 beta2 beta3 var; *default starting value of 0; 
HYPERPRIOR var~igamma(shape=3,scale=0.2); *distribution with mode at 0.05; 
PRIOR beta0~normal(0, var=1e6); 
PRIOR beta1~normal(0, var=var); *var is the hyperprior defined above; 
PRIOR beta2 beta3~normal(0, var=0.68); 
OR1=exp(beta1); 
mu1=(beta0+beta1*snp+beta2*age+beta3*ances+offset); 
logl= ((case=0)*(0-log(1+exp(mu1))) + (case=1)*(mu1-log(1+exp(mu1)))); 
MODEL case~general(logl); 
RUN; 
QUIT; 
 
Hierarchical model with identity covariance matrix, 3 SNPs in LD block 
DATA covar3; 
INPUT covp1-covp3; 
DATALINES; 
0.05 0.05 0.05 
; 
RUN; 
 
DATA data; 
SET data; 
LD= snp1+snp2+snp3; 
RUN; 
 
PROC GLIMMIX data=data; 
MODEL CASE= age ancestry LD / 
SOLUTION DIST=binomial LINK=logit OFFSET=OFF; 
PARMS / pdata=covar3 hold= 1,2,3; 
RANDOM snp1 snp2 snp3 / TYPE=VC G SOLUTION; 
ESTIMATE "snp1" intercept 0 age 0 ancestry 0 LD 1 | snp1 1 / cl exp; 
ESTIMATE "snp2" intercept 0 age 0 ancestry 0 LD 1 | snp2 1 / cl exp; 
ESTIMATE "snp3" intercept 0 age 0 ancestry 0 LD 1 | snp3 1 / cl exp; 
RUN; 
 
Hierarchical model with exponential decay matrix  
For 3 SNPs at positions 7518935, 7519370, and 7520197, such that 
|d12| = 435 
|d13| = 1262 
|d12| = 827 
 t!" = exp! − !!"1000  
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T= 
1 0.6473 0.28310.6473 1 0.43740.2831 0.4374 1  
 
σ2T= 
0.05 0.03236 0.014150.03236 0.05 0.021870.01415 0.02187 0.05  
 
*Input covariances left of and including the diagonal, reading right to left across rows 
DATA covar_LDdist; 
INPUT covp1-covp6; 
DATALINES; 
0.05 0.03236 0.05 0.01415 0.02187 0.05 
; 
RUN; 
 
PROC GLIMMIX data=data; 
MODEL CASE= age ancestry LD / 
SOLUTION DIST=binomial LINK=logit OFFSET=OFF; 
PARMS / pdata=covar_LDdist hold= 1,2,3,4,5,6; 
RANDOM snp1 snp2 snp3 / TYPE=UN G SOLUTION; 
ESTIMATE "snp1" intercept 0 age 0 ancestry 0 LD 1 | snp1 1 / cl exp; 
ESTIMATE "snp2" intercept 0 age 0 ancestry 0 LD 1 | snp2 1 / cl exp; 
ESTIMATE "snp3" intercept 0 age 0 ancestry 0 LD 1 | snp3 1 / cl exp; 
RUN; 
 
Bayesian model, polytomous outcome 
In the code below, subtype is a variable with 6 levels, where subtype=0 corresponds to 
controls (the referent group). SNP is a 3 level ordinal variable, age and ancestry are mean-
centered continuous variables, race is a 2 level categorical variable and offset is the offset 
term.  
 
 
PROC MCMC DATA=data NMC=50000 NBI=1000 THIN=10 SEED=3342 
 MONITOR=(var OR1 OR2 OR3 OR4 OR5 b01 b02 b03 b04 b05 b11 b12 b13 b14 b15 b21 
b22 b23 b24 b25 b31 b32 b33 b34 b35 b41 b42 b43 b44 b45);  
  
 PARMS var b01 b02 b03 b04 b05 b11 b12 b13 b14 b15 b21 b22 b23 b24 b25 b31 b32 b33 
b34 b35 b41 b42 b43 b44 b45 0; *this starting value should be arbitrary 
 
 HYPERPRIOR var~igamma(shape=4,scale=0.5); *distribution with mode at 0.1; 
 PRIOR b01 b02 b03 b04 b05~normal(0, var=1e6); 
 PRIOR b11 b12 b13 b14 b15~normal(0, var=var); *var is the hyperprior defined above; 
 PRIOR b21 b22 b23 b24 b25 b31 b32 b33 b34 b35~normal(0, var=0.68); 
 PRIOR b41 b42 b43 b44 b45~normal(0,var=1); 
  
 mu1=b01+b11*snp+b21*age+b31*ances+b41*race+offset; 
 mu2=b02+b12*snp+b22*age+b32*ances+b42*race+offset 
 mu3=b03+b13*snp+b23*age+b33*ances+b43*race+offset; 
 mu4=b04+b14*snp+b24*age+b34*ances+b44*race+offset; 
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 mu5=b05+b15*snp+b25*age+b35*ances+b45*race+offset; 
 
 logl= (subtype=0)*(0-log(1+exp(mu1)+exp(mu2)+exp(mu3)+exp(mu4)+exp(mu5)))  
 + (subtype=1)*(mu1-log(1+exp(mu1)+ exp(mu2)+exp(mu3)+ exp(mu4)+exp(mu5)))  
 + (subtype=2)*(mu2-log(1+exp(mu1)+ exp(mu2)+exp(mu3)+ exp(mu4)+exp(mu5)))  
 + (subtype=3)*(mu3-log(1+exp(mu1)+ exp(mu2)+exp(mu3)+ exp(mu4)+exp(mu5)))  
 + (subtype=4)*(mu4-log(1+exp(mu1)+ exp(mu2)+exp(mu3)+ exp(mu4)+exp(mu5)))  
 + (subtype=5)*(mu5-log(1+exp(mu1)+exp(mu2)+exp(mu3)+ exp(mu4)+exp(mu5)));  
  
 MODEL subtype~general(logl); 
 
 OR1=exp(b11); 
 OR2=exp(b12); 
 OR3=exp(b13); 
 OR4=exp(b14); 
 OR5=exp(b15); 
  
RUN;  
 
  
  
 
 
 
 
 
233 
 
Fi
gu
re
 A
2.
1 
C
om
pa
ri
so
n 
of
 M
L
E
 a
nd
 B
ay
es
 O
R
s, 
C
B
C
S 
w
hi
te
s 
 
 
Appendix 2: Extra figures, overall breast cancer analysis 
  
 
 
 
 
 
234 
Fi
gu
re
 A
2.
2 
C
om
pa
ri
so
n 
of
 M
L
E
 a
nd
 B
ay
es
 O
R
s, 
C
B
C
S 
A
fr
ic
an
 A
m
er
ic
an
s 
 
 
 
 
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
Su
pp
le
m
en
ta
ry
 F
ig
ur
e 
2:
 M
ax
im
um
 li
ke
lih
oo
d 
vs
. B
ay
es
 O
dd
s 
Ra
tio
s,
 A
fri
ca
n−
Am
er
ic
an
s
 
 
1p1
2:rs
112
494
33
CAS
P8:r
s10
454
85
CAS
P8:r
s17
468
277
2q3
5:rs
133
870
42
2p:r
s46
664
51
SLC
4A7
:rs4
973
768
4p:r
s12
505
080
TLR
1:rs
769
617
5
MRP
S30
:rs4
415
084
MRP
S30
:rs1
094
167
9
5p1
2:rs
981
782
5q:r
s30
099
MAP
3K1
:rs8
893
12
ESR
1:rs
204
621
0
ESR
1:rs
851
974
ESR
1:rs
207
764
7
ESR
1:rs
223
469
3
ESR
1:rs
180
113
2
ESR
1:rs
302
031
4
ESR
1:rs
379
857
7
ECH
DC1
:rs2
180
341
REL
N:rs
171
579
03
8q2
4:rs
132
816
15
8q2
4:rs
156
243
0
CDK
N2A
/B:r
s37
312
57
CDK
N2A
/B:r
s51
839
4
CDK
N2A
/B:r
s56
439
8
CDK
N2A
/B:r
s10
119
70
CDK
N2A
/B:r
s10
757
278
CDK
N2A
/B:r
s10
811
661
ANK
RD1
6:rs
238
020
5
ZNF
365
:rs1
099
519
0
ZMI
Z1:r
s70
401
0
FGF
R2:r
s18
963
95
FGF
R2:r
s37
508
17
FGF
R2:r
s10
736
303
FGF
R2:r
s11
200
014
FGF
R2:r
s29
815
79
FGF
R2:r
s10
788
06
FGF
R2:r
s29
815
78
FGF
R2:r
s12
196
48
FGF
R2:r
s29
127
74
FGF
R2:r
s29
368
70
FGF
R2:r
s24
209
46
FGF
R2:r
s21
625
40
FGF
R2:r
s29
815
82
FGF
R2:r
s31
357
18
10q
:rs1
051
012
6
ATM
:rs1
801
516
ATM
:rs6
641
43
ATM
:rs1
705
48
ATM
:rs3
092
993
LSP
1:rs
381
719
8
LSP
1:rs
909
116
MYE
OV/
CCN
D1:r
s61
436
7
H19
:rs2
107
425
TNR
C9/T
OX3
:rs8
049
149
TNR
C9/T
OX3
:rs1
695
118
6
TNR
C9/T
OX3
:rs8
051
542
TNR
C9/T
OX3
:rs1
244
362
1
TNR
C9/T
OX3
:rs3
803
662
TNR
C9/T
OX3
:rs4
784
227
TNR
C9/T
OX3
:rs3
104
746
TNR
C9/T
OX3
:rs3
112
562
TNR
C9/T
OX3
:rs9
940
048
TP5
3:rs
989
494
6
TP5
3:rs
161
498
4
TP5
3:rs
129
510
53
TP5
3:rs
290
943
0
TP5
3:rs
104
252
2
TP5
3:rs
807
954
4
COX
11:r
s72
221
97
COX
11:r
s65
049
50
0.
5
0.
751
1.
251.
523
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
M
LE
 O
R 
an
d 
95
%
 C
I
Ba
ye
s O
R 
an
d 
95
%
 P
I
  
 
 
 
 
 
235 
Fi
gu
re
 A
2.
3 
C
om
pa
ri
so
n 
of
 M
L
E
 a
nd
 h
ie
ra
rc
hi
ca
l O
R
s, 
C
B
C
S 
W
hi
te
s 
 
 
 
 
  
 
 
 
 
 
236 
Fi
gu
re
 A
2.
4 
C
om
pa
ri
so
n 
of
 M
L
E
 a
nd
 h
ie
ra
rc
hi
ca
l O
R
s, 
C
B
C
S 
A
fr
ic
an
 A
m
er
ic
an
s 
 
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
Su
pp
le
m
en
ta
ry
 F
ig
ur
e 
4:
 M
ax
im
um
 li
ke
lih
oo
d 
vs
. H
ie
ra
rc
hi
ca
l O
dd
s 
Ra
tio
s,
 A
fri
ca
n−
Am
er
ic
an
s
 
 
CAS
P8:r
s10
454
85
CAS
P8:r
s17
468
277
CDK
N2A
/B:r
s51
839
4
CDK
N2A
/B:r
s56
439
8
FGF
R2:r
s37
508
17
FGF
R2:r
s10
736
303
FGF
R2:r
s11
200
014
FGF
R2:r
s29
815
79
FGF
R2:r
s10
788
06
FGF
R2:r
s29
815
78
FGF
R2:r
s12
196
48
FGF
R2:r
s29
127
74
FGF
R2:r
s29
368
70
FGF
R2:r
s24
209
46
FGF
R2:r
s21
625
40
TNR
C9/T
OX3
:rs3
803
662
TNR
C9/T
OX3
:rs4
784
227T
NRC
9/TO
X3:r
s31
047
46
TNR
C9/T
OX3
:rs3
112
562
TP5
3:rs
129
510
53TP5
3:rs
290
943
0TP5
3:rs
104
252
2
COX
11:r
s72
221
97
COX
11:r
s65
049
50
0.
5
0.
751
1.
251.
523
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
●
M
LE
 O
R 
an
d 
95
%
 C
I
Hi
er
ar
ch
ica
l O
R 
an
d 
95
%
 P
I
  
     
237 
References 
1. SEER Incidence Statistics - SEER Cancer Query Systems. 
http://seer.cancer.gov/canques/incidence.html. Accessed January 9, 2013. 
 
2. US Cancer Morality Statistics. http://seer.cancer.gov/canques/mortality.html. Accessed 
January 9, 2013. 
 
3. Carey LA, Perou CM, Livasy CA, et al. Race, breast cancer subtypes, and survival in the 
Carolina Breast Cancer Study. JAMA. 2006;295:2492-2502. 
 
4. Millikan RC, Newman B, Tse C, et al. Epidemiology of basal-like breast cancer. Breast 
Cancer Res Treat. 2008;109:123-139, 2008. 
 
5. Cheang MCU, Voduc D, Bajdik C, et al. Basal-like breast cancer defined by five 
biomarkers has superior prognostic value than triple-negative phenotype. Clin Cancer Res. 
2008;14:1368-1376. 
 
6. Shin BK, Lee Y, Lee JB, et al. Breast carcinomas expressing basal markers have poor 
clinical outcome regardless of estrogen receptor status. Oncol Rep. 2008;19:617-625. 
 
7. Kurian AW, Fish K, Shema SJ, Clarke CA. Lifetime risks of specific breast cancer 
subtypes among women in four racial/ethnic groups. Breast Cancer Res, 2010;12:R99. 
doi:10.1186/bcr2780. 
 
8. Lund MJ, Trivers KF, Porter PL, et al. Race and triple negative threats to breast cancer 
survival: a population-based study in Atlanta, GA. Breast Cancer Res Treat. 2009;113:357-
370. 
 
9. International HapMap Consortium, Frazer KA, Ballinger DG, et al. A second generation 
human haplotype map of over 3.1 million SNPs. Nature. 2007;449:851-861. 
 
10. Haffty BG, Silber A, Matloff E, Chung J, Lannin D. Racial differences in the incidence 
of BRCA1 and BRCA2 mutations in a cohort of early onset breast cancer patients: African 
American compared to white women. J Med Genet. 2006;43:133-137. 
 
11. Hutter CM, Young AM, Ochs-Balcom HM, et al. Replication of Breast Cancer GWAS 
Susceptibility Loci in the Women's Health Initiative African American SHARe Study. 
Cancer Epidemiol Biomarkers Prev. 2011;20:1950-1959. 
 
12. Zheng W, Cai Q, Signorello LB, et al. Evaluation of 11 breast cancer susceptibility loci 
in African-American women. Cancer Epidemiol Biomarkers Prev. 2009;18:2761-2764. 
 
13. Greenland S. Principles of multilevel modelling. Int J Epidemiol. 2000;29:158-167. 
 
  
     
238 
14. Greenland S. Bayesian perspectives for epidemiological research: I. Foundations and 
basic methods. Int J Epidemiol. 2006;35:765-775. 
 
15. Stephens M, Balding DJ. Bayesian statistical methods for genetic association studies. Nat 
Rev Genet. 2009;10:681-690. 
 
16. Hung RJ, Brennan P, Malaveille C, et al. Using hierarchical modeling in genetic 
association studies with multiple markers: application to a case-control study of bladder 
cancer. Cancer Epidemiol Biomarkers Prev. 2004;13:1013-1021. 
 
17. Hamra GB, Maclehose RF, Cole SR. Sensitivity Analyses for Sparse-Data Problems-
Using Weakly Informative Bayesian Priors. Epidemiology. 2013;24:233-239. 
 
18. Hindorff LA, MacArthur J (European Bioinformatics Institute), Morales J (European 
Bioinformatics Institute), et al. A Catalog of Published Genome-Wide Association Studies. 
Available at: www.genome.gov/gwastudies. Accessed January 13, 2013. 
 
19. Varghese JS, Easton DF. Genome-wide association studies in common cancers-what 
have we learnt? Curr Opin Genet Dev. 2010;20:201-209. 
 
20. Zhang B, Beeghly-Fadiel A, Long J, Zheng W. Genetic variants associated with breast-
cancer risk: comprehensive research synopsis, meta-analysis, and epidemiological evidence. 
Lancet Oncol. 2011;12:477-488. 
 
21. GLOBOCAN: Country Fast Stat. 
http://globocan.iarc.fr/factsheets/populations/factsheet.asp?uno=900. Accessed January 9, 
2013. 
 
22. Breast Cancer Home Page - National Cancer Institute. 
http://www.cancer.gov/cancertopics/types/breast. Accessed January 9, 2013. 
 
23. Cancer of the Breast - SEER Stat Fact Sheets. 
http://www.seer.cancer.gov/statfacts/html/breast.html. Accessed January 9, 2013. 
 
24. Cancer - State Cancer Facts - North Carolina vs. United States Comparisons. 
http://apps.nccd.cdc.gov/statecancerfacts/Table.aspx?Group=5f&TableType=INCI&Selected
State=North%20Carolina. Accessed January 9, 2013. 
 
25. Breast Equivalent Terms, Definitions, Tables and Illustration. 
http://seer.cancer.gov/manuals/2010/AppendixC/breast/terms_defs.pdf. Accessed July 25, 
2011. 
 
26. Anderson WF, Chu KC, Chang S, Sherman ME. Comparison of age-specific incidence 
rate patterns for different histopathologic types of breast carcinoma. Cancer Epidemiol 
Biomarkers Prev. 2004;13:1128-1135. 
 
  
     
239 
27. Li CI. Risk of mortality by histologic type of breast cancer in the United States. Horm 
Cancer. 2010;1:156-165. 
 
28. Dontu G, El-Ashry D, Wicha MS. Breast cancer, stem/progenitor cells and the estrogen 
receptor. Trends Endocrinol Metab. 2004;15:193-197. 
 
29. Melchor L, Benítez J. An integrative hypothesis about the origin and development of 
sporadic and familial breast cancer subtypes. Carcinogenesis. 2008;29:1475-1482. 
 
30. Stingl J. Estrogen and progesterone in normal mammary gland development and in 
cancer. Horm Cancer. 2011;2:85-90. 
 
31. Jatoi I, Chen BE, Anderson WF, Rosenberg PS. Breast cancer mortality trends in the 
United States according to estrogen receptor status and age at diagnosis. J Clin Oncol. 
2007;25:1683-1690. 
 
32. Li CI, Uribe DJ, Daling JR. Clinical characteristics of different histologic types of breast 
cancer. Br J Cancer. 2005;93:1046-1052. 
 
33. Anderson WF, Luo S, Chatterjee N, et al. Human epidermal growth factor receptor-2 and 
estrogen receptor expression, a demonstration project using the residual tissue repository of 
the Surveillance, Epidemiology, and End Results (SEER) program. Breast Cancer Res Treat. 
2009;113:189-196. 
 
34. Li CI, Moe RE, Daling JR. Risk of mortality by histologic type of breast cancer among 
women aged 50 to 79 years. Arch Intern Med. 2003;163:2149-2153. 
 
35. Ma H, Wang Y, Sullivan-Halley J, et al. Breast cancer receptor status: do results from a 
centralized pathology laboratory agree with SEER registry reports? Cancer Epidemiol 
Biomarkers Prev. 2009;18:2214-2220. 
 
36. Grann VR, Troxel AB, Zojwalla NJ, Jacobson JS, Hershman D, Neugut AI. Hormone 
receptor status and survival in a population-based cohort of patients with breast carcinoma. 
Cancer. 2005;103:2241-2251. 
 
37. Joslyn SA. Hormone receptors in breast cancer: racial differences in distribution and 
survival. Breast Cancer Res Treat. 2002;73:45-59. 
 
38. Al-Abbadi MA, Washington TA, Saleh HA, Tekyi-Mensah SE, Lucas DR, Briston CA. 
Differential expression of HER-2/NEU receptor of invasive mammary carcinoma between 
Caucasian and African American patients in the Detroit metropolitan area. Correlation with 
overall survival and other prognostic factors. Breast Cancer Res Treat. 2006;97:3-8. 
 
39. Perou CM, Sørlie T, Eisen MB, et al. Molecular portraits of human breast tumours. 
Nature. 2000;406:747-752. 
 
  
     
240 
40. Sørlie T, Perou CM, Tibshirani R, et al. Gene expression patterns of breast carcinomas 
distinguish tumor subclasses with clinical implications. Proc Natl Acad Sci U S A. 
2001;98:10869-10874. 
 
41. Sorlie T, Tibshirani R, Parker J, et al. Repeated observation of breast tumor subtypes in 
independent gene expression data sets. Proc Natl Acad Sci U S A. 2003;100:8418-8423. 
 
42. Nielsen TO, Hsu FD, Jensen K, et al. Immunohistochemical and clinical characterization 
of the basal-like subtype of invasive breast carcinoma. Clin Cancer Res. 2004;10:5367-5374. 
 
43. Kreike B, van Kouwenhove M, Horlings H, et al. Gene expression profiling and 
histopathological characterization of triple-negative/basal-like breast carcinomas. Breast 
Cancer Res, 2007;9:R65. doi:10.1186/bcr1771. 
 
44. Ma CX, Luo J, Ellis MJ. Molecular Profiling of Triple Negative Breast Cancer. Breast 
Dis. 2011;32:73-84. 
 
45. Perou CM. Molecular stratification of triple-negative breast cancers. Oncologist. 2011;16 
Suppl 1:61-70. 
 
46. Rody A, Karn T, Liedtke C, et al. A clinically relevant gene signature in triple negative 
and basal-like breast cancer. Breast Cancer Res, 2011;13:R97. doi:10.1186/bcr3035. 
 
47. Cancer Genome Atlas Network. Comprehensive molecular portraits of human breast 
tumours. Nature. 2012;490:61-70. 
 
48. Calza S, Hall P, Auer G, et al. Intrinsic molecular signature of breast cancer in a 
population-based cohort of 412 patients. Breast Cancer Res, 2006;8:R34. 
doi:10.1186/bcr1517. 
 
49. Hines LM, Risendal B, Byers T, Mengshol S, Lowery J, Singh M. Ethnic Disparities in 
Breast Tumor Phenotypic Subtypes in Hispanic and Non-Hispanic White Women. J Womens 
Health (Larchmt). 2011;20:1543-1550. 
 
50. Huo D, Ikpatt F, Khramtsov A, et al. Population differences in breast cancer: survey in 
indigenous African women reveals over-representation of triple-negative breast cancer. J 
Clin Oncol. 2009;27:4515-4521. 
 
51. Kennecke H, Yerushalmi R, Woods R, et al. Metastatic behavior of breast cancer 
subtypes. J Clin Oncol. 2010;28:3271-3277. 
 
52. Kim M, Ro JY, Ahn S, Kim HH, Kim S, Gong G. Clinicopathologic significance of the 
basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-
overexpressing phenotypes. Hum Pathol. 2006;37:1217-1226. 
 
  
     
241 
53. Kurebayashi J, Moriya T, Ishida T, et al. The prevalence of intrinsic subtypes and 
prognosis in breast cancer patients of different races. Breast. 2007;16 Suppl 2:S72-77. 
 
54. Liu H, Fan Q, Zhang Z, Li X, Yu H, Meng F. Basal-HER2 phenotype shows poorer 
survival than basal-like phenotype in hormone receptor-negative invasive breast cancers. 
Hum Pathol. 2008;39:167-174. 
 
55. Munirah MA, Siti-Aishah MA, Reena MZ, et al. Identification of different subtypes of 
breast cancer using tissue microarray. Rom J Morphol Embryol. 2011;52:669-677. 
 
56. Sihto H, Lundin J, Lehtimäki T, et al. Molecular subtypes of breast cancers detected in 
mammography screening and outside of screening. Clin Cancer Res. 2008;14:4103-4110. 
 
57. Voduc KD, Cheang MCU, Tyldesley S, Gelmon K, Nielsen TO, Kennecke H. Breast 
cancer subtypes and the risk of local and regional relapse. J Clin Oncol. 2010;28:1684-1691. 
 
58. Yamamoto Y, Ibusuki M, Nakano M, Kawasoe T, Hiki R, Iwase H. Clinical significance 
of basal-like subtype in triple-negative breast cancer. Breast Cancer. 2009;16:260-267. 
 
59. Zaha DC, Lazăr E, Lăzureanu C. Clinicopathologic features and five years survival 
analysis in molecular subtypes of breast cancer. Rom J Morphol Embryol. 2010;51:85-89. 
 
60. Bauer KR, Brown M, Cress RD, Parise CA, Caggiano V. Descriptive analysis of estrogen 
receptor (ER)-negative, progesterone receptor (PR)-negative, and HER2-negative invasive 
breast cancer, the so-called triple-negative phenotype: a population-based study from the 
California cancer Registry. Cancer. 2007;109:1721-1728. 
 
61. Ihemelandu CU, Leffall LD Jr, Dewitty RL, et al. Molecular breast cancer subtypes in 
premenopausal African-American women, tumor biologic factors and clinical outcome. Ann 
Surg Oncol. 2007;14:2994-3003. 
 
62. Kwan ML, Kushi LH, Weltzien E, et al. Epidemiology of breast cancer subtypes in two 
prospective cohort studies of breast cancer survivors. Breast Cancer Res, 2009;11:R31. 
doi:10.1186/bcr2261.  
 
63. Parise CA, Bauer KR, Caggiano V. Variation in breast cancer subtypes with age and 
race/ethnicity. Crit Rev Oncol Hematol. 2010;76:44-52. 
 
64. Stark A, Kleer CG, Martin I, et al. African ancestry and higher prevalence of triple-
negative breast cancer: findings from an international study. Cancer. 2010;116:4926-4932. 
 
65. Stead LA, Lash TL, Sobieraj JE, et al. Triple-negative breast cancers are increased in 
black women regardless of age or body mass index. Breast Cancer Res 2009;11:R18. 
doi:10.1186/bcr2242. 
 
  
     
242 
66. Trivers KF, Lund MJ, Porter PL, et al. The epidemiology of triple-negative breast cancer, 
including race. Cancer Causes Control. 2009;20:1071-1082. 
 
67. Brown M, Tsodikov A, Bauer KR, Parise CA, Caggiano V. The role of human epidermal 
growth factor receptor 2 in the survival of women with estrogen and progesterone receptor-
negative, invasive breast cancer: the California Cancer Registry, 1999-2004. Cancer. 
2008;112:737-747. 
 
68. Nalwoga H, Arnes JB, Wabinga H, Akslen LA. Frequency of the basal-like phenotype in 
African breast cancer. APMIS. 2007;115:1391-1399. 
 
69. Agboola AJ, Musa AA, Wanangwa N, et al. Molecular characteristics and prognostic 
features of breast cancer in Nigerian compared with UK women. Breast Cancer Res Treat. 
2012;135:555-569. 
 
70. Caldarella A, Crocetti E, Bianchi S, Vet al. Female Breast Cancer Status According to 
ER, PR and HER2 Expression: A Population Based Analysis. Pathol Oncol Res. 
2011;17:753-758. 
 
71. Muñoz M, Fernández-Aceñero MJ, Martín S, Schneider J. Prognostic significance of 
molecular classification of breast invasive ductal carcinoma. Arch Gynecol Obstet. 
2009;280:43-48. 
 
72. Spitale A, Mazzola P, Soldini D, Mazzucchelli L, Bordoni A. Breast cancer classification 
according to immunohistochemical markers: clinicopathologic features and short-term 
survival analysis in a population-based study from the South of Switzerland. Ann Oncol. 
2009;20:628-635. 
 
73. Zarcone M, Amodio R, Campisi I, et al. Application of a new classification to a breast 
tumor series from a population-based cancer registry: demographic, clinical, and prognostic 
features of incident cases, Palermo Province, 2002-2004. Ann N Y Acad Sci. 2009;1155:222-
226. 
 
74. Lin C, Liau J, Lu Y, et al. Molecular subtypes of breast cancer emerging in young women 
in Taiwan: evidence for more than just westernization as a reason for the disease in Asia. 
Cancer Epidemiol Biomarkers Prev. 2009;18:1807-1814. 
 
75. Kim E, Noh WC, Han W, Noh D. Prognostic significance of young age (<35 years) by 
subtype based on ER, PR, and HER2 status in breast cancer: a nationwide registry-based 
study. World J Surg. 2011;35:1244-1253. 
 
76. Nakajima H, Fujiwara I, Mizuta N, et al. Prognosis of Japanese breast cancer based on 
hormone receptor and HER2 expression determined by immunohistochemical staining. 
World J Surg. 2008;32:2477-2482. 
 
  
     
243 
77. Su Y, Zheng Y, Zheng W, et al. Distinct distribution and prognostic significance of 
molecular subtypes of breast cancer in Chinese women: a population-based cohort study. 
BMC Cancer, 2011. 11:292. doi:10.1186/1471-2407-11-292. 
 
78. Telli ML, Chang ET, Kurian AW, et al. Asian ethnicity and breast cancer subtypes: a 
study from the California Cancer Registry. Breast Cancer Res Treat. 2011;127:471-478. 
 
79. Xing P, Li J, Jin F. A case-control study of reproductive factors associated with subtypes 
of breast cancer in Northeast China. Med Oncol. 2010;27:926-931. 
 
80. Kwong A, Mang OWK, Wong CHN, Chau WW, The Hong Kong Breast Cancer 
Research Group, Law SCK. Breast Cancer in Hong Kong, Southern China: The First 
Population-Based Analysis of Epidemiological Characteristics, Stage-Specific, Cancer-
Specific, and Disease-Free Survival in Breast Cancer Patients: 1997-2001. Ann Surg Oncol. 
2011;18:3072-3078. 
 
81. Zhao J, Liu H, Wang M, et al. Characteristics and prognosis for molecular breast cancer 
subtypes in Chinese women. J Surg Oncol. 2009;100:89-94. 
 
82. Yang XR, Sherman ME, Rimm DL, et al. Differences in risk factors for breast cancer 
molecular subtypes in a population-based study. Cancer Epidemiol Biomarkers Prev. 
2007;16:439-443. 
 
83. Tamimi RM, Colditz GA, Hazra A, et al. Traditional breast cancer risk factors in relation 
to molecular subtypes of breast cancer. Breast Cancer Res Treat. 2012;131:159-167. 
 
84. Lara-Medina F, Pérez-Sánchez V, Saavedra-Pérez D, et al. Triple-negative breast cancer 
in Hispanic patients: High prevalence, poor prognosis, and association with menopausal 
status, body mass index, and parity. Cancer. 2011;117:3658-3669. 
 
85. Parise CA, Bauer KR, Brown MM, Caggiano V. Breast cancer subtypes as defined by the 
estrogen receptor (ER), progesterone receptor (PR), and the human epidermal growth factor 
receptor 2 (HER2) among women with invasive breast cancer in California, 1999-2004. 
Breast J. 2009;15:593-602. 
 
86. O'Brien KM, Cole SR, Tse C, et al. Intrinsic breast tumor subtypes, race, and long-term 
survival in the Carolina Breast Cancer Study. 2010;Clin Cancer Res. 16:6100-110. 
 
87. Liu Z, Wu J, Ping B, et al. Basal cytokeratin expression in relation to 
immunohistochemical and clinical characterization in breast cancer patients with triple 
negative phenotype. Tumori. 2009;95:53-62. 
 
88. Malorni L, Shetty PB, De Angelis C, et al. Clinical and biologic features of triple-
negative breast cancers in a large cohort of patients with long-term follow-up. Breast Cancer 
Res Treat. 2012;136:795-804. 
 
  
     
244 
89. Livasy CA, Perou CM, Karaca G, et al. Identification of a basal-like subtype of breast 
ductal carcinoma in situ. Hum Pathol. 2007;38:197-204. 
 
90. de Ruijter TC, Veeck J, de Hoon JPJ, van Engeland M, Tjan-Heijnen VC. Characteristics 
of triple-negative breast cancer. J Cancer Res Clin Oncol. 2011;137:183-192. 
 
91. Seal MD, Chia SK. What is the difference between triple-negative and basal breast 
cancers? Cancer J. 2010;16:12-16. 
 
92. Tamoxifen - National Cancer Institute. 
http://www.cancer.gov/cancertopics/factsheet/Therapy/tamoxifen. Accessed August 31, 
2011. 
 
93. Dictionary of Cancer Terms. 
http://www.cancer.gov/common/popUps/popDefinition.aspx?term=letrozole. Accessed 
August 31, 2011. 
 
94. Herceptin® (Trastuzumab): Questions and Answers - National Cancer Institute. 
http://www.cancer.gov/cancertopics/factsheet/Therapy/herceptin. Accessed August 31, 2011. 
 
95. Perez EA, Romond EH, Suman VJ, et al. Four-year follow-up of trastuzumab plus 
adjuvant chemotherapy for operable human epidermal growth factor receptor 2-positive 
breast cancer: joint analysis of data from NCCTG N9831 and NSABP B-31. J Clin Oncol. 
2011;29:3366-3373. 
 
96. Morin PJ. Claudin proteins in human cancer: promising new targets for diagnosis and 
therapy. Cancer Res. 2005;65:9603-9606. 
 
97. What are the risk factors for breast cancer?. 
http://www.cancer.org/Cancer/BreastCancer/DetailedGuide/breast-cancer-risk-factors. 
Accessed September 29, 2011. 
 
98. NCI Breast Cancer Prevention. 
http://www.cancer.gov/cancertopics/pdq/prevention/breast/HealthProfessional. Accessed 
January 10, 2013. 
 
99. Hankinson SE, Colditz GA, Willett WC. Towards an integrated model for breast cancer 
etiology: the lifelong interplay of genes, lifestyle, and hormones. Breast Cancer Res. 
2004;6:213-218. 
 
100. Bernstein L. Epidemiology of endocrine-related risk factors for breast cancer. J 
Mammary Gland Biol Neoplasia. 2002;7:3-15. 
 
101. Althuis MD, Fergenbaum JH, Garcia-Closas M, Brinton LA, Madigan MP, Sherman 
ME. Etiology of hormone receptor-defined breast cancer: a systematic review of the 
  
     
245 
literature. Cancer Epidemiol Biomarkers Prev. 2004;13:1558-1568. 
 
102. Ma H, Bernstein L, Pike MC, Ursin G. Reproductive factors and breast cancer risk 
according to joint estrogen and progesterone receptor status: a meta-analysis of 
epidemiological studies. Breast Cancer Res, 2006;8:R43. doi:10.1186/bcr1525. 
 
103. Yang XR, Chang-Claude J, Goode EL, et al. Associations of breast cancer risk factors 
with tumor subtypes: a pooled analysis from the Breast Cancer Association Consortium 
studies. J Natl Cancer Inst. 2011;103:250-263. 
 
104. Suzuki R, Orsini N, Saji S, Key TJ, Wolk A. Body weight and incidence of breast 
cancer defined by estrogen and progesterone receptor status-a meta-analysis. Int J Cancer. 
2009;124:698-712. 
 
105. Morabia A. Smoking (active and passive) and breast cancer: epidemiologic evidence up 
to June 2001. Environ Mol Mutagen. 2002;39:89-95. 
 
106. Suzuki R, Orsini N, Mignone L, Saji S, Wolk A. Alcohol intake and risk of breast 
cancer defined by estrogen and progesterone receptor status-a meta-analysis of 
epidemiological studies. Int J Cancer. 2008;122:1832-1841. 
 
107. Stark A, Schultz D, Kapke A, et al. Obesity and risk of the less commonly diagnosed 
subtypes of breast cancer. Eur J Surg Oncol. 2009;35:928-935. 
 
108. Shinde SS, Forman MR, Kuerer HM, et al. Higher parity and shorter breastfeeding 
duration: association with triple-negative phenotype of breast cancer. Cancer. 
2010;116:4933-4943. 
 
109. Dolle JM, Daling JR, White E, et al. Risk factors for triple-negative breast cancer in 
women under the age of 45 years. Cancer Epidemiol Biomarkers Prev. 2009;18:1157-1166. 
 
110. Gaudet MM, Press MF, Haile RW, et al. Risk factors by molecular subtypes of breast 
cancer across a population-based study of women 56 years or younger. Breast Cancer Res 
Treat. 2011;130:587-597. 
 
111. Phipps AI, Buist DSM, Malone KE, et al. Family history of breast cancer in first-degree 
relatives and triple-negative breast cancer risk. Breast Cancer Res Treat. 2011;126:671-678. 
 
112. Welsh ML, Buist DSM, Aiello Bowles EJ, Anderson ML, Elmore JG, Li CI. 
Population-based estimates of the relation between breast cancer risk, tumor subtype, and 
family history. Breast Cancer Res Treat. 2009;114:549-558. 
 
113. Islam T, Matsuo K, Ito H, et al. Reproductive and hormonal risk factors for luminal, 
HER2-overexpressing, and triple-negative breast cancer in Japanese women. Ann Oncol. 
2012;23:2435-2441. 
 
  
     
246 
114. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI. Reproductive and hormonal risk 
factors for postmenopausal luminal, HER-2-overexpressing, and triple-negative breast 
cancer. Cancer. 2008;113:1521-1526. 
 
115. Phipps AI, Chlebowski RT, Prentice R, et al. Reproductive history and oral 
contraceptive use in relation to risk of triple-negative breast cancer. J Natl Cancer Inst. 
2011;103:470-477. 
 
116. Li CI, Beaber EF, Tang MC, Porter PL, Daling JR, Malone KE. Reproductive factors 
and risk of estrogen receptor positive, triple-negative, and HER2-neu overexpressing breast 
cancer among women 20-44 years of age. Breast Cancer Res Treat. 2013;137:579-587. 
 
117. Ma H, Wang Y, Sullivan-Halley J, et al. Use of four biomarkers to evaluate the risk of 
breast cancer subtypes in the women's contraceptive and reproductive experiences study. 
Cancer Res. 2010;70:575-587. 
 
118. Phipps AI, Buist DSM, Malone KE, et al. Reproductive history and risk of three breast 
cancer subtypes defined by three biomarkers. Cancer Causes Control. 2011;22:399-405. 
 
119. Saxena T, Lee E, Henderson KD, et al. Menopausal hormone therapy and subsequent 
risk of specific invasive breast cancer subtypes in the California Teachers Study. Cancer 
Epidemiol Biomarkers Prev. 2010;19:2366-2378. 
 
120. Cruz GI, Martínez ME, Natarajan L, et al. Hypothesized role of pregnancy hormones on 
HER2+ breast tumor development. Breast Cancer Res Treat. 2013;137:237-246. 
 
121. WHO: Global Database on Body Mass Index. 
http://apps.who.int/bmi/index.jsp?introPage=intro_3.html. Accessed October 30, 2011. 
 
122. Phipps AI, Chlebowski RT, Prentice R, et al. Body size, physical activity, and risk of 
triple-negative and estrogen receptor-positive breast cancer. Cancer Epidemiol Biomarkers 
Prev. 2011;20:454-463. 
 
123. Phipps AI, Malone KE, Porter PL, Daling JR, Li CI. Body size and risk of luminal, 
HER2-overexpressing, and triple-negative breast cancer in postmenopausal women. Cancer 
Epidemiol Biomarkers Prev. 2008;17:2078-2086. 
 
124. Pierobon M, Frankenfeld CL. Obesity as a risk factor for triple-negative breast cancers: 
a systematic review and meta-analysis. Breast Cancer Res Treat. 2013;137:307-314. 
 
125. Kabat GC, Kim M, Phipps AI, et al. Smoking and alcohol consumption in relation to 
risk of triple-negative breast cancer in a cohort of postmenopausal women. Cancer Causes 
Control. 2011;22:775-783. 
 
126. Ma H, Luo J, Press MF, Wang Y, Bernstein L, Ursin G. Is there a difference in the 
association between percent mammographic density and subtypes of breast cancer? Luminal 
  
     
247 
A and triple-negative breast cancer. Cancer Epidemiol Biomarkers Prev. 2009;18:479-485. 
 
127. Antoniou A, Pharoah PDP, Narod S, et al. Average risks of breast and ovarian cancer 
associated with BRCA1 or BRCA2 mutations detected in case series unselected for family 
history: a combined analysis of 22 studies. Am J Hum Genet. 2003;72:1117-1130. 
 
128. Machiela MJ, Chen C, Chen C, Chanock SJ, Hunter DJ, Kraft P. Evaluation of 
polygenic risk scores for predicting breast and prostate cancer risk. Genet Epidemiol. 
2011;35:506-514. 
 
129. Jostins L, Barrett JC. Genetic risk prediction in complex disease. Hum Mol Genet, 
2011;20:R182-8. doi:10.1093/hmg/ddr378. 
 
130. Hall JM, Lee MK, Newman B, et al. Linkage of early-onset familial breast cancer to 
chromosome 17q21. Science. 1990;250:1684-1689. 
 
131. Narod SA, Feunteun J, Lynch HT, et al. Familial breast-ovarian cancer locus on 
chromosome 17q12-q23. Lancet. 1991;338:82-83. 
 
132. Wooster R, Neuhausen SL, Mangion J, et al. Localization of a breast cancer 
susceptibility gene, BRCA2, to chromosome 13q12-13. Science. 1994;265:2088-2090. 
 
133. Welcsh PL, King MC. BRCA1 and BRCA2 and the genetics of breast and ovarian 
cancer. Hum Mol Genet. 2001;10:705-713. 
 
134. Yoshida K, Miki Y. Role of BRCA1 and BRCA2 as regulators of DNA repair, 
transcription, and cell cycle in response to DNA damage. Cancer Sci. 2004;95:866-871. 
 
135. Malone KE, Daling JR, Doody DR, et al. Prevalence and predictors of BRCA1 and 
BRCA2 mutations in a population-based study of breast cancer in white and black American 
women ages 35 to 64 years. Cancer Res. 2006;66:8297-8308. 
 
136. Whittemore AS, Gong G, John EM, et al. Prevalence of BRCA1 mutation carriers 
among U.S. non-Hispanic Whites. Cancer Epidemiol Biomarkers Prev. 2004;13:2078-2083. 
 
137. John EM, Miron A, Gong G, et al. Prevalence of pathogenic BRCA1 mutation carriers 
in 5 US racial/ethnic groups. JAMA. 2007;298:2869-2876. 
 
138. Chen S, Parmigiani G. Meta-analysis of BRCA1 and BRCA2 penetrance. J Clin Oncol. 
2007;25:1329-1333. 
 
139. Comen E, Davids M, Kirchhoff T, Hudis C, Offit K, Robson M. Relative contributions 
of BRCA1 and BRCA2 mutations to "triple-negative" breast cancer in Ashkenazi Women. 
Breast Cancer Res Treat. 2011;129:185-190. 
 
  
     
248 
140. Evans DG, Howell A, Ward D, Lalloo F, Jones JL, Eccles DM. Prevalence of BRCA1 
and BRCA2 mutations in triple negative breast cancer. J Med Genet. 2011;48:520-522. 
 
141. Haffty BG, Yang Q, Reiss M, et al. Locoregional relapse and distant metastasis in 
conservatively managed triple negative early-stage breast cancer. J Clin Oncol. 
2006;24:5652-5657. 
 
142. Kwong A, Wong LP, Wong HN, et al. Clinical and pathological characteristics of 
Chinese patients with BRCA related breast cancer. Hugo J. 2009;3:63-76. 
 
143. Lee E, McKean-Cowdin R, Ma H, et al. Characteristics of Triple-Negative Breast 
Cancer in Patients With a BRCA1 Mutation: Results From a Population-Based Study of 
Young Women. J Clin Oncol. 2011;29:4373-4380. 
 
144. Xu J, Wang B, Zhang Y, Li R, Wang Y, Zhang S. Clinical implications for BRCA gene 
mutation in breast cancer. Mol Biol Rep. 2012;39:3097-3012. 
 
145. Young SR, Pilarski RT, Donenberg T, et al. The prevalence of BRCA1 mutations 
among young women with triple-negative breast cancer. BMC Cancer, 2008;9:86, 
doi:10.1186/1471-2407-9-86. 
 
146. Zhang J, Pei R, Pang Z, et al. Prevalence and characterization of BRCA1 and BRCA2 
germline mutations in Chinese women with familial breast cancer. Breast Cancer Res Treat. 
2011;132:421-428. 
 
147. Mavaddat N, Barrowdale D, Andrulis IL, et al. Pathology of breast and ovarian cancers 
among BRCA1 and BRCA2 mutation carriers: results from the Consortium of Investigators 
of Modifiers of BRCA1/2 (CIMBA). Cancer Epidemiol Biomarkers Prev. 2012;21:134-147. 
 
148. Foulkes WD, Stefansson IM, Chappuis PO, et al. Germline BRCA1 mutations and a 
basal epithelial phenotype in breast cancer. J Natl Cancer Inst. 2003;95:1482-1485. 
 
149. Antoniou AC, Easton DF. Models of genetic susceptibility to breast cancer. Oncogene. 
2006;25:5898-5905. 
 
150. Freisinger F, Domchek SM. Clinical implications of low-penetrance breast cancer 
susceptibility alleles. Curr Oncol Rep. 2009;11:8-14. 
 
151. Hirshfield KM, Rebbeck TR, Levine AJ. Germline mutations and polymorphisms in the 
origins of cancers in women. J Oncol 2010. doi:10.1155/2010/297671. 
152. de Bock GH, Mourits MJE, Schutte M, et al. Association between the 
CHEK2*1100delC germ line mutation and estrogen receptor status. Int J Gynecol Cancer. 16 
Suppl 2006;2:552-555. 
 
  
     
249 
153. Cybulski C, Huzarski T, Byrski T, et al. Estrogen receptor status in CHEK2-positive 
breast cancers: implications for chemoprevention. Clin Genet. 2009;75:72-78. 
 
154. Kilpivaara O, Bartkova J, Eerola H, et al. Correlation of CHEK2 protein expression and 
c.1100delC mutation status with tumor characteristics among unselected breast cancer 
patients. Int J Cancer. 2005;113:575-580. 
 
155. Schmidt MK, Tollenaar RAEM, de Kemp SR, et al. Breast cancer survival and tumor 
characteristics in premenopausal women carrying the CHEK2*1100delC germline mutation. 
J Clin Oncol. 2007;25:64-69. 
 
156. Meyer A, Dörk T, Sohn C, Karstens JH, Bremer M. Breast cancer in patients carrying a 
germ-line CHEK2 mutation: Outcome after breast conserving surgery and adjuvant 
radiotherapy. Radiother Oncol. 2007;82:349-353. 
 
157. Weischer M, Bojesen SE, Tybjaerg-Hansen A, Axelsson CK, Nordestgaard BG. 
Increased risk of breast cancer associated with CHEK2*1100delC. J Clin Oncol. 2007;25:57-
63. 
 
158. Nagel JHA, Peeters JK, Smid M, et al. Gene expression profiling assigns CHEK2 
1100delC breast cancers to the luminal intrinsic subtypes. Breast Cancer Res Treat. 
2012;132:439-448. 
 
159. Domagala P, Wokolorczyk D, Cybulski C, Huzarski T, Lubinski J, Domagala W. 
Different CHEK2 germline mutations are associated with distinct immunophenotypic 
molecular subtypes of breast cancer. Breast Cancer Res Treat. 2012;132:937-945. 
 
160. Cox A, Dunning AM, Garcia-Closas M, et al. A common coding variant in CASP8 is 
associated with breast cancer risk. Nat Genet. 2007;39:352-358. 
 
161. Barroso E, Pita G, Arias JI, et al. The Fanconi anemia family of genes and its correlation 
with breast cancer susceptibility and breast cancer features. Breast Cancer Res Treat. 
2009;118:655-660. 
 
162. Reeves GK, Travis RC, Green J, et al. Incidence of breast cancer and its subtypes in 
relation to individual and multiple low-penetrance genetic susceptibility loci. JAMA. 
2010;304:426-434. 
 
163. Tapper W, Hammond V, Gerty S, et al. The influence of genetic variation in 30 selected 
genes on the clinical characteristics of early onset breast cancer. Breast Cancer Res, 
2008;10:R108. doi:10.1186/bcr2213. 
 
164. Barrett JC. Haploview: Visualization and analysis of SNP genotype data. Cold Spring 
Harb Protoc 2009. doi:10.1101/pdb.ip71. 
 
  
     
250 
165. Gabriel SB, Schaffner SF, Nguyen H, et al. The structure of haplotype blocks in the 
human genome. Science. 2002;296:2225-2229. 
 
166. Haiman CA, Chen GK, Vachon CM, et al. A common variant at the TERT-CLPTM1L 
locus is associated with estrogen receptor-negative breast cancer. Nat Genet. 2011;43:1210-
1214. 
 
167. Stevens KN, Vachon CM, Lee AM, et al. Common breast cancer susceptibility loci are 
associated with triple-negative breast cancer. Cancer Res. 2011;71:6240-6249. 
 
168. Broeks A, Schmidt MK, Sherman ME, et al. Low penetrance breast cancer susceptibility 
loci are associated with specific breast tumor subtypes: findings from the Breast Cancer 
Association Consortium. Hum Mol Genet. 2011;20:3289-3303. 
 
169. Campa D, Kaaks R, Le Marchand L, et al. Interactions between genetic variants and 
breast cancer risk factors in the breast and prostate cancer cohort consortium. J Natl Cancer 
Inst. 2011;103:1252-1263. 
 
170. Han S, Lee K, Choi J, et al. CASP8 polymorphisms, estrogen and progesterone receptor 
status, and breast cancer risk. Breast Cancer Res Treat. 2008;110:387-393. 
 
171. Hamaguchi M, Nishio M, Toyama T, et al. Possible difference in frequencies of genetic 
polymorphisms of estrogen receptor alpha, estrogen metabolism and P53 genes between 
estrogen receptor-positive and -negative breast cancers. Jpn J Clin Oncol. 2008;38:734-742. 
 
172. Han W, Kang D, Park IA, et al. Associations between breast cancer susceptibility gene 
polymorphisms and clinicopathological features. Clin Cancer Res. 2004;10:124-130. 
 
173. Noma C, Miyoshi Y, Taguchi T, Tamaki Y, Noguchi S. Association of p53 genetic 
polymorphism (Arg72Pro) with estrogen receptor positive breast cancer risk in Japanese 
women. Cancer Lett. 2004;210:197-203. 
 
174. Yoshimoto N, Nishiyama T, Toyama T, et al. Genetic and environmental predictors, 
endogenous hormones and growth factors and risk of estrogen receptor-positive breast cancer 
in Japanese women. Cancer Sci. 2011;102:2065-2072. 
 
175. Dufloth RM, Arruda A, Heinrich JKR, Schmitt F, Zeferino LC. The investigation of 
DNA repair polymorphisms with histopathological characteristics and hormone receptors in a 
group of Brazilian women with breast cancer. Genet Mol Res. 2008;7:574-582. 
 
176. Erfani N, Razmkhah M, Talei AR, et al. Cytotoxic T lymphocyte antigen-4 promoter 
variants in breast cancer. Cancer Genet Cytogenet. 2006;165:114-120. 
 
177. Fasching PA, Loehberg CR, Strissel PL, et al. Single nucleotide polymorphisms of the 
aromatase gene (CYP19A1), HER2/neu status, and prognosis in breast cancer patients. 
  
     
251 
Breast Cancer Res Treat. 2008;112:89-98. 
 
178. Heikkinen T, Kärkkäinen H, Aaltonen K, et al. The breast cancer susceptibility mutation 
PALB2 1592delT is associated with an aggressive tumor phenotype. Clin Cancer Res. 
2009;15:3214-3222. 
 
179. Krupa R, Synowiec E, Pawlowska E, et al. Polymorphism of the homologous 
recombination repair genes RAD51 and XRCC3 in breast cancer. Exp Mol Pathol. 
2009;87:32-35. 
 
180. Pooley KA, Baynes C, Driver KE, et al. Common single-nucleotide polymorphisms in 
DNA double-strand break repair genes and breast cancer risk. Cancer Epidemiol Biomarkers 
Prev. 2008;17:3482-3489. 
 
181. Synowiec E, Stefanska J, Morawiec Z, Blasiak J, Wozniak K. Association between 
DNA damage, DNA repair genes variability and clinical characteristics in breast cancer 
patients. Mutat Res. 2008;648:65-72. 
 
182. Zhang L, Gu L, Qian B, et al. Association of genetic polymorphisms of ER-alpha and 
the estradiol-synthesizing enzyme genes CYP17 and CYP19 with breast cancer risk in 
Chinese women. Breast Cancer Res Treat. 2009;114:327-338. 
 
183. Definition of genome-wide association study - NCI Dictionary of Cancer Terms - 
National Cancer Institute. http://www.cancer.gov/dictionary?cdrid=636779. Accessed 
December 7, 2011. 
 
184. Genome.gov | GWAS: Full Description of Methods. http://www.genome.gov/27529028. 
Accessed December 7, 2011. 
 
185. Genome.gov | A Catalog of Published Genome-Wide Association Studies. 
http://www.genome.gov/26525384. Accessed, January 10, 2013. 
 
186. Thomas G, Jacobs KB, Kraft P, et al. A multistage genome-wide association study in 
breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet. 
2009;41:579-584. 
 
187. Stacey SN, Manolescu A, Sulem P, et al. Common variants on chromosomes 2q35 and 
16q12 confer susceptibility to estrogen receptor-positive breast cancer. Nat Genet. 
2007;39:865-869. 
 
188. Murabito JM, Rosenberg CL, Finger D, et al. A genome-wide association study of 
breast and prostate cancer in the NHLBI's Framingham Heart Study. BMC Med Genet, 
2007;8 Suppl 1:S6. doi:10.1186/1471-2350-8-S1-S6. 
 
189. Turnbull C, Ahmed S, Morrison J, et al. Genome-wide association study identifies five 
new breast cancer susceptibility loci. Nat Genet. 2010;42:504-507. 
 
  
     
252 
190. Fletcher O, Johnson N, Orr N, et al. Novel breast cancer susceptibility locus at 9q31.2: 
results of a genome-wide association study. J Natl Cancer Inst. 2011;103:425-435. 
 
191. Li J, Humphreys K, Heikkinen T, et al. A combined analysis of genome-wide 
association studies in breast cancer. Breast Cancer Res Treat. 2011;126:717-727 
 
192. Kim H, Lee J, Sung H, et al. A genome-wide association study identifies a breast cancer 
risk variant in ERBB4 at 2q34: results from the Seoul Breast Cancer Study. Breast Cancer 
Res, 2012;14:R56. doi:10.1186/bcr3158. 
 
193. Elgazzar S, Zembutsu H, Takahashi A, et al. A genome-wide association study 
identifies a genetic variant in the SIAH2 locus associated with hormonal receptor-positive 
breast cancer in Japanese. J Hum Genet. 2012;57:766-771. 
 
194. Easton DF, Pooley KA, Dunning AM, et al. Genome-wide association study identifies 
novel breast cancer susceptibility loci. Nature. 2007;447:1087-1093. 
 
195. Sehrawat B, Sridharan M, Ghosh S, et al. Potential novel candidate polymorphisms 
identified in genome-wide association study for breast cancer susceptibility. Hum Genet. 
2011;130:529-537. 
 
196. Gold B, Kirchhoff T, Stefanov S, et al. Genome-wide association study provides 
evidence for a breast cancer risk locus at 6q22.33. Proc Natl Acad Sci U S A. 2008;105:4340-
4345. 
 
197. Zheng W, Long J, Gao Y, et al. Genome-wide association study identifies a new breast 
cancer susceptibility locus at 6q25.1. Nat Genet. 2009;41:324-328. 
 
198. Siddiq A, Couch FJ, Chen GK, et al. A meta-analysis of genome-wide association 
studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol 
Genet. 2012;21:5373-5384. 
 
199. Long J, Cai Q, Sung H, et al. Genome-wide association study in east Asians identifies 
novel susceptibility loci for breast cancer. PLoS Genet, 2012 8(2):e1002532, 
doi:10.1371/journal.pgen.1002532. 
200. Cai Q, Long J, Lu W, et al. Genome-wide association study identifies breast cancer risk 
variant at 10q21.2: results from the Asia Breast Cancer Consortium. Hum Mol Genet. 
2012;20:4991-4999. 
 
201. Hunter DJ, Kraft P, Jacobs KB, et al. A genome-wide association study identifies alleles 
in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet. 
2007;39:870-874. 
 
202. Gaudet MM, Kirchhoff T, Green T, et al. Common genetic variants and modification of 
penetrance of BRCA2-associated breast cancer. PLoS Genet, 2010;6(10):e1001183, 
  
     
253 
doi:10.1371/journal.pgen.1001183. 
 
203. Chen F, Chen GK, Stram DO, et al. A genome-wide association study of breast cancer 
in women of African ancestry. Hum Genet. 2013;132:39-48. 
 
204. Kibriya MG, Jasmine F, Argos M, et al. A pilot genome-wide association study of early-
onset breast cancer. Breast Cancer Res Treat. 2009;114:463-477. 
 
205. Long J, Cai Q, Shu X, et al. Identification of a functional genetic variant at 16q12.1 for 
breast cancer risk: results from the Asia Breast Cancer Consortium. PLoS Genet, 
2010;6(6):e1001002. doi:10.1371/journal.pgen.1001002. 
 
206. Antoniou AC, Wang X, Fredericksen ZS, et al. A locus on 19p13 modifies risk of breast 
cancer in BRCA1 mutation carriers and is associated with hormone receptor-negative breast 
cancer in the general population. Nat Genet. 2010;42:885-892. 
 
207. Li J, Humphreys K, Darabi H, et al. A genome-wide association scan on estrogen 
receptor-negative breast cancer. Breast Cancer Res, 2010;12:R93. 10.1186/bcr2772. 
 
208. Stacey SN, Manolescu A, Sulem P, et al. Common variants on chromosome 5p12 confer 
susceptibility to estrogen receptor-positive breast cancer. Nat Genet. 2008;40:703-706. 
 
209. Ahmed S, Thomas G, Ghoussaini M, et al. Newly discovered breast cancer 
susceptibility loci on 3p24 and 17q23.2. Nat Genet. 2009;41:585-590. 
 
210. Barnholtz-Sloan JS, Shetty PB, Guan X, et al. FGFR2 and other loci identified in 
genome-wide association studies are associated with breast cancer in African-American and 
younger women. Carcinogenesis. 2010;31:1417-1423. 
 
211. Bhatti P, Doody MM, Rajaraman P, et al. Novel breast cancer risk alleles and 
interaction with ionizing radiation among U.S. radiologic technologists. Radiat Res. 
2010;173:214-224. 
 
212. Figueroa JD, Garcia-Closas M, Humphreys M, et al. Associations of common variants 
at 1p11.2 and 14q24.1 (RAD51L1) with breast cancer risk and heterogeneity by tumor 
subtype: findings from the Breast Cancer Association Consortium. Hum Mol Genet. 
2011;20:4693-4706. 
 
213. Loizidou MA, Hadjisavvas A, Ioannidis JPA, Kyriacou K. Replication of genome-wide 
discovered breast cancer risk loci in the Cypriot population. Breast Cancer Res Treat. 
2011;128:267-272. 
 
214. Chen F, Chen GK, Millikan RC, et al. Fine-mapping of breast cancer susceptibility loci 
characterizes genetic risk in African Americans. Hum Mol Genet. 2011;20:4491-4503. 
 
  
     
254 
215. Huo D, Zheng Y, Ogundiran TO, et al. Evaluation of 19 susceptibility loci of breast 
cancer in women of African ancestry. Carcinogenesis. 2012;33:835-840. 
 
216. Palmer JR, Ruiz-Narvaez EA, Rotimi CN, et al. Genetic susceptibility Loci for subtypes 
of breast cancer in an african american population. Cancer Epidemiol Biomarkers Prev. 
2013;22:127-134. 
 
217. Long J, Shu X, Cai Q, et al. Evaluation of breast cancer susceptibility loci in Chinese 
women. Cancer Epidemiol Biomarkers Prev. 2010;19:2357-2365. 
 
218. Harlid S, Ivarsson MIL, Butt S, et al. Combined effect of low-penetrant SNPs on breast 
cancer risk. Br J Cancer. 2012;106:389-396. 
 
219. Hemminki K, Müller-Myhsok B, Lichtner P, et al. Low-risk variants FGFR2, TNRC9 
and LSP1 in German familial breast cancer patients. Int J Cancer. 2010;126:2858-2862. 
 
220. Milne RL, Gaudet MM, Spurdle AB, et al. Assessing interactions between the 
associations of common genetic susceptibility variants, reproductive history and body mass 
index with breast cancer risk in the breast cancer association consortium: a combined case-
control study. Breast Cancer Res, 2010;12:R110. doi:10.1186/bcr2797. 
 
221. Milne RL, Benítez J, Nevanlinna H, et al. Risk of estrogen receptor-positive and -
negative breast cancer and single-nucleotide polymorphism 2q35-rs13387042. J Natl Cancer 
Inst. 2009;101:1012-1018. 
 
222. Slattery ML, Baumgartner KB, Giuliano AR, Byers T, Herrick JS, Wolff RK. 
Replication of five GWAS-identified loci and breast cancer risk among Hispanic and non-
Hispanic white women living in the Southwestern United States. Breast Cancer Res Treat. 
2011;129:531-539. 
 
223. Higginbotham KS, Breyer JP, McReynolds KM, et al. A multistage genetic association 
study identifies breast cancer risk Loci at 10q25 and 16q24. Cancer Epidemiol Biomarkers 
Prev. 2012;21:1565-1573. 
 
224. Jiang Y, Han J, Liu J, et al. Risk of genome-wide association study newly identified 
genetic variants for breast cancer in Chinese women of Heilongjiang Province. Breast 
Cancer Res Treat. 2011;128:251-257. 
 
225. Chen W, Zhong R, Ming J, et al. The SLC4A7 variant rs4973768 is associated with 
breast cancer risk: evidence from a case-control study and a meta-analysis. Breast Cancer 
Res Treat. 2012;136:847-857. 
 
226. Han W, Woo JH, Yu J, et al. Common genetic variants associated with breast cancer in 
Korean women and differential susceptibility according to intrinsic subtype. Cancer 
Epidemiol Biomarkers Prev. 2011;20:793-798. 
 
  
     
255 
227. Chan M, Ji S, Liaw C, et al. Association of common genetic variants with breast cancer 
risk and clinicopathological characteristics in a Chinese population. Breast Cancer Res Treat. 
2012;136:209-220. 
 
228. Huang Y, Ballinger DG, Dai JY, et al. Genetic variants in the MRPS30 region and 
postmenopausal breast cancer risk. Genome Med. 2011;3:42. 
 
229. Mcinerney N, Colleran G, Rowan A, et al. Low penetrance breast cancer predisposition 
SNPs are site specific. Breast Cancer Res Treat. 2009;117:151-159. 
 
230. Milne RL, Goode EL, García-Closas M, et al. Confirmation of 5p12 As a susceptibility 
locus for progesterone-receptor-positive, lower grade breast cancer. Cancer Epidemiol 
Biomarkers Prev. 2011;20:2222-2231. 
 
231. Ruiz-Narvaez EA, Rosenberg L, Rotimi CN, et al. Genetic variants on chromosome 
5p12 are associated with risk of breast cancer in African American women: the Black 
Women's Health Study. Breast Cancer Res Treat. 2010;123:525-530. 
 
232. Garcia-Closas M, Hall P, Nevanlinna H, et al. Heterogeneity of breast cancer 
associations with five susceptibility loci by clinical and pathological characteristics. PLoS 
Genet, 2008;4(4):e1000054. doi:10.1371/journal.pgen.1000054. 
 
233. Gorodnova TV, Kuligina ES, Yanus GA, et al. Distribution of FGFR2, TNRC9, 
MAP3K1, LSP1, and 8q24 alleles in genetically enriched breast cancer patients versus 
elderly tumor-free women. Cancer Genet Cytogenet. 2010;199:69-72. 
 
234. Huijts PEA, Vreeswijk MPG, Kroeze-Jansema KHG, et al. Clinical correlates of low-
risk variants in FGFR2, TNRC9, MAP3K1, LSP1 and 8q24 in a Dutch cohort of incident 
breast cancer cases. Breast Cancer Res, 2007;9:R78. doi:10.1186/bcr1793. 
 
235. Latif A, Hadfield KD, Roberts SA, et al. Breast cancer susceptibility variants alter risks 
in familial disease. J Med Genet. 2010;47:126-131. 
 
236. Rebbeck TR, DeMichele A, Tran TV, et al. Hormone-dependent effects of FGFR2 and 
MAP3K1 in breast cancer susceptibility in a population-based sample of post-menopausal 
African-American and European-American women. Carcinogenesis. 2009;30:269-274. 
 
237. Tamimi RM, Lagiou P, Czene K, et al. Birth weight, breast cancer susceptibility loci, 
and breast cancer risk. Cancer Causes Control. 2010;21:689-696. 
 
238. Zheng W, Wen W, Gao Y, et al. Genetic and clinical predictors for breast cancer risk 
assessment and stratification among Chinese women. J Natl Cancer Inst. 2010;102:972-981. 
 
239. Lu P, Yang J, Li C, et al. Association between mitogen-activated protein kinase kinase 
kinase 1 rs889312 polymorphism and breast cancer risk: evidence from 59,977 subjects. 
  
     
256 
Breast Cancer Res Treat. 2011;126:663-670. 
 
240. Sueta A, Ito H, Kawase T, et al. A genetic risk predictor for breast cancer using a 
combination of low-penetrance polymorphisms in a Japanese population. Breast Cancer Res 
Treat. 2012;132:711-721. 
 
241. Kirchhoff T, Chen Z, Gold B, et al. The 6q22.33 locus and breast cancer susceptibility. 
Cancer Epidemiol Biomarkers Prev. 2009;18:2468-2475. 
 
242. Cai Q, Wen W, Qu S, et al. Replication and functional genomic analyses of the breast 
cancer susceptibility locus at 6q25.1 generalize its importance in women of chinese, 
Japanese, and European ancestry. Cancer Res. 2011;71:1344-1355. 
 
243. Stacey SN, Sulem P, Zanon C, et al. Ancestry-shift refinement mapping of the C6orf97-
ESR1 breast cancer susceptibility locus. PLoS Genet, 2010;6(7):e1001029, 
doi:10.1371/journal.pgen.1001029. 
 
244. Dai J, Hu Z, Jiang Y, et al. Breast cancer risk assessment with five independent genetic 
variants and two risk factors in Chinese women. Breast Cancer Res, 2012;14:R17. 
doi:10.1186/bcr3101. 
 
245. Fletcher O, Johnson N, Gibson L, et al. Association of genetic variants at 8q24 with 
breast cancer risk. Cancer Epidemiol Biomarkers Prev. 2008;17:702-705. 
 
246. Jiang Y, Shen H, Liu X, et al. Genetic variants at 1p11.2 and breast cancer risk: a two-
stage study in Chinese women. PLoS One, 2011;6(6):e21563. 
doi:10.1371/journal.pone.0021563. 
 
247. Lambrechts D, Truong T, Justenhoven C, et al. 11q13 is a susceptibility locus for 
hormone receptor positive breast cancer. Hum Mutat. 2012;33:1123-1132. 
 
248. Debniak T, Górski B, Huzarski T, et al. A common variant of CDKN2A (p16) 
predisposes to breast cancer. J Med Genet. 2005;42:763-765. 
 
249. Driver KE, Song H, Lesueur F, et al. Association of single-nucleotide polymorphisms in 
the cell cycle genes with breast cancer in the British population. Carcinogenesis. 
2008;29:333-341. 
 
250. Lindström S, Vachon CM, Li J, et al. Common variants in ZNF365 are associated with 
both mammographic density and breast cancer risk. Nat Genet. 2011;43:185-187. 
 
251. Boyarskikh UA, Zarubina NA, Biltueva JA, et al. Association of FGFR2 gene 
polymorphisms with the risk of breast cancer in population of West Siberia. Eur J Hum 
Genet. 2009;17:1688-1691. 
 
  
     
257 
252. Prentice RL, Huang Y, Hinds DA, et al. Variation in the FGFR2 gene and the effects of 
postmenopausal hormone therapy on invasive breast cancer. Cancer Epidemiol Biomarkers 
Prev. 2009;18:3079-3085. 
 
253. Cherdyntseva NV, Denisov EV, Litviakov NV, et al. Crosstalk Between the FGFR2 and 
TP53 Genes in breast cancer: Data from an association study and epistatic interaction 
analysis. DNA Cell Biol. 2012;31:305-315. 
 
254. Higginbotham KSP, Breyer JP, Bradley KM, et al. A multistage association study 
identifies a breast cancer genetic locus at NCOA7. Cancer Res. 2011;71:3881-3888. 
 
255. Marian C, Ochs-Balcom HM, Nie J, et al. FGFR2 intronic SNPs and breast cancer risk: 
Associations with tumor characteristics and interactions with exogenous exposures and other 
known breast cancer risk factors. Int J Cancer. 2011;129:702-712. 
 
256. Raskin L, Pinchev M, Arad C, et al. FGFR2 is a breast cancer susceptibility gene in 
Jewish and Arab Israeli populations. Cancer Epidemiol Biomarkers Prev. 2008;17:1060-
1065. 
 
257. Wang H, Yang Z, Zhang H. Assessing interactions between the associations of 
fibroblast growth factor receptor 2 common genetic variants and hormone receptor status 
with breast cancer risk. Breast Cancer Res Treat. 2013;137:511-522. 
 
258. Zhou L, Yao F, Luan H, et al. Three novel functional polymorphisms in the promoter of 
FGFR2 gene and breast cancer risk: a HuGE review and meta-analysis. Breast Cancer Res 
Treat. 2012;136:885-897. 
 
259. Udler MS, Meyer KB, Pooley KA, et al. FGFR2 variants and breast cancer risk: fine-
scale mapping using African American studies and analysis of chromatin conformation. Hum 
Mol Genet. 2009;18:1692-1703. 
 
260. Chen M, Li C, Shen W, Guo Y, Shen W, Lu P. Association of a LSP1 gene 
rs3817198T>C polymorphism with breast cancer risk: evidence from 33,920 cases and 
35,671 controls. Mol Biol Rep. 2011;38:4687-4695. 
 
261. Teraoka SN, Bernstein JL, Reiner AS, et al. Single nucleotide polymorphisms 
associated with risk for contralateral breast cancer in the Women's Environment, Cancer and 
Radiation Epidemiology (WECARE) study. Breast Cancer Res, 2011;13:R114. 
doi:10.1186/bcr3057. 
 
262. Udler MS, Ahmed S, Healey CS, et al. Fine scale mapping of the breast cancer 16q12 
locus. Hum Mol Genet. 2010;19:2507-2515. 
 
263. Ruiz-Narváez EA, Rosenberg L, Cozier YC, Cupples LA, Adams-Campbell LL, Palmer 
JR. Polymorphisms in the TOX3/LOC643714 locus and risk of breast cancer in African-
American women. Cancer Epidemiol Biomarkers Prev. 2010;19:1320-1327. 
 
  
     
258 
264. Chen M, Wu X, Shen W, et al. Association between polymorphisms of trinucleotide 
repeat containing 9 gene and breast cancer risk: evidence from 62,005 subjects. Breast 
Cancer Res Treat. 2011;126:177-183. 
 
265. Li L, Zhou X, Huang Z, Liu Z, Song M, Guo Z. TNRC9/LOC643714 polymorphisms 
are not associated with breast cancer risk in Chinese women. Eur J Cancer Prev. 
2009;18:285-290. 
 
266. Liang J, Chen P, Hu Z, et al. Genetic variants in trinucleotide repeat-containing 9 
(TNRC9) are associated with risk of estrogen receptor positive breast cancer in a Chinese 
population. Breast Cancer Res Treat. 2010;124:237-241. 
 
267. Tang L, Xu J, Wei F, et al. Association of STXBP4/COX11 rs6504950 (G>A) 
polymorphism with breast cancer risk: evidence from 17,960 cases and 22,713 controls. Arch 
Med Res. 2012;43:383-388. 
 
268. Bensen JT, Xu Z, Smith GJ, Mohler JL, Fontham ETH, Taylor JA. Genetic 
polymorphism and prostate cancer aggressiveness: A case-only study of 1,536 GWAS and 
candidate SNPs in African-Americans and European-Americans. Prostate. 2013;73:11-22. 
 
269. Haiman CA, Stram DO. Exploring genetic susceptibility to cancer in diverse 
populations. Curr Opin Genet Dev. 2010;20:330-335. 
 
270. Hinch AG, Tandon A, Patterson N, et al. The landscape of recombination in African 
Americans. Nature. 2011;476:170-175. 
 
271. Aldrich TE, Vann D, Moorman PG, Newman B. Rapid reporting of cancer incidence in 
a population-based study of breast cancer: one constructive use of a central cancer registry. 
Breast Cancer Res Treat. 1995; 35:61-64. 
 
272. Newman B, Moorman PG, Millikan R, et al. The Carolina Breast Cancer Study: 
integrating population-based epidemiology and molecular biology. Breast Cancer Res Treat. 
1995; 35:51-60. 
 
273.Nyante, SJ. Single nucleotide polymorphisms and the etiology of basal-like and luminal 
A breast cancer: a pathway-based approach. Ph.D. dissertation, 2009;University of North 
Carolina at Chapel Hill.  
 
274. Furberg H, Millikan R, Dressler L, Newman B, Geradts J. Tumor characteristics in 
African American and white women. Breast Cancer Res Treat. 2001;68:33-43. 
 
275. Barnholtz-Sloan JS, McEvoy B, Shriver MD, Rebbeck TR. Ancestry estimation and 
correction for population stratification in molecular epidemiologic association studies. 
Cancer Epidemiol Biomarkers Prev. 2008;17:471-477. 
 
  
     
259 
276. Tian C, Hinds DA, Shigeta R, Kittles R, Ballinger DG, Seldin MF. A genomewide 
single-nucleotide-polymorphism panel with high ancestry information for African American 
admixture mapping. Am J Hum Genet. 2006;79:640-649. 
 
277. Pfaff CL, Barnholtz-Sloan J, Wagner JK, Long JC. Information on ancestry from 
genetic markers. Genet Epidemiol. 2004;26:305-315. 
 
278. dbSNP Home Page. http://www.ncbi.nlm.nih.gov/projects/SNP. Accessed February 20, 
2012. 
 
279. Sherry ST, Ward MH, Kholodov M, et al. dbSNP: the NCBI database of genetic 
variation. Nucleic Acids Res. 2001;29:308-311. 
 
280. Shen R, Fan J, Campbell D, et al. High-throughput SNP genotyping on universal bead 
arrays. Mutat Res. 2005;573:70-82. 
 
281. TaqMan SNP Genotyping Assays. 
http://www3.appliedbiosystems.com/cms/groups/mcb_support/documents/generaldocuments/
cms_042998.pdf. Accessed February 20, 2012. 
 
282. Hall IJ, Moorman PG, Millikan RC, Newman B. Comparative analysis of breast cancer 
risk factors among African-American women and White women.. Am J Epidemiol. 
2005;161:40-51. 
 
283. Huang WY, Newman B, Millikan RC, Schell MJ, Hulka BS, Moorman PG. Hormone-
related factors and risk of breast cancer in relation to estrogen receptor and progesterone 
receptor status. Am J Epidemiol. 2000;151:703-714. 
 
284. Millikan R, Eaton A, Worley K, et al. HER2 codon 655 polymorphism and risk of 
breast cancer in African Americans and whites. Breast Cancer Res Treat. 2003;79:355-364. 
 
285. AJCC Cancer Staging Manual, 7th edition. 
http://www.cancerstaging.org/staging/index.html. Accessed December 9, 2012. 
 
286. Barnholtz-Sloan JS, Chakraborty R, Sellers TA, Schwartz AG. Examining population 
stratification via individual ancestry estimates versus self-reported race. Cancer Epidemiol 
Biomarkers Prev. 2005;14:1545-1551. 
 
287. Nyante SJ, Gammon MD, Kaufman JS, et al. Common genetic variation in adiponectin, 
leptin, and leptin receptor and association with breast cancer subtypes. Breast Cancer Res 
Treat. 2011;129:593-606. 
 
288. Ziegler, A and Konig, IR. A statistical approach to genetic epidemiology, 1st edition.  
Weinheim, Germany: Wiley-VCH Verlag GmbH & Co. KGaA; 2006. 
 
  
     
260 
289. Souren NYP, Zeegers MP. Is Hardy-Weinberg on its retreat? J Clin Epidemiol. 
2011;64:819-820. 
 
290. Weale, ME. Quality Control for Genome-Wide Association Studies. In: Barnes MR and 
Breen G, eds, Genetic Variation: Methods and Protocols. New York: Humana Press; 2010: 
341-372. 
 
291. Rothman, KJ, Greenland, S, Lash, TL. Modern Epidemiology. 3rd edition.  
Philadelphia: Lippincott, Williams, and Wilkins; 2008. 
 
292. Thomas DC, Witte JS. Point: population stratification: a problem for case-control 
studies of candidate-gene associations? Cancer Epidemiol Biomarkers Prev. 2002;11:505-
512. 
 
293. Weinberg CR, Sandler DP. Randomized recruitment in case-control studies. Am J 
Epidemiol. 1991;134:421-432. 
 
294. Weinberg CR, Wacholder S. The design and analysis of case-control studies with biased 
sampling. Biometrics. 1990;46:963-975. 
 
295. Anghel A, Raica M, Narita D, et al. Estrogen receptor alpha polymorphisms: correlation 
with clinicopathological parameters in breast cancer. Neoplasma. 2010;57:306-315. 
 
296. Ding S, Yu J, Chen S, et al. Diverse associations between ESR1 polymorphism and 
breast cancer development and progression. Clin Cancer Res. 2010;16:3473-3484. 
 
297. Dunning AM, Healey CS, Baynes C, et al. Association of ESR1 gene tagging SNPs with 
breast cancer risk. Hum Mol Genet. 2009;18:1131-1139. 
 
298. Fernández LP, Milne RL, Barroso E, et al. Estrogen and progesterone receptor gene 
polymorphisms and sporadic breast cancer risk: a Spanish case-control study. Int J Cancer. 
2006;119:467-471. 
 
299. Ghoussaini M, Fletcher O, Michailidou K, et al. Genome-wide association analysis 
identifies three new breast cancer susceptibility loci. Nat Genet. 2012;44:312-318. 
 
300. Sonestedt E, Ivarsson MIL, Harlid S, et al. The protective association of high plasma 
enterolactone with breast cancer is reasonably robust in women with polymorphisms in the 
estrogen receptor alpha and beta genes. J Nutr. 2009;139:993-1001. 
 
301. Wang J, Higuchi R, Modugno F, et al. Estrogen receptor alpha haplotypes and breast 
cancer risk in older Caucasian women. Breast Cancer Res Treat. 2007;106:273-280. 
 
302. Bretsky P, Haiman CA, Gilad S, et al. The relationship between twenty missense ATM 
variants and breast cancer risk: the Multiethnic Cohort. Cancer Epidemiol Biomarkers Prev. 
  
     
261 
2003;12:733-738. 
 
303. Buchholz TA, Weil MM, Ashorn CL, et al. A Ser49Cys variant in the ataxia 
telangiectasia, mutated, gene that is more common in patients with breast carcinoma 
compared with population controls. Cancer. 2004;100:1345-1351. 
 
304. Dombernowsky SL, Weischer M, Allin KH, Bojesen SE, Tybjaerg-Hansen A, 
Nordestgaard BG. Risk of cancer by ATM missense mutations in the general population. J 
Clin Oncol. 2008;26:3057-3062. 
 
305. Edvardsen H, Tefre T, Jansen L, et al. Linkage disequilibrium pattern of the ATM gene 
in breast cancer patients and controls; association of SNPs and haplotypes to radio-sensitivity 
and post-lumpectomy local recurrence. Radiat Oncol. 2007;2:25. 
 
306. Hirsch AE, Atencio DP, Rosenstein BS. Screening for ATM sequence alterations in 
African-American women diagnosed with breast cancer. Breast Cancer Res Treat. 
2008;107:139-144. 
 
307. Shen L, Yin Z, Wan Y, Zhang Y, Li K, Zhou B. Association between ATM 
polymorphisms and cancer risk: a meta-analysis. Mol Biol Rep. 2012;39:5719-5725. 
 
308. Spurdle AB, Hopper JL, Chen X, et al. No evidence for association of ataxia-
telangiectasia mutated gene T2119C and C3161G amino acid substitution variants with risk 
of breast cancer. Breast Cancer Res, 2002;4:R15. doi:10.1186/bcr534. 
 
309. Ye C, Dai Q, Lu W, et al. Two-stage case-control study of common ATM gene variants 
in relation to breast cancer risk. Breast Cancer Res Treat. 2007;106:121-126. 
 
310. Gao L, Pan X, Sun H, et al. The association between ATM D1853N polymorphism and 
breast cancer susceptibility: a meta-analysis. J Exp Clin Cancer Res. 2010;29:117. 
 
311. Mao C, Chung VCH, He B, Luo R, Tang J. Association between ATM 5557G>A 
polymorphism and breast cancer risk: a meta-analysis. Mol Biol Rep. 2012;39:1113-1118. 
 
312. Agresti, A. Logit Models for Multinomial Responses. In: Agresti, A. Categorical Data 
Analysis, 2nd ed. Hoboken, New York: John Wiley & Sons, Inc.; 2002:267-314.   
 
313. Greenland S. Bayesian interpretation and analysis of research results. Semin Hematol. 
2008;45:141-9, 2008. 
 
314. Greenland S. Bayesian perspectives for epidemiological research. II. Regression 
analysis. Int J Epidemiol. 2007;36:195-202. 
 
315. Gill, J. Bayesian methods: A social and behavioral sciences approach, 2nd edition. 
Washington, DC, USA: CRC press; 2002.    
 
  
     
262 
316. Yu X, Xun P, Hu Z, Liu P, Shen H, Chen F. Combining previously published studies 
with current data in Bayesian logistic regression model: an example for identifying 
susceptibility genes related to lung cancer in humans. J Toxicol Environ Health A. 
2009;72:683-689. 
 
317. Newcombe PJ, Reck BH, Sun J, et al. A comparison of Bayesian and frequentist 
approaches to incorporating external information for the prediction of prostate cancer risk. 
Genet Epidemiol. 2012;36:71-83. 
 
318. Hunter DJ. Lessons from genome-wide association studies for epidemiology. 
Epidemiology. 2012;23:363-367. 
 
319. Greenland S, Robins JM. Empirical-Bayes adjustments for multiple comparisons are 
sometimes useful. Epidemiology. 1991;2:244-251. 
 
320. Ferguson JP, Cho JH, Yang C, Zhao H. Empirical Bayes Correction for the Winner's 
Curse in Genetic Association Studies. Genet Epidemiol. 2013;37:60-68. 
 
321. Corbin M, Richiardi L, Vermeulen R, et al. Hierarchical regression for multiple 
comparisons in a case-control study of occupational risks for lung cancer. PLoS One, 
2012;7(6):e38944. doi:10.1371/journal.pone.0038944. 
 
322. Greenland S, Poole C. Empirical-Bayes and semi-Bayes approaches to occupational and 
environmental hazard surveillance. Arch Environ Health. 1994;49:9-16. 
 
323. The MCMC Procedure: The MCMC Procedure :: SAS/STAT(R) 9.2 User's Guide, 
Second Edition. 
http://support.sas.com/documentation/cdl/en/statug/63033/HTML/default/viewer.htm#mcmc
_toc.htm. Accessed March 5, 2012. 
 
324. Capanu M, Orlow I, Berwick M, Hummer AJ, Thomas DC, Begg CB. The use of 
hierarchical models for estimating relative risks of individual genetic variants: an application 
to a study of melanoma. Stat Med. 2008;27:1973-1992. 
 
325. Carmichael SL, Witte JS, Shaw GM. Nutrient pathways and neural tube defects: a semi-
Bayesian hierarchical analysis. Epidemiology. 2009;20:67-73. 
 
326. Chen GK, Witte JS. Enriching the analysis of genomewide association studies with 
hierarchical modeling. Am J Hum Genet. 2007;81:397-404. 
 
327. Conti DV, Gauderman WJ. SNPs, haplotypes, and model selection in a candidate gene 
region: the SIMPle analysis for multilocus data. Genet Epidemiol. 2004;27:429-441. 
 
328. Conti DV, Witte JS. Hierarchical modeling of linkage disequilibrium: genetic structure 
and spatial relations. Am J Hum Genet. 2003;72:351-363. 
 
  
     
263 
329. Fridley BL, Jenkins GD. Localizing putative markers in genetic association studies by 
incorporating linkage disequilibrium into bayesian hierarchical models. Hum Hered. 
2010;70:63-73. 
 
330. MacLehose RF, Dunson DB, Herring AH, Hoppin JA. Bayesian methods for highly 
correlated exposure data. Epidemiology. 2007;18:199-207. 
 
331. Thomas DC, Stram DO, Conti D, Molitor J, Marjoram P. Bayesian spatial modeling of 
haplotype associations. Hum Hered. 2003;56:32-40. 
 
332. Witte JS, Greenland S, Haile RW, Bird CL. Hierarchical regression analysis applied to a 
study of multiple dietary exposures and breast cancer. Epidemiology. 1994;5:612-621. 
 
333. Hung RJ, Baragatti M, Thomas D, et al. Inherited predisposition of lung cancer: a 
hierarchical modeling approach to DNA repair and cell cycle control pathways. Cancer 
Epidemiol Biomarkers Prev. 2007;16:2736-2744. 
 
334. Witte JS. Genetic analysis with hierarchical models. Genet Epidemiol. 1997; 14:1137-
1142. 
 
335. Reding KW, Chen C, Lowe K, et al. Estrogen-related genes and their contribution to 
racial differences in breast cancer risk. Cancer Causes Control. 2012;23:671-681. 
 
336. Chen J, Jiang Y, Liu X, et al. Genetic variants at chromosome 9p21, 10p15 and 10q22 
and breast cancer susceptibility in a Chinese population. Breast Cancer Res Treat. 
2012;132:741-746. 
 
337. Kawase T, Matsuo K, Suzuki T, et al. FGFR2 intronic polymorphisms interact with 
reproductive risk factors of breast cancer: results of a case control study in Japan. Int J 
Cancer. 2009;125:1946-1952. 
 
338. Liang J, Chen P, Hu Z, et al. Genetic variants in fibroblast growth factor receptor 2 
(FGFR2) contribute to susceptibility of breast cancer in Chinese women. Carcinogenesis. 
2008;29:2341-2346. 
 
339. Xu W, Shu X, Long J, et al. Relation of FGFR2 genetic polymorphisms to the 
association between oral contraceptive use and the risk of breast cancer in Chinese women. 
Am J Epidemiol. 2011;173:923-931. 
 
340. Bortsov AV, Millikan RC, Belfer I, Boortz-Marx RL, Arora H, McLean SA. µ-Opioid 
receptor gene A118G polymorphism predicts survival in patients with breast cancer. 
Anesthesiology. 2012;116:896-902. 
 
341. Kerlikowske K. Epidemiology of ductal carcinoma in situ. J Natl Cancer Inst Monogr. 
2010;2010:139-141. 
 
  
     
264 
342. Gierach G, Burke A, Anderson WF. Epidemiology of triple negative breast cancers. 
Breast Dis. 2010;32:5-24. 
 
343. Cole SR, Chu H, Greenland S, Hamra G, Richardson DB. Bayesian posterior 
distributions without Markov chains. Am J Epidemiol. 2012;175:368-375. 
 
344. Stevens KN, Fredericksen Z, Vachon CM, et al. 19p13.1 is a triple-negative-specific 
breast cancer susceptibility locus. Cancer Res. 2012;72:1795-1803. 
 
345. Phillips LS, Millikan RC, Schroeder JC, Barnholtz-Sloan JS, Levine BJ. Reproductive 
and hormonal risk factors for ductal carcinoma in situ of the breast. Cancer Epidemiol 
Biomarkers Prev. 2009;18:1507-1514. 
 
346. Zhou W, Jirström K, Johansson C, et al. Long-term survival of women with basal-like 
ductal carcinoma in situ of the breast: a population-based cohort study. BMC Cancer. 
2010;10:653. 
 
347. Jia C, Jia C, Cai Y, Ma Y, Fu D. Quantitative assessment of the effect of FGFR2 gene 
polymorphism on the risk of breast cancer. Breast Cancer Res Treat. 2010;124:521-528. 
 
348. Zhang J, Qiu L, Wang Z, et al. Current evidence on the relationship between three 
polymorphisms in the FGFR2 gene and breast cancer risk: a meta-analysis. Breast Cancer 
Res Treat. 2010;124:419-424. 
 
349. Shan J, Mahfoudh W, Dsouza SP, et al. Genome-Wide Association Studies (GWAS) 
breast cancer susceptibility loci in Arabs: susceptibility and prognostic implications in 
Tunisians. Breast Cancer Res Treat. 2012;135:715-724. 
 
350. Cheang MCU, Chia SK, Voduc D, et al. Ki67 index, HER2 status, and prognosis of 
patients with luminal B breast cancer. J Natl Cancer Inst. 2009;101:736-750. 
 
 
 
 
  
 
